HUNTINGTON’S DISEASE A M EDICAL D ICTIONARY , B IBLIOGRAPHY , AND A NNOTATED R ESEARCH G UIDE TO I NTERNET R E FERENCES
J AMES N. P ARKER , M.D. AND P HILIP M. P ARKER , P H .D., E DITORS
ii
ICON Health Publications ICON Group International, Inc. 4370 La Jolla Village Drive, 4th Floor San Diego, CA 92122 USA Copyright ©2003 by ICON Group International, Inc. Copyright ©2003 by ICON Group International, Inc. All rights reserved. This book is protected by copyright. No part of it may be reproduced, stored in a retrieval system, or transmitted in any form or by any means, electronic, mechanical, photocopying, recording, or otherwise, without written permission from the publisher. Printed in the United States of America. Last digit indicates print number: 10 9 8 7 6 4 5 3 2 1
Publisher, Health Care: Philip Parker, Ph.D. Editor(s): James Parker, M.D., Philip Parker, Ph.D. Publisher's note: The ideas, procedures, and suggestions contained in this book are not intended for the diagnosis or treatment of a health problem. As new medical or scientific information becomes available from academic and clinical research, recommended treatments and drug therapies may undergo changes. The authors, editors, and publisher have attempted to make the information in this book up to date and accurate in accord with accepted standards at the time of publication. The authors, editors, and publisher are not responsible for errors or omissions or for consequences from application of the book, and make no warranty, expressed or implied, in regard to the contents of this book. Any practice described in this book should be applied by the reader in accordance with professional standards of care used in regard to the unique circumstances that may apply in each situation. The reader is advised to always check product information (package inserts) for changes and new information regarding dosage and contraindications before prescribing any drug or pharmacological product. Caution is especially urged when using new or infrequently ordered drugs, herbal remedies, vitamins and supplements, alternative therapies, complementary therapies and medicines, and integrative medical treatments. Cataloging-in-Publication Data Parker, James N., 1961Parker, Philip M., 1960Huntington’s Disease: A Medical Dictionary, Bibliography, and Annotated Research Guide to Internet References / James N. Parker and Philip M. Parker, editors p. cm. Includes bibliographical references, glossary, and index. ISBN: 0-597-83933-6 1. Huntington’s Disease-Popular works. I. Title.
iii
Disclaimer This publication is not intended to be used for the diagnosis or treatment of a health problem. It is sold with the understanding that the publisher, editors, and authors are not engaging in the rendering of medical, psychological, financial, legal, or other professional services. References to any entity, product, service, or source of information that may be contained in this publication should not be considered an endorsement, either direct or implied, by the publisher, editors, or authors. ICON Group International, Inc., the editors, and the authors are not responsible for the content of any Web pages or publications referenced in this publication.
Copyright Notice If a physician wishes to copy limited passages from this book for patient use, this right is automatically granted without written permission from ICON Group International, Inc. (ICON Group). However, all of ICON Group publications have copyrights. With exception to the above, copying our publications in whole or in part, for whatever reason, is a violation of copyright laws and can lead to penalties and fines. Should you want to copy tables, graphs, or other materials, please contact us to request permission (E-mail:
[email protected]). ICON Group often grants permission for very limited reproduction of our publications for internal use, press releases, and academic research. Such reproduction requires confirmed permission from ICON Group International Inc. The disclaimer above must accompany all reproductions, in whole or in part, of this book.
iv
Acknowledgements The collective knowledge generated from academic and applied research summarized in various references has been critical in the creation of this book which is best viewed as a comprehensive compilation and collection of information prepared by various official agencies which produce publications on Huntington’s disease. Books in this series draw from various agencies and institutions associated with the United States Department of Health and Human Services, and in particular, the Office of the Secretary of Health and Human Services (OS), the Administration for Children and Families (ACF), the Administration on Aging (AOA), the Agency for Healthcare Research and Quality (AHRQ), the Agency for Toxic Substances and Disease Registry (ATSDR), the Centers for Disease Control and Prevention (CDC), the Food and Drug Administration (FDA), the Healthcare Financing Administration (HCFA), the Health Resources and Services Administration (HRSA), the Indian Health Service (IHS), the institutions of the National Institutes of Health (NIH), the Program Support Center (PSC), and the Substance Abuse and Mental Health Services Administration (SAMHSA). In addition to these sources, information gathered from the National Library of Medicine, the United States Patent Office, the European Union, and their related organizations has been invaluable in the creation of this book. Some of the work represented was financially supported by the Research and Development Committee at INSEAD. This support is gratefully acknowledged. Finally, special thanks are owed to Tiffany Freeman for her excellent editorial support.
v
About the Editors James N. Parker, M.D. Dr. James N. Parker received his Bachelor of Science degree in Psychobiology from the University of California, Riverside and his M.D. from the University of California, San Diego. In addition to authoring numerous research publications, he has lectured at various academic institutions. Dr. Parker is the medical editor for health books by ICON Health Publications. Philip M. Parker, Ph.D. Philip M. Parker is the Eli Lilly Chair Professor of Innovation, Business and Society at INSEAD (Fontainebleau, France and Singapore). Dr. Parker has also been Professor at the University of California, San Diego and has taught courses at Harvard University, the Hong Kong University of Science and Technology, the Massachusetts Institute of Technology, Stanford University, and UCLA. Dr. Parker is the associate editor for ICON Health Publications.
vi
About ICON Health Publications To discover more about ICON Health Publications, simply check with your preferred online booksellers, including Barnes & Noble.com and Amazon.com which currently carry all of our titles. Or, feel free to contact us directly for bulk purchases or institutional discounts: ICON Group International, Inc. 4370 La Jolla Village Drive, Fourth Floor San Diego, CA 92122 USA Fax: 858-546-4341 Web site: www.icongrouponline.com/health
vii
Table of Contents FORWARD .......................................................................................................................................... 1 CHAPTER 1. STUDIES ON HUNTINGTON’S DISEASE.......................................................................... 3 Overview........................................................................................................................................ 3 The Combined Health Information Database................................................................................. 3 Federally Funded Research on Huntington’s Disease ................................................................... 5 E-Journals: PubMed Central ....................................................................................................... 60 The National Library of Medicine: PubMed ................................................................................ 62 CHAPTER 2. NUTRITION AND HUNTINGTON’S DISEASE .............................................................. 109 Overview.................................................................................................................................... 109 Finding Nutrition Studies on Huntington’s Disease ................................................................ 109 Federal Resources on Nutrition ................................................................................................. 117 Additional Web Resources ......................................................................................................... 118 CHAPTER 3. ALTERNATIVE MEDICINE AND HUNTINGTON’S DISEASE ....................................... 119 Overview.................................................................................................................................... 119 National Center for Complementary and Alternative Medicine................................................ 119 Additional Web Resources ......................................................................................................... 127 General References ..................................................................................................................... 127 CHAPTER 4. DISSERTATIONS ON HUNTINGTON’S DISEASE ......................................................... 129 Overview.................................................................................................................................... 129 Dissertations on Huntington’s Disease ..................................................................................... 129 Keeping Current ........................................................................................................................ 130 CHAPTER 5. CLINICAL TRIALS AND HUNTINGTON’S DISEASE .................................................... 131 Overview.................................................................................................................................... 131 Recent Trials on Huntington’s Disease ..................................................................................... 131 Keeping Current on Clinical Trials ........................................................................................... 133 CHAPTER 6. BOOKS ON HUNTINGTON’S DISEASE ........................................................................ 135 Overview.................................................................................................................................... 135 Book Summaries: Online Booksellers......................................................................................... 135 The National Library of Medicine Book Index ........................................................................... 136 Chapters on Huntington’s Disease ............................................................................................ 137 CHAPTER 7. MULTIMEDIA ON HUNTINGTON’S DISEASE ............................................................. 139 Overview.................................................................................................................................... 139 Bibliography: Multimedia on Huntington’s Disease................................................................. 139 CHAPTER 8. PERIODICALS AND NEWS ON HUNTINGTON’S DISEASE .......................................... 141 Overview.................................................................................................................................... 141 News Services and Press Releases.............................................................................................. 141 Academic Periodicals covering Huntington’s Disease............................................................... 145 CHAPTER 9. RESEARCHING MEDICATIONS .................................................................................. 147 Overview.................................................................................................................................... 147 U.S. Pharmacopeia..................................................................................................................... 147 Commercial Databases ............................................................................................................... 149 Researching Orphan Drugs ....................................................................................................... 149 APPENDIX A. PHYSICIAN RESOURCES .......................................................................................... 153 Overview.................................................................................................................................... 153 NIH Guidelines.......................................................................................................................... 153 NIH Databases........................................................................................................................... 155 Other Commercial Databases..................................................................................................... 157 APPENDIX B. PATIENT RESOURCES ............................................................................................... 159 Overview.................................................................................................................................... 159 Patient Guideline Sources.......................................................................................................... 159 Associations and Huntington’s Disease .................................................................................... 163
viii Contents
Finding Associations.................................................................................................................. 164 APPENDIX C. FINDING MEDICAL LIBRARIES ................................................................................ 167 Overview.................................................................................................................................... 167 Preparation................................................................................................................................. 167 Finding a Local Medical Library................................................................................................ 167 Medical Libraries in the U.S. and Canada ................................................................................. 167 ONLINE GLOSSARIES................................................................................................................ 173 Online Dictionary Directories ................................................................................................... 175 HUNTINGTON’S DISEASE DICTIONARY ........................................................................... 177 INDEX .............................................................................................................................................. 233
1
FORWARD In March 2001, the National Institutes of Health issued the following warning: "The number of Web sites offering health-related resources grows every day. Many sites provide valuable information, while others may have information that is unreliable or misleading."1 Furthermore, because of the rapid increase in Internet-based information, many hours can be wasted searching, selecting, and printing. Since only the smallest fraction of information dealing with Huntington’s disease is indexed in search engines, such as www.google.com or others, a non-systematic approach to Internet research can be not only time consuming, but also incomplete. This book was created for medical professionals, students, and members of the general public who want to know as much as possible about Huntington’s disease, using the most advanced research tools available and spending the least amount of time doing so. In addition to offering a structured and comprehensive bibliography, the pages that follow will tell you where and how to find reliable information covering virtually all topics related to Huntington’s disease, from the essentials to the most advanced areas of research. Public, academic, government, and peer-reviewed research studies are emphasized. Various abstracts are reproduced to give you some of the latest official information available to date on Huntington’s disease. Abundant guidance is given on how to obtain free-of-charge primary research results via the Internet. While this book focuses on the field of medicine, when some sources provide access to non-medical information relating to Huntington’s disease, these are noted in the text. E-book and electronic versions of this book are fully interactive with each of the Internet sites mentioned (clicking on a hyperlink automatically opens your browser to the site indicated). If you are using the hard copy version of this book, you can access a cited Web site by typing the provided Web address directly into your Internet browser. You may find it useful to refer to synonyms or related terms when accessing these Internet databases. NOTE: At the time of publication, the Web addresses were functional. However, some links may fail due to URL address changes, which is a common occurrence on the Internet. For readers unfamiliar with the Internet, detailed instructions are offered on how to access electronic resources. For readers unfamiliar with medical terminology, a comprehensive glossary is provided. For readers without access to Internet resources, a directory of medical libraries, that have or can locate references cited here, is given. We hope these resources will prove useful to the widest possible audience seeking information on Huntington’s disease. The Editors
1
From the NIH, National Cancer Institute (NCI): http://www.cancer.gov/cancerinfo/ten-things-to-know.
3
CHAPTER 1. STUDIES ON HUNTINGTON’S DISEASE Overview In this chapter, we will show you how to locate peer-reviewed references and studies on Huntington’s disease.
The Combined Health Information Database The Combined Health Information Database summarizes studies across numerous federal agencies. To limit your investigation to research studies and Huntington’s disease, you will need to use the advanced search options. First, go to http://chid.nih.gov/index.html. From there, select the “Detailed Search” option (or go directly to that page with the following hyperlink: http://chid.nih.gov/detail/detail.html). The trick in extracting studies is found in the drop boxes at the bottom of the search page where “You may refine your search by.” Select the dates and language you prefer, and the format option “Journal Article.” At the top of the search form, select the number of records you would like to see (we recommend 100) and check the box to display “whole records.” We recommend that you type “Huntington’s disease” (or synonyms) into the “For these words:” box. Consider using the option “anywhere in record” to make your search as broad as possible. If you want to limit the search to only a particular field, such as the title of the journal, then select this option in the “Search in these fields” drop box. The following is what you can expect from this type of search: •
Dysphagia Caused by Neurologic Deficits Source: Otolaryngologic Clinics of North America. 31(3): 507-524. June 1998. Contact: Available from W.B. Saunders Company. 6277 Sea Harbor Drive, Orlando, FL 32887-4800. Summary: Normal swallowing is a complex, dynamic neuromuscular activity that depends on a set of physiologic behaviors resulting in liquid and solid material moving efficiently and safely from the mouth to the stomach. Problems with swallowing in the oropharynx (oropharyngeal dysphagia) are often linked to neurologic or muscular diseases. This article reviews the neurologic lesions and conditions that account for the majority of oropharyngeal dysphagia cases. The authors first review the physiology and
4
Huntington’s Disease
neurophysiology of both normal and abnormal swallowing, then outline the recommended patient physical examination and laboratory work up. Each neurological disease that may contribute to oropharyngeal dysphagia is then discussed: amyotrophic lateral sclerosis, Parkinson's disease, Huntington's disease, multiple sclerosis, myasthenia gravis, stroke (cerebrovascular accident), and laryngeal nerve injury. Dysphagia secondary to acute neurologic deficits, along with other abnormalities, tends to improve with time. Dysphagia resulting from chronic neurologic conditions, however, often worsens as the disease process evolves. 4 tables. 62 references. •
Severity of Cognitive Impairment in Juvenile and Late-Onset Huntington Disease Source: Archives of Neurology. 55: 835-843. June 1998. Summary: This journal article describes a study of the severity of cognitive impairment and the influence of motor and cognitive deficits on functional disability across different ages of onset of Huntington's disease (HD). The participants were 71 patients seen at the HD program in the Departments of Neurology and Genetics at the Fundacion Jimenez Diaz in Madrid, Spain. The patients were divided into three groups based on onset of motor symptoms: juvenile onset (at age 25 years or younger, n=15), adult onset (at age 26 to 50 years, n=43), and late onset (at age 51 years or older, n=13). Healthy controls, matched on age and education to groups 1 and 3, also were studied. All patients were assessed with a battery of neuropsychological tests, measures of motor and functional abilities, and a genetic analysis to determine the number of CAG trinucleotide repeats. Patients with juvenile onset had the longest CAG repeat lengths and those with late onset had the shortest. Cognitive impairment was less severe in the juvenile-onset group than at other ages of onset. Visuospatial function was more impaired in patients with late onset, and prefrontal functions were more impaired in those with juvenile onset. Functional disability was associated with global cognitive status in patients with late onset, and with motor deficits and prefrontal dysfunction in those with early onset. 3 figures, 5 tables, 54 references.
•
Electrophysiological Analysis of Altered Cognitive Functions in Huntington Disease Source: Archives of Neurology. 54: 1089-1098. September 1997. Summary: This journal article describes an electrophysiological analysis of altered cognitive functions in Huntington's disease (HD) in the domains of visual processing and memory. Nine patients with HD and 9 controls matched for age, sex, and education participated. Cognitive event-related potentials (ERPs) were measured, using an electroencephalogram, under three conditions: a parallel visual search task, a serial visual search task, and a word-recognition memory task. The components of averaged ERPs were quantified by latency and amplitude measures, and analyzed along with behavioral measures (search time, hit rate, and recognition accuracy). The results suggest that compared with controls, the patients with HD showed a significant delay in the early visual components and abnormalities in the ERP indexes of word recognition and target detection. These changes were accompanied by a marked delay in search times and a greatly reduced accuracy on the memory task. The ERPs on the memory task were different from those found in studies of patients with Alzheimer's disease, suggesting a different neural basis for the deficits in HD. 6 figures, 4 tables, 77 references.
•
Inherited Neurodegenerative Diseases and Transgenic Models Source: Brain Pathology. 6(4): 467-480. 1996.
Studies
5
Summary: This journal describes the clinical features, neuropathological changes, and genetics of several neurodegenerative diseases, outlines transgenic strategies for creating animal models, and reviews investigations in which these approaches have been used to model several genetic neurodegenerative diseases. The discussion focuses on the familial forms of Alzheimer's disease (FAD) and amyotrophic lateral sclerosis (FALS), and the spectrum of triplet-repeat disorders. Researchers have linked some cases of FAD to mutations in genes encoding the amyloid precursor protein or presenilin 1 or 2. Some cases of FALS have been linked to mutations in the superoxide dismutase 1 gene. Spinocerebellar ataxia and Huntington's disease are associated with trinucleotide repeat expansions in the genes encoding ataxin 1 and huntington, respectively. Recently, investigators have used transgenic mouse models of these disorders to examine the mechanisms by which the expression of mutant proteins causes autosomal dominant disease. Their collective experience suggests that the expression of high levels of mutant transgenes in nervous tissue can significantly increase the chance that the transgenic mice will develop phenotypes resembling those occurring in autosomal dominant human diseases. The emerging view is that each of these diseases results from the gain of a toxic property by the mutant protein. Future research will be aimed at understanding the biological basis of these toxic properties and, ultimately, to the development of new treatments for the neurodegenerative disorders. 220 references. •
Apolipoprotein E Alleles as Risk Factors in Alzheimer's Disease Source: Annual Review of Medicine. 47: 387-400. 1996. Summary: This review article discusses apolipoprotein E (apoE) alleles as risk factors in Alzheimer's disease (AD). Three early-onset forms of AD inherited as autosomal dominant traits account for less than 2 percent of prevalent AD. A major susceptibility locus, apoE, is associated with risk and age of onset distributions for the common familial and sporadic late-onset AD. The identification of additional genetic susceptibility genes in the etiology of AD and the metabolic mechanisms leading to differences in age of onset and disease pathogenesis are active areas of current research. The operational difference between using apoE genotyping in differential diagnosis from the application of autosomal dominant traits, such as the triplet repeat size of the Huntington gene in Huntington's disease, is that the absence of the disease-associated marker does not rule out the disease. 1 table, 2 figures, 66 references. (AA- M).
Federally Funded Research on Huntington’s Disease The U.S. Government supports a variety of research studies relating to Huntington’s disease. These studies are tracked by the Office of Extramural Research at the National Institutes of Health.2 CRISP (Computerized Retrieval of Information on Scientific Projects) is a searchable database of federally funded biomedical research projects conducted at universities, hospitals, and other institutions.
2 Healthcare projects are funded by the National Institutes of Health (NIH), Substance Abuse and Mental Health Services (SAMHSA), Health Resources and Services Administration (HRSA), Food and Drug Administration (FDA), Centers for Disease Control and Prevention (CDCP), Agency for Healthcare Research and Quality (AHRQ), and Office of Assistant Secretary of Health (OASH).
6
Huntington’s Disease
Search the CRISP Web site at http://crisp.cit.nih.gov/crisp/crisp_query.generate_screen. You will have the option to perform targeted searches by various criteria, including geography, date, and topics related to Huntington’s disease. For most of the studies, the agencies reporting into CRISP provide summaries or abstracts. As opposed to clinical trial research using patients, many federally funded studies use animals or simulated models to explore Huntington’s disease. The following is typical of the type of information found when searching the CRISP database for Huntington’s disease: •
Project Title: 2001 CAG TRIPLET REPEAT DISORDERS Principal Investigator & Institution: Brundin, Patrick; Gordon Research Conferences Box 984, 512 Liberty Ln West Kingston, Ri 02892 Timing: Fiscal Year 2001; Project Start 01-APR-2001; Project End 31-MAR-2002 Summary: This application is to request funding for the 2001 Gordon Research Conference on CAG triplet repeat disorders to be held in Mount Holyoke College, MA, USA, July 15-20, 2001. Two major groups of genetic neurological disorders were recently identified as unstable triplet repeat diseases. Their discovery represents the foundation of a new set of principles in genetics. One group of diseases includes fragile X, myotonic dystrophy and Friedreich's ataxia. Patients with these disorders all exhibit an expansion of triplet repeats in a non-coding sequence of the DNA genome. In the contrast, the other group of neurologic disorders exhibit expanded triplet repeats (coding for CAG bases) in the coding part of the genome, resulting in a polyglutamine tract. This latter group includes Huntington's disease, spino-cerebellar ataxia 1, 2, 3, 6 and 7, spinobulbar muscular atrophy and dentato-rubral pallido-luysian atrophy. These disorders results in a selective loss of neurons in the brain and spinal cord, with a different anatomical distribution in each disease. Although the genetic defects are established, it remains to be elucidated how the mutant gene in each case generates the specific pathogenetic process and how this leads to a characteristic anatomical pattern of changes. The identification of these mutant genes raises hopes for many affected by severe genetic disease. However, before development of novel therapies can be expected, it is necessary to better understand the disease processes. This requires a multi-disciplinary research effort with collaborative projects between scientists from diverse specialties ranging from fruit fly genetics to clinical neurology and neuropathology. This conference on CAG triplet repeat disorders will gather both young and senior, key scientists who will present provoking lectures on the cuttingedge of science. In keeping with the Gordon Research Conference format, there will be generous time allocated to both structured discussions led by peers and for informal discussions and social generous time allocated to both structured discussions led by peers and for informal discussions and social interaction. Strong emphasis is placed on training and mentoring of young scientists and time is also devoted to career issues. All participants (except speakers and discussants) will be encouraged to present posters. When participants are selected there will also be priority given to women, minorities, and persons with disabilities Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
•
Project Title: A NEW METHOD OF DRUG DISCOVERY FOR CNS DISEASES Principal Investigator & Institution: Lowe, David; Envivo Pharmaceuticals, Inc. 3696 Haven Ave, Ste B Redwood City, Ca 94063 Timing: Fiscal Year 2002; Project Start 30-SEP-2002; Project End 31-DEC-2003
Studies
7
Summary: (provided by applicant): The discovery and development of small molecule therapeutics for disorders of the Central Nervous System (CNS), particularly for neurodegenerative diseases, is one of the major challenges of modern biomedical research. Although great advances have been made in understanding the biological basis of neurological disorders, this scientific progress has not yet been translated into effective new treatments for these devastating disorders. This application proposes to exploit recently developed disease models in the fruit fly Drosophila melanogaster to develop a new and innovative method of small molecule drug discovery that is articularly well suited for CNS diseases. We propose to use automated procedures to screen well-validated disease models of two trinucleotide repeat disorders, Huntington's disease and spinocerebellar ataxia type I, for compounds that improve motor function. In Phase I of this project, we will use an automated screening system to develop and validate disease-specific assays, and establish by proof-of-principle experiments that the system can provide high-throughput assays that are rapid, reproducible, and highly sensitive to improved motor function in the two disease models. In Phase II, we will use this system to carry out a moderately large-scale screen (12,000 compounds) against both disorders and will begin a characterization of the "hits" that we obtain in both Drosophila and mouse disease models. The proposed project has two important outcomes. The first is to validate a method of drug discovery by in vivo screening of disease models that can be used not only for further screening for these two diseases, but also as a more general method for neurological and behavioral disorders. The second is the discovery of new bioactive compounds that can ameliorate these diseases in Drosophila, and are thus suitable lead candidates for further preclinical and clinical development in mammals, and ultimately in humans. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: ACTIVATION OF STRESS RESPONSE IN NEURODEGENERATION Principal Investigator & Institution: Sagara, Yutaka; Neurosciences; University of California San Diego 9500 Gilman Dr, Dept. 0934 La Jolla, Ca 92093 Timing: Fiscal Year 2001; Project Start 30-SEP-2001; Project End 31-JUL-2004 Summary: (Applicant s abstract) The deleterious effects of age-related neurodegenerative diseases are not only felt at the personal level but also as an everincreasing financial burden on the national healthcare system. However, there is no cure or a preventive treatment currently available for neurodegenerative diseases such as Alzheimer's disease (AD). Elucidation of the mechanisms underlying selective neuronal death observed in AD may help conceptualize a new treatment or a therapeutic approach. Oxidative stress, though a culprit of neuronal death observed in AD and other neurodegenerative diseases, may also activate a survival response by regulating a subset of proteins and genes, resulting in selective protection of neurons. Characterization of such a survival response, therefore, is an important step toward prevention of neuronal death as well as promotion of neuronal survival. The central hypothesis of this proposal is that the activation of the signal transduction cascade involving phosphatidylinositol 3-OH kinases (PI3K) confers resistance to oxidative injury caused by amyloid beta (ABI-42), while the down regulation of this pathway by chronic exposure to AB results in neurodegeneration. In this context, the main objectives of this project is to define the role of PI3K cascade in neurodegeneration observed in AD by investigating the effects of AB on PI3K in a comprehensive multi-system which includes human brains with AD, APP transgenic mice, and neuronal cell cultures. During the course of the proposal, the applicant will receive additional training in clinical aspects of neuroscience such as neuropathology in the context of AD
8
Huntington’s Disease
neurodegeneration. Also, with the aid of the sponsor and consultants, the applicant will obtain training in the transgenic mouse models, which can be used to test the above hypothesis as well as to develop therapies for treatment of age-related neurological disorders. Finally, the award will assist the applicant to become an independent faculty member actively involved in research in age-related neuro-degeneration as well as in teaching at a biomedical research institution such as UCSD. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: ACTIVITY-DEPENDENT REGULATION OF SYNAPSES BY SHANK Principal Investigator & Institution: Hung, Albert Y.; Massachusetts General Hospital 55 Fruit St Boston, Ma 02114 Timing: Fiscal Year 2001; Project Start 01-AUG-2001; Project End 31-JUL-2006 Summary: (provided by applicant): The goal of this project is to investigate the role of a newly discovered postsynaptic protein, Shank, in the regulation of dendritic spine morphology and cytoskeleton. Local electrical stimulation induces growth of dendritic spines, suggesting that synaptic activity directly modulates neuronal architecture and circuitry. The molecular basis for these activitydependent changes is not known, but probably involves postsynaptic proteins that interact with receptors and/or cytoskeletal elements. Shank acts as a putative scaffold for multiple glutamate receptor subtypes and also binds to the actinbinding protein cortactin, which has been implicated in dynamic cytoskeletal rearrangement and translocates to synapses in response to glutamate. This study examines the role of Shank in the regulation of dendritic spines and its in vivo function through three specific aims. First a combination of cell biological, biochemical, and dominant inhibitory approaches will be used to determine the mechanism for glutamateregulated cortactin translocation to synapses, and to identify if Shankcortactin interaction is required for this response. Second, how Shank induces spine growth will be studied by structurefunction analysis. Finally, a genetic approach, generation of a Shank1 "knockout" mouse, will be used to investigate the role of Shank proteins in brain development, in postsynaptic receptor organization, and in learning and memory. The longterm goal of the candidate is to understand how aberrant synaptic transmission contributes to neurologic disease. Synapses are the signal processing units of the brain, and overexcitation of synapses by glutamate is thought to play a role in both acute neuronal injury (such as stroke and seizure) and chronic neurodegenerative conditions (including Huntington's disease, Parkinson's disease, and amyotrophic lateral sclerosis). Understanding how postsynaptic proteins, such as Shank, regulate activitydependent synaptic plasticity may shed light on mechanisms of glutamate toxicity. The immediate goal is to obtain training in the most uptodate techniques in molecular genetics, protein biochemistry, and cellular neurobiology, sponsored by Dr. Morgan Sheng, which will enable him to become a productive, independent molecular neurologist. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
•
Project Title: ANALYSIS OF TORSIN PROTEIN FUNCTION IN C. ELEGANS Principal Investigator & Institution: Caldwell, Guy A.; Biological Sciences; University of Alabama in Tuscaloosa Tuscaloosa, Al 35487 Timing: Fiscal Year 2003; Project Start 01-FEB-2003; Project End 31-JAN-2006 Summary: (provided by applicant): Dystonia is estimated to be six times more prevalent than Huntington's Disease, ALS, or Muscular Dystrophy. However, as few as 5% of the over 350,000 persons in North America estimated to be affected have been correctly
Studies
9
diagnosed and are under treatment (NIH Budget Office). The most severe early-onset form of this disorder has been linked to a mutation in a human gene named TOR1A that encodes torsinA, a protein that is also localized to inclusions in the brains of Parkinson's patients termed Lewy bodies. While a causative genetic mutation has been identified, the cellular mechanisms of pathogenesis underlying dystonia remain unknown. We are applying the advantages of the model organism, Caenorhabditis elegans, towards a detailed analysis of two specific torsin-related gene products in this nematode. The chromosomal positioning of these genes suggests that they may represent a functionally co-expressed unit and preliminary studies from our laboratory indicate they act neuronally. Phylogenetic analysis of the torsin family indicates these proteins share distant sequence similarity with the functionally diverse AAA+ family of proteins. We have determined that ectopic overexpression of a C. elegans torsin homolog results in a reduction of polyglutamine repeat-induced protein aggregation in a manner similar to that previously reported for molecular chaperones. The suppressive effects of torsin overexpression quantitatively persisted as animals aged. Antibody staining of transgenic animals using antisera specific to TOR-2 indicated this protein was highly localized to sites of protein aggregation. We propose to extend these preliminary studies through a combination of reverse genetic approaches designed to investigate the cellular role of torsin proteins in the nematode. The specific aims of the proposed project include: 1) to determine what phenotypes are associated with C. elegans torsin homologues; 2) to define sites of C. elegans torsin protein function; and 3) to determine potential effectors of torsin activity. These studies will further our understanding of the molecular mechanisms responsible for early-onset torsion dystonia. Moreover, the aberrant protein deposition associated with diverse neurodegenerative disorders like Parkinson's Disease and those caused by polyglutamine expansion such as Huntington's Disease warrants further investigation of any putative neuroprotective effects of torsins. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: AUTOMATED BRAIN PARCELLATION AND MORPHOMETRY Principal Investigator & Institution: Halgren, Eric; President; Cortechs Labs, Inc. Charlestown, Ma 02129 Timing: Fiscal Year 2002; Project Start 15-JUN-2002; Project End 31-DEC-2002 Summary: Non-invasive visualization of the living human brain with MRI (magnetic resonance imaging) is an essential part of clinical neurology. Until now, evaluation of structural changes in diseases have mainly relied upon qualitative visual judgements, or tedious hand labeling. This project aims to develop MRI image processing software that will automatically segment the entire brain volume into its constituent tissues and structures. This segmentation allows quantification of tissue volumes and intrinsic parameters. The software will be interoperable with our suite of structural and functional MRI software tools, allowing, for example, subcortical regions of interest to be examined for functional activation. We propose to base the tissue segmentation of intrinsic properties of brain tissue, thus rendering it independent of pulse sequence or scanner manufacturer. This will greatly increase scan/rescan reliability which is crucial for multi-site clinical trials, or for within-subject repeated measures (e.g., comparing tumors or multiple sclerosis plaques over time). The proposed software will allow MRI data to be used to detect neuropsychiatric disease monitor the course of such diseases, and evaluate the effectiveness of treatments. Research and clinical applications can be expected in several neurodegenerative and psychiatric diseases such as schizophrenia, Alzheimer's and Huntington's disease. PROPOSED COMMERCIAL APPLICATIONS:
10
Huntington’s Disease
The proposed product would be of interest to researchers and clinicians using MRI, i.e., >10000 scanners worldwide. The proposed software could become a standard part of many brain MRI scans, in order to detect and quantify pathology, and thus could potentially be used in a substantial proportion of the millions of brain scans performed every year. Initially, the software would be used to perform surrogate markers of CNS effectiveness in drug evaluation. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: BEHAVIORAL ASSESSMENT OF HUNTINGTON'S DISEASE Principal Investigator & Institution: Bazzett, Terence J.; Psychology; College at Geneseo 1 College Cir Geneseo, Ny 14454 Timing: Fiscal Year 2002; Project Start 01-JAN-2002; Project End 31-DEC-2005 Summary: (provided by applicant): Huntington's disease (HD) is a devastating neurodegenerative disease that manifests initially as motor and cognitive dysfunction followed by a relentlessly chronic progression of symptoms culminating in death. The cause of HD is a genetic aberration on the short arm of the 4th chromosome identified as an expansion of a CAG trinucleotide repeat. Molecular biologists have very recently begun developing genetically altered mice, designed to mimic the expanded CAG repeat in HD. Technology advances have created a unique situation whereby development of new lines of mice has outpaced careful behavioral analysis of phenotypes. As a result, numerous models have been created without a clear understanding of how genetic differences affect phenotype differences. Perhaps more importantly, there is currently no consensus on what features of these models best mimic features of the disease they represent. Lacking a clear understanding of behavioral deficits vastly reduces the usefulness of any genetic model designed to mimic a disease that manifests with profound behavioral symptoms. The current proposal is a series of experiments designed to undertake detailed assessment of motor abnormalities and some cognitive dysfunction in mouse models of HD. In particular abnormalities in coordinated limb movements will be assessed beginning at a relatively early age. The first aim is to conduct experiments in a model currently known to express other gross behavioral abnormalities later in development. Once methods for assessing early subtle motor/cognitive deficits are established, the second aim is to assess genetically more appropriate models that reportedly express few gross behavioral abnormalities. The long-term objective will be initiated in the third aim where potentially therapeutic drugs will be assessed. Drug therapies that attenuate early/subtle deficits in mice may be useful in treating HD. Such therapeutic potential may not be recognized using current methods that assess only major dysfunction expressed late in development. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
•
Project Title: BEOWULF LINUX CLUSTER COMPUTER Principal Investigator & Institution: Destefano, Anita L.; Neurology; Boston University Medical Campus 715 Albany St, 560 Boston, Ma 02118 Timing: Fiscal Year 2003; Project Start 01-JUN-2003; Project End 31-MAY-2004 Summary: (provided by applicant): A major goal of the human genome initiative is to access genetic information to understand and to prevent and/or treat human disease. The recently completed "draft" sequencing of the human genome and the recent advances in biotechnology that allow rapid throughput of samples for genotyping have created a vast resource of information. However, the challenge to dissect the genetic and
Studies
11
environmental factors influencing susceptibility for common diseases remains statistically complex and computationally intensive. The genetic epidemiologists and statistical geneticists at the Boston University Medical Campus have a long history of success in identifying genes associated with risk for both simple Mendelian diseases as well as complex traits. In order to continue this success and to implement the most recent advances in statistical genetics, we are requesting, a Beowulf class LINUX cluster of 192 Intel processors. This computing system will be dedicated to genetic analysis including linkage analyses and association testing. The system will support the research of 14 NIH funded projects. Although the phenotypes and study populations differ widely among the funded projects of the major users, there is substantial overlap in the computationally intensive genetic analysis techniques that will be performed on this system. This cluster will enable computation of identity by decent relationships in extended pedigrees, computation of empirical p-values via simulation, and application of complex gene by gene and gene by environment interaction models. There is strong institutional support for this system evidenced by the administration's commitment to funding a full time systems administrator and long term support of upgrades and maintenance The placement of this computing resource among the investigators of this proposal will have a broad impact in the field of genetics and further our understanding of the genetics of Huntington's Disease, Alzheimer's Disease, Obesity, Stroke and Hemostatic Factors, Cognitive Decline, Hypertension, Cardiovascular traits, and Cocaine and Opioid Dependency among others. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: BIOENERGETICS IN ANIMAL MODELS OF HUNTINGTON'S DISEASE Principal Investigator & Institution: Beal, M Flint.; Professor; Neurology and Neuroscience; Weill Medical College of Cornell Univ New York, Ny 10021 Timing: Fiscal Year 2003; Project Start 15-APR-1999; Project End 31-MAR-2008 Summary: (provided by applicant): The pathogenesis of Huntington's Disease (HD) is as yet unknown but there is substantial evidence that both altered gene transcription as well as mitochondrial dysfunction play an important role. There is evidence that huntingtin binds to transcription factors which results in decreased expression of genes which may play a critical role in neuronal survival. A secondary consequence of this appears to be impaired oxidative phosphorylation and increased generation of reactive oxygen species. In our prior grant, we showed that there was impaired oxidative phosphorylation in transgenic mouse models of Huntington's disease, and that this was associated with increased oxidative damage. We also showed that agents such as creatine and coenzyme Q, which improve cellular bioenergetics, exert neuroprotective effects in transgenic mouse models of Huntington's disease. In the present proposal, we intend to extend these studies to two further unique transgenic mouse models of Huntington's disease. We will determine whether there is mitochondrial dysfunction and oxidative damage in a knock-in mouse model developed by MacDonald and colleagues. These mice are a very accurate genetic model of Huntington's disease. We will also examine the tetracycline-off model developed by Yamamoto and colleagues to determine whether there is mitochondrial dysfunction and oxidative damage with the gene turned on, which then resolves once the gone is turned off. We will carry out similar studies with an inducible cell culture model. We will investigate whether histone deacetylase (HDAC) inhibitors exert neuroprotective effects by altering gene transcription in transgenic mouse models of Huntington's disease. We will examine whether a phosphodiesterase IV inhibitor can exert neuroprotective effects in transgenic
12
Huntington’s Disease
mouse models of HD by increasing cyclic AMP levels, leading to increased CREB transcriptional activity, and whether this improves mitochondrial function. Our prior studies showed that combinations of agents, which target different disease mechanisms in Huntington's disease, may exert additive neuroprotective effects. We will, therefore, examine whether a combination of creatine or coenzyme Q with either a HDAC inhibitor or a phosphodiesterase IV inhibitor can exert additive neuroprotective effects. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: CELL GROWTH AND DIFFERENTIATION IN THE VERTEBRATE EMBRYO Principal Investigator & Institution: Lacy, Elizabeth H.; Professor; Sloan-Kettering Institute for Cancer Res New York, Ny 10021 Timing: Fiscal Year 2001; Project Start 01-JAN-1999; Project End 31-DEC-2001 Summary: (Adapted from the Investigator's Abstract): Gastrulation is a fundamental developmental process, and in the mouse it coordinates complex cell and tissue movements with cell growth and proliferation to reorganize and differentiate the embryonic ectoderm into the definitive ectoderm, mesoderm, and endoderm germ layers of the fetus. The genetic pathways directing gastrulation are only beginning to be unraveled by both targeted and random mutagenesis in the mouse and fish. Intriguingly, a number of gastrulation stage mouse mutants have been discovered through the targeted disruption of genes that are known, through their involvement with human disease, to participate in the basic cellular processes of proliferation, differentiation, and signal transduction. Recent examples include the fibroblast growth factor receptor (Fgfr-1), Brca1, Brca2, Huntington's disease homologue (Hdh), and the tumor suppressor Smad4/Dpc4. Thus the study of novel gastrulation stage mouse mutants is likely to lead to the identification of genes that serve pivotal functions in the coordination of cell growth, proliferation, and differentiation. The subject of this proposal is amnionless (amn), a recessive transgene insertional mutation that disrupts the assembly of the middle streak, this portion of the primitive streak that gives rise to non-axial embryonic mesoderm, such as somitic mesoderm. This novel phenotype reveals that the formation of the middle streak is mediated by a previously unknown pathway, one that is genetically separable from those directing the formation and specification of the proximal and distal streak regions. Therefore, a disrupted gene at the amn locus must play a key role in this pathway. Chimera analyses have shown that this gene, the amn gene, functions in the visceral endoderm to direct the formation of the middle streak and thus, that amn defines a new role for the visceral endoderm during gastrulation. The primary objective of this proposal is to positionally clone the amn gene. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
•
Project Title: CELLULAR PATHOGENIC MECHANISMS IN HUNTINGTON'S DISEASE Principal Investigator & Institution: Tobin, Allan J.; Professor and Director; Brain Research Institute; University of California Los Angeles 10920 Wilshire Blvd., Suite 1200 Los Angeles, Ca 90024 Timing: Fiscal Year 2001; Project Start 25-JAN-2001; Project End 31-DEC-2004 Summary: Huntington's disease is a devastating neurodegenerative disease that is inherited as an autosomal dominant. Disease-causing alleles encode expanded polyglutamine tracts in the aminoterminal region of huntingtin (htt), a large protein
Studies
13
whose normal function is unknown. The unifying hypothesis in this proposal is that htt containing an expanded polyglutamine tract (htt-ex) causes proteasome poisoning by irreversibly blocking proteasomes. We argue that poisoned proteasomes in postmitotic neurons results in a failure of normal protein turnover and in cell dysfunction and death. Wild-type htt (htt-wt should not produce such effect. The proposed studies will consider not only the poisoned- proteasome hypothesis but also alternative hypotheses, in which the pathogenic action of htt-ex does not depend on proteasomes. We have organized these studies around three Specific Aims: 1. To determine whether the intracellular distribution and the pathogenic effects of htt-ex expression vary with cell type and proliferative state. 2. To examine the effect of htt-ex expression on proteasome function and on the turnover of specific proteins, including htt itself. 3. To examine the effects of htt-ex expression on neuronal function and to determine whether known proteasome inhibitors can mimic these effects. At the conclusion of these three sets of proposed experiments we will know 1) whether proteasome location and function change in response to cell cycle and htt expression; (2) whether htt affects proteasome function and protein turnover either directly or indirectly; (3) whether htt-ex alters cellular function in dividing and stationary, differentiated cells; and (4) whether proteasome inhibitors mimic htt-ex-induced changes in neuronal function. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: CENTER FOR GENE-ENVIRONMENT STUDIES IN PARKINSON DISEASE Principal Investigator & Institution: Chesselet, Marie-Francoise S.; Charles H. Markham Professor of Neurolog; Brain Research Institute; University of California Los Angeles 10920 Wilshire Blvd., Suite 1200 Los Angeles, Ca 90024 Timing: Fiscal Year 2002; Project Start 26-AUG-2002; Project End 31-JUL-2007 Summary: The Center for Gene-Environment studies in Parkinson disease at UCLA (UCLA-CGEP) will bridge three major NIH and VA-supported awards in Parkinson's disease (PD) and one NIH-sponsored study of Huntington's disease. The central hypothesis of the proposed UCLA-CGEP is that gene and environmental toxins combine to increase the risk for PD in susceptible individuals through an interplay between pesticides and mechanisms regulating dopamine homeostasis. We postulate that critical factors in this interaction are oxidative stress and resulting alterations in proteasomal function. Project I "Environmental toxins and genes that influence dopamine in Drosophila and humans" will examine interindividual variability of dopamine vesicular transporter (VMAT) expression due to promoter variants in two human populations in parallel with a reporter gene assay. These populations will be genotyped for functional VMAT2 variants and association analyses of gene-environment interactions and pesticide exposures collected in the parent grant will be conducted. In addition, Drosophila genetics will be used to determine how the expression of VMAT affects dopamine-mediated toxicity and identify genes that modulate VMAT function, which will then be examined in the human population for their relevance to increased risk of PD. Project II "Interaction between pesticides and genetic alterations in dopamine homeostasis in mice" will test the hypothesis that pesticides and genetic variations in combination increase the vulnerability of dopaminergic neurons, and that one of the mechanisms involved is oxidative stress. Genetically engineered mice with a reduction in expression of VMAT or the cytoplasmic dopamine transporters, and mice with altered expression of alpha-synuclein and parkin, two proteins known to cause familial PD, will be examined. Behavior and quantitative anatomy will be used to assess the effect of pesticides on dopaminergic neurons in these genetically altered mice.
14
Huntington’s Disease
Histology, gene expression profiling, in vivo neurochemistry and slice electrophysiology will be used to examine the role of oxidative stress in this interaction. Project III, "Pesticides and Proteasomal Dysfunction: genetic susceptibility in cellular models" will test the hypothesis that proteasomal dysfunction is central to the deleterious effects of the combined environmental and genetic insults. Cell lines, primary neuronal cultures from genetically altered mice, and human lymphoblasts will be examined. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: CEREBRAL NEURODEGENERATION
MITOCHONDRIAL
METABOLISM
IN
Principal Investigator & Institution: Powers, William J.; Associate Professor; Neurology; Washington University Lindell and Skinker Blvd St. Louis, Mo 63130 Timing: Fiscal Year 2001; Project Start 15-JUN-2001; Project End 31-MAY-2005 Summary: (Adapted from the abstract provided by the applicant): Several lines of evidence suggest that Huntington's disease (HD) and Parkinson's disease (PD) have defects in mitochondrial function that impair oxidative phosphorylation and play a key role in the mechanism of neuronal death. To date, however, there have been no direct measurements of cerebral oxygen to glucose metabolic ratios to demonstrate an in vivo defect in cerebral mitochondrial metabolism in these diseases. We will use positron emission tomography (PET) to measure in vivo regional cerebral oxygen metabolism (CMR02) and cerebral glucose metabolism (CMRglc) to test two primary hypotheses: 1) Patients with HD have a generalized defect in cerebral mitochondrial metabolism. To test this hypothesis, we will measure whole brain CMR02/CMRgIc in 15 gene-positive pre-symptomatic patients with HD, 15 gene-positive patients with HD and definite motor signs and 30 age/gender-matched normal controls. 2) Patients with PD have a generalized defect in cerebral mitochondrial metabolism. To test this hypothesis, we will measure whole brain CMR02/CMRgIc in 15 never-medicated, early PD patients and 15 age/gender-matched normal controls. In the same subjects, we also will test two secondary hypotheses: 3) Regions vulnerable to pathologic insult have larger magnitude or selective defects in cerebral mitochodrial metabolism - caudate and putamen in HD and substantia nigra and putamen in PD. 4) In PD and HD, the degree of dysfunction in platelet electron transport complex function measured in vitro correlates with the degree of abnormal cerebral mitochondrial metabolism measured in vivo. At this time it is not clear how the abnormalities in electron transport chain activity measured in vitro in these two diseases correspond to cerebral mitochondrial metabolism in vivo. Direct in vivo regional PET measurements of CMR02 and CMRglc will allow us to demonstrate the extent and magnitude of mitochondrial dysfunction in vivo. Establishing the existence of cerebral mitochondrial dysfunction early in the course of these diseases will not only provide insights into the pathogenesis, but it will provide a measurable biological abnormality that can be monitored to determine the effect of treatments aimed at slowing or halting the progression of neuronal loss. The opportunity to determine the relation between platelet mitochondrial function and cerebral mitochondrial metabolism in patients with PD and HD is uniquely important. If such a relationship can be established in untreated patients in this study, then we would pursue further studies to determine the effects on cerebral mitochondrial metabolism of agents that alter platelet mitochondrial function. If such studies yield consistent results, they will establish the basis for the utilization of platelet rnitochondrial function assays to monitor cerebral mitochondrial metabolism. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
Studies
•
15
Project Title: CHEMICAL MODELS OF PROTEIN BETA SHEET INTERACTIONS Principal Investigator & Institution: Nowick, James S.; Professor; Chemistry; University of California Irvine Irvine, Ca 926977600 Timing: Fiscal Year 2001; Project Start 01-APR-1994; Project End 31-MAR-2003 Summary: beta-Sheet interactions between proteins play a critical role in many biological processes associated with diseases and with normal function. Examples including the binding of Ras and Rap by the serine/threonine kinase Raf in cell signaling and oncogene expression, the dimerization of HIV protease, and the interaction between the CD4 receptor and the HIV viral protein gp120. beta-Sheet formation is also involved in the aggregation of peptides and proteins to form insoluble beta-sheet structures that are associated with a variety of devastating neurological disorders, including Alzheimer's disease, Creutzfeld-Jacob disease and other prion diseases, and Huntington's disease. This proposal seeks to mimic and to disrupt betasheet interactions by using chemical model systems called "artificial beta-sheets." The broad, long-term objectives of this research encompass both the development of drugs for diseases involving beta-sheet formation between proteins (e.g., cancer, Huntington's disease, and Alzheimer's disease) and the development for general strategies for creating compounds that disrupt beta-sheet interactions. The specific aims are as follows: (1) Artificial beta-sheet structures based upon the beta-sheet at the interface of the two halves of the met repressor dimer will be synthesized dimer will be synthesized, and their structures will be studied by NMR and CD spectroscopy. (2) An artificial betasheet designed to mimic the protein G binding region of the Fab portion of the immunoglobulin G will be synthesized, and its interaction with domain III of protein G will be studied by NMR spectroscopy. (3) An artificial beta sheet designed to mimic the beta-sheet interface between Ras proteins and the c-Rafl kinase (Raf) and artificial betasheets that mimic the binding regions of Ras and Raf will be synthesized. Their structures and interactions will be studied by CD and NMR spectroscopy, and the latter two compounds will be evaluated for anti-cancer activity by the NCI using an in vitro 60 human tumor cell line screen. (4) Artificial beta-sheets designed to mimic polyglutamine beta-sheet aggregates, which are involved in Huntington's disease and other genetic neurodegenerative diseases will be synthesized. Their structures will be studied by CD and NMR spectroscopy, and their ability to block polyglutamine beta-sheet aggregation will be determined using an in vitro assay. (5) Artificial beta-sheets designed to block beta-amyloid aggregation will be synthesized, and their abilities to block its aggregation and deposition will be studied using in vitro assays. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
•
Project Title: CHROMATIN REMODELING IN TRANSGENIC MOUSE MODELS OF HD Principal Investigator & Institution: Cha, Jang-Ho J.; Massachusetts General Hospital 55 Fruit St Boston, Ma 02114 Timing: Fiscal Year 2003; Project Start 15-APR-2003; Project End 31-MAR-2008 Summary: Huntington's disease is an autosomal dominant neurodegenerative disease for which there is currently no effective treatment. Although a number of pathogenic mechanisms have been proposed, transcriptional dysregulation has emerged as a potential critical aspect. In transgenic mouse models of HD, numerous alterations in the steady state levels of mRNA have been described. However, the mechanisms underlying mRNA perturbation are undefined. Elucidation of such mechanisms will have significant relevance to the understanding and development of future treatment of
16
Huntington’s Disease
HD. In eukaryotes, gene expression is regulated through modification of chromatin and association with specific transcription factors. While alteration of steady state mRNA levels in transgenic HD mouse (R6/2) brain is de facto evidence of transcriptional dysregulation, it is yet unknown whether there are specific alterations in chromatin structure. In this project, we will explore chromatin remodeling in a transgenic HD mouse model. First, we will determine if mithramycin--an aureolic antibiotic that binds to GC-rich regions of DNA and which has been shown to extend lifespan in R6/2 mice-corrects mRNA expression abnormalities that we have previously described in these mice. We will use receptor binding autoradiography and in situ hybridization to perform these analyses. Next, we will seek to determine the role of a fatnily of transcription factors, the Sp family, with a set of genes whose expression is known to be altered in R6/2 mice. We will explore the interactions of Sp and related zinc finger transcription factors by using Chromatin ImmunoPrecipitation (CHIP) assays with realtime PCR detection. Finally, we will explore the ability of mithramycin to reverse chromatin abnormalities in the R6/2 mice. Taken together, these experiments will elucidate the molecular mechanisms underlying transcriptional dysregulation in a model of Huntington's disease. Such elucidation of a central pathogenic mechanism will open the way towards rational, mechanism-targeted therapy for this devastating disease. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: DISEASES
COMPARATIVE
MODELING
OF
NEURODEGENERATIVE
Principal Investigator & Institution: Link, Christopher D.; Inst of Behavioral Genetics; University of Colorado at Boulder Boulder, Co 80309 Timing: Fiscal Year 2003; Project Start 01-JUN-2003; Project End 31-MAY-2007 Summary: (provided by applicant): Numerous age-associated neurodegenerative diseases [e.g., Alzheimer's disease (AD), Parkinson's disease (PD), Amyotrophic Lateral Sclerosis (ALS), Huntington's disease (HD), etc.] are associated with aggregation of disease-specific proteins. The finding that the genes encoding these proteins are mutated in some familial forms of these diseases strongly argues that these aggregating proteins cause these diseases. However, for all these diseases the relationship between protein aggregation and cellular pathology has not been clearly established. It is also unknown if the common association of protein aggregation with these diseases reflects a common underlying toxic mechanism, or, alternatively, a common downstream result of cell pathology. We will seek to identify the molecular consequences resulting from the aggregation of three different disease-associated proteins by individually expressing these proteins in a transgenic Caenorhabditis elegans model system. These molecular consequences will be determined by DNA microarray-based gene expression studies and co-immunoprecipitation analyses. Comparison of the molecular responses to expression of different disease-associated proteins will allow identification of common and disease-specific responses. We will then use the molecular genetic tools available in C. elegans to manipulate these molecular responses to determine their role in disease protein toxicity. These studies will directly test whether there is a common underlying toxic mechanism for these neurodegenerative diseases. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
Studies
•
17
Project Title: COMPUTATIONAL ANALYSIS OF HUMAN 'AT-RISK' DNA MOTIFS Principal Investigator & Institution: Stenger, Judith E.; Assistant Professor; Medicine; Duke University Durham, Nc 27706 Timing: Fiscal Year 2001; Project Start 01-JUN-2001; Project End 31-MAY-2005 Summary: (Taken from the Candidate's Abstract) At-Risk DNA Motifs (ARMS), which include repetitive elements such as Alu sequences, homonucleotide runs and triplet repeats, are potentially unstable segments of the human genome. ARMS are a factor in genetic susceptibility to disease, requiring particular combinations of genetic backgrounds and environmental triggers to express a disease phenotype. While some of the mechanisms are understood, it is not clear under what circumstances repetitive DNA elements mediate pathological mutagenesis. Although a high burden of these sequences is generally tolerated in humans, they can have an enormous impact on health by contributing to diseases that have devastating effects on afflicted individuals. For example, Alus have been linked to numerous diseases including Fanconi anemia, alphazerothalassemia, leukemia, hypertension, neurofibromatosis, breast, and colon cancers. Trinucleotide repeat expansions have been linked with Kennedy's Disease, Huntington's Disease, myotonic muscular dystrophy, and Friedreich ataxia. The long term objective of this proposal is to gain insight into the genetic factors that mitigate gene rearrangement in hopes of predicting when the presence of a repetitive element truly constitutes a threat to the health of an individual. The hypothesis is that the characterization of ARMS according to all possible attributes (i.e. size of repeats, separation distances between repeats, orientation, sequence similarity between repeats, nucleotide base constitution and proximity and/or containment of mutagenic and/or toxicological agent targets, DNA processive or other enzymatic target sites) can reveal largely excluded situations that can be viewed as unstable. It is also postulated that a multidimensional database of repetitive sequences characterized according to the aforementioned attributes can be used to predict repetitive elements that are most prone to mutation, ARMS, while increasing our understanding of the interactions between these genetic elements and their environment. The approach is to use a combination of computational biology and molecular genomic analysis to locate and analyze ARMS. The specific aims of this proposal are to: 1) characterize available data according to the conceivable relevant attributes of size, distance, orientation, degree of homology, base constitution and containment of known target sequences. 2) To test the hypothesis by computationally identifying loci that have already known to contain ARMS linked to a mutation resulting in disease, and then to identify specific genes that may be at-risk for mutation and experimentally testing them using molecular biological approaches. 3) To set up an interactive on-line database and program server so that the scientific community can use the information and apply it to drive experimental research. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
•
Project Title: CORE--GENE EXPRESSION PROFILING Principal Investigator & Institution: Luthi-Carter, Ruth; Massachusetts General Hospital 55 Fruit St Boston, Ma 02114 Timing: Fiscal Year 2003; Project Start 15-APR-2003; Project End 31-MAR-2008 Summary: Extensive genome sequencing efforts and advances in microarray technology have converged to create revolutionary new opportunities for high-throughput analyses of gene expression. Within the context of the Program, gene expression analyses will provide information critical to elucidating the mechanisms by which huntingtin and
18
Huntington’s Disease
DNA-binding therapeutic agents alter gene expression. The Gene Expression Profiling Core will support the Program's individual Projects by tracking the expression of thousands of mRNAs simultaneously in the respective experimental systems, thereby identifying the specific gene targets of a given pathological or pharmacologic manipulation. Identifying the gene promoters subject to a particular effect will allow the promoter elements and transcription factor(s) responsible for the change to be elucidated. The Gene Expression Core will provide expertise in the design, execution and analysis of microarray profiling studies and will carry out confirmatory analyses using independent methodologies, such as northern blotting. The Principal Investigator of the Core has extensive experience in microarray based expression analyses, including several previous studies of mouse models of polyglutamine disease. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: DEPRESSION IN HUNTINGTON'S DISEASE Principal Investigator & Institution: Nehl, Carissa R.; Psychiatry; University of Iowa Iowa City, Ia 52242 Timing: Fiscal Year 2002; Project Start 06-SEP-2002; Project End 31-JUL-2006 Summary: (provided by applicant): The proposed study will examine depression in presymptomatic Huntington's disease (HD). Presymptomatic individuals will be recruited through the NIH-funded PREDICT-HD study. This training proposal consists of two distinct stages. During the first stage, data collected during the PREDICT-HD study will be analyzed. The relationship between reported depression symptom severity, approximate nearness to disease onset, verbal memory, working memory, and visuospatial ability will be assessed. Additional information will be collected during the second stage of this proposal: a subgroup of individuals participating in PREDICT-HD will be assessed for mood disorders using the SCID and will complete a measure of relationship distress. This study will assess the relationship between mood disorders, nearness to disease onset, relationship distress, working, memory, and visuospatial ability. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
•
Project Title: DOES CORTEX KILL STRIATUM IN HD? Principal Investigator & Institution: Meade, Christopher A.; Anatomy and Neurobiology; University of Tennessee Health Sci Ctr Health Science Center Memphis, Tn 38163 Timing: Fiscal Year 2003; Project Start 01-JUN-2003; Project End 31-MAY-2005 Summary: (provided by applicant): An important question in Huntington's disease (HD) pathogenesis is whether mutant huntingtin (Ht) effects striatal cell death directly by perturbing striatal cell fL motion or whether it alters areas outside the striatum (notably cortex) that influence the striatum, leading indirectly to striatal cell death. This could be studied by examining the effect of a 100% mutant cortex on a 100% wild-type (VVT) striatum, and vice versa. We propose to develop a novel model system, creating in oculo co-transplants of mixed genotypic pairings, using embryonic HD mutant mouse and WT tissue, of cortex and striatum. Our studies will develop the in oculo method to test the competing hypotheses: 1) that a cortical action of mutant Ht drives striatal injury, even in the absence of the HD mutation in striatum, 2) that striatal injury can occur in a mutant striatum, even in the presence of an input from a WT cortex or in the absence of any cortical input or 3) that striatal injury is driven by a combination of a cortical and striatal action of mutant Ht. In Aim 1 we will create in oculo co-transplants
Studies
19
using embryonic HD mutant cortical tissue and embryonic WT striatal tissue and look for signs of striatal cell injury as compared to co-transplants of WT cortex and WT striatum. If the hypothesis is correct, WT striatum wilt show increased signs of injury when co-transplanted with a HD mutant cortex. In Aim 2 we will create in oculo co transplants using embryonic WT cortical tissue and embryonic HD mutant striatal tissue and look for signs of striatal injury as compared to WT controls. If striatal injury depends on cortical input, but not mutant input per se, a HD mutant striatum will show signs of injury when co-transplanted with a WT cortex. Additionally, we will create single transplants of embryonic mutant striatum and look for signs of striatal injury. If striatal cell death is entirely cell autonomous, even in the absence of cortical input, striatal injury will occur in a HD mutant striatum, in Aim 3 we will create co-transplants using embryonic HD mutant cortex and embryonic HD mutant striatum and look for signs of striatal injury as compared to controls. This hypothesis predicts that striatal injury will only occur when an HD mutant cortex is co-transplanted with an HD mutant striatum or that it will be more severe than if only cortex or striatum is mutant. These studies will validate the in oculo technique as an effective HD model system, which might be useful in further testing hypotheses of mutant Ht mechanism of action and in testing possible drug therapies. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: DOPAMINERGIC MODULATION OF WORKING MEMORY IN PD Principal Investigator & Institution: Hershey, Tamara G.; Psychiatry; Washington University Lindell and Skinker Blvd St. Louis, Mo 63130 Timing: Fiscal Year 2001; Project Start 15-JUL-2001; Project End 31-MAY-2006 Summary: (provided by applicant): The applicant is a clinical neuropsychologist with graduate training in neuropsychology and postdoctoral training in neuropharmacology and positron emission tomography (PET). The goal of this career development award is to integrate and advance these two areas of interest to answer questions about the neuropharmacological and neurophysiological basis of cognitive dysfunction in movement disorders such as Parkinson's disease (PD). This award will provide the applicant with training in the technical and theoretical issues related to using cognitive and pharmacological activation techniques in functional magnetic resonance imaging (fMRI). Long-term objectives are to address questions about the neural basis of cognitive dysfunction in movement disorders related to dopaminergic and/or basal ganglia dysfunction, such as PD, Tourette's syndrome and Huntington's disease. In addition, questions about the effects of dopaminergic treatments for these and other disorders (e.g. dystonia) on cognitive and neurophysiological functioning are also of interest. Cognitive dysfunction in these diseases, either due to the disease process itself or its treatments, can be limiting and disabling. Understanding the neurophysiologic basis for these symptoms may aid in assessing the effectiveness of current treatments or in developing better treatments. During the award period, the applicant will develop expertise in the use of fMRI, cognitive and neuropharmacological techniques to study these disorders, and will continue to hone her clinical skills in the neuropsychological assessment of movement disorders. The applicant will apply these new techniques to investigate the role of dopamine in working memory. The specific aims of the proposed studies are to test the hypothesis that 1) PD affects prefrontal cortex involvement in working memory and 2) dopaminergic modulation of working memory primarily occurs due to changes in lateral prefrontal cortical activity. To test these hypotheses, the applicant will first perform a behavioral study examining the effects of a steady-state infusion of levodopa, a dopamine precursor, on verbal and spatial working memory in
20
Huntington’s Disease
PD patients and controls. The results of this study will then guide the choices of working memory tasks for an fMRl study. Subjects will be asked to perform working memory tasks before and during a steady-state infusion of levodopa. Modulation of the lateral prefrontal cortex is predicted during levodopa infusion. The degree of modulation is predicted to depend on baseline dopaminergic status (PD vs control) and the degree of memory load (low vs high). Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: EDUCATING PHYSICIANS ABOUT GENETICS AND BRAIN DISORDERS Principal Investigator & Institution: Tanner, T Bradley.; President; Clinical Tools, Inc. 431 W Franklin St, #30 Chapel Hill, Nc 27516 Timing: Fiscal Year 2001; Project Start 20-SEP-2001; Project End 31-MAR-2002 Summary: The expanding field of molecular genetics has quickly outpaced the knowledge of medical providers, due in part to the Human Genome Project. The genetics of brain illnesses are only beginning to be understood, nevertheless, providers treating patients with mental health, substance abuse and neurological disorders need to understand clearly what is and is not known about genetics and brain illnesses. It is likely that genetic aspects of schizophrenia, autism, mental retardation, bipolar disorder, among others, will be further identified in the near future, creating confusion and difficult choices for patients and families. Current and future providers must be prepared to explain and understand genetic susceptibility as it applies to a full range of illnesses. In Phase I, we will develop and evaluate an Internet-based CE program focusing on genetic issues related to alcoholism. We will also use the course the discuss upcoming technologies as well as issues related to discussing genetic risk with a patient. Phase II will produce 7 additional course on a variety of topic related to illnesses of the brain including Mixed Substance Abuse, Alzheimer's Disease, Schizophrenia, Affective Disorders, Attention Deficit, Huntington's Disease, and Mental Retardation. For each course we will highlight: 1) how genetic knowledge may affect patients and be used in clinical practice; 2) communication of genetic knowledge with patients and families: preparing for patients' questions; 3) where relevant, ethical, legal and psychosocial issues related to genetic testing, and 4) understanding emerging technologies and findings in genetics. A multidisciplinary team including representatives from psychiatry, genetics, genetic counseling, and primary care will create the content. We will evaluate the courses' effect on knowledge, clinical skills and self-efficacy using simple randomized studies comparing subjects using the genetics course to subjects using an online CE course on another topic. If successful, the training will expand the capabilities of the existing pool of providers and improve the training of future providers regarding the role of genetics in illnesses of the brain. PROPOSED COMMERCIAL APPLICATIONS: Physicians are required to obtain CME credit to maintain licensure and privileges. Managed care organizations (MCOs), such as large HMOs, may be interested in purchasing access to CE that can be offered to participant professionals. Pharmaceutical companies may also want to support development of courses based on the model described in this application. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
•
Project Title: EMBRYONIC STEM CELL MODEL OF POLYGLUTAMINE DISEASE Principal Investigator & Institution: Lorincz, Matthew T.; Neurology; University of Michigan at Ann Arbor 3003 South State, Room 1040 Ann Arbor, Mi 481091274
Studies
21
Timing: Fiscal Year 2003; Project Start 01-SEP-2003; Project End 31-AUG-2008 Summary: (provided by applicant): Huntington's disease (HD) is one of nine fatal neurodegenerative disorders without effective treatment or cure, caused by an expanded CAG/polyglutamine repeat. The roles of the normal and mutant HD gene product, huntingtin remain uncertain. The objective of the proposed Mentored Clinical Scientist Development Award is to explore huntingtin mediated neurodegeneration. We propose to evaluate the roles of transcriptional dysregulation and protein processing in HD by pursuing the following Specific Aims: Specific Aim 1: Define the role of the NMDA receptor subunit NR2B, CBP, histone acetylation, and BDNF in aberrant neurite outgrowth and decreased survival of embryonic stem (ES) cells with expanded CAG repeats. Specific Aim 2: Identify transcripts involved in expanded polyglutaminemediated transcriptional dysregulation. Specific Aim 3: Characterize the processing of polyglutamine containing proteins in undifferentiated and neuronally differentiated ES cells. We will pursue these Specific Aims utilizing an accurate, easily accessible, murine ES cell model. We find that neuronally differentiated ES cells with expanded CAG repeat domains develop features consistent with polyglutamine-mediated toxicity. Proposed experiments are expected to characterize full-length huntingtin protein processing and identify if the NMDA receptor subunit NR2B, CBP, histone acetylation, or BDNF are mediating neuronal dysfunction that precedes neurodegeneration in HD. Comparison of transcriptional profiles from neuronally differentiated ES cells with and without CAG repeats will be utilized to identify novel factors involved in HD pathogenesis. Once the pathologic mechanisms of mutant huntingtin are understood it will become possible to design rational therapeutics. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: EXPRESSION PROFILING FROM MICRODISSECTED SAMPLES Principal Investigator & Institution: Goldrick, Marianna M.; Senior Scientist; Ambion, Inc. 2130 Woodward St, #200 Austin, Tx 78746 Timing: Fiscal Year 2003; Project Start 01-FEB-2001; Project End 31-MAR-2005 Summary: (provided by applicant): One objective of the proposal is to develop a product line that will consist of amplified RNA (aRNA) derived from pure populations of cells from various regions of mouse brain. The target cells will be selected by Laser Capture Micro-dissection (LCM). The product line will include aRNA derived from normal mice and from mutant mice that serve as models of human neurodegenative disorders, including Alzheimer's disease, Huntington's disease, and ataxia telangiectasia. The product will be targeted to researchers carrying out expression profiling studies that aim to understand the molecular basis of normal neurological function and the molecular pathology of neurological disease. During the first year, efforts will be focused on scaling up procedures for sample processing, micro-dissection, and RNA isolation and amplification from normal mice. During the second year the procedures will be applied to the mutant strains. The aRNA will be produced using T7mediated in vitro transcription. In order to help meet the anticipated Production-scale goals, efforts will be directed to adapting the procedures, especially RNA amplification, to a robotic platform. In order to assess the RNA from micro-dissected samples for quality assurance purposes, molecular markers will be identified to use for verifying that the RNA is derived from the intended cell population. Efforts will also be directed to improving methods for identifying target cells for micro-dissection in samples such as tumors, where target cells (e.g. malignant cells) cannot always be distinguished by histological staining. The methods will be compatible with isolation of intact RNA from the selected cells, so that it can be amplified for use in microarray expression profiling
22
Huntington’s Disease
assays. To meet this goal we will develop rapid fluorescent detection methods using primary fluorescent antibodies directed to tumor antigens, and we will also adapt detection of target cells in transgenic animals expressing Green Fluorescent Protein for use with LCM. Achieving these goals will provide aRNA from distinct cellular subtypes to neuroscience researchers who do not currently have access to this resource. Use of aRNA from defined cell subtypes, as opposed to bulk tissue, will improve the ability to make biologically meaningful conclusions from expression profiling experiments carried out on highly heterogeneous tissues such as brain. Another goal of the project is to release a kit for recovery of high-quality total RNA from microdissected samples, especially those obtained by LCM. The kit will be of general use to life science researchers working with micro-scale samples. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: EXTRAPYRAMIDAL SYSTEMS Principal Investigator & Institution: Graybiel, Ann M.; Professor; Brain and Cognitive Sciences; Massachusetts Institute of Technology Cambridge, Ma 02139 Timing: Fiscal Year 2001; Project Start 01-JUL-1988; Project End 31-MAY-2002 Summary: (Investigator's Abstract): Dysfunctions of the basal ganglia have been implicated in extrapyramidal movement disorders such as Parkinson's disease and Huntington's disease, and the basal ganglia are abnormal in some neuropsyctuatric disorders as well. No clear idea has yet emerged, however, about what neural operations are performed in the basal ganglia. Strong evidence suggests that the functions of the basal ganglia must depend heavily on their cortical inputs, because the neocortex provides most of the inputs that the basal ganglia receive. These inputs enter mainly by way of corticostriatal projections to the striatum, and indirectly via the thalamus. The largest outputs of the basal ganglia in turn link these nuclei, through series of synaptic steps, to the motor, promotor and prefrontal cortex. The basal ganglia thus appear. to receive cortical input, process it under the influence of modulatory inputs (for example dopaminergic) and return it to the frontal lobes (and to some brainstem sites). We propose a coordinated series of experiments in monkeys and rats to study cortical-based ganglia linkages. Specifically, we propose to analyze in detail the sensorimotor cortical projections to the striatum. This sensorimotor system has significant advantages for study: the inputs are strong, they can be identified electrophysiologically by recording and microstimulation in the cortex, they can be mapped rigorously with sensitive tracer methods, and they thus can be analyzed in depth to permit stud of the map-transformations that occur between cortex and striatum. Much of the proposed work on this system (AIMS 1,2 and 4) is to be in squirrel monkey, in which we and others have found a distributed, catchy organization of inputs from primary somatosensory and motor cortex to the putamen. We will attempt to determine the rules of organization of these distributed and modular sensorimotor inputs. A series of studies is also proposed in the rat to attempt delineation of striatal cells activated by the sensorimotor cortex. In these experiments we propose (in AIM 3, with follow-up in the squirrel monkey in AIM 4) to use electrical and chemical stimulation of sensorimotor cortex to activate immediatearly genes in striatal neurons. The gene expression will be used as a cellular-level readout of neural ensembles activated by cortical input in the striatum and its output targets, and the pathways necessary for this activation will be determined. With these two complimentary techniques, our goal is to delineate the organization of corticostriatal sensorimotor maps in sufficient detail to gain insight into the functions of the striatum. The significance of this work is twofold. First, it may help uncover the neural substrates of focal and
Studies
23
somatotypically distributed banal ganglia movement disorders. Second, it should help identifying what transformations occur in cortical-basal ganglia loops. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: FUNCTIONAL NEUROANATOMY OF MOVEMENT DISORDERS Principal Investigator & Institution: Brown, Lucy L.; Associate Professor; Neurology; Yeshiva University 500 W 185Th St New York, Ny 10033 Timing: Fiscal Year 2002; Project Start 01-APR-1998; Project End 31-MAY-2007 Summary: (provided by applicant): Although the gene for Huntington's disease (HD) has been identified, the processes that lead to cell pathology and degeneration are still unclear. The proposed studies examine early pathology and pathophysiology in two transgenic mouse models of Huntington's disease. Our preliminary data in one mutant model, the reversible HD94 model, suggest that the chemoarchitecture of the striatum is altered in early symptomatic stages of the disease: there are more mu opioid receptorrich striosomes in mutants than in controls, which may lead to an imbalance of activity between the striosome and matrix compartments and produce the symptoms of chorea and involuntary activity. The studies will determine whether there are more striosomes in mutants by using immunocytochemical methods to identify striosomes. The working hypothesis states that the early stages of the disease are associated with abnormal developmental processes. The specific hypothesis is that a critical part of the pathology underlying the symptoms and final degenerative process of Huntington's disease is abnormal neurogenesis prenatally and postnatally, and that the number of striosomes in mutants reflects neurogenesis abnormalities. In addition, our model of the behavioral functions of striosomes predicts that mutants will be more sensitive to dopamine agonists. Finally, the studies will investigate prenatal and adult cell proliferation and neurogenesis in mutants and their controls by using a thymidine analogue, bromodeoxyuridine (BrdU). The studies may provide clues to the function of the gene huntingtin, and define a target for therapeutic strategies. In addition, these studies address the plastic and proliferative capacity of the adult brain. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
•
Project Title: GENE-ENVIROMENT INTERACTION IN COGNITION Principal Investigator & Institution: Gilliam, T Conrad.; Borne Professor of Genetics and Developm; Genome Center; Columbia University Health Sciences New York, Ny 10032 Timing: Fiscal Year 2003; Project Start 30-SEP-2003; Project End 31-JUL-2005 Summary: (provided by applicant): We propose a collaborative effort between Columbia University (CU) and University of Zulia (LUZ), Maracaibo-Venezuela, to investigate the effects of life conditions and environmental exposures together with genetic factors upon the expression of specific cognitive abilities. We aim to strengthen the capacity of Venezuelan scientists to design and execute research centered on cognitive impairment from birth to advanced age, with emphasis in disorders common in the State of Zulia; including Alzheimer's disease, Huntington's disease and Vascular Dementia. We propose the following specific aims for this exploratory project: 1. To assess the social impact of dementias in the State of Zulia. We will conduct a qualitative ethnographic study among family and caregivers of demented patients, as well as among primary care health professionals, identifying beliefs about cognitive impairment, dementia, knowledge, impact of disease on family life, self esteem, family identity, social reactions, access to health care and quality of care by professionals. 2. To assess current resources and needs and develop and initiate a plan to address these needs to promote the
24
Huntington’s Disease
successful conduct of the proposed research and capacity building. 3. To show feasibility and generate preliminary data to justify submission of collaborative research via an R01 grant mechanism and to identify specific research questions that show the greatest promise for advancement. We will test whether a catecoI-O-methyltransferase (COMT) gene variant affects working memory and executive function in Venezuelan families segregating subcortical white matter hyperintensities. Variance accounted for by the gene variant and life conditions and environmental exposures will be examined. 4. To identify training and other capacity-building opportunities in the context of brain health promotion throughout life. At the end of the planning period, we hope to have initiated preliminary studies and to have organized, planned, prepared and assembled an application for a more comprehensive R01 grant involving collaboration between CU and LUZ investigators incorporating both research and capacity building. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: GENETIC MODEL OF NEURODEGENERATION Principal Investigator & Institution: Feany, Mel B.; Assistant Professor; Brigham and Women's Hospital 75 Francis Street Boston, Ma 02115 Timing: Fiscal Year 2001; Project Start 30-SEP-1998; Project End 31-AUG-2004 Summary: (Adapted from the application): Neurodegenerative diseases exact a massive toll on human and health care resources. They also pose the fundamental question of the mechanisms underlying selective degeneration of particular neuronal populations. Recent identification of the genes involved in several major neurodegenerative disorders, including Huntington's disease and Alzheimer's disease, represent major advances, but have not yet revealed how the encoded proteins produce cell death. Additional components of the neurodegenerative pathway must be identified. The applicants propose to use Drosophila as a model system to identify proteins required for neuronal degeneration. Both Huntington's disease and Alzheimer s disease are dominantly inherited neurodegenerative disorders most likely produced by toxic actions of the encoded gene products. Appropriate forms of both proteins will be expressed in Drosophila using the GAL4 system that facilitates transgene expression in a variety of defined tissue-specific and temporal patterns. The anatomic and behavioral abnormalities resulting from expression of the human transgenes will be characterized, and a phenotype suitable for generating second site suppressors and enhancers will be defined. Flies will then be mutagenized and genetic modifiers isolated. Mammalian homologues of these Drosophila modifiers will be human disease gene candidates and likely components of mammalian neurodegenerative pathways. The ability of many Drosophila proteins, including several discussed in the current application, to substitute functionally for their mammalian counterparts, suggests close analogies between the two systems. Even seemingly highly unique processes such as hindbrain compartmentalization and learning and memory show remarkable similarities. The basic cell biology of neurodegeneration should prove no exception. The applicant is an M.D./Ph.D. who will have completed a residency in anatomic pathology and subspecialty training in neuropathology prior to the proposed start date. She also holds a doctoral degree in neurobiology. The research will be carried out in a Drosophila laboratory group within the Harvard Medical School. A co-sponsor expert in human molecular genetics and neurodegenerative diseases has been selected to complement the primary laboratory's expertise in Drosophila molecular genetics and development. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
Studies
•
25
Project Title: GLUTAMATE TRANSPORTER REGULATION IN HUNTINGTON'S DISEASE Principal Investigator & Institution: Widnell, Katherine L.; Neurology; Johns Hopkins University 3400 N Charles St Baltimore, Md 21218 Timing: Fiscal Year 2001; Project Start 15-AUG-2001; Project End 31-JUL-2006 Summary: (provided by applicant): Glutamate transport is essential for the synaptic inactivation of the neurotransmitter glutamate. A family of glutamate transporters has been identified in both astroglia and neurons. These transporters play important roles in the pathophysiology of neurologic disorders, notably amyotrophic lateral sclerosis and stroke. GLT1 is a glutamate transporter localized on astrocytes. We have determined that in a murine transgenic model of Huntington's Disease (HD) expressing Nterminally truncated huntingtin (N I 7182Q), there are decreased levels of GLT1, but not other glutamate transporter subtypes, in the striatum. In this proposal, experiments are presented to study the possible role of GLT1 and other molecular transporter subtypes in the development of striatal cell pathology seen in HD. First, a technique for the establishment of organotypic striatal cultures will be developed. These cultures will provide the ability to manipulate conditions, assess factors that affect GLT1 expression, and monitor for excitotoxic changes. Second, in order to further assess the role of GLT1 downregulation, behavior and striatal histology will be examined after GLT1 anti-sense infusion into rat striatum. Third, the regulation of glutamate transporters in N17182Q transgenic mice will be further evaluated in various brain regions and at various time points related to behavioral and histologic abnormalities. Human tissue from HD postmortem brains will also be evaluated. The effect of upregulation of the GLT1 transporter subtype by the neurotrophin glialcell linederived neurotrophin (GDNF), and by the neuroinimunophilin GPI1046, will be evaluated in organotypic striatal cultures, and in vivo in transgenic HD mice. Finally, an EAAT2 (GLT1) overexpressing mouse will be crossed with transgenic mouse models of HD to determine if GLT1 over-expression can reverse some of the observed behavioral or pathologic phenotypes of HD. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
•
Project Title: HUNTINGTON AND VESICLE TRANSPORT Principal Investigator & Institution: Difiglia, Marian; Associate Professor; Massachusetts General Hospital 55 Fruit St Boston, Ma 02114 Timing: Fiscal Year 2001; Project Start 15-AUG-1998; Project End 31-JUL-2002 Summary: Huntington's disease causes motor and cognitive dysfunctions, the degeneration of striatal and cortical neurons in the brain, and death of its victim within 15-20 years. The genetic mutation is an expanded region of polyglutamines at the Nterminus of huntingtin. The function of wild-type huntingtin and the mechanism of HD pathogenesis caused by mutant huntingtin are unknown. We have observed an abnormal accumulation and transport of huntintin in affected neurons of the HD brain. Similar patterns of mutant huntintin accumulation appear in clonal striatal cells transfected with cDNAs encoding huntingtin with an expanded polyglutamine region. Published studies and our preliminary observations suggest that wild-type huntingtin may function in receptor- mediated endocytosis. Mutant huntintin, like wild-type huntingtin, associates with clathrin-enriched membranes. Our overall hypothesis is that mutant huntintin causes neuronal dysfunction through its direct effects on receptormediated endocytosis and by its abnormal accumulation and transport. We propose a series of studies in clonal striatal cells to explore wild-type huntingtin's association with endosomes (Aimsl), to analyze the consequences of polyglutamine expansion in
26
Huntington’s Disease
huntintin on endocytic function (Aim 2), and to evaluate the subcellular compartments that accumulate mutant huntingtin and contribute to cell death (Aim 3). Our studies will include techniques in confocal immunofluorescence microscopy, immunogold/electron microscopy, subcellular membrane fractionation, immunoisolation and Western blot. The results will identify the subcellular processes involved in HD pathogenesis and will lead to a rational strategy for treatment of this devastating disorder. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: HUNTINGTON DISEASE IN VENEZUELA AND OTHER STUDIES Principal Investigator & Institution: Wexler, Nancy S.; Higgins Professor of Neuropsychology; Hereditary Disease Foundation 1427 7Th St, Ste 2 Santa Monica, Ca 90401 Timing: Fiscal Year 2001; Project Start 01-APR-1985; Project End 31-JUL-2002 Summary: (Investigator's Abstract): Through the study of a unique Venezuelan Huntington's disease kindred the gene for HD was localized to chromosome 4p using new molecular genetic techniques; homozygotes for the disease were identified "and the phenomenon of complete dominance" genetically documented for the first time in human medical genetics; key genetic recombinants were found, permitting more precise chromosomal localization of the HD gene and high resolution geneiic and physical mapping of the candidate region; and the HD gene itself was discovered to be an unstable trinucleotide CAG repeat in a novel protein called "huntington." The Venezuelan kindred now has an unparalleled role to play in this next phase of understanding the disorder, from the molecular behavior of the repeat to its clinical manifestations. It is the only existing kindred in which the HD allele has been inherited from a progenitor and passed through ten generations and hundreds of meioses, eliminating allelic heterogeneity and ensuring that all those in the kindred who have inherited the HD gene have the identical allele and terrain surrounding it. The enormity of the kindred, over 14,000 people, the huge sibship size, the shared background genes and environment, and the cooperativity of family members provide an unmatched research resource. The aims of the project are: 1 ) To understand the relationship between genotype and phenotype in their natural habitat, unbiased by ascertainment. To study the behavior of the CAG repeat segregating on a single haplotype as it has already afflicted over 400 people and as it now threatens 4,697 at risk children, 1,653 of whom will die of the disease in the ensuing years. To learn how genetic characteristics contribute to clinical consequences and seek to explain why people with the same number repeat units have widely varying clinical manifestations. 2) To discover modifiers, either genetic or environmental, that may regulate the frequency or magnitude of CAG expansion or influence phenotypic expression. 3) To analyze juvenile cases in more detail and the fathers who produce them; to understand what governs the plasticity of the repeat and why huge expansion produce juvenile onset. 4) To characterize genetically and phenotypically the growing population of homozygotes and learn how they cope with two doses of expanded alleles. The Venezuelan HD kindred is the largest single source of these rare homozygous individuals in the world; 8 have been identified already and 28 should be in the kindred. 5) To collect tissue samples that can provide insight on the expansion process, including lymphoblast lines and sperm samples. As a prospective, longitudinal study, to examine the effect of age, disease duration, birth order or environmental factors on sperm, in which mosaicism has been identified. 6) To collect brain and other post-mortem tissues from genetically and clinically well characterized members of the kindred to understand how the huntington protein specifically devastates striatal neurons. These tissues will enable us
Studies
27
to tie together the behavior of the gene, its target in the brain and the clinical repercussions these two produce. 7) To develop a molecular cognitive neuroscience approach to understanding how the expansion produces profound cognitive and behavioral disturbances. To develop a more precise neuropsychological battery to ascertain capacities and limitations that are germane to the underlying neuropathology. 8) To explore how psychiatric and cognitive symptomatology can also be regulated by the expanded repeat or some other genetic modifiers. 9) To characterize the kind-red for common disorders and genetic traits or markers. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: IN VIVO EFFECTS OF A LONG REPEAT IN THE HD GENE Principal Investigator & Institution: Detloff, Peter J.; Assistant Professor; Biochem & Molecular Genetics; University of Alabama at Birmingham Uab Station Birmingham, Al 35294 Timing: Fiscal Year 2001; Project Start 30-SEP-1998; Project End 31-JUL-2002 Summary: The long term goal for this work is to determine the molecular basis of Huntington's disease (HD). The basis for this progressive neurological disorder is an expanded CAG repeat in the Huntington gene that codes for a long polyglutamine repeat (11, 28, 51, 63, 69). The work proposed in this competitive renewal extends work completed during the first 2 years of funding during which the PI made a mouse with a 90 unit CAG repeat in the murine HD homolog (Hdh (CAG) 90). Recent work has shown the presence of Neuronal intranuclear inclusions (NIIs). The PI will also make mice with modifications of Hdh (CAG) 90 designed to enhance access of the polyglutamine-containing portion of the mutant protein to the nucleus. The PI will assess the role these modifications play in the formation of NIIs and the possible role NIIs play in causing abnormalities. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
•
Project Title: INHIBITION OF FIBRILLOGENESIS WITH B-STRAND MIMICS Principal Investigator & Institution: Hammer, Robert P.; Associate Professor; Chemistry; Louisiana State Univ A&M Col Baton Rouge Office of Sponsored Programs Baton Rouge, La 70803 Timing: Fiscal Year 2001; Project Start 01-APR-2000; Project End 31-MAR-2004 Summary: (Adapted from the Application). Several age-associated degenerative diseases such as Alzheimer's disease (AD), Parkinson's disease, and Huntington's disease are characterized by the formation of fibrillar structures called amyloid plaques. The long-range goal of this work is to develop inhibitors of amyloidogenesis and to test whether or not such "blocker" molecules can be effective suppressors of toxicity and ultimately therapeutic agents for amyloid associated diseases. The specific aims and the hypotheses to be tested are: (1) Design and synthesis of new B-strand mimics that block the fibril and protofibril formation of the Alzheimer-associated B-amyloid peptide (All). Oligomerization of B-sheet structures, like those in A-Beta fibrils, can be inhibited or reversed by extended peptide structures that have only one edge available for hydrogen bonding. (2) Determination of the inhibition mechanism of protofibrillogenesis with Bstrand mimics. Potentially neurotoxic protofibril formation can also be inhibited by "blocker" molecules, the formation and dissolution of A-Beta protofibrils in the presence and absence of molecules known to inhibit fibril formation will be studied using scanning force microscopy (SFM), static light scattering (SLS), dynamic light scattering (DLS), analytical ultracentrifugation (AU) and fluorescence photobleaching recovery
28
Huntington’s Disease
(FPR). (3) Detection of early intermediates in protofibril assembly by fluorescence photobleaching recovery (FPR) and AU and determination of molecularity of these early intermediates. Early aggregates can be dissociated in the presence of p-strand mimics. (4) Initiation of fibrillogenesis on hydrophobic and hydrophilic surfaces. Formation of protofibrils and fibrils of A-Beta in vivo is the result of interactions between soluble ABeta and various moieties on the surface of neuronal cells and "surface-induced" or nucleated A-Beta polymerization can be stopped or reversed by the presence of B-strand mimics. The potential impact of this work is gaining a better understanding of the etiology of AD and development of pharmaceutical agents for treating AD and other amyloid diseases. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: INTRABODY THERAPY OF PARKINSON'S DISEASE Principal Investigator & Institution: Messer, Anne; Director/Research Scientist; Wadsworth Center Empire State Plaza Albany, Ny 12237 Timing: Fiscal Year 2002; Project Start 01-FEB-2002; Project End 31-JAN-2004 Summary: (provided by applicant) This proposal seeks to develop engineered intracellular antibodies (intrabodies) as novel potential clinical reagents and drug discovery tools for the treatment of Parkinson's disease (PD). Intrabodies make use of the specificity of antibodies to form complexes with intracellular proteins, and are already in clinical trials for treatment of cancers and AIDS. Recently, we published the first application of this powerful technology to a neurodegenerative disease, showing that human single-chain Fv intrabodies, selected from a phage display library, can counteract in situ Huntington aggregation in cellular models of Huntington's Disease (HD). By choosing an epitope adjacent to the abnormally folding expanded polyglutamine of the HD protein, we can alter the abnormal protein-protein interactions that characterize the mutant protein. Parkinson's Disease brains show formation of filamentous intracellular inclusions (Lewy bodies) as their most striking pathology. These appear to be composed of abnormally aggregated alpha-synuclein in both sporadic and hereditary forms of the disease. The alpha-synuclein protein data to date suggest several candidate target sequences that might prevent misfolding of synuclein, or be used to clear abnormal material in Parkinson's cells. We propose to select antisynuclein single-chain Fv intrabodies against unique, defined domains and forms of asyn, using human phage display libraries. These will then be tested for their capacity to reverse reported physiological defects in model systems. Models will include several that over-express wild-type alpha-synuclein to mimic sporadic P.D: transient transfections in cell lines and brain slice cultures, moving on to transgenic Drosophila and eventually transgenic mice. All of these studies will take advantage of the technologies and expertise coming out of the HD studies, which are actively and successfully ongoing in the lab. Long-term goals include administering these antibody reagents via gene therapy vectors, or as stable, multi-functional proteins. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
•
Project Title: ION CHANNEL DYSFUNCTION IN HUNTINGTON'S DISEASE Principal Investigator & Institution: Cantrell, Angela R.; Assistant Professor; Anatomy and Neurobiology; University of Tennessee Health Sci Ctr Health Science Center Memphis, Tn 38163 Timing: Fiscal Year 2003; Project Start 01-SEP-2003; Project End 31-AUG-2008
Studies
29
Summary: (provided by applicant): It has recently been suggested that neuronal degeneration may occur as a secondary phenomenon in response to neuronal dysfunction in HD. In support of this idea, recent reports have indicated that electrophysiological abnormalities occur in the brains of HD transgenic animals. These abnormalities include altered somatic discharge, broadening of the excitatory postsynaptic potential and failure to induce long term potentiation following high frequency stimulation. These abnormalities precede neurobehavioral and neuropathological alterations suggesting to some researchers that cytoplasmic functions including neurotransmitter regulation of ion channels and regulation of intracellular Ca2+ may play a role in this disease. If this is in fact the case, then understanding neuronal dysfunction in HD may be critical to the development of rational treatment strategies and early intervention programs. An extrinisic mechanism such as glutamate excitotoxicity has been proposed to account for the ultimate degeneration of medium spiny neostriatal neurons, therefore, we hypothesized that changes in the membrane properties of the cortical projection neurons which provide input to the medium spiny neostriatal neurons might be important in HD. This idea, while intriguing, has not been fully investigated using the newly available animal models of HD. We present preliminary data to support this idea and demonstrate that electrophysiological abnormalities occur in the presynaptic corticostriatal projection neurons in HD transgenic mice. Since the electrical activity of a neuron is regulated by its own intrinsic cytoplasmic properties as well as its synaptic inputs, it will be important to conduct a thorough study of these alterations in the electrophysiological properties of the presynaptic cortical projection neurons in HD. These electrophysiological abnormalities in corticostriatal projection neurons may contribute to neuronal dysfunction and the subsequent neuropathology observed in HD. This hypothesis will be tested in acutely isolated, identified cortical projection neurons obtained from HD mouse models in which expression of mutant huntingtin has been induced. Techniques employed include patch-clamp recording methods, single-cell RT-PCR and immunohistochemistry. This proposal has 3 Specific Aims: 1) To define the physiological properties of pharmacologically isolated HVA Ca2+ channels, voltage-gated Na+ channels and voltage-gated K+ channels in acutely isolated corticostriatal projection neurons from HD transgenic mouse models. 2) To determine the molecular mechanisms underlying the observed increase in HVA Ca2+ channel activity in corticostriatal neurons from R6/2 transgenic mice. 3) To expand our studies to include other classes of cortical projection neurons. These studies will provide valuable information for the elucidation and treatment of a variety of motor deficits and neurodegeneration observed in HD and a host of other neurological disorders. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: LONGITUDINAL STUDIES AMONG AT-RISK HD GENE CARRIERS Principal Investigator & Institution: Foroud, Tatiana M.; Associate Professor; Molecular and Medical Genetics; Indiana Univ-Purdue Univ at Indianapolis 620 Union Drive, Room 618 Indianapolis, in 462025167 Timing: Fiscal Year 2002; Project Start 01-APR-2002; Project End 31-MAR-2007 Summary: (provided by applicant) To identify and quantify changes among presymptomatic Huntington disease gene carriers who had not yet developed definite chorea, we performed the largest, study of individuals at-risk for HD (n=657) Subtle abnormalities in oculomotor, extrapyramidal and pyramidal motor, and cognitive measures were identified. We propose to reexamine this unique sample of at-risk individuals using an expanded test battery that includes more sensitive and specific
30
Huntington’s Disease
quantitative measures for each subset of variables for which significant differences between presymptomatic gene carriers and nongene carriers were initially observed. These new measures increase the power of our proposed longitudinal studies of the rate of change among presymptomatic gene carriers as they approach the manifestation of clinically diagnosable HD. These novel studies are designed to: 1) Further delineate the deficits observed in the subclinical and early symptomatic phase of disease; 2) measure the rate of increasing abnormality among presymptomatic gene carriers; 3) investigate the interrelationships among the variables so as to identify measures with similar rates of deterioration, which might suggest common pathways affected early in the disease process; 4) quantify the relationship of CAG repeat number with disease onset and progression. The results of these studies will improve the understanding of the presymptomatic and early symptomatic phase of HD allowing for earlier diagnosis and identify subclinical biomarkers that can be utilized in clinical trials to evaluate therapeutic agents designed to slow progression and delay the onset of clinical HD. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: MECHANISMS OF ATAXIN-1 MEDIATED PURKINJE CELL DEATH Principal Investigator & Institution: Vig, Parminder J.; Neurology; University of Mississippi Medical Center 2500 N State St Jackson, Ms 39216 Timing: Fiscal Year 2003; Project Start 01-FEB-2003; Project End 31-JAN-2007 Summary: (provided by applicant): Spinocerebellar ataxia-1 (SCA-1) belongs to a group of dominantly inherited neurodegenerative diseases caused by a mutant expansion of a polyglutamine-repeated sequence within the affected gene product ataxin-1. One of the major cell types affected by ataxin-1 is the cerebellar Purkinje cell. The mechanism by which ataxin-1 causes Purkinje cell degeneration in SCA-1 is not known, however, ataxin-1 down regulates Purkinje cell specific proteins involved in calcium homeostasis and signaling in patients with SCA-1, and in presymptomatic SCA-1 transgenic mice. Therefore, the present proposal is designed to determine if targeted deprivation of one of the specific proteins involved in calcium homeostasis will further enhance ataxin-1 toxicity and if trophic upregulation of this protein will rescue SCA-1 Purkinje cells from degeneration. The long-term goal of this project is to understand the role of calcium signaling pathways in neuronal degeneration in order to design therapeutic approaches in clinical management of SCA-1 and other dominantly inherited cerebellar ataxias. To determine if decreased expression of calcium binding protein calbindin-D 28k (CAB) will increase the toxic effects of ataxin-1 on Purkinje cells, double mutant mice will be generated by mating CaB null mice with SCA-1 transgenic mice. To determine if overexpression of insulin-like growth factor - I (IGF-I) will rescue SCA-1 Purkinje cells from degeneration, double mutant mice will be generated by mating mice overexpressing IGF-I with SCA-1 transgenic mice. The changes in Purkinje cells will be assessed by behavioral, biochemical, immunochemical and immunohistochemical methods, focusing on the alterations in the expression of Purkinje cell markers, calcium binding proteins, and proteins involved in calcium signaling. Purkinje cells cultured from 0-1 day old SCA-1 transgenic mice will be used to determine if cultured Purkinje cells expressing mutant ataxin-1 show (i) altered expression of calcium binding proteins and proteins involved in calcium signaling (ii) sensitivity to increased Ca 2+-influx (iii) altered response to the inhibitors of calcium-dependent proteases and (iv) if treatment with IGF-I can reverse ataxin-1 mediated pathological changes. Purkinje cell cultures from non-transgenic mice will be used as controls. Complementary analysis to compare changes in cultured Purkinje cells with those cultured from CaB null and transgenics with Huntington's disease will also be performed. Further, changes observed in SCA-1
Studies
31
patients and in transgenic mice will be compared with that in Machado-Joseph disease/SCA-3, other cerebellar ataxias and normal controls. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: MECHANISMS OF GENE DYSREGULATION IN HD Principal Investigator & Institution: Olson, James M.; Assistant Professor; Fred Hutchinson Cancer Research Center Box 19024, 1100 Fairview Ave N Seattle, Wa 98109 Timing: Fiscal Year 2001; Project Start 15-AUG-2001; Project End 31-JUL-2005 Summary: (Adapted from applicant's abstract): Several lines of evidence suggest that mutant huntingtin affects gene transcription by sequestering transcription activating and repressing proteins. This does not explain the gene expression changes that occur before mutant huntingtin is detectable in the nucleus, nor does it account for transcription changes caused by abnormal signaling from damaged afferent neurons. The overall aim of this application is to test the hypothesis that the earliest gene expression changes in Huntington's disease (HD) reflect a response of the neuron to misfolded huntingtin protein and to abnormal signaling between afferent and target neurons. To accomplish this the investigator proposes two Specific Aims 1) use mice and cell culture models that express mutant huntingtin protein in eitherthe nucleus orthe cytoplasm to determine how cells transcriptionally respond to each and 2) use mice that express mutant huntingtin protein in eitherafferent neurons ortarget neurons to determine transcriptional responses in neurons. The transcriptional responses will be correlated with pathogenic changes that occur in response to the transgenes. This will generate information and tools needed to further model and test early processes in Huntington's disease. Our long-term goal is to identify early pathogenic events in Huntington's disease in order to provide rational targets for the development of prophylactic drugs. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
•
Project Title: MECHANISMS OF LONG-TERM DEPRESSION IN THE STRIATUM Principal Investigator & Institution: Kreitzer, Anatol C.; Psychiatry and Behavioral Sci; Stanford University Stanford, Ca 94305 Timing: Fiscal Year 2003; Project Start 01-SEP-2003; Project End 31-AUG-2006 Summary: (provided by applicant): Long-term changes in synaptic strength are thought to represent a cellular correlate of learning and memory. In the hippocampus, long-term potentiation (LTP) and long-term depression (LTD) have been studied extensively, and a number of different mechanisms have been elucidated, some of which coexist at the same synapses. In the striatum, changes in synaptic function are thought to correlate with behaviors such as habit formation, as well as with pathologies such as Parkinson's and Huntington's disease and drug addiction. However, the mechanisms, or even the types of plasticities present at these synapses, have not been fully described. The goal of this research proposal is to examine LTD in both the dorsal striatum and its ventral extension, the nucleus accumbens. A number of studies have found various and conflicting results regarding LTD in these areas. To examine the types of LTD present at synapses in both dorsal striatum and nucleus accumbens, various induction protocols and experimental paradigms will be tested. Specific mechanisms of LTD induction and expression will then be studied using electrophysioiogical recordings combined with molecular techniques such as viral-mediated gene transfer. These studies will provide a framework for understanding how long-term changes in synaptic strength in the striatum are related to such health issues as addiction and neurodegenerative disease.
32
Huntington’s Disease
Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: MECHANISMS OF MOTOR LEARNING IN NEUROLOGICAL DISEASE Principal Investigator & Institution: Krakauer, John W.; Assistant Professor; Neurology; Columbia University Health Sciences New York, Ny 10032 Timing: Fiscal Year 2001; Project Start 30-SEP-1999; Project End 31-AUG-2004 Summary: The proposed award is designed to develop the candidate's clinical research skills to prepare him for a career as an independent investigator in the application of motor psychophysics and functional brain imaging to the study of neurological disease. Research Plan: Stroke, Huntington's disease (HD), and Idiopathic Torsion Dystonia (ITD) are diseases that rob people of motor function in the prime of life. Many of the measures of motor performance and functional status commonly used in clinical trials and rehabilitation suffer from subjectivity and lack of scientific validation. The first goal of the proposed study is to characterize and quantify the motor deficit in these diseases using methods previously developed in the study of arm movements in normal subjects. In particular, we will emphasize the importance of examining motor learning abnormalities because we hypothesize that these will give a direct measure of a patient's capacity to compensate or recover from neurological disease. The second goal is to correlate psychophysical parameters of motor performance and motor learning to the degree of expression of brain networks as revealed by functional imaging. This will provide considerable insight into the brain mechanisms underlying abnormalities in motor control. HD and ITD each have an established genetic basis allowing asymptomatic carriers to be identified. Our preliminary studies indicate that these subjects have psychophysical and network abnormalities even though more conventional assessments fail to find any evidence of neurological disturbance. If we confirm and extend these observations, then we will have the tools to follow therapeutic intervention at the earliest stages of disease. In the long term, we hope that our work will lead to the development of a battery of motor tasks that, in conjunction with functional imaging, will be applicable to any neurological disease. This battery will quantify motor deficits; allow monitoring of therapy; provide insight into brain mechanisms: and may serve a rehabilitative function. Educational Plan: By completing this project, I will accomplish six main educational objectives: (1) The design and application of motor psychophysics to neurological disease; (2) Learning PET imaging techniques; (3) The development of skills in brain network analysis and modeling; (4) Learning advanced statistical methods; (5) Learning the principles of functional magnetic resonance imaging; (5) Learning to conduct ethical scientific research, collaborate with colleagues, and produce high quality presentations and publications; and (6) Learning to place experimental findings within their clinical context, and relate them to clinical assessments. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
•
Project Title: METABOTROPIC NEURODEGENERATION
GLUTAMATE
RECEPTORS
IN
Principal Investigator & Institution: Young, Anne B.; Professor; Massachusetts General Hospital 55 Fruit St Boston, Ma 02114 Timing: Fiscal Year 2001; Project Start 15-AUG-1995; Project End 31-JUL-2005 Summary: Description (From the applicant's abstract): Human neurodegenerative diseases such as Alzheimer's disease (AD), Parkinson's disease (PD), Huntington's
Studies
33
disease (HD) and amyotrophic lateral sclerosis (ALS) are characterized by adult onset, progressive neurologic dysfunction, and a paucity of effective therapies. These common disorders produce substantial disability, and their importance to public health is expected to increase as the population ages. One or more causative genes have now been isolated for familial forms of each of these four devastating neurologic illnesses, making possible the development of transgenic mouse models. Although such animals now exist, the exact mechanisms by which mutant genes cause neurologic disease remains unclear. Unless the etiologic mechanisms underlying the neurodegenerative diseases are clearly identified, rational therapeutic interventions will be impossible. The neurotransmitter glutamate has been implicated as a causative factor in the etiology of neurodegenerative disorders. Specifically, one class of glutamate receptors, the metabotropic glutamate receptors (mGluRs), may be specifically abnormal in many of the neurodegenerative disorders. This project will examine metabotropic glutamate receptors in transgenic mouse models of AD, PD, HD, and ALS using ligand binding, in situ hybridization, immunohistochemistry, and Western blotting. Alteration of mGluR expression level is also predicted to have direct implications for the abnormal synaptic functioning which is characteristic of neurodegenerative diseases. Thus, we will also explore glutamate-related intracellular signaling pathways in the brains of transgenic mice. Finally, if mGluR dysfunction is an important part of disease etiology, drugs targeting mGluRs may ameliorate symptoms in certain of these models. We will test if administration of mGluR-active medications improves clinical outcome in mouse models of these diseases. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: MODULATION OF CASPASE PATHWAYS IN HUNTINGTON'S DISEASE Principal Investigator & Institution: Friedlander, Robert M.; Associate Director; Brigham and Women's Hospital 75 Francis Street Boston, Ma 02115 Timing: Fiscal Year 2001; Project Start 01-JAN-2000; Project End 31-DEC-2004 Summary: The interleukin-1beta converting enzyme (caspase-1 or caspase-1) cell death gene family, also known as the caspase family, plays an important role in apoptosis. Evidence indicates that caspase- 1 is involved in mediating brain damange in ischemia, trauma, and in amyotrophic lateral sclerosis. We have evidence implicating caspase-1 as an important mediator of cell dysfunction and disease progression in Huntington s disease (HD). The broad objective of this project is to evaluate the mechanisms of caspase-1-mediates disease progression in HD. Preliminary results indicate that caspase1 is activated in human and mouse HD brain specimens. In addition, inhibiting caspase function slows the progression and delays the mortality in a mouse model of HD. The specific aims are: 1) evaluate the expression and activation status of different members of the caspase family in human and mouse HD brain specimens, 2) evaluate the role of mature IL-1beta, a product of caspase-1 activation, in the pathogenesis of HD, 3) determine whether bc1-2 might be a neuroprotector in HD, and whether its effects might be synergistic with caspase-1 inhibition, 4) evaluate pharmacological approaches to slow the progression of HD, and 5) evaluate the mechanism of inhibition of weight loss in HD mice by caspase-1 inhibition, 6) evaluate the impact of HD on neural stem cell proliferation and differentiation. Significance: To elucidate the mechanistic pathways by which caspase-1 mediates disease progression and death in HD. Since caspase-1-mediated cell death is a common pathway shared by a variety of neurological disorders, understanding the mechanistic pathways mediating neurodegeneration in
34
Huntington’s Disease
HD should provide important information for the development of treatments for diseases sharing this cell death pathway. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: MOLECULAR GENETIC APPROACHES TO LEARNING AND MEMORY Principal Investigator & Institution: Tonegawa, Susumu; None; Massachusetts Institute of Technology Cambridge, Ma 02139 Timing: Fiscal Year 2001; Project Start 06-SEP-1994; Project End 31-MAR-2006 Summary: (provided by applicant): The long-term objectives of this competing renewal are to apply conditional gene manipulation techniques developed for mice to the analyses of molecular, cellular, and neuronal ensemble mechanisms underlying hippocampus-dependent learning and memory. Using the molecular genetic methods developed in this laboratory, mouse strains will be generated in which the gene encoding the a isoform of Ca2+/calmodulin-dependent protein kinase-II (CaMKII), or the g or B isoform of protein kinase C (PKC) is deleted (knocked out) specifically and separately in CAl or CA3 pyramidal cells of the hippocampus. Several transgenic mice will be generated in which the CaMKII inhibitor protein (CaMKII-IN) is overexpressed specifically in CAl or CA3 pyramidal cells, or a dominant negative form of Ca2+/calmodulin-dependent protein kinase-IV (dnCaMKIV) is overexpressed in the forebrain. The issue of whether expression of long term potentiation (LTP) at Schaffer collateral CAl synapses is based on a pre- or postsynaptic mechanism will be examined by subjecting the CAl- or CA3- specific CaMKII knockout, PKC knockout and CaMKIIIN transgenic mice to electrophysiological analysis of brain slices. This study will also examine whether LTP underlies learning and memory by analyzing the CAl-specific alphaCaMKII knockout, CAl-specific CaMKII-IN transgenic, and the forebrain-specific CaMKIV transgenic mice with electrophysiological and behavioral methods. Furthermore, the role of CaMKIV in different phases of the mnemonic process, namely acquisition, consolidation, and retrieval of memory, will be assessed by analyzing dnCaMKIV transgenic mice in which the level of expression of dnCaMKIV can be reversibly controlled. It is proposed to identify and characterize genes that are activated in the CAl region upon the formation of a long term memory by combining mouse genetics technology developed in this laboratory with DNA chip and DNA microarray technologies. Finally, it is proposed to study roles of CA3 NMDA receptors and the CA3 recurrent network in learning and memory, and in the formation of memory representation in the hippocampus by creating CA3-specific NMDA receptor knockout mice and subjecting them to a variety of memory tasks and to in vivo multielectrode recordings, respectively. The knowledge gained from these studies will constitute the basis for developing diagnostic and therapeutic methods for neurodegenerative diseases such as Alzheimer's disease and Huntington's disease as well as for the development of learning enhancement methods. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
•
Project Title: MOLECULAR MECHANISMS OF AXONAL TRANSPORT Principal Investigator & Institution: Brady, Scott T.; Professor and Head; Cell Biology; University of Texas Sw Med Ctr/Dallas Dallas, Tx 753909105 Timing: Fiscal Year 2001; Project Start 01-JUL-1986; Project End 31-AUG-2005 Summary: (From the Applicant's Abstract): Understanding axonal transport processes is a key to understanding the dynamics of the nervous system, because they underlie
Studies
35
neuronal growth, maintenance and regeneration. As a result, elucidation of molecular mechanisms for fast axonal transport can provide essential insights into the function and pathology of the nervous system. Functions as diverse as conduction of the action potential, release of neurotransmitter, creating and sustaining the presynaptic terminal, neuronal development and regeneration, and maintenance of neuronal architecture depend critically on fast axonal transport of membrane bounded organelles (MBOs) along microtubules. Similarly, disruption of fast axonal transport has been implicated in pathogenesis for a wide range of neuropathological conditions, including diabetic and toxic neuropathies, motor neuron disease (ALS and others) and degenerative diseases of the nervous system (Huntington's disease and others). Our original studies of fast axonal transport in isolated axoplasm from the squid giant axon led to discovery of a new family of mechanochemical ATPases: the kinesins. Kinesins are motors for movement of membrane bounded organelles in the anterograde direction of fast axonal transport. Previous work supported by this application answered many questions about the biochemistry and molecular biology, cell biology, and neurobiology of kinesin. Future experiments will extend our current studies on molecular mechanisms of fast axonal transport in three areas. First, we propose that physiological properties of different kinesins are determined by variation within specific functional domains among kinesin isoforms of the neuron. Studies proposed in this application combine methods from biophysics, cell biology, and molecular biology to delineate the functional architecture of neuronal kinesins and determine physiological functions for each domain. Second, specificity of kinesin interactions with different organelles suggest that kinesin isoforms are uniquely targeted to specific classes of MBOs through a combination of specific membrane receptors and general kinesin interacting proteins. Proposed experiments will identify kinesin receptors and interacting proteins in nervous tissues. Finally, kinesins are subject to posttranslational modifications in neurons that vary among the different isoforms. We propose that posttranslational modifications of kinesin serve to regulate kinesin function in neurons. Pathways associated with these modifications may control kinesin interactions with specific classes of MBOs as well as kinesin-mediated motility and ATPase activity. Planned experiments will determine the functional significance of posttranslational modifications on kinesin heavy and light chains, as well as defining relevant regulatory pathways. The proposed studies will help us understand the role of the kinesins in both normal neuronal function and neuropathology. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: MOTOR LEARNING AND MEMORY IN HEALTH AND DISEASE Principal Investigator & Institution: Shadmehr, Reza; Biomedical Engineering; Johns Hopkins University 3400 N Charles St Baltimore, Md 21218 Timing: Fiscal Year 2003; Project Start 01-APR-1999; Project End 31-MAR-2007 Summary: (provided by applicant): When one moves their hand from one point to another, the brain guides the arm by relying on neural structures that estimate physical dynamics of the task and transform the desired motion into motor commands. If our hand is holding an object, the subtle changes in the dynamics of the arm are taken into account by these neural structures and this is reflected in the altered motor commands. These observations have suggested that in generating motor commands, the brain strongly relies on internal models that predict physical dynamics of the external world. The internal models are learned with practice, and appear to be a fundamental part of voluntary motor control. However, we know very little about which neural structures in the brain are involved in formation of internal models for motor control and how they
36
Huntington’s Disease
learn to represent these models. Our aim here is to combine behavioral and mathematical tools to infer how humans learn internal models, and how the process is affected when there is damage to specific motor structures in the brain. We approach the problem by considering a task where physical dynamics of reaching movements are altered. As people practice the task, we ask how did an error that was experienced in a given movement affect subsequent movements? We arrive at a generalization function that mathematically describes how the brain changes the internal model in response to an error. The shape of the generalization function predicts the receptive field of the elements that took part in representing the internal model with respect to movement kinematics. We study these generalization functions in position, velocity, and acceleration space of the arm. Preliminary results demonstrate a remarkable similarity between these behaviorally inferred bases and typical tuning properties of cells in the primary motor cortex. This suggests that tuning properties of these cells might be reflected in human behavior in the way that we learn and generalize patterns of force. We extend the studies to include generalization from one arm to the other. We further extend the studies to movements where dynamics are not dependent only on arm kinematics, but also on other cues: external cues where dynamics are linked to an arbitrary spatial or color cue, internal cues where dynamics depends on position of a movement with in a sequence. We compare how damage to the brain in Huntington's disease vs. cerebellar disease affects this learning. However, motor memories are not static. Their functional properties change within hours after a task is learned. We ask how this change affects the generalization function. Is the brain different in the way it responds to an error after a memory has consolidated vs. early in the learning phase? Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: MTDNA DAMAGE AND APOPTOSIS IN NEURODEGENERATION Principal Investigator & Institution: Ayala-Torres, Sylvette; Universidad Central Del Caribe Bayamon, Pr 009606032 Timing: Fiscal Year 2002; Project Start 01-AUG-1994; Project End 31-DEC-2005 Summary: Many forms of neurodegeneration are associated with oxidative stress. Although the molecular mechanisms of neurodegeneration remain unknown, it has been proposed that the symptoms associated with several late-onset neurodegenerative diseases are the result of mitochondrial dysfunction and increased production of mitochondrial- generated reactive oxygen species (ROS). Preliminary studies using quantitative polymerase chain reaction show an age-associated increase in basal levels of mouse brain mitochondrial DNA (mrDNA) damage. We hypothesize that oxidative damage to mtDNA leads to a decline in mitochondrial function with concomitant increase in mitochondrial- generated ROS. The hypothesis predicts that impairment of mitochondrial function due to oxidative mtDNA damage can lead to neuronal apoptosis. Increasing evidence implicates apoptosis as a major mechanism of cell death in neurodegeneration is yet not known. This project will explore the molecular mechanisms of neuronal cell death by using the 3-nitropropionic acid (3-NPA) animal model of Huntington's disease. Recent evidence has suggested that 3-NPA, a mitochondrial neurotoxin, can lead to striatal apoptosis and neurodegeneration. is caused by an accumulation of mtDNA damage induced by oxidative stress. To test this hypothesis this application proposes: 1) to examine the association between mtDNA damage and apoptosis in mouse brain exposed to 3-NPA; 3) to examine the association between mitochondrial dysfunction and oxidative stress exposed to 3-NPA; 3) to determine the association between mtDNA damage, ROS production, and apoptosis in mouse striatum exposed to 3-NPA; and 4) to analyze the effect of inhibitors of caspases
Studies
37
in mouse striatum on mtDNA damage, generation of mitochondrial ROS, and apoptosis after treatment with 3-NPA. This study will lead to a better understanding of the role of oxidative stress and mitochondria in apoptosis associated with neurodegeneration. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: MTOR ACTIVATION AND FUNCTION DURING CNTF SIGNALING Principal Investigator & Institution: Reeves, Steven A.; Massachusetts General Hospital 55 Fruit St Boston, Ma 02114
Assistant
Professor;
Timing: Fiscal Year 2003; Project Start 24-JUL-1998; Project End 31-JAN-2008 Summary: (provided by applicant): Signal transduction initiated by the neuroregulatory cytokine ciliary neurotrophic factor (CNTF) has been shown to promote neuronal survival in the injured or diseased nervous system. These findings have provided a basis for using CNTF as a therapeutic agent aimed at the treatment or prevention of a variety of neuropathological diseases, including amyotrophic lateral sclerosis, Huntington's disease, Alzheimer's disease, stroke, and several forms of cerebellar ataxias. The precise manner in which CNTF activates and coordinately regulates the signaling cascades it employs for its neuroprotective effects remains largely undefined. One important component in this cascade that we have recently identified is the mammalian target of rapamycin (mTOR). The TOR proteins have been shown to be key regulators of a diverse set of cell processes, and recent reports have indicated that mTOR may play a critical role in synaptic plasticity and memory. We hypothesize that mTOR is a critical link in one or more of the CNTF signal transduction pathways. Thus the research we are proposing in this application aims to determine the mechanism by which CNTF activates mTOR and to identify the role(s) that mTOR plays in CNTF-stimulated sympathetic neurons. This work could identify novel targets for therapies aimed at the treatment or prevention of a variety of central nervous system disorders as well as provide a sound scientific foundation for the clinical use of CNTF and CNTF analogues now being tested in clinical trials. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: NANOSCALE IRON PHASES IN NEURODEGENERATIVE DISEASES Principal Investigator & Institution: Dobson, Jon P.; Keele University Keele St5 5Bg, England Keele, Timing: Fiscal Year 2003; Project Start 15-APR-2003; Project End 31-MAR-2006 Summary: (provided by applicant): AIMS:. To develop multi-modal imaging methods for high-resolution mapping of iron in neurodegenerative brain tissue. To examine the magnetic properties of neurodegenerative tissue for the possible presence of anomalous magnetic iron oxides. To examine the effects of biogenic, magnetic iron biominerals (primarily magnetite) on amyloid-beta aggregation in vitro. Research Design & Methods: The primary method for mapping iron distribution in tissue sections is via synchrotron x-ray scanning which will be conducted at Argonne National Laboratory. This technique will be used to identify iron anomalies eventually on a cellular level. And to compose composit images using a variety of imaing techniques. This work will enable correlation of iron anomalies and structural form to specific cellular and tissue structures for the first time. Examination of the magnetic properties of neurodegenerative tissue will be carried out pdmarily using Superconducting Quantum Interference Device (SQUID) magnetometry and Magnetic Force Microscopy (MFM). Using these methods the magnetic iron biominerals in the tissue will be characterized and compared to published data on non-pathologic and epileptic tissue samples. This
38
Huntington’s Disease
will provide information on the relative abundance and type of magnetic iron biomineral present in the tissue and will help to either confirm or refute preliminary studies of nanoscale magnetic iron biominerals in Alzheimer's disease (AD) tissue. The effects of strong, local magnetic fields generated by nanoscale magnetic iron biominerals on amyloid-beta peptide aggregation rates will be examined using thioflavin-T assay and TEM imaging of peptide aggregates. Aggregation rates will be assessed in control solutions, solutions of peptide with coated magnetic nanoparticles and sham solutions containing the same concentrations of non-magnetic nanoparticles with the same size distribution and surface chemistry. Gla: FOREIGN GRANT: As the PI is a US citizen based at Keele University in the United Kingdom, the project will be administered through a foreign institution - Keele. The PI has considerable and unique experience in the analysis of magnetic iron biominerals in the brain (he has led all of the previous work described in this proposal) and is one of the few people in the wodd working in this field. The proposed project is highly interdisciplinary, incorporating aspects of biophysics, chemistry, neurobiology and biomedical engineering. The PI has a uniquely diverse background related to the proposed research, having worked in physics, chemistry and biomedical engineering departments and the UF Brain Institute since obtaining his PhD in 1991. He has published extensively in nanoscale magnetic iron biomineralization in the brain and his work has been featured by the media in such journals as Science,The Economist, Fact/Switzerland, The Los Angeles Times/Washington Post wire service as well as newspaper, radio and television coverage in six countries. The Pl's combination of skills and experience related to the research proposed here is unique and unavailable in the US. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: NEURAL BASIS OF INSTRUMENTAL ACTION Principal Investigator & Institution: Balleine, Bernard W.; Assistant Professor; Psychology; University of California Los Angeles 10920 Wilshire Blvd., Suite 1200 Los Angeles, Ca 90024 Timing: Fiscal Year 2001; Project Start 15-JAN-1997; Project End 31-DEC-2002 Summary: (Adapted from applicant's abstract): The organization of goal-directed action is influenced significantly by the agent's ability to inhibit or gate responses to sensory, motor and cognitive information. Deficits in these central inhibitory mechanisms are manifest in a number of neuropsychiatric syndromes characterized by disorders of 'voluntary' movement, e.g., Parkinson's disease, and intrusive involuntary movement, e.g., Tourette's syndrome and Huntington's disease. These cases make it clear that the capacity for goal-directed action is highly adaptive, indeed it is this capacity that allows us and other animals to control the environment in the service of our needs and desires. Nevertheless, although research into the physiological systems that subserve learning processes in humans and other animals has been of ongoing concern to the neuroscience research community, the neural basis of instrumental action is very poorly understood. The broad, long term objective of the current project is, therefore, to understand the neural mechanisms that control the learning and performance of goal directed or instrumental actions. Over the last decade striking advances have been achieved in the PI's understanding of the behavioral determinants of instrumental conditioning in animals. Specifically, instrumental performance has been found to reflect the integration of (I) representations of the relations between an action and its consequences; with (ii) representations of the incentive value of those consequences. Elegant but powerful behavioral procedures will be used to focus on the role of cortico-striatal interactions and feedback to cortex via pallidal and limbic structures on processes involved in the
Studies
39
representation of the relation between an action and its consequences. In other experiments, the role of parallel interactions between insular cortex and basal forebrain structures in the representation of the incentive or 'goal' value of the instrumental outcome will be assessed. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: NEUROBIOLOGICAL PREDICTORS OF HUNTINGTON'S DISEASE Principal Investigator & Institution: Paulsen, Jane S.; Professor; Psychiatry; University of Iowa Iowa City, Ia 52242 Timing: Fiscal Year 2001; Project Start 01-SEP-2001; Project End 31-AUG-2004 Summary: The proposal is a longitudinal study of potential neurobiological and neurobehavioral markers of disease onset and progression in pre-symptomatic individuals who have the CAG expansion in the HD gene. A total of 500 subjects will be enrolled. Study subjects will be 30 to 55 years old and have a parental history of Huntington's disease. The study will enroll 425 cases with >39 CAG repeats (affected), and 75 controls with <30 CAG repeats (wildtype). The patients will be recruited from 20 research sites in the United States and Canada. Subjects will be evaluated every 12 months for up to 5 years. At baseline, blood will be drawn for centralized confirmatory gene testing. At every visit, subjects will undergo standardized assessments of motor, cognitive, functional, and psychiatric signs of HD using the Unified Huntington's Disease Rating Scale (UHDRS). More comprehensive evaluations will be done at baseline, and 24 and 48 months of follow-up. These more comprehensive evaluations will include a videotaped examination, volumetric magnetic resonance imaging, detailed neuropsychometric testing and behavioral ratings. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
•
Project Title: NEURODEGENERATION AND POLYGLUTAMINE TOXICITY DRPLA Principal Investigator & Institution: Ross, Christopher A.; Professor; Psychiatry and Behavioral Scis; Johns Hopkins University 3400 N Charles St Baltimore, Md 21218 Timing: Fiscal Year 2003; Project Start 01-MAY-1995; Project End 31-MAY-2008 Summary: (provided by applicant): DentatoRubral and PallidoLuysian Atrophy (DRPLA) is a progressive neurodegenerative disease caused by a polyglutamine expansion in atrophin-1. The clinical features and areas of the brain affected resemble the more common Huntington's disease (HD), and we study the two diseases in parallel, since changes observed in both may represent common pathogenic features for all of the polyglutamine neurodegenerative diseases. In the previous grant period we generated a transgenic mouse model of DRPLA, and gathered some preliminary evidence suggesting the hypotheses that atrophin-1 undergoes proteolytic cleavage and nuclear translocation, resulting in gene transcription changes, as part of the pathogenesis of DRPLA. We gathered cell culture data to suggest that atrophin-1 has nuclear localization and export signals and that these are involved in toxicity. We now propose to conduct mechanistic in vivo experiments to test these ideas. In Specific Aim 1, we will generate transgenic mice expressing mutant full-length atrophin-1 with the putative nuclear localization signal altered, in order to determine whether nuclear localization contributes to pathogenesis in vivo. In Specific Aim 2, we will generate transgenic mice expressing mutant full-length atrophin-1 with the putative nuclear export signal altered, in order to determine whether nuclear localization contributes to pathogenesis in vivo. In Specific Aim 3, we will establish the site of cleavage of atrophin-
40
Huntington’s Disease
1 with our collaborators at the Buck Institute, and generate mice transgenic for a construct expressing full-length atrophin-1 with this site altered. We will cross our atrophin-1 transgenic mice with mice hemizygous for a targeted deletion in the CBP gene in order to test the hypothesis that transcriptional misregulation contributes to pathogenesis in vivo. We predict that these experiments taken together will confirm roles in vivo for proteolytic cleavage, and nuclear localization, and support a role for alterations in gene transcription as critical for pathogenesis in DRPLA, and supporting the idea that these are general features of polyglutamine pathogenesis. Proteolytic cleavage would be an especially good target for therapeutic interventions. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: NEUROIMAGING OF HYPERKINETIC MOVEMENT DISORDERS Principal Investigator & Institution: Hutchinson, Michael; Neurology; New York University School of Medicine 550 1St Ave New York, Ny 10016 Timing: Fiscal Year 2001; Project Start 13-AUG-1997; Project End 31-JUL-2003 Summary: Despite recent progress, there is still uncertainty about the pathophysiology of movement disorders in man. However there is an awareness that neurologic disease affects motor and cognitive processes by altering neural networks in functionally specific ways. Recently, covariance analysis has been applied to the analysis of Positron Emission Tomography (PET) images of brain glucose metabolism, and has identified some of the underlying abnormal circuitry in idiopathic torsion dystonia and Parkinson's disease. Yet there studies require fairly large numbers of patients and normal controls. Furthermore they do not definitively identify the primary locus of metabolic abnormality, since the abnormal profiles may be an epiphenomenon reflecting maintenance of the dystonic posture. A way of increasing sensitivity is to use the fact that in most movement disorders the abnormal movements disappear in sleep. Sleep is therefore a useful internal reference state uncontaminated by movement. Brain regions showing focal differences between wake and sleep are therefore associated with the anatomic substrate of the disorder. This approach has been validated in a study of craniocervical dystonia (Meige syndrome). Yet is does not reveal the functional interactions of these brain regions. It is therefore proposed to combine the two approaches, in order to obtain a sensitive measure of the underlying neural circuitry. Four hyperkinetic disorders will be studied using regional measures of cerebral glucose metabolism and blood flow: blepharospasm, idiopathic torsion dystonia, Huntington's chorea and levodopa-induced dyskinesia. In addition, covariance analysis of sleeping patients and sleeping normals is expected, finally, to reveal the primary metabolic substrate. Validation of this approach will mediate between existing theories of corticalsubcortical interactions, and may suggest possible surgical or pharmacological intervention in these disorders. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
•
Project Title: NEUROPATHOLOGY AND PATHOGENESIS OF HUNTINGTON' DISEASE Principal Investigator & Institution: Reiner, Anton J.; Professor; Anatomy and Neurobiology; University of Tennessee Health Sci Ctr Health Science Center Memphis, Tn 38163 Timing: Fiscal Year 2001; Project Start 15-JUL-1990; Project End 31-MAR-2005 Summary: (Verbatim from the Applicant's Abstract) This is a competing continuation of NS 28721. In this upcoming 5-year project, the applicant will examine the hypothesis
Studies
41
that Huntington's disease (HD) is caused by AMPA receptor (AMPAR)-mediated excitotoxicity. He proposes that the HD gene defect leads to selective striatal neuronal death by 1) enrichment in AMPARs and cortical inputs in striatal projection neurons and parvalbuminergic interneurons in HD. 2) A preponderance of GluR2 containing AMPARs in striatal neurons projecting to the internal pallidal segment accounts for their lesser vulnerability in HD and 3) The HD mutation decreases the numbers of group II mGluRs on corticostriatal terminals, thereby increasing cortical activation and excitotoxicity of striatal neurons. The main hypotheses are based on the following observations: a. The HD gene product is widely expressed in the brain, whereas the neurons killed in HD are localized to the striatum b. No cell-type specific proteins that interact with HD proteins are specific to vulnerable striatal neurons. c. The level of huntingtin in a given type of striatal neuron does not seem to correlate with vulnerability. d. There is suggestion that in HD transgenic mice (Bates R6/2), group II mGluRs are downregulated and that sEPSP frequency is increased. e. HD pathology can be reproduced by 3-NP and by quinolinic acid administration f. Neurons that die are rich in cortical input. g. Neurons that die are rich in AMPARs, some of which appear to be more deficient in GluR2 (the GluR2 hypothesis). From these observations, the applicant concludes "the HD mutation may render corticostriatal neurons destructive rather than render striatal neurons vulnerable." These hypotheses will be tested in 5 Specific Aims: Aim 1: Use single cell RT-PCR, immunoprecipitation and LM and EM immunolabeling to characterize the abundance and subunit composition of AMPA receptors present on HD-vulnerable and HD-resistant striatal interneuron and projection neuron types in rats. Aim 2: Characterize differences between striatal interneurons and projection neurons in AMPAR mediated synaptic responses to cortical input and in subunit dependent AMPA physiology (Ca permeability, rectification and desensitization) in rats Aim 3: Pharmacologically characterize the role of AMPARs and mGluR2/3-regulatable corticostriatal glutamate release in the selective death of striatal neurons in rats chronically administered 3NP, a model of HD. Aim 4: Use in-situ hybridization histochemistry, LM and EM immuno to determine in striatal neurons in monkey and in HD striatum whether the distribution of AMPAR subunits in HD vulnerable and HD resistant striatal neurons is consistent with their hypothesized role in selective neurodegeneration. Aim 5: Use in-situ hybridization histochemistry, LM and EM immuno to determine in a transgenic rat model of HD and in human HD specimens whether or not the HD mutation decreases mGluR2/3 in corticostriatal neurons and their intrastriatal terminals. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: NEUROSCIENCE EDUCATION--TEACHING BRAIN ATLAS Principal Investigator & Institution: Anderson, William J.; Professor; Arizona Institute for Bio-Medical Res Bio-Medical Research Scottsdale, Az 85260 Timing: Fiscal Year 2001; Project Start 01-JUN-1999; Project End 31-JAN-2003 Summary: (Verbatim from the Applicant's Abstract) Neuroscience is a compelling area of science that not only touches upon a diverse array of disciplines, but also provides insights to the essence of what it is to be human. We propose to develop and create a multimedia CD-ROM aimed at teaching neuroscience (particularly Neuroanatomy) to college level students. This CD-ROM would be useful in disseminating this information and insights to this audience in a manner that is both engaging and educational. We will deliver this information in a computer-based, multimedia format series of electronic lessons that will be mastered onto a user-friendly CD-ROM, and delivered on both major personal computer platforms used in colleges and schools in the United States
42
Huntington’s Disease
today: Macintosh and PC. The neuroscience information will be in the form of a selflearning program, such that students will be able to learn at any place and any time. The neuroscience information will reflect on brain disorders and neuropathological correlations of disease. For example, such a CD-ROM will enable the study of neuron perturbations in aging, synaptic degeneration in Huntington's Disease, Parkinson's, schizophrenia and cortical atrophy in AIDS-associated dementia. PROPOSED COMMERCIAL APPLICATION: NOT AVAILABLE Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: NEURTURIN DELIVERY FOR HUNTINGTON'S DISEASE Principal Investigator & Institution: Brandon, Eugene P.; Ceregene, Inc. 9381 Judicial Dr, Ste 130 San Diego, Ca 92121 Timing: Fiscal Year 2003; Project Start 30-SEP-2003; Project End 31-AUG-2004 Summary: (provided by applicant): Huntington's disease (HD) is a severely debilitating heritable neurodegenerative condition for which there currently is no treatment. Because there is a genetic test available for HD, intervention prior to disease onset would be possible if an effective treatment were available. The growth factor neurturin (NTN) has been shown to effectively ameliorate neural degeneration in rodent models of HD when delivered to the brain. However, as a protein growth factor, NTN will not readily access brain targets following systemic administration. Gene transfer using a viral vector is a promising method for delivering growth factors to specific regions of the brain, and the adeno-associated virus (AAV) based vector is in many ways the bestsuited vector for this application. As a first step towards developing AAV-delivered NTN (AAV-NTN) for the treatment of HD, we will test the efficacy of AAV-NTN in two distinct rodent models of HD: the 3-nitroproprionic acid (3NP) lesion in Lewis rats, and N171-82Q transgenic mice. The ability of AAV-NTN to prevent neurodegeneration and motor deficits in 3NP lesioned rats, and reduce accumulation of neuronal intranuclear inclusions, and motor and cognitive deficits in N171-82Q transgenic mice will be assessed. Successful results from these studies will lead to safety studies in rats, safety and efficacy studies in non-human primates, and if indicated, the filing of an IND and clinical trials in HD patients. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
•
Project Title: N-METHYL FIBRILLOGENESIS
AND
OTHER
PEPTIDE
INHIBITORS
OF
Principal Investigator & Institution: Meredith, Stephen C.; Associate Professor; Pathology; University of Chicago 5801 S Ellis Ave Chicago, Il 60637 Timing: Fiscal Year 2003; Project Start 15-JAN-2003; Project End 31-DEC-2007 Summary: (provided by applicant): We have synthesized several potent inhibitors of beta-amyloid and other peptide fibrillogenesis containing N-methyl amino acids in alternate positions of sequences homologous to putative aggregation sites. Thus far, we have made inhibitors of beta-amyloid and prion peptide, and have recently synthesized a peptide designed to inhibit aggregation of huntingtin. The overall goal of this research is to understand the forces that promote the binding of these inhibitors to Alzheimer's beta-amyloid and related fibrils, in particular, the relative importance of hydrogen bonds involving the peptide backbone, and side chain interactions, including hydrophobic interactions and hydrogen bonds. Specific aim 1 is to determine the modes of interaction between Abeta(1-40) and inhibitors of Abeta fibrillogenesis. We will determine the site of binding and orientation (parallel or antiparallel) between
Studies
43
fibrillogenesis inhibitor peptides and Abeta(1-40) using solid state NMR spectroscopy, in particular, heteronuclear 15N-13C-REDOR pulse sequence NMR, with Dr. Robert Tycko of N.I.H. We will also study these peptide interactions and determine the structure of complexes between a fibrillogenesis inhibitor, Abeta(16-20)m and Abeta(140), using solution state NMR and other biophysical approaches. Specific aim 2 is to understand the modes of association of inhibitor peptides with Abeta, and to understand the roles of hydrogen bonds, the hydrophobic effect, and conformational rigidity in these interactions. Specific Aim 3 is to examine the role of amphiphilicity in determining the orientation, parallel or antiparallel of beta-sheet fibrils. We hope, with these to resolve a controversy in the Abeta literature. We hypothesize that whereas nonamphiphilic peptides tend to form fibrils with antiparallel beta-sheets, amphiphilic peptides such as Abeta(1-40) are driven towards forming fibrils with parallel betasheets. This hypothesis will be tested using REDOR and other biophysical techniques on short Abeta peptides known to form antiparallel beta-sheet fibrils. We will test the hypothesis that the addition of fatty acids to render these peptides amphiphilic will reverse their orientation to parallel beta-sheets. Specific aim 4 is to examine the ability of a peptide backbone and side chain methylated polyglutaminyl peptide to inhibit aggregation and disaggregate fibrils of huntingtin, and to examine their mode of interaction with huntingtin peptides in vitro and in vivo. These inhibitor designs may be useful for understanding the forces that promote fibrillogenesis in neuro-degenerative diseases, and in designing novel diagnostic or therapeutic agents for these diseases. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: PATHOPHYSIOLOGY OF CHOREA Principal Investigator & Institution: Mink, Jonathan W.; Associate Professor, Chief Child Neurolo; Neurology; University of Rochester Orpa - Rc Box 270140 Rochester, Ny 14627 Timing: Fiscal Year 2001; Project Start 19-JUN-2000; Project End 31-MAY-2003 Summary: Chorea is a movement disorder that results from basal ganglia injury due to a variety of causes in children. Chorea is characterized by sudden, brief, involuntary muscle contractions causing movements that appear to flow from body part to body part in an unpredictable manner. Disorders associated with chorea include CNS infections, post-infectious and other autoimmune diseases, ischemia during cardiopulmonary bypass, 'extrapyramidal' cerebral palsy, a variety of toxic and acute metabolic processes, degenerative conditions, and inborn errors of metabolism. In many cases the cause is unknown. In diseases with well defined neuropathology, chorea has been associated with abnormalities in the striatum (caudate and putamen) and the subthalamic nucleus (STN). However, the fundamental pathophysiology of chorea is not known. This is due in part to the lack of non-primate models and in part to the difficulty of measuring involuntary movements in the primate models that do exist. Current medical treatment options for chorea are few, may have significant side effects, and are often ineffective. The proposed experiments will develop quantitative 3-dimensional kinematic measures of chorea and use them measure spatial and temporal properties of chorea in adults and children with different disorders. Focal pharmacologic manipulation of basal ganglia nuclei will be used in monkeys to produce chorea. The resulting chorea will be measured in the monkeys and compared to human chorea in order to validate the monkey models, especially with respect to childhood chorea. The monkey models will then be used to investigate the fundamental pathophysiology of chorea by recording the activity of individual globus pallidus internal segment neurons before and during chorea. Through a combination of neurophysiologic and kinematic techniques to study experimentally produced chorea, the prevailing hypotheses of
44
Huntington’s Disease
chorea pathophysiology can be tested rigorously. There is strong potential to identify the fundamental mechanisms of chorea. Development of a non-invasive method to quantify chorea in children and in monkeys will be an important advance toward better characterization of the pathophysiology of involuntary movements and development of more effective medical therapies. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: POLYCYSTIN-1 INTERACTION WITH TSC-2 IN POLYCYSTIC KIDNEY DISEASE Principal Investigator & Institution: Guan, Kun-Liang; Associate Professor; University of Michigan at Ann Arbor 3003 South State, Room 1040 Ann Arbor, Mi 481091274 Timing: Fiscal Year 2003; Project Start 01-SEP-2003; Project End 31-AUG-2008 Summary: Autosomal dominant polycystic kidney disease (ADPKD) is one of the most common genetic disorders in humans. In the United States, ADPKD is more common than cystic fibrosis, Huntington's disease, and muscular dystrophy. ADPKD is characterized by the formation of cysts in kidney and caused by mutation in either PKD1 (85%) or PKD2 (15%) gene. Tuberous sclerosis (TSC) is an autosomal dominant inheritable genetic disorder due to mutation in either TSC1 or TSC2 gene. TSC is characterized by formation of hamartomas in various tissues. Cyst formation in kidney is also observed in TSC. The PKD1 and TSC2 genes are located adjacent to each other on human chromosome 16p and deletion of both genes results in a contiguous gene syndrome responsible for the severe infantile polycystic kidney disease. TSC2 has been implicated to play a role in the proper functions of polycystin-1, the product of PKD1 gene. The long-term goals of this project are to understand the functional relationship between TSC2 and PKD1 and to elucidate the molecular mechanism of TSC2 in regulation of PKD1 function and ADPKD. The specific aims of this proposal are to elucidate the mechanism of TSC2 regulation by osmotic stress and to investigate the function of TSC2 in regulation of the plasma membrane localization of polycystin-1. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
•
Project Title: POLYGLUTAMINE AGGREGATES Principal Investigator & Institution: Wetzel, Ronald B.; Professor; Medicine; University of Tennessee Knoxville Knoxville, Tn 37996 Timing: Fiscal Year 2001; Project Start 15-JUN-2001; Project End 31-MAY-2005 Summary: (Adapted from applicant's abstract): In the expanded CAG repeat diseases, such as Huntington's Disease, abnormally long polyglutamine sequences have been implicated as the principle causative factor of the disease. The mechanism by which these molecules promote neurodegeneration is not clear, but a large body of evidence suggests that the mechanism has something to do with the enhanced ability of lengthened polyglutamine sequences to self-associate into oligomers or aggregates. While there is an imperfect correlation of disease physiology with the appearance of large aggregates in cellular nuclei, there is also a lot of indirect evidence, such as the widely reported involvement of cellular chaperones, that a misfolding / aggregation process is involved in these diseases. One limitation in our ability to progress more deeply into the disease mechanism is our ignorance of the details of the process and products of polyglutamine aggregation. For example, improved correlation of disease development with polyglutamine aggregation might be obtained if it were possible to distinguish different sizes and types of aggregates. There is significant information on the behavior of polyglutamine sequences from cellular expression experiments, but,
Studies
45
owing to the very poor solubility properties of these molecules, there is much less mechanistic and structural information on defined polyglutamine sequences at the in vitro chemical level. This application is based on recent advances in this laboratory in the ability to solubilize these molecules and control their aggregation in vitro. A series of chemically synthesized polyglutamine sequences of different lengths will be developed and used to pursue the following aims. The length dependence of the kinetics and thermodynamics of the aggregation process will be characterized. The length dependence of aggregate structure will also be characterized. Mutational analysis o f the polyglutamine sequence will be conducted in order to better define the unique role of glutamine in aggregation and to better understand aggregate structure at the atomic level. Finally, the abilities of a series of molecular chaperones to retard and reverse the aggregation process will be characterized in vitro. The work should lead to a better understanding of the role of polyglutamine self-association in the disease mechanism and the nature of the toxic entity in turn; this should stimulate new work on the therapeutic intervention. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: POLYGLUTAMINE NEURODEGENERATION
CONFORMATION
AND
Principal Investigator & Institution: Finkbeiner, Steven M.; Assistant Professor; J. David Gladstone Institutes 365 Vermont St San Francisco, Ca 94103 Timing: Fiscal Year 2003; Project Start 01-APR-2003; Project End 31-MAR-2008 Summary: Huntington's disease belongs to a family of eight inherited, untreatable neurodegenerative diseases. Each is caused by an abnormal polyglutamine expansion in a different protein, In all eight, disease occurs when the polyglutamine stretch exceeds a certain length and symptom onset is inversely related to its length. Abnormal deposits of protein called inclusion bodies characterize many of these diseases. Whether Inclusion bodies are pathogenic, an epiphenomenon, or a beneficial defense response is controversial. Abnormal polyglutamine expansions probably cause degeneration by conferring a toxic gain of function to proteins. Polyglutamine expansions may adopt a conformation that is different depending on whether huntingtin is in Inclusion bodies or not. We hypothesize that abnormal polyglutamine expansion alters the conformation of soluble mutant huntingtin, enabling it to interact with cellular targets and produce neurodegeneration, independent of inclusion body formation. Certain heat shock proteins can protect cells against polyglutamine and regulate inclusion body formation. It is unknown whether they act mainly on inclusion bodies, oligomers, or malfolded monomers. It is unknown whether huntingtin needs to oligornerize to adopt a toxic conformation and whether the length or the composition of the polyglutamine stretch is critical to conformation or aggregation. We have used primary neurons to develop a model of Huntington's disease that recapitulates polyglutamine-dependent and neuron-specific death and inclusion body formation. We have also developed monoclonal antibodies that bind a conformation of huntingtin that correlates closely with Huntington's disease symptoms and which distinguishes huntingtin in inclusion bodies from more soluble forms. Finally, we have built a robotic microscope so we can simultaneously measure inclusion body formation within living neurons and then track their individual fates. We propose to use these tools to accomplish the following specific aims: Aim 1. To determine whether the availability of a disease-associated conformation is a better predictor of neurodegeneration than inclusion body formation. Aim 2. To determine whether heat shock proteins regulate huntingtin conformation and to relate the effects of heat shock proteins on neuronal survival to conformation and to inclusion
46
Huntington’s Disease
body formation. Aim 3. To examine how the oligomeric state of mutant huntingtin and the length and composition of the polyglutamine stretch determine its ability to form a disease-associated conformation and to aggregate. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: PROTEIN AGGREGATION AND INCLUSION BODY FORMATION Principal Investigator & Institution: Kopito, Ron R.; Professor; Biological Sciences; Stanford University Stanford, Ca 94305 Timing: Fiscal Year 2002; Project Start 01-JUN-2002; Project End 31-MAY-2007 Summary: (provided by applicant): Deposition of aggregates of misfolded protein into intracellular inclusion bodies is a prominent cytopathological feature of nearly every known neurodegenerative disease. Despite mounting genetic and biochemical evidence linking protein aggregation to pathogenesis in these and other diseases, it is unclear bow -or indeed whether- protein aggregation and inclusion body formation are primary toxic events or cytoprotective responses. My lab has recently described a general pathway by which aggregated proteins in mammalian cells are collected into specialized inclusion bodies called aggresomes (AG). The studies described in this proposal are intended to test the hypothesis that delivery of protein aggregates to AG is a specific, microtubuledependent transport process which facilitates the neutralization and elimination of potentially toxic gene products. Towards this end, three specific aims are proposed. The first aim will use biochemical and biophysical techniques to study the cellular mechanism of AG formation to identify transport intermediates in AG formation. These intermediates will be subject to extensive biochemical, biophysical and structural characterization. The second aim of the proposed research will be to reconstitute AG formation in a cell-free system in order to identify the cytoplasmic components required for retrograde transport of protein aggregates on microtubule tracks. Finally, the last aim will investigate the role of retrograde transport in the neutralization and elimination of protein aggregates. These last studies will specifically test the hypothesis that retrograde transport of aggregated protein is linked to the lysosomal/autophagic pathway of protein degradation. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
•
Project Title: PROTEIN PALMITOYLATION IN YEAST Principal Investigator & Institution: Davis, Nicholas G.; Surgery; Wayne State University 656 W. Kirby Detroit, Mi 48202 Timing: Fiscal Year 2002; Project Start 01-JUN-2002; Project End 31-MAY-2006 Summary: (provided by applicant): Palmitoylation is one of several different lipid modifications that serve to target and anchor proteins to membranes in eukaryotic cells. Palmitoylation has been long-recognized for its role in directing the localization of a variety of signaling proteins, including key players in cancer like H- and K-Ras, Src, Lck, and Rho, to plasma membrane sites of action. Despite the long history, little has been learned regarding the enzymology of this modification - the responsible enzymatic activities have not been identified. Our recent work in the yeast Saccharornyces cerevisiae, indicates that the ankyrin-repeat protein Akr1p is required for palmitoylation and consequent membrane localization of the type I casein kinase, Yck2p; in akr1delta cells, Yck2p is not palmitoylated and as a consequence is mislocalized diffusely throughout the cytoplasm, rather than to the plasma membrane. The major goal of this proposal is to characterize the role of Akr1p in the palmitoylation process. Preliminary work indicates that Akr1p is a strong candidate to be an enzymatic component of the
Studies
47
palmitoyl transferase. This will be tested. In addition, Akr1p-containing complexes will be purified from yeast to identify the proteins that collaborate with Akr1p for palmitoylation. Another significant fact regarding Akr1p is that is its closest human homolog is a protein identified for its possible role in Huntington's disease. Thus, these fundamental studies on the function of Akr1p in yeast may well impact our understanding of the disease processes in both cancer and in Huntington's disease. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: PROTEOPATHIES OF THE AGING CENTRAL NERVOUS SYSTEM Principal Investigator & Institution: Mucke, Lennart; Associate Professor; J. David Gladstone Institutes 365 Vermont St San Francisco, Ca 94103 Timing: Fiscal Year 2003; Project Start 15-JUN-2003; Project End 31-MAY-2008 Summary: (provided by applicant): We will address the hypothesis that different neurodegenerative diseases are caused by the accumulation of distinct proteins with pathogenic conformations (proteopathies). These disorders are a complex biomedical, behavioral, and social problem as they are increasing in frequency, cause major disability, and remain largely untreatable. If the ways in which different proteins damage nerve cells overlap, treatments may be developed to prevent and reverse more than one of these conditions. We have assembled five interactive projects and four essential cores to study the mechanisms by which proteins associated with Alzheimer's, Parkinson's, or Huntington's disease impair neuronal function and survival. The program is multidisciplinary and relies on state-of the-art technology, including X-ray crystallography, robotic microscopy, transgenic and gene-targeted mouse models, cellular biology, neuropathology, and behavioral neuroscience. Project 1, "Polyglutamine Conformation and Neurodegeneration," aims to differentiate whether visible aggregates or other conformational states of mutant huntingtin are responsible for Huntington's disease-related neurodegeneration. Project 2, "Protein Structure in Apolipoprotein E4-associated Neurodegeneration," will test whether the Alzheimer's disease-promoting effect of apolipoprotein E4 depends on the conformation and stability of this molecule. Project 3, "Apolipoprotein E in Neurobiology: Cellular Mechanisms," will examine whether apolipoprotein E4 promotes Alzheimer's diseaselike pathology through amyloid beta peptide (Abeta)-dependent pathways or via independent mechanisms. Project 4, "Causes and Consequences of alpha-Synuclein Aggregation," will assess whether pathogenic interactions between Abeta and alphasynuclein could contribute to the development of Parkinson's disease and other Lewy body diseases. Project 5, "Mechanisms of AbetaD-induced Neuronal Deficits," will analyze the molecular cascades that link the formation of neurotoxic Abeta assemblies to Alzheimer's disease-related cognitive decline and test whether these cascades can be modulated by apolipoprotein E isoforms and alpha-synuclein. The Cores (A: Administrative; B: Tissue Culture; C: Animal; D: Neuropathology/Imaging) will provide the common services necessary to accomplish the goals of the program project. Our studies will shed light on diverse neurodegenerative diseases and could provide the knowledge needed to better treat and prevent them. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
•
Project Title: REGULATION AND FUNCTION OF ERK5 IN CNS NEURONS Principal Investigator & Institution: Xia, Zhengui; Associate Professor; Environmental Health; University of Washington Seattle, Wa 98195 Timing: Fiscal Year 2001; Project Start 01-MAY-2001; Project End 31-MAR-2005
48
Huntington’s Disease
Summary: (provided by applicant): Apoptosis is a form of programmed cell death and is evolutionarily conserved. Apoptosis plays an important role in the nervous system both during development and in homeostasis of adults. Inappropriate apoptosis may contribute to various neurodegenerative conditions including stroke, epilepsy, Down's syndrome, Parkinson's disease, Huntington's disease, ALS, and Alzheimer's disease. Hence, elucidation of mechanisms that regulate neuronal apoptosis is of fundamental importance for neurobiology and may ultimately contribute to the development of pharmacological interventions and clinical strategies for treatment of various neurodegenerative disorders. Neuronal activity and neurotrophins are critical for the differentiation, survival, and adaptive responses of neurons both during development and in the adult brain. Activation of the extracellular signal regulated kinases (ERK) 1 and 2 by neurotrophins, Ca2+ and cAMP have been strongly implicated in these processes. Recently, a new member of the mitogen-activated protein (MAP) kinase family, ERK5, was discovered. Like ERK1 and ERK2, EGF stimulation of ERK5 is blocked by the MEK inhibitors, PD98059 and U0126. This suggests the interesting possibility that some of the functions attributed to ERK1/2 may be mediated by ERK5. However, the regulatory properties of ERK5 in neurons have not been reported. Our preliminary data suggest that neurotrophins including BDNF activated ERK5 in primary cultured cortical neurons. We hypothesize that mechanisms for regulation of ERK5 and downstream transcriptional pathways regulated by ERK5 are distinct from ERK1/2 in neurons. We also hypothesize that ERK5 has unique physiological functions in the central nervous system (CNS). The overall objective of this proposal is to define the signal transduction pathway for ERK5 activation in primary cultured neurons, and the role for the ERK5 pathway in promoting neuronal survival. Cortical neurons were chosen because cerebral cortex is important for higher order learning and memory, and neurons in the cortex are frequently damaged in neurodegenerative diseases. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: RETROGRADE SIGNALING BY ENDOGENOUS CANNABINOIDS Principal Investigator & Institution: Regehr, Wade G.; Professor; Neurobiology; Harvard University (Medical School) Medical School Campus Boston, Ma 02115 Timing: Fiscal Year 2002; Project Start 01-JUL-2002; Project End 31-MAY-2007 Summary: (provided by applicant): Cannabinoids, such as d9-THC, affect the brain by activating G-protein coupled CB1 receptors that can inhibit adenylate cyclase, modulate a variety of ion channels, and inhibit synaptic transmission. These receptors are expressed widely throughout the brain, with particularly high levels of expression found in the cerebellum, the cortex, the hippocampus and the striatum. Recent studies provide new insight into the physiological role of the cannabinoid system and suggest that cannabinoids can act as retrograde messengers. Elevations of calcium in the dendrites of some types of neurons result in the cleavage of phospholipids leading to the formation and liberation of endogenous cannabinoids, which bind to presynaptic CB1 receptors to inhibit synaptic transmission. This retrograde inhibition lasts for tens of seconds. Our primary goal is to clarify the properties and mechanisms of this retrograde inhibition and to determine its physiological role. Studies will be performed in rodent cerebellar brain slice on excitatory and inhibitory synapses that are known to be retrogradely inhibited by cannabinoids released from Purkinje cell dendrites. These synapses are well suited to these studies because cells are readily identified, whole cell voltage clamp is straight forward, and both presynaptic and postsynaptic calcium levels can be monitored optically. Mechanistic studies will concentrate on the calcium dependence of cannabinoid release, identification of the presynaptic targets of that
Studies
49
modulation, and determination of the factors governing its time course. Factors governing the spread of retrograde inhibition to synapses onto neighboring cells and its spatial extent will also be determined. In addition, we will determine the physiological role of retrograde inhibition in controlling synaptic strength and determine if it is a mechanism that can provide synapse-specific regulation or if it provides a homeostatic mechanism for a cell to regulate all of the synaptic inputs it receives. These basic mechanistic studies promise to help cannabinoids realize their great therapeuptic potential as an appetite stimulant, as an anticonvulsant, and in the treatment of Huntington's disease and Parkinson's disease. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: ROLE NEURODEGENERATION
OF
SOMATIC
MTDNA
MUTATIONS
IN
Principal Investigator & Institution: Khrapko, Konstantin; Beth Israel Deaconess Medical Center St 1005 Boston, Ma 02215 Timing: Fiscal Year 2001; Project Start 01-JUL-2001; Project End 31-MAY-2006 Summary: (Adapted from the abstract provided by the applicant): The long-term goal of the proposed research is to study the mechanisms responsible for the slow progression of late-onset neurodegenerative diseases. The understanding of these mechanisms may help to find ways to make these processes even slower, thus moving the onset of these debilitating diseases outside the normal human lifespan. Specifically, we propose to test the hypothesis that accumulation of somatic mutations in mtDNA of critical cell types in the brain is one of the conditions necessary for the progression of at least some neurodegenerative processes. One of the possibilities is that once the fraction of mutated mtDNA in specific cells exceeds a certain threshold, these cells become sensitive to biochemical insults associated with some diseases. This hypothesis has arisen from the preliminary finding that individual pigmented neurons in substantia nigra accumulate very high levels of mtDNA deletions, which are highly likely to compromise cell's resistance to various stresses. Moreover, there are indications that cells with a heavy mutational load are the first to die in Parkinson's brain. It is also possible that progression of the disease accelerates accumulation of mutations thus creating a positive feedback. The efforts will be focused first on Parkinson's Disease (PD) patients and pigmented neurons of substantia nigra. Then research will be extended to Alzheimer's Disease (AD), Huntington's Disease (HD) and the various corresponding brain areas and critical cell types. The Specific Aims of the proposal are: 1) To develop and optimize the arsenal of methods necessary for the precise quantification and characterization of mtDNA mutations in single cells of the brain. These methods will include laser capture micro-dissection for single cell isolation, amplification of full-length mitochondrial genomes from single cells, single cell competitive PCR, and single cell limiting dilution PCR. 2) To identify brain areas and cell types in which mtDNA mutations are most likely to contribute to neurodegeneration. This will be done by measuring mutation load in individual cells of substantia nigra, cortex and putamen that are known to be rich in mtDNA deletions and are critical for PD, AD, and HD, respectively. 3) To test the hypothesis that clonal expansions of mtDNA mutations in individual cells contribute to mitochondrial defects and to neurodegeneration and death of neurons. This will be done by comparing the mutational load of cells that stained positive for various markers of mitochondrial dysfunction, cell degeneration and death to non-staining control cells. We will also study the distribution the mutations as a function of age and the presence and severity of the disease. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
50
Huntington’s Disease
•
Project Title: STRIATAL CONTRIBUTIONS TO CATEGORY LEARNING Principal Investigator & Institution: Filoteo, J V.; Veterans Medical Research Fdn/San Diego Foundation of San Diego San Diego, Ca 92161 Timing: Fiscal Year 2002; Project Start 15-FEB-2002; Project End 31-JAN-2006 Summary: (provided by applicant): Previous studies indicate that patients with damage to the striatum, such as patients with Parkinson's disease (PD) or Huntington's disease (HD), are impaired in certain categorization tasks, but show no impairment in other categorization tasks. These studies suggest that the striatum may be involved in category learning under some circumstances but not others. One possible role of the striatum in category learning is that these structures are involved in learning nonverbal rules, but only when learning is based on corrective feedback under supervised learning conditions. Such a hypothesis is consistent with current models of striatal functioning. However, it is difficult to draw strong conclusions regarding the proposed role of the striatum based on past work because most of these studies used very different categorization tasks that vary along a number of important dimensions. The proposed research remedies these problems by conducting highly systematic studies of category learning in patients with PD. Factors known to impact the verbalizability of categorization rules will be explored, including (1) whether the rule is linear or nonlinear, (2) whether the rule requires information integration across dimensions or selective attention, and (3) whether the stimulus dimensions are separable or integral. In addition, the nature of training (corrective feedback or observation) will also be examined. These factors likely determine the extent to which the striatum is involved in category learning. Each of these factors will be explored within the framework of a highly successful categorization paradigm that has been used extensively in studies of normal cognition, and recently has been extended to some patient populations and normal aging. The paradigm, called the perceptual categorization task, is rigid enough that strong controls can be placed on factors that vary widely across other tasks, but is flexible enough that each of the factors outlined above can be studied in isolation. Further, quantitative models will be applied to the data of PD patients and controls in order to determine more precisely the nature of any observed category learning deficits in the PD patients. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
•
Project Title: STRIATAL ENERGETICS AND HUNTINGTON'S DISEASE Principal Investigator & Institution: Dubinsky, Janet M.; Associate Professor; Neuroscience; University of Minnesota Twin Cities 200 Oak Street Se Minneapolis, Mn 554552070 Timing: Fiscal Year 2001; Project Start 01-SEP-2000; Project End 31-AUG-2004 Summary: (Adapted from the Aplicant's Abstract) Metabolic impairment is a physiological characteristic in the selective neurodegeneration associated with Huntington's disease and transgenic and knock-in mouse models of Huntington's disease. Most importantly, it is not known how the unique striatal ener aboutv deficit activated or aggravated by ubiquitous, mutant huntington expression leads to selective striatal cell death. The objective of the current proposal is to investigate the relationship between the expression of expanded CGA repeats and the bioenergetic defects associated with Huntington's disease and activation of the mitochondrial permeability transition. Our working hypothesis postulates that the metabolic impairment results in a restricted substrate supply to neuronal mitochondria. Application of exogenous metabolic inhibitors used to model Huntington's disease, e.g. 3-nitropropionic acid
Studies
51
(3NP), would mimic this genetic defect. Under these conditions, elevations in cytosolic Ca2+, perhaps accompanying normal postsynaptic glutamate receptor activation, would cause activation of the mitochondrial permeability transition (mPT) in its low conductance state. Sustained opening of this proton permeable pathway would depolarize mitochondria, inhibit energy-dependent transhydrogenases, lowering antioxidant defenses and increasing the probability of high conductance mPT activation. Striatal neurons may be metabolically more susceptible to this sequence of events than neurons from other brain regions. Experiments are proposed to investigate key elements in this hypothesis: 1) the substrate dependence of induction of the low conductance mPT and the increased vulnerability to reactive oxygen species production, 2) antagonist sensitivity of the permeability transition in brain, 3) the ability of expanded CGA repeats and 4) 3NP to shift mitochondrial responses to Ca2+ towards low conductance mPT induction, and 5) the selective susceptibility of striatal mitochondria to this type of injury. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: THE INFLUENCE OF NICOTINE ON FRACTIONATED REACTION TIMEN Principal Investigator & Institution: Marzilli, Thomas S.; Health/Leisure & Exercise Sci; University of West Florida 11000 University Pky Pensacola, Fl 32514 Timing: Fiscal Year 2003; Project Start 01-AUG-2003; Project End 31-JUL-2005 Summary: (provided by applicant): This R03 grant, in response to NIDA's PAR-00-059 "Small Grant Program," will importantly support the implementation of exploratory research that incorporates a novel and extremely fine-grained approach to the study of nicotine and human performance. This innovative methodology uses electromyography to dissociate the central (cognitive) and peripheral (neuromuscular) processing related to the successful completion of a variety of reaction time tasks. To further discriminate at what level of the central processing stream nicotine is most likely to have an effect, a basic chronometric approach to studying information processing will be incorporated. This chronometric approach will allow for the independent examination of each of the three theoretically nonoverlapping information processing stages which include stimulus identification, response selection and response programming. This methodology provides the opportunity to investigate nicotine's effects on the time between the initiation of the stimulus and the initiation of the motor response (central processing) as well as the time delay between the initiation of the motor response and the actual movement or button release (neuromuscular processing) during a variety of reaction time tasks. This paradigm has been shown to be sensitive to a number of variables such as: intensity of stimulus, number of response alternatives, complexity of movement, age, physical activity and pathologies, but has yet to be used to investigate the affects of nicotine on movement preparation, initiation and execution. These methodologies are well grounded in the field of Motor Learning and Cognitive Psychology, and will be a definite addition to the literature in regards to nicotine effects on human performance. Moreover, the methodologies offered herein could have clinical payoffs in populations, such as Parkinson's disease, Huntington's disease and other pathologies where the planning of movement is thought to be intact, but the initiation of movement may be compromised. This laboratory-based project uses cigarette smokers to better understand how nicotine affects the individual components (pre-motor and motor time) of a variety of reaction time tasks. This disassociation of central and neuromuscular components within a reaction time paradigm offers a substantial positive deviation from previous research utilizing only simple or choice reaction time
52
Huntington’s Disease
methodologies because it may be that individual task components are influenced differentially by nicotine, which would not be evident if only a single, summary measure of reaction time was used. This study will be accomplished by systematically varying experimenter supplied nicotinised and denicotinised cigarettes while administering a variety of subjective, physiological and performance measures under double blind, placebo controlled conditions. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: THE RGS-9 MOUSE: INDUCIBLE EXPRESSION IN THE STRIATUM Principal Investigator & Institution: Lai, Cary H.; Assistant Professor; Scripps Research Institute Tpc7 La Jolla, Ca 92037 Timing: Fiscal Year 2003; Project Start 01-APR-2003; Project End 31-MAR-2005 Summary: (provided by applicant): Our ability to develop useful treatments for neurodegenerative diseases such as Parkinson's and Huntington's disease is hampered by our lack of understanding of the etiology of these disorders. One way of addressing the problem is to develop animal models of the disease and to use these to test hypotheses concerning the origin and progression of the neural degeneration. The ability to test these hypotheses and to create new models for these disorders would be greatly facilitated by the ability to generate mice that express a selected gene exclusively in the striatum. Here we propose to produce transgenic mice permitting the regulated expression of genes in a subset of striatal neurons. We propose to construct a transgenic mouse line ("the RGS-9 mouse") using the promoter and other regulatory elements for the gene encoding the regulator of G-protein signaling-9 (RGS-9) to drive the expression of the tetracycline transactivator. When mated to a distinct transgenic line containing a candidate gene whose transcription is regulated by the tetracycline operator, the resulting offspring should express the candidate gene in striatal neurons in the presence of the inducer, tetracycline. The availability of mice that inducibly express genes in striatal neurons should help neuroscientists tackle Parkinson's and Huntington's disease by facilitating the production of new models for these diseases. As additional genetic loci related to the etiology or progression of these diseases emerge from our improved understanding of the human genome, these genes or altered versions of these genes can be specifically re-inserted into striatal neurons to assess their effects. Use of the RGS-9 mouse would be superior to currently available systems, which express genes in larger collections of cells. Through these efforts, we hope to create a genetic tool that will accelerate the development of therapeutics for the patient with Parkinson's and Huntington's disease. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
•
Project Title: THE ROLE OF NFKB IN HUNTINGTON'S DISEASE Principal Investigator & Institution: Patterson, Paul H.; None; California Institute of Technology Mail Code 201-15 Pasadena, Ca 91125 Timing: Fiscal Year 2003; Project Start 01-JUN-2003; Project End 31-MAY-2006 Summary: (provided by applicant): Huntington's disease (HD) is a fatal neurodegenerative disorder caused by the expansion of CAG repeats in the huntingtin (Htt) gene. Mutant Htt forms intracellular aggregates and is cytotoxic to specific neurons in the striatum and cortex. Causes of cell death in HD include the activation of cell death genes and/or alteration of normal transcription. The objective of this proposal is to investigate how mutant Htt interacts with NF-kappaB signaling pathway. This pathway regulates expression of pro-survival genes, is central to the function of neurotrophic
Studies
53
factors and cytokines, and is activated during excitotoxic cell death mediated by NMDA receptors. We are investigating the interaction of mutant Htt with the IkappaB kinase (IKK) complex that regulates NF-kappaB, and how this affects neuronal responses to extracellular signals. We will focus on the mechanism of how the direct interaction between mutant Htt and IKKgamma, a regulatory component of IKK, influences neurodegeneration in HD. Molecular, cell culture, brain slice and animal model approaches will help to explore the nature and consequence of this interaction. We have preliminary evidence that IKKgamma influences NF- kappaB-regulated neuronal gene expression, as well as mutant Htt-induced cell death and aggregation. (i) Using in vitro and cellular assays, we are mapping the domains in mutant Htt and IKKgamma that mediate their binding. (ii) The functional consequences of Htt-IKKgamma interaction are assessed by isolating IKK complex from mutant and normal Htt-expressing cultured cells and HD transgenic mouse brain. Its kinase activity and ability to regulated NFkappaB mediated gene expression is then tested using in vitro kinase and gene reporter assays. (iii) Downstream genes influenced by the Htt-IKKgamma interaction will be identified by cDNA mini-arrays. mRNA will be isolated from several brain regions from HD and normal mice. (iv) The influence of IKKgamma on mutant Htt-induced cell death and aggregation is being examined in HD transgenic mice and in PC12 cells that inducibly express Htt and/or IKKgamma. We have constructed lentiviral vectors expressing a dominant negative form of IKKgamma as well as cell permeable peptides that block IKKgamma activity in cells. These reagents will be injected into the brains of HD mice in tests of their efficacy in inhibiting mutant Htt toxicity and aggregation. They will also be tested on brain slices from HD mice, in the presence and absence of NMDA. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: TISSUE TRANSGLUTAMINASE: A ROLE IN HUNTINGTON'S DISEASE Principal Investigator & Institution: Lesort, Mathieu J.; Assistant Professor; Psychiatry & Behav Neurobiol; University of Alabama at Birmingham Uab Station Birmingham, Al 35294 Timing: Fiscal Year 2001; Project Start 01-APR-2001; Project End 31-MAR-2005 Summary: (Provided by applicant): Huntington's disease (HD) is an autosomal dominant neurodegenerative disorder caused by a pathological expansion of a polyglutamine domain within the protein huntingtin. The precise mechanisms involved in the etiology are still unknown, however there is evidence that impaired mitochondrial function is likely an important factor in HD. A possible clue to the pathogenesis of HD came with the discovery of neuronal intranuclear and cytoplasmic inclusions composed of mutant huntingtin. It has been suggested that Tissue Transglutaminase (tTG) may be a contributing factor to the formation of these aggregates. Tissue TG is a calcium-dependent transamidating enzyme that catalyzed the formation of isopeptide bonds between specific proteins to produce insoluble polymeric structures. Recently we have demonstrated that TG activity and tTG levels are significantly increased in specific brain regions affected by the disease as compared to control cases. Further, studies from the laboratory demonstrated that tTG associates with a truncated huntingtin protein and activation of tTG resulted in the modification of specific proteins associated only with the mutant truncated huntingtin protein. These results suggest that tTG may have a role in the etiology of HD. Our working hypothesis is that impaired mitochondrial function results in an increase in tTG activity and this subsequently results in an increased association of tTG with truncated huntingtin and modification of specific mutant huntingtin associated protein. In this proposal the
54
Huntington’s Disease
majority of the experiments will be carried out in human neuroblastoma cells that express in a stable or inducible manner, physiological or pathological huntingtin protein constructs. In this proposal we will: (1) test the hypothesis that mitochondria impairment results in an increase in TG activity, and that the presence of mutant huntingtin potentiates this response, (2) test the hypothesis that tTG interacts selectively with the N-terminal truncated huntingtin protein, and that mitochondria impairment results in an increase in this interaction, (3) test the hypothesis that tTG contributes to the formation and/or stabilization of the aggregates, and that mitochondrial impairment may potentiate this effect, and (4) identify the mutant huntingtin-associated proteins that are tTG substrates and test the hypothesis that modification of these proteins may contribute to the selective neuronal death in HD. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: TOWARDS MECHANISTIC EXPLANATIONS OF STRIATAL DISORDERS Principal Investigator & Institution: Thomas, Elizabeth A.; Scripps Research Institute Tpc7 La Jolla, Ca 92037 Timing: Fiscal Year 2002; Project Start 01-JUN-2002; Project End 31-MAY-2007 Summary: (provided by applicant): The broad goals of this application are to identify mechanisms associated with the functions of the striatum under normal and pathological conditions. The striatum is the primary region of dysfunction in several neurodegenerative disorders, such as Huntington's and Parkinson's diseases, and is also associated with movement disorders and psychiatric disturbances. Presently, treatment strategies for these disorders are not curative, but rather are aimed at reducing symptoms. Hence, a better understanding of the mechanisms and pathways that contribute to striatal function is essential. The logic that has motivated our studies is that mRNA molecules with restricted expression in the striatum are likely to encode proteins that are preferentially associated with particular physiological processes of this region. In Specific Aim 1, we will identify and isolate all known genes with specific or enriched expression in the striatum using the systematic, automated mRNA display technology TOGA (Total Gene expression Analysis). We will then create a cDNA microarray chip containing all known and newly discovered striatal-enriched species ( 100). This will provide us with a DNA tool for analyzing the expression status of all striatal-evident genes under various pathological conditions. In this application, we will focus on the pathology of Huntington's disease (HD), (although additional/future studies will investigate other striatum disorders). HD is an inherited, neurodegenerative disorder characterized by progressive motor, psychiatric, and cognitive disturbances. In Specific Aim 2, we will identify genes associated with HD by screening the striatal-enriched DNA chip with RNA from the brains of transgenic HD mice. These mice express exon 1 of the human HD gene carrying an extremely expanded CAG repeat. Finally, we will test the hypothesis that the HD gene product, huntingtin, interacts with proteins that are enriched in the striatum, hence, giving rise to the tissue-specific degenerative patterns observed in this disease. We will screen all striatum-enriched proteins simultaneously for specific interactions with both normal and mutated forms of the huntingtin. This will be achieved by creating a protein microarray chip containing GST-fusion proteins of each striatal-enriched gene and then probing with biotinylated-labeled huntingtin. The molecules identified in these studies could targets for novel therapies that would prevent or slow the onset of symptoms as well as the progression of Huntington's disease, and very well may lead to cures for this and other devastating
Studies
55
neurodegenerative disorders. An important advantage of these potential pharmaceutical targets is that they would act only at the restricted site of expression, the striatum. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: TRAFFICKING DEFECTS IN HUNTINGTONS DISEASE Principal Investigator & Institution: Mcmurray, Cynthia T.; Professor; Mayo Clinic Rochester 200 1St St Sw Rochester, Mn 55905 Timing: Fiscal Year 2001; Project Start 01-APR-2001; Project End 31-MAR-2005 Summary: (from applicant's abstract) It is the aim of this grant to understand defects in vesicular trafficking and cytoskeleton that may underlie Huntington's disease. Expansion of a trinucleotide repeat CAG, encoding glutamine, results in at least eight progressive neurodegenerative disorders, including Huntington's disease (HD). The mechanism by which polyglutamine expansion selectively kills neurons is largely unknown. Aggregation is generally accepted as part of pathogenesis, but it is not known whether toxicity initiates in the nucleus or the cytoplasm. Using time lapse imaging, we have tracked the localization of huntingtin in individual neurons from expression of the mutant protein to cell death. Toxicity initiates in the cytoplasm of primary neurons. Further, we have identified targets of huntingtin-mediated aggregation directly from aggregates in human brain. We show that the expanded Huntington's protein sequesters tubulin and vesicular trafficking motors into insoluble complexes. Direct video imaging of vesicles indicates that the mutant protein indeed inhibits vesicular transport particularly in the anterograde direction. The motor that is most affected appears to be kinesin and the cargo that appears most affected is mitochondria. Our data support a model for HD pathogenesis in which aggregation inhibits proteolysis of the HD protein, disrupts cytoskeletal architecture and impairs motors required for vesicular/organelle trafficking. In this proposal, we aim to test the hypothesis that sequestration of tubulindependent motors underlies HD regional pathology. Using gel filtration, immunoblotting and immunoprecipitation reactions, we will evaluate whether sequestration of tubulin-dependent complexes underlies HD regional pathology in human brain. By establishing primary cultures of affected and resistant neurons, we will directly test whether vesicular trafficking is altered in the presence of normal and expanded HD protein. Since mitochondria are reduced in number in the presence of the mutant huntingtin, we will monitor the fate and subcellular localization of mitochondria by confocal imaging. Alteration in transport will be correlated with the subcellular localization of the HD protein and trafficking motors using fluorescence-labeled proteins and confocal microscopy. Finally, we will refine our understanding of pathogenesis by identifying other proteins present in aggregates by mass spectrometry. The recent observations that tubulin-dependent complexes and vesicular transport may play a role in pathogenesis of ALS and Alzheimer's disease suggest that there may be common aspects to these neurological diseases. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
•
Project Title: APPROACH
TRANSCRIPTIONAL
DYSREGULATION
IN
HD:
THERAPY
Principal Investigator & Institution: Ferrante, Robert J.; Professor; Massachusetts General Hospital 55 Fruit St Boston, Ma 02114 Timing: Fiscal Year 2003; Project Start 15-APR-2003; Project End 31-MAR-2008 Summary: Huntington's disease (HD) is a progressive and fatal neurological disorder caused by an expanded CAG repeat in the gene coding for a protein of unknown
56
Huntington’s Disease
function, huntingtin (HD). There is no known treatment for HD. Although the exact cause of neuronal death in HD remains unknown, there is substantial evidence linking oxidative stress, apoptosis, mitochonddal and energy metabolism dysfunction, and excitotoxicity. These events may be secondary to transcriptional dysregulation caused by direct binding of the mutant HD protein or cleaved products to DNA. Altered protein-protein interactions associated with mutant htt are a consistent finding in HD. Mutant htt recruits other proteins into insoluble aggregates. Mutant HD-induced transcriptional dysregulation may occur early on in the disease process, altering gene expression in those pathogenic mechanisms proposed in HD and causing subsequent neuronal death. We hypothesize that compounds that inhibit or modify transcription factors and also prevent their sequestration may provide novel therapeutic interventions in HD. This hypothesis is based on our novel preliminary data that mithramycin A, an aureolic acid antibiotic that inhibits transcriptional initiation; sodium butyrate, a histone deacetylase inhibitor that modifies transcription by reducing levels of acetylated histones; and cystamine, which blocks huntingtin aggregation, are all effective in significantly extending survival and delaying the neuropathological phenotype in transgeniC HD mice. We will examine the therapeutic effects of mithramycin A and its analogs in HD mouse models, determine optimal intraperitoneal dosing, and complete cross-longitudinal studies on behavioral and neuropathological outcome measures, as pre-clinical trials for human studies. We will compare treatment started both before and after clinical symptoms appear. Secondly, we will characterize the efficacy of histone deacetylase inhibitors and determine whether their administration will improve the clinical and neuropathological phenotype found in transgenic HD mice. Lastly, we propose to identify any cumulative synergies using mithramycin and HDAC inhibitors, while using these compounds in combination with cystamine in targeting eady molecular events in the pathogenesis of HD. Cystamine significantly reduces huntingtin aggregates in HD mice and early treatment may reduce transcription factor sequestration, preventing relocalization of transcription factors, co-activators, and repressor proteins over the temporal sequence of disease in HD mice. This combined multi-pharmaceutical treatment may have a significant neuroprotective effect in HD mice and provide preclinical data for prospective clinical drug-trials in HD patients. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: TRANSCRIPTIONAL REGULATION OF OXIDATIVE DEATH Principal Investigator & Institution: Ratan, Rajiv R.; Director; Massachusetts General Hospital 55 Fruit St Boston, Ma 02114 Timing: Fiscal Year 2003; Project Start 15-APR-2003; Project End 31-MAR-2008 Summary: Huntington's Disease (HD) is an autosomal dominant disorder resulting from selective loss of neurons in the striatum and cerebral cortex. Loss of neurons in HD results from pathological expansion of CAG repeats encoding glutamine. Though the precise mechanisms by which glutamine repeats lead to neuronal loss in HD are unclear, oxidative stress, apoptosis, and transcriptional dysregulation have all been implicated in disease pathogenesis. To understand better oxidative and transcriptional mechanisms that may lead to neuronal loss in HD, we have utilized an in vitro model of oxidative stress in primary cortical neurons. In preliminary studies we have shown that oxidative cell death can be fully abrogated by sequence-selective DNA binding drugs, including mithramycin A (MMA) and chromomcyin A3. These agents are members of the aureolic acid antitumor antibiotics that share a common chromophore, aglycon ring, but differ in the nature of the sugar moieties connected to either side of the aglycone ring. Both antibiotics inhibit transcription during macromoleclar biosynthesis by
Studies
57
binding to the "GC" rich transcriptional response elements. To test whether aureolic antibiotics can protect neurons in an in vivo model ofneurodegeneration that may inolve oxidative stress, we examined the effect of MMA in the R6/2 transgenic model of HD. We found that MMA prolongs survival in these mice by nearly 30%, a magnitude superior to any other single neuroprotective agent. These preliminary data are consistent with the overall hypothesis to be tested in this proposal: MMA inhibits neuronal death due to oxidative stress and/or mutant Huntington protein in vitro and in vivo by inhibiting the binding of pro-apoptotic zinc finger transcription factors such as TIEG, and enhancing the DNA binding of pro-survival transcription factors such as CREB. We will examine this hypothesis by determining whether protective concentrations of MMA inhibit TIEG binding to its GC rich DNA binding sites and whether TIEG is critical for oxidative death in cortical neurons. In the second aim, we will determine how MMA affects CREB DNA binding and whether increases in CREB DNA binding contribute to MMA's salutary effects. In the last specific aim, we will compare the mechanism of neuroprotection of MMA to those ofhistone deacetylase inhibitors, another class of transcriptional regulators. These studies will provide critical, mechanistic data on neuroprotective modulators of transcription. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: TRANSGENIC MOUSE MODELS OF HUNTINGTON'S DISEASE Principal Investigator & Institution: Levine, Michael S.; Professor; Mental Retardation Res Center; University of California Los Angeles 10920 Wilshire Blvd., Suite 1200 Los Angeles, Ca 90024 Timing: Fiscal Year 2002; Project Start 01-JUN-2002; Project End 31-MAY-2007 Summary: (provided by applicant): This proposal will examine cellular mechanisms underlying the dysfunctions detected in Huntington's disease (HD) using four different murine models. The lethal mutation in HD produces an expanded trinucleotide (GAG) repeat within the protein huntingtin. It causes selective neurodegeneration especially in the striatum and cortex, by an unidentified mechanism. Each of the HD models we will examine exhibits a different phenotype produced by unique transgene constructs or 'knocked-in" GAG repeat lengths. By evaluating multiple models we will be able to examine the dysfunctions in more detail and understand the specificity and sequence of physiological changes common to HD and the models. Based on our preliminary studies, we have uncovered several common cellular deficits in two models. These are enhanced responsiveness of N-methyl-D-aspartate (NMDA) receptors in the striatum associated with increased Ca2+ flux, a marked decrease in K+ conductances and a change in the corticostriatal synaptic response. A third model also displays the enhanced response to NMDA. Some of these changes potentially predispose striatal medium-sized spiny neurons to excitotoxic damage. Using a physiological approach, we will examine four hypotheses concerning the cellular mechanisms of dysfunction in HD: 1) alterations in ionotropic glutamate receptor function and changes in evoked and spontaneous excitatory synaptic inputs to striatal neurons 2) alterations in metabotropic glutamate and dopaminergic receptor modulation of ionotropic glutamate receptor function, 3) alterations in K+ conductances and 4) alterations in Ca2+ conductances. The precise onset of changes will be investigated in relationship to the expression of behavioral deficits by using animals that are presymptomatic or after development of overt motor signs. We will examine striatal and corticostriatal neurons, visualized in the slice preparation or acutely dissociated cells, to characterize basic functions by currentand voltage-clamp analyses. Because HD destroys so many different capabilities intellectual, physical and emotional - the insights gained from this research elucidating
58
Huntington’s Disease
the cellular malfunctions in HD are relevant to understanding other GAG repeat disorders and neurological diseases associated with protein aggregate pathologies like Alzheimer's and Parkinson's disease. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: DISEASE
TRANSGENIC
XENOTRANSPLANTS
FOR
HUNTINGTON'S
Principal Investigator & Institution: Isacson, Ole; Professor; Mc Lean Hospital (Belmont, Ma) Belmont, Ma 02478 Timing: Fiscal Year 2001; Project Start 01-JAN-1992; Project End 31-MAR-2003 Summary: (Verbatim from the Applicant's Abstract) Brain cell transplantation research has shown that structural and functional repair of the adult brain is possible. We are testing the functional hypothesis that embryonic striatal neurons can replace neurons lost in adult primate striatum and improve signs of Huntinton's disease (HD). The lack of an optimal human donor cell source in a clinical scenario has led us to utilize zenogeneic (here transgenic pig) embryonic donor cells. Our preliminary in vivo data show that successful xenografts survival in the primate brain requires immunosuppression by cyclosporine, azathiopirne, methylprednisolone and complement inhibition (CD59 transgenic donor tissue and monoclonal antibodies against complement C5). To test the functional hypothesis, we proposed the following experiments: We will transplant CD59 complement aggregation inhibitor expressing transgenic porcine fetal striatal (E35 LGE) cells to the caudate-putamen of non-human primate (Macaca mulatta) with neuronal loss similar to that seen in HD. To determine how functional recovery depends on survival and growth of porcine striatal transplants, we will collect physiological in vivo data by PET/MRI/MRS and behavioral data by examining motor and cognitive function. The physiological analysis of LBE graft function by in vivo imaging and behavioral assays is followed by detailed morphological studies. Combine, these studies will provide essential data on the relationship between structural and functional integration of embryonic neuronal xenografts in a HD primate model. These experiments will improve our knowledge of basal ganglia function and plasticity, as well as determine parameters for optimal cell transplantation in patients with neurological disease. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: TRANSGLUTAMINASE IN NEURODEGENERATIVE DISEASES Principal Investigator & Institution: Johnson, Gail V W.; Professor; Psychiatry; University of Alabama at Birmingham Uab Station Birmingham, Al 35294 Timing: Fiscal Year 2003; Project Start 01-JAN-2003; Project End 31-DEC-2004 Summary: (provided by applicant): Transglutaminases (TGs) are highly regulated, calcium-dependent enzymes that likely play key roles in several critical processes in the nervous system. TGs catalyze a transamidating reaction that results in the incorporation of polyamines into specific glutatmine residues within proteins, or if a protein-bound lysine is the amine donor, the tTG-catalyzed reaction results in the formation of a crosslink between the glutamine and lysine residues in proteins. This is highly specific reaction and only a limited number of proteins have been identified as in situ substrates of TG. Tissue TG (tTG), a member of this family, is the most abundant TG in the human brain and is found within neurons. The levels of tTG and TG activity are increased in neurodegenerative conditions such as Alzheimer's disease and Huntington's disease, and increases in tTG can facilitate neuronal cell death in response to specific stressors.
Studies
59
Further, in a recent study it was found that treatment with cystamine, a drug that inhibits transglutaminase in vitro, prolonged surviv approximately 8-10% in a mouse model of Huntington's disease. These and other results suggest that transglutaminase inhibitors may be beneficial in studying the pathological mechanisms and in the treatment of neurodegenerative diseases such as Huntington's Disease and Alzheimer's Disease. However, there are numerous problems with using cystamine as a drug to treat human neurodegenerative diseases, including the fact that it is a non-specific drug with a very steep toxicity curve. Further, it is a charged molecule that likely does not efficiently cross the blood brain barrier. Therefore it is clear that more selective and efficacious TG inhibitors need to be developed for the study and treatment of neurodegenerative disorders. This laboratory has a longstanding interest in the regulation and function of TGs, and therefore is optimally suited to develop TG assays, both in vitro and in situ, that can be used in high throughput drug screening to identify and develop TG inhibitors that are neuroprotective. The aims of this proposal are to: 1. To develop an assay to measure TG activity for a 96 well format that is robust, reproducible and has a simple readout. 2. To develop an assay to measure TG activity in a cellular model using a 96 well format that is reproducible and easily measured. 3. To validate the assays using pharmacological standards, and then use these assays in an initial screen of a small but diverse collection of FDA approved drugs to demonstrate feasibility. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: VIEWS OF PRIVACY OF GENETIC INFORMATION Principal Investigator & Institution: Klitzman, Robert; New York State Psychiatric Institute 1051 Riverside Dr New York, Ny 10032 Timing: Fiscal Year 2002; Project Start 08-FEB-2002; Project End 31-JAN-2006 Summary: The increasing availability of genetic information on individuals raises a series of critical questions concerning privacy and confidentiality that have not been fully explored. The rise of computers, the Internet, and managed care all threaten the privacy of individuals' health information; and the sequencing of the human genome makes these issues particularly acute. Sharing genetic information may lead to stigma, discrimination, and threats to jobs and life and health insurance. Former President Clinton released privacy regulations, and some states have genetic privacy laws, yet numerous questions and controversies remain. The implementation of such safeguards remains unclear, and patient advocates feel further policies are needed. It is also unclear how privacy concerns and such regulations may affect behavior (e.g., participation in genetic testing) and to what degree new safeguards will allay patient concerns. It is critical to understand patients' underlying conceptions, views and approaches to privacy, and to policy and threats to privacy, and factors involved in these views. Yet no published research has investigated in-depth the perspectives and experiences of individuals confronting genetic diseases, concerning these issues. The aims of this study are thus 1) to explore views of privacy issues among individuals who are at risk of or have genetic disorders concerning privacy of genetic and other health information, threats to privacy, possible policies, and tradeoffs between privacy and benefits that might accrue from sharing genetic information (e.g., for research); 2) to explore the experiences of these individuals concerning privacy and disclosure - to whom they have disclosed that they confront a genetic disease (e.g., to health care professionals, family members, co-workers, employers, and insurance companies); when, why and what they disclosed; what reactions (e.g., stigma and discrimination) they have encountered; and how they view and make these privacy and disclosure decisions; 3) to explore the
60
Huntington’s Disease
relationship of these views of privacy to health behaviors (e.g., delaying or avoiding diagnostic tests or treatment); and 4) to assess how type of genetic or other illness, or other factors may affect these views and experiences. We will conduct in-depth semistructured interviews with 160 individuals -40 each who confront Huntington's Disease, genetically-linked breast cancer, alpha 1 antitrypsin deficiency, and, as a comparison group, coronary artery disease. We have chosen the first 3 of these disorders because our pilot work suggests that critical privacy concerns arise with all 3 of these genetic diseases, but are related to different aspects of these conditions. The findings of this study can enhance further policy, professional and public education, and future research in this area. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
E-Journals: PubMed Central3 PubMed Central (PMC) is a digital archive of life sciences journal literature developed and managed by the National Center for Biotechnology Information (NCBI) at the U.S. National Library of Medicine (NLM).4 Access to this growing archive of e-journals is free and unrestricted.5 To search, go to http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=Pmc, and type “Huntington’s disease” (or synonyms) into the search box. This search gives you access to full-text articles. The following is a sample of items found for Huntington’s disease in the PubMed Central database: •
Bacterial and yeast chaperones reduce both aggregate formation and cell death in mammalian cell models of Huntington's disease. by Carmichael J, Chatellier J, Woolfson A, Milstein C, Fersht AR, Rubinsztein DC.; 2000 Aug 15; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=16928
•
Caspase 3-cleaved N-terminal fragments of wild-type and mutant huntingtin are present in normal and Huntington's disease brains, associate with membranes, and undergo calpain-dependent proteolysis. by Kim YJ, Yi Y, Sapp E, Wang Y, Cuiffo B, Kegel KB, Qin ZH, Aronin N, DiFiglia M.; 2001 Oct 23; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=60131
•
Cdc42-interacting protein 4 binds to huntingtin: Neuropathologic and biological evidence for a role in Huntington's disease. by Holbert S, Dedeoglu A, Humbert S, Saudou F, Ferrante RJ, Neri C.; 2003 Mar 4; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=151406
•
Counting CAG repeats in the Huntington's disease gene by restriction endonuclease EcoP15I cleavage. by Moncke-Buchner E, Reich S, Mucke M, Reuter M, Messer W, Wanker EE, Kruger DH.; 2002 Aug 15; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=134256
3 4
Adapted from the National Library of Medicine: http://www.pubmedcentral.nih.gov/about/intro.html.
With PubMed Central, NCBI is taking the lead in preservation and maintenance of open access to electronic literature, just as NLM has done for decades with printed biomedical literature. PubMed Central aims to become a world-class library of the digital age. 5 The value of PubMed Central, in addition to its role as an archive, lies in the availability of data from diverse sources stored in a common format in a single repository. Many journals already have online publishing operations, and there is a growing tendency to publish material online only, to the exclusion of print.
Studies
61
•
Effects of heat shock, heat shock protein 40 (HDJ-2), and proteasome inhibition on protein aggregation in cellular models of Huntington's disease. by Wyttenbach A, Carmichael J, Swartz J, Furlong RA, Narain Y, Rankin J, Rubinsztein DC.; 2000 Mar 14; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=16027
•
Human single-chain Fv intrabodies counteract in situ huntingtin aggregation in cellular models of Huntington's disease. by Lecerf JM, Shirley TL, Zhu Q, Kazantsev A, Amersdorfer P, Housman DE, Messer A, Huston JS.; 2001 Apr 10; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=31908
•
Huntington's disease age-of-onset linked to polyglutamine aggregation nucleation. by Chen S, Ferrone FA, Wetzel R.; 2002 Sep 3; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=129363
•
Identification of benzothiazoles as potential polyglutamine aggregation inhibitors of Huntington's disease by using an automated filter retardation assay. by Heiser V, Engemann S, Brocker W, Dunkel I, Boeddrich A, Waelter S, Nordhoff E, Lurz R, Schugardt N, Rautenberg S, Herhaus C, Barnickel G, Bottcher H, Lehrach H, Wanker EE.; 2002 Dec 10; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=139900
•
Inhibition of huntingtin fibrillogenesis by specific antibodies and small molecules: Implications for Huntington's disease therapy. by Heiser V, Scherzinger E, Boeddrich A, Nordhoff E, Lurz R, Schugardt N, Lehrach H, Wanker EE.; 2000 Jun 6; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=18723
•
Nonapoptotic neurodegeneration in a transgenic mouse model of Huntington's disease. by Turmaine M, Raza A, Mahal A, Mangiarini L, Bates GP, Davies SW.; 2000 Jul 5; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=16675
•
Novel therapies in the search for a cure for Huntington's disease. by Beal MF, Hantraye P.; 2001 Jan 2; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=33346
•
Self-assembly of polyglutamine-containing huntingtin fragments into amyloid-like fibrils: Implications for Huntington's disease pathology. by Scherzinger E, Sittler A, Schweiger K, Heiser V, Lurz R, Hasenbank R, Bates GP, Lehrach H, Wanker EE.; 1999 Apr 13; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=16379
•
Severe deficiencies in dopamine signaling in presymptomatic Huntington's disease mice. by Bibb JA, Yan Z, Svenningsson P, Snyder GL, Pieribone VA, Horiuchi A, Nairn AC, Messer A, Greengard P.; 2000 Jun 6; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=18747
•
Suberoylanilide hydroxamic acid, a histone deacetylase inhibitor, ameliorates motor deficits in a mouse model of Huntington's disease. by Hockly E, Richon VM, Woodman B, Smith DL, Zhou X, Rosa E, Sathasivam K, Ghazi-Noori S, Mahal A, Lowden PA, Steffan JS, Marsh JL, Thompson LM, Lewis CM, Marks PA, Bates GP.; 2003 Feb 18; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=149955
•
Tauroursodeoxycholic acid, a bile acid, is neuroprotective in a transgenic animal model of Huntington's disease. by Keene CD, Rodrigues CM, Eich T, Chhabra MS, Steer CJ, Low WC.; 2002 Aug 6; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=125009
62
Huntington’s Disease
•
The Gln-Ala repeat transcriptional activator CA150 interacts with huntingtin: Neuropathologic and genetic evidence for a role in Huntington's disease pathogenesis. by Holbert S, Denghien I, Kiechle T, Rosenblatt A, Wellington C, Hayden MR, Margolis RL, Ross CA, Dausset J, Ferrante RJ, Neri C.; 2001 Feb 13; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=29339
•
The Huntington's disease protein interacts with p53 and CREB-binding protein and represses transcription. by Steffan JS, Kazantsev A, Spasic-Boskovic O, Greenwald M, Zhu YZ, Gohler H, Wanker EE, Bates GP, Housman DE, Thompson LM.; 2000 Jun 6; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=18731
•
Transgenic mice expressing a Huntington's disease mutation are resistant to quinolinic acid-induced striatal excitotoxicity. by Hansson O, Petersen A, Leist M, Nicotera P, Castilho RF, Brundin P.; 1999 Jul 20; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=17584
•
Transglutaminase aggregates huntingtin into nonamyloidogenic polymers, and its enzymatic activity increases in Huntington's disease brain nuclei. by Karpuj MV, Garren H, Slunt H, Price DL, Gusella J, Becher MW, Steinman L.; 1999 Jun 22; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=22095
•
Transplanted fetal striatum in Huntington's disease: Phenotypic development and lack of pathology. by Freeman TB, Cicchetti F, Hauser RA, Deacon TW, Li XJ, Hersch SM, Nauert GM, Sanberg PR, Kordower JH, Saporta S, Isacson O.; 2000 Dec 5; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=17669
The National Library of Medicine: PubMed One of the quickest and most comprehensive ways to find academic studies in both English and other languages is to use PubMed, maintained by the National Library of Medicine.6 The advantage of PubMed over previously mentioned sources is that it covers a greater number of domestic and foreign references. It is also free to use. If the publisher has a Web site that offers full text of its journals, PubMed will provide links to that site, as well as to sites offering other related data. User registration, a subscription fee, or some other type of fee may be required to access the full text of articles in some journals. To generate your own bibliography of studies dealing with Huntington’s disease, simply go to the PubMed Web site at http://www.ncbi.nlm.nih.gov/pubmed. Type “Huntington’s disease” (or synonyms) into the search box, and click “Go.” The following is the type of output you can expect from PubMed for Huntington’s disease (hyperlinks lead to article summaries):
6 PubMed was developed by the National Center for Biotechnology Information (NCBI) at the National Library of Medicine (NLM) at the National Institutes of Health (NIH). The PubMed database was developed in conjunction with publishers of biomedical literature as a search tool for accessing literature citations and linking to full-text journal articles at Web sites of participating publishers. Publishers that participate in PubMed supply NLM with their citations electronically prior to or at the time of publication.
Studies
63
•
A case of unilateral neglect in Huntington's disease. Author(s): Ho AK, Manly T, Nestor PJ, Sahakian BJ, Bak TH, Robbins TW, Rosser AE, Barker RA. Source: Neurocase : Case Studies in Neuropsychology, Neuropsychiatry, and Behavioural Neurology. 2003 June; 9(3): 261-73. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12925932&dopt=Abstract
•
A clinical study of patients with genetically confirmed Huntington's disease from India. Author(s): Murgod UA, Saleem Q, Anand A, Brahmachari SK, Jain S, Muthane UB. Source: Journal of the Neurological Sciences. 2001 September 15; 190(1-2): 73-8. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11574110&dopt=Abstract
•
A disorder similar to Huntington's disease is associated with a novel CAG repeat expansion. Author(s): Margolis RL, O'Hearn E, Rosenblatt A, Willour V, Holmes SE, Franz ML, Callahan C, Hwang HS, Troncoso JC, Ross CA. Source: Annals of Neurology. 2001 December; 50(6): 373-80. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11761463&dopt=Abstract
•
A disorder similar to Huntington's disease is associated with a novel CAG repeat expansion. Author(s): Margolis RL, O'Hearn E, Rosenblatt A, Willour V, Holmes SE, Franz ML, Callahan C, Hwang HS, Troncoso JC, Ross CA. Source: Annals of Neurology. 2001 September; 50(3): 373-80. Corrected and Republished In: http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11558794&dopt=Abstract
•
A randomised, placebo-controlled, double blind study of treatment of Huntington's disease with unsaturated fatty acids. Author(s): Vaddadi KS, Soosai E, Chiu E, Dingjan P. Source: Neuroreport. 2002 January 21; 13(1): 29-33. Erratum In: Neuroreport 2002 February; 13(2): Inside Back Cover. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11924889&dopt=Abstract
•
A regression-based method to identify differentially expressed genes in microarray time course studies and its application in an inducible Huntington's disease transgenic model. Author(s): Xu XL, Olson JM, Zhao LP. Source: Human Molecular Genetics. 2002 August 15; 11(17): 1977-85. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12165559&dopt=Abstract
64
Huntington’s Disease
•
A study of arm movements in Huntington's disease under visually controlled and blindfolded conditions. Author(s): Carella F, Bressanelli M, Piacentini S, Soliveri P, Geminiani G, Monza D, Albanese A, Girotti F. Source: Neurological Sciences : Official Journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology. 2003 February; 23(6): 287-93. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12624715&dopt=Abstract
•
Abnormalities in the synaptic vesicle fusion machinery in Huntington's disease. Author(s): Morton AJ, Faull RL, Edwardson JM. Source: Brain Research Bulletin. 2001 September 15; 56(2): 111-7. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11704347&dopt=Abstract
•
Advances in Huntington's disease: implications for experimental therapeutics. Author(s): Feigin A. Source: Current Opinion in Neurology. 1998 August; 11(4): 357-62. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=9725082&dopt=Abstract
•
Alteration of nuclear glyceraldehyde-3-phosphate dehydrogenase structure in Huntington's disease fibroblasts. Author(s): Mazzola JL, Sirover MA. Source: Brain Research. Molecular Brain Research. 2002 April 30; 100(1-2): 95-101. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12008025&dopt=Abstract
•
Alterations in the mouse and human proteome caused by Huntington's disease. Author(s): Zabel C, Chamrad DC, Priller J, Woodman B, Meyer HE, Bates GP, Klose J. Source: Molecular & Cellular Proteomics : Mcp. 2002 May; 1(5): 366-75. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12118078&dopt=Abstract
•
Altered functional MRI responses in Huntington's disease. Author(s): Clark VP, Lai S, Deckel AW. Source: Neuroreport. 2002 April 16; 13(5): 703-6. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11973474&dopt=Abstract
•
Amantadine in Huntington's disease: open-label video-blinded study. Author(s): Lucetti C, Gambaccini G, Bernardini S, Dell'Agnello G, Petrozzi L, Rossi G, Bonuccelli U. Source: Neurological Sciences : Official Journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology. 2002 September; 23 Suppl 2: S83-4. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12548355&dopt=Abstract
Studies
65
•
An overview of psychiatric symptoms in Huntington's disease. Author(s): Anderson KE, Marder KS. Source: Current Psychiatry Reports. 2001 October; 3(5): 379-88. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11559474&dopt=Abstract
•
Anonymous predictive testing for Huntington's disease in the United States. Author(s): Visintainer CL, Matthias-Hagen V, Nance MA; U.S. Huntington Disease Genetic Testing Group. Source: Genetic Testing. 2001 Fall; 5(3): 213-8. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11788086&dopt=Abstract
•
Apolipoprotein E polymorphism in Pick's disease and in Huntington's disease. Author(s): Kalman J, Juhasz A, Majtenyi K, Rimanoczy A, Jakab K, Gardian G, Rasko I, Janka Z. Source: Neurobiology of Aging. 2000 July-August; 21(4): 555-8. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=10924769&dopt=Abstract
•
Apoptosis in Huntington's disease. Author(s): Hickey MA, Chesselet MF. Source: Progress in Neuro-Psychopharmacology & Biological Psychiatry. 2003 April; 27(2): 255-65. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12657365&dopt=Abstract
•
Apraxia of eyelid closure in Huntington's disease. Author(s): Bonelli RM, Niederwieser G. Source: Journal of Neural Transmission (Vienna, Austria : 1996). 2002 February; 109(2): 197-201. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12075860&dopt=Abstract
•
Atrophy of caudate nucleus in Huntington's disease measured by computed tomography. Author(s): Roth J, Havrdova E, Ruzicka E. Source: Journal of Neurology. 2000 November; 247(11): 880-1. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11151423&dopt=Abstract
•
Autonomic nervous system function in Huntington's disease. Author(s): Andrich J, Schmitz T, Saft C, Postert T, Kraus P, Epplen JT, Przuntek H, Agelink MW. Source: Journal of Neurology, Neurosurgery, and Psychiatry. 2002 June; 72(6): 726-31. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12023413&dopt=Abstract
66
Huntington’s Disease
•
Basal ganglia alterations and brain atrophy in Huntington's disease depicted by transcranial real time sonography. Author(s): Postert T, Lack B, Kuhn W, Jergas M, Andrich J, Braun B, Przuntek H, Sprengelmeyer R, Agelink M, Buttner T. Source: Journal of Neurology, Neurosurgery, and Psychiatry. 1999 October; 67(4): 45762. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=10486391&dopt=Abstract
•
Behavior in Huntington's disease: dissociating cognition-based and mood-based changes. Author(s): Thompson JC, Snowden JS, Craufurd D, Neary D. Source: The Journal of Neuropsychiatry and Clinical Neurosciences. 2002 Winter; 14(1): 37-43. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11884653&dopt=Abstract
•
Behavioral and morphological comparison of two nonhuman primate models of Huntington's disease. Author(s): Rafael H. Source: Neurosurgery. 2002 September; 51(3): 852-3. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12229869&dopt=Abstract
•
Behavioral and morphological comparison of two nonhuman primate models of Huntington's disease. Author(s): Roitberg BZ, Emborg ME, Sramek JG, Palfi S, Kordower JH. Source: Neurosurgery. 2002 January; 50(1): 137-45; Discussion 145-6. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11844244&dopt=Abstract
•
Behavioural complaints in participants who underwent predictive testing for Huntington's disease. Author(s): Witjes-Ane MN, Zwinderman AH, Tibben A, van Ommen GJ, Roos RA. Source: Journal of Medical Genetics. 2002 November; 39(11): 857-62. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12414829&dopt=Abstract
•
Bilateral fetal striatal grafts in the 3-nitropropionic acid-induced hypoactive model of Huntington's disease. Author(s): Borlongan CV, Koutouzis TK, Poulos SG, Saporta S, Sanberg PR. Source: Cell Transplantation. 1998 March-April; 7(2): 131-5. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=9588595&dopt=Abstract
•
Bilateral human fetal striatal transplantation in Huntington's disease. Author(s): Hauser RA, Sandberg PR, Freeman TB, Stoessl AJ. Source: Neurology. 2002 June 11; 58(11): 1704; Author Reply 1704. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12058114&dopt=Abstract
Studies
67
•
Bilateral human fetal striatal transplantation in Huntington's disease. Author(s): Hauser RA, Furtado S, Cimino CR, Delgado H, Eichler S, Schwartz S, Scott D, Nauert GM, Soety E, Sossi V, Holt DA, Sanberg PR, Stoessl AJ, Freeman TB. Source: Neurology. 2002 March 12; 58(5): 687-95. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11889229&dopt=Abstract
•
Bimanual co-ordination in Huntington's disease. Author(s): Johnson KA, Bennett JE, Georgiou N, Bradshaw JL, Chiu E, Cunnington R, Iansek R. Source: Experimental Brain Research. Experimentelle Hirnforschung. Experimentation Cerebrale. 2000 October; 134(4): 483-9. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11081830&dopt=Abstract
•
Biochemical abnormalities and excitotoxicity in Huntington's disease brain. Author(s): Tabrizi SJ, Cleeter MW, Xuereb J, Taanman JW, Cooper JM, Schapira AH. Source: Annals of Neurology. 1999 January; 45(1): 25-32. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=9894873&dopt=Abstract
•
Bioenergetics in Huntington's disease. Author(s): Grunewald T, Beal MF. Source: Annals of the New York Academy of Sciences. 1999; 893: 203-13. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=10672239&dopt=Abstract
•
Borderline repeat expansion in Huntington's disease. Author(s): de Rooij KE, de Koning Gans PA, Losekoot M, Bakker E, den Dunnen JT, Vegter-van der Vlis M, Roos RA, van Ommen GJ. Source: Lancet. 1993 December 11; 342(8885): 1491-2. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=7902514&dopt=Abstract
•
Bradykinesia and movement precision in Huntington's disease. Author(s): Phillips JG, Bradshaw JL, Chiu E, Teasdale N, Iansek R, Bradshaw JA. Source: Neuropsychologia. 1996 December; 34(12): 1241-5. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=8951836&dopt=Abstract
•
Bradykinesia in early Huntington's disease. Author(s): Sanchez-Pernaute R, Kunig G, del Barrio Alba A, de Yebenes JG, Vontobel P, Leenders KL. Source: Neurology. 2000 January 11; 54(1): 119-25. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=10636136&dopt=Abstract
68
Huntington’s Disease
•
Bradykinesia in Huntington's disease. Author(s): Garcia Ruiz PJ, Gomez Tortosa E, Sanchez Bernados V, Rojo A, Fontan A, Garcia de Yebenes J. Source: Clinical Neuropharmacology. 2000 January-February; 23(1): 50-2. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=10682231&dopt=Abstract
•
Bradykinesia in Huntington's disease. A prospective, follow-up study. Author(s): Garcia Ruiz PJ, Hernandez J, Cantarero S, Bartolome M, Sanchez Bernardos V, Garcia de Yebenez J. Source: Journal of Neurology. 2002 April; 249(4): 437-40. Erratum In: J Neurol 2002 June; 249(6): 790. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11967649&dopt=Abstract
•
Brain SPECT imaging in Huntington's disease before and after therapy with olanzapine. Case report. Author(s): Etchebehere EC, Lima MC, Passos W, Maciel Junior JA, Santos AO, Ramos CD, Camargo EE. Source: Arquivos De Neuro-Psiquiatria. 1999 September; 57(3B): 863-6. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=10751925&dopt=Abstract
•
Bruxism in Huntington's disease. Author(s): Tan EK, Jankovic J, Ondo W. Source: Movement Disorders : Official Journal of the Movement Disorder Society. 2000 January; 15(1): 171-3. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=10634263&dopt=Abstract
•
Bruxism in Huntington's disease. Author(s): Louis ED, Tampone E. Source: Movement Disorders : Official Journal of the Movement Disorder Society. 2001 July; 16(4): 785-6. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11481718&dopt=Abstract
•
Buspirone in the management of disruptive behaviors due to Huntington's disease and other neurological disorders. Author(s): Bhandary AN, Masand PS. Source: Psychosomatics. 1997 July-August; 38(4): 389-91. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=9217410&dopt=Abstract
•
CAG mutation effect on rate of progression in Huntington's disease. Author(s): Squitieri F, Cannella M, Simonelli M. Source: Neurological Sciences : Official Journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology. 2002 September; 23 Suppl 2: S107-8. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12548366&dopt=Abstract
Studies
69
•
CAG/CTG repeat expansions at the Huntington's disease-like 2 locus are rare in Huntington's disease patients. Author(s): Stevanin G, Camuzat A, Holmes SE, Julien C, Sahloul R, Dode C, HahnBarma V, Ross CA, Margolis RL, Durr A, Brice A. Source: Neurology. 2002 March 26; 58(6): 965-7. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11914418&dopt=Abstract
•
Calpain activation in Huntington's disease. Author(s): Gafni J, Ellerby LM. Source: The Journal of Neuroscience : the Official Journal of the Society for Neuroscience. 2002 June 15; 22(12): 4842-9. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12077181&dopt=Abstract
•
Caspase 3-cleaved N-terminal fragments of wild-type and mutant huntingtin are present in normal and Huntington's disease brains, associate with membranes, and undergo calpain-dependent proteolysis. Author(s): Kim YJ, Yi Y, Sapp E, Wang Y, Cuiffo B, Kegel KB, Qin ZH, Aronin N, DiFiglia M. Source: Proceedings of the National Academy of Sciences of the United States of America. 2001 October 23; 98(22): 12784-9. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11675509&dopt=Abstract
•
Caspase cleavage of mutant huntingtin precedes neurodegeneration in Huntington's disease. Author(s): Wellington CL, Ellerby LM, Gutekunst CA, Rogers D, Warby S, Graham RK, Loubser O, van Raamsdonk J, Singaraja R, Yang YZ, Gafni J, Bredesen D, Hersch SM, Leavitt BR, Roy S, Nicholson DW, Hayden MR. Source: The Journal of Neuroscience : the Official Journal of the Society for Neuroscience. 2002 September 15; 22(18): 7862-72. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12223539&dopt=Abstract
•
Caspases in Huntington's disease. Author(s): Sanchez Mejia RO, Friedlander RM. Source: The Neuroscientist : a Review Journal Bringing Neurobiology, Neurology and Psychiatry. 2001 December; 7(6): 480-9. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11765125&dopt=Abstract
•
Cdc42-interacting protein 4 binds to huntingtin: neuropathologic and biological evidence for a role in Huntington's disease. Author(s): Holbert S, Dedeoglu A, Humbert S, Saudou F, Ferrante RJ, Neri C. Source: Proceedings of the National Academy of Sciences of the United States of America. 2003 March 4; 100(5): 2712-7. Epub 2003 February 25. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12604778&dopt=Abstract
70
Huntington’s Disease
•
Cell therapy for Huntington's disease, the next step forward. Author(s): Peschanski M, Dunnett SB. Source: Lancet. Neurology. 2002 June; 1(2): 81. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12849508&dopt=Abstract
•
Centrosome disorganization in fibroblast cultures derived from R6/2 Huntington's disease (HD) transgenic mice and HD patients. Author(s): Sathasivam K, Woodman B, Mahal A, Bertaux F, Wanker EE, Shima DT, Bates GP. Source: Human Molecular Genetics. 2001 October 1; 10(21): 2425-35. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11689489&dopt=Abstract
•
Clinical and counselling implications of preimplantation genetic diagnosis for Huntington's disease in the UK. Author(s): Lashwood A, Flinter F. Source: Hum Fertil (Camb). 2001; 4(4): 235-8. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11719718&dopt=Abstract
•
Clinical and research advances in Huntington's disease. Author(s): SuttonBrown M, Suchowersky O. Source: The Canadian Journal of Neurological Sciences. Le Journal Canadien Des Sciences Neurologiques. 2003 March; 30 Suppl 1: S45-52. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12691476&dopt=Abstract
•
Clinical relevance of electrophysiological tests in the assessment of patients with Huntington's disease. Author(s): Lefaucheur JP, Bachoud-Levi AC, Bourdet C, Grandmougin T, Hantraye P, Cesaro P, Degos JD, Peschanski M, Lisovoski F. Source: Movement Disorders : Official Journal of the Movement Disorder Society. 2002 November; 17(6): 1294-301. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12465071&dopt=Abstract
•
Cognitive and motor functioning in gene carriers for Huntington's disease: a baseline study. Author(s): Witjes-Ane MN, Vegter-van der Vlis M, van Vugt JP, Lanser JB, Hermans J, Zwinderman AH, van Ommen GJ, Roos RA. Source: The Journal of Neuropsychiatry and Clinical Neurosciences. 2003 Winter; 15(1): 7-16. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12556566&dopt=Abstract
Studies
71
•
Cognitive and psychiatric characterization of patients with Huntington's disease and their at-risk relatives. Author(s): Soliveri P, Monza D, Piacentini S, Paridi D, Nespolo C, Gellera C, Mariotti C, Albanese A, Girotti F. Source: Neurological Sciences : Official Journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology. 2002 September; 23 Suppl 2: S105-6. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12548365&dopt=Abstract
•
Complex language functions and subcortical mechanisms: evidence from Huntington's disease and patients with non-thalamic subcortical lesions. Author(s): Chenery HJ, Copland DA, Murdoch BE. Source: International Journal of Language & Communication Disorders / Royal College of Speech & Language Therapists. 2002 October-December; 37(4): 459-74. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12396844&dopt=Abstract
•
Control of manipulative forces during unimanual and bimanual tasks in patients with Huntington's disease. Author(s): Serrien DJ, Burgunder JM, Wiesendanger M. Source: Experimental Brain Research. Experimentelle Hirnforschung. Experimentation Cerebrale. 2002 April; 143(3): 328-34. Epub 2002 January 30. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11889510&dopt=Abstract
•
Counting CAG repeats in the Huntington's disease gene by restriction endonuclease EcoP15I cleavage. Author(s): Moncke-Buchner E, Reich S, Mucke M, Reuter M, Messer W, Wanker EE, Kruger DH. Source: Nucleic Acids Research. 2002 August 15; 30(16): E83. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12177311&dopt=Abstract
•
Crime in Huntington's disease. Author(s): Ring HA. Source: Journal of Neurology, Neurosurgery, and Psychiatry. 1998 October; 65(4): 435. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=9771762&dopt=Abstract
•
Crime in Huntington's disease: a study of registered offences among patients, relatives, and controls. Author(s): Jensen P, Fenger K, Bolwig TG, Sorensen SA. Source: Journal of Neurology, Neurosurgery, and Psychiatry. 1998 October; 65(4): 46771. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=9771767&dopt=Abstract
72
Huntington’s Disease
•
Cytochrome C and caspase-9 expression in Huntington's disease. Author(s): Kiechle T, Dedeoglu A, Kubilus J, Kowall NW, Beal MF, Friedlander RM, Hersch SM, Ferrante RJ. Source: Neuromolecular Medicine. 2002; 1(3): 183-95. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12095160&dopt=Abstract
•
De novo expansion of a CAG repeat in a Japanese patient with sporadic Huntington's disease. Author(s): Watanabe M, Satoh A, Kanemoto M, Ohkoshi N, Shoji S. Source: Journal of the Neurological Sciences. 2000 September 15; 178(2): 159-62. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11018708&dopt=Abstract
•
Decreased expression of striatal signaling genes in a mouse model of Huntington's disease. Author(s): Luthi-Carter R, Strand A, Peters NL, Solano SM, Hollingsworth ZR, Menon AS, Frey AS, Spektor BS, Penney EB, Schilling G, Ross CA, Borchelt DR, Tapscott SJ, Young AB, Cha JH, Olson JM. Source: Human Molecular Genetics. 2000 May 22; 9(9): 1259-71. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=10814708&dopt=Abstract
•
Decreased plasma alanine and isoleucine in Huntington's disease. Author(s): Reilmann R, Rolf LH, Lange HW. Source: Acta Neurologica Scandinavica. 1995 March; 91(3): 222-4. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=7793240&dopt=Abstract
•
Deep brain stimulation in Huntington's disease. Author(s): Bonelli RM, Gruber A. Source: Movement Disorders : Official Journal of the Movement Disorder Society. 2002 March; 17(2): 429-30; Author Reply 431-2. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11921144&dopt=Abstract
•
Deficits in sensorimotor control during precise hand movements in Huntington's disease. Author(s): Schwarz M, Fellows SJ, Schaffrath C, Noth J. Source: Clinical Neurophysiology : Official Journal of the International Federation of Clinical Neurophysiology. 2001 January; 112(1): 95-106. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11137666&dopt=Abstract
Studies
73
•
Detection of subclinical brain electrical activity changes in Huntington's disease using artificial neural networks. Author(s): de Tommaso M, De Carlo F, Difruscolo O, Massafra R, Sciruicchio V, Bellotti R. Source: Clinical Neurophysiology : Official Journal of the International Federation of Clinical Neurophysiology. 2003 July; 114(7): 1237-45. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12842720&dopt=Abstract
•
Diagnostic re-evaluation of a case of 'cerebellar atrophy with Huntington's disease'. Author(s): White SM, Gubbay SS, Norbury CG, Rosser EM, Huson SM. Source: Journal of the Neurological Sciences. 2000 March 1; 174(1): 47-8. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=10798915&dopt=Abstract
•
Differential deficits in expression recognition in gene-carriers and patients with Huntington's disease. Author(s): Milders M, Crawford JR, Lamb A, Simpson SA. Source: Neuropsychologia. 2003; 41(11): 1484-92. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12849766&dopt=Abstract
•
Disclosure of Huntington's disease to family members: the dilemma of known but unknowing parties. Author(s): Hakimian R. Source: Genetic Testing. 2000; 4(4): 359-64. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11216659&dopt=Abstract
•
Dissociation between intentional and incidental sequence learning in Huntington's disease. Author(s): Brown RG, Redondo-Verge L, Chacon JR, Lucas ML, Channon S. Source: Brain; a Journal of Neurology. 2001 November; 124(Pt 11): 2188-202. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11673321&dopt=Abstract
•
Distractibility during selection-for-action: differential deficits in Huntington's disease and following frontal lobe damage. Author(s): Aron AR, Sahakian BJ, Robbins TW. Source: Neuropsychologia. 2003; 41(9): 1137-47. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12753954&dopt=Abstract
•
Distribution of CAG repeats in normal and Huntington's disease patients in Israel. Author(s): Gazit E, Lubomirov L, Munakov O, Topper A, Frydman M, Fried K, Borochovitz Z, Dangoor N, Bogolubov A, Carp HJ. Source: Clinical Genetics. 1998 September; 54(3): 250-1. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=9788733&dopt=Abstract
74
Huntington’s Disease
•
Disturbance of “extrinsic alertness” in Huntington's disease. Author(s): Muller SV, Jung A, Preinfalk J, Kolbe H, Ridao-Alonso M, Dengler R, Munte TF. Source: J Clin Exp Neuropsychol. 2002 June; 24(4): 517-26. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12187464&dopt=Abstract
•
Does CAG repeat number predict the rate of pathological changes in Huntington's disease? Author(s): Rosenblatt A, Margolis RL, Becher MW, Aylward E, Franz ML, Sherr M, Abbott MH, Lian KY, Ross CA. Source: Annals of Neurology. 1998 October; 44(4): 708-9. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=9778276&dopt=Abstract
•
Does mRNA translation starting from an alternative initiation site contribute to the pathology of Huntington's disease? Author(s): Santos AD, Padlan EA. Source: Medical Hypotheses. 2000 May; 54(5): 689-90. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=10859666&dopt=Abstract
•
Does tissue transglutaminase play a role in Huntington's disease? Author(s): Lesort M, Chun W, Tucholski J, Johnson GV. Source: Neurochemistry International. 2002 January; 40(1): 37-52. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11738471&dopt=Abstract
•
Donepezil for Huntington's disease. Author(s): Fernandez HH, Friedman JH, Grace J, Beason-Hazen S. Source: Movement Disorders : Official Journal of the Movement Disorder Society. 2000 January; 15(1): 173-6. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=10634264&dopt=Abstract
•
Dopamine and cognitive functioning: brain imaging findings in Huntington's disease and normal aging. Author(s): Backman L, Farde L. Source: Scandinavian Journal of Psychology. 2001 July; 42(3): 287-96. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11501742&dopt=Abstract
•
Dose-dependent neuroprotective effect of ciliary neurotrophic factor delivered via tetracycline-regulated lentiviral vectors in the quinolinic acid rat model of Huntington's disease. Author(s): Regulier E, Pereira de Almeida L, Sommer B, Aebischer P, Deglon N. Source: Human Gene Therapy. 2002 November 1; 13(16): 1981-90. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12427308&dopt=Abstract
Studies
75
•
Double-stranded RNA-dependent protein kinase, PKR, binds preferentially to Huntington's disease (HD) transcripts and is activated in HD tissue. Author(s): Peel AL, Rao RV, Cottrell BA, Hayden MR, Ellerby LM, Bredesen DE. Source: Human Molecular Genetics. 2001 July 15; 10(15): 1531-8. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11468270&dopt=Abstract
•
Early alterations in gene expression and cell morphology in a mouse model of Huntington's disease. Author(s): Iannicola C, Moreno S, Oliverio S, Nardacci R, Ciofi-Luzzatto A, Piacentini M. Source: Journal of Neurochemistry. 2000 August; 75(2): 830-9. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=10899961&dopt=Abstract
•
Early kynurenergic impairment in Huntington's disease and in a transgenic animal model. Author(s): Guidetti P, Reddy PH, Tagle DA, Schwarcz R. Source: Neuroscience Letters. 2000 April 14; 283(3): 233-5. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=10754231&dopt=Abstract
•
Early mitochondrial calcium defects in Huntington's disease are a direct effect of polyglutamines. Author(s): Panov AV, Gutekunst CA, Leavitt BR, Hayden MR, Burke JR, Strittmatter WJ, Greenamyre JT. Source: Nature Neuroscience. 2002 August; 5(8): 731-6. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12089530&dopt=Abstract
•
Effect of an attentional strategy on movement-related potentials recorded from subjects with Huntington's disease. Author(s): Johnson KA, Cunnington R, Bradshaw JL, Chiu E, Iansek R. Source: Movement Disorders : Official Journal of the Movement Disorder Society. 2002 September; 17(5): 998-1003. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12360549&dopt=Abstract
•
Effectiveness of physiotherapy, occupational therapy, and speech pathology for people with Huntington's disease: a systematic review. Author(s): Bilney B, Morris ME, Perry A. Source: Neurorehabilitation and Neural Repair. 2003 March; 17(1): 12-24. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12645441&dopt=Abstract
76
Huntington’s Disease
•
Effects of depression on working memory in presymptomatic Huntington's disease. Author(s): Nehl C, Ready RE, Hamilton J, Paulsen JS. Source: The Journal of Neuropsychiatry and Clinical Neurosciences. 2001 Summer; 13(3): 342-6. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11514640&dopt=Abstract
•
Effects of heat shock, heat shock protein 40 (HDJ-2), and proteasome inhibition on protein aggregation in cellular models of Huntington's disease. Author(s): Wyttenbach A, Carmichael J, Swartz J, Furlong RA, Narain Y, Rankin J, Rubinsztein DC. Source: Proceedings of the National Academy of Sciences of the United States of America. 2000 March 14; 97(6): 2898-903. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=10717003&dopt=Abstract
•
Effects of multisensory stimulation in people with Huntington's disease: a randomized controlled pilot study. Author(s): Leng TR, Woodward MJ, Stokes MJ, Swan AV, Wareing LA, Baker R. Source: Clinical Rehabilitation. 2003 February; 17(1): 30-41. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12617377&dopt=Abstract
•
Electrophysiological and morphological changes in striatal spiny neurons in R6/2 Huntington's disease transgenic mice. Author(s): Klapstein GJ, Fisher RS, Zanjani H, Cepeda C, Jokel ES, Chesselet MF, Levine MS. Source: Journal of Neurophysiology. 2001 December; 86(6): 2667-77. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11731527&dopt=Abstract
•
Encapsulated CNTF-producing cells for Huntington's disease. Author(s): Emerich DF. Source: Cell Transplantation. 1999 November-December; 8(6): 581-2. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=10701486&dopt=Abstract
•
Endogenous sodium-potassium ATPase inhibition related biochemical cascade in trisomy 21 and Huntington's disease: neural regulation of genomic function. Author(s): Kumar AR, Kurup PA. Source: Neurology India. 2002 June; 50(2): 174-80. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12134182&dopt=Abstract
Studies
77
•
Enhanced sensitivity to N-methyl-D-aspartate receptor activation in transgenic and knockin mouse models of Huntington's disease. Author(s): Levine MS, Klapstein GJ, Koppel A, Gruen E, Cepeda C, Vargas ME, Jokel ES, Carpenter EM, Zanjani H, Hurst RS, Efstratiadis A, Zeitlin S, Chesselet MF. Source: Journal of Neuroscience Research. 1999 November 15; 58(4): 515-32. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=10533044&dopt=Abstract
•
Environmental stimulation increases survival in mice transgenic for exon 1 of the Huntington's disease gene. Author(s): Carter RJ, Hunt MJ, Morton AJ. Source: Movement Disorders : Official Journal of the Movement Disorder Society. 2000 September; 15(5): 925-37. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11009201&dopt=Abstract
•
Evidence for a recruitment and sequestration mechanism in Huntington's disease. Author(s): Preisinger E, Jordan BM, Kazantsev A, Housman D. Source: Philosophical Transactions of the Royal Society of London. Series B, Biological Sciences. 1999 June 29; 354(1386): 1029-34. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=10434302&dopt=Abstract
•
Evidence for a role for transglutaminase in Huntington's disease and the potential therapeutic implications. Author(s): Karpuj MV, Becher MW, Steinman L. Source: Neurochemistry International. 2002 January; 40(1): 31-6. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11738470&dopt=Abstract
•
Evidence for both the nucleus and cytoplasm as subcellular sites of pathogenesis in Huntington's disease in cell culture and in transgenic mice expressing mutant huntingtin. Author(s): Hackam AS, Hodgson JG, Singaraja R, Zhang T, Gan L, Gutekunst CA, Hersch SM, Hayden MR. Source: Philosophical Transactions of the Royal Society of London. Series B, Biological Sciences. 1999 June 29; 354(1386): 1047-55. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=10434304&dopt=Abstract
•
Evidence for the GluR6 gene associated with younger onset age of Huntington's disease. Author(s): MacDonald ME, Vonsattel JP, Shrinidhi J, Couropmitree NN, Cupples LA, Bird ED, Gusella JF, Myers RH. Source: Neurology. 1999 October 12; 53(6): 1330-2. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=10522893&dopt=Abstract
78
Huntington’s Disease
•
Exclusion mapping of the benign hereditary chorea gene from the Huntington's disease locus: report of a family. Author(s): Yapijakis C, Kapaki E, Zournas C, Rentzos M, Loukopoulos D, Papageorgiou C. Source: Clinical Genetics. 1995 March; 47(3): 133-8. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=7634535&dopt=Abstract
•
Expanded CAG repeats in exon 1 of the Huntington's disease gene stimulate dopamine-mediated striatal neuron autophagy and degeneration. Author(s): Petersen A, Larsen KE, Behr GG, Romero N, Przedborski S, Brundin P, Sulzer D. Source: Human Molecular Genetics. 2001 June 1; 10(12): 1243-54. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11406606&dopt=Abstract
•
Experience in prenatal testing for Huntington's disease in The Netherlands: procedures, results and guidelines (1987-1997). Author(s): Maat-Kievit A, Vegter-van der Vlis M, Zoeteweij M, Losekoot M, van Haeringen A, Kanhai H, Roos R. Source: Prenatal Diagnosis. 1999 May; 19(5): 450-7. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=10360514&dopt=Abstract
•
Familial aggregation of psychotic symptoms in Huntington's disease. Author(s): Tsuang D, Almqvist EW, Lipe H, Strgar F, DiGiacomo L, Hoff D, Eugenio C, Hayden MR, Bird TD. Source: The American Journal of Psychiatry. 2000 December; 157(12): 1955-9. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11097960&dopt=Abstract
•
Familial aggregation of schizophrenia-like symptoms in Huntington's disease. Author(s): Tsuang D, DiGiacomo L, Lipe H, Bird TD. Source: American Journal of Medical Genetics. 1998 July 10; 81(4): 323-7. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=9674979&dopt=Abstract
•
Family history and DNA analysis in patients with suspected Huntington's disease. Author(s): Siesling S, Vegter-van de Vlis M, Losekoot M, Belfroid RD, Maat-Kievit JA, Kremer HP, Roos RA. Source: Journal of Neurology, Neurosurgery, and Psychiatry. 2000 July; 69(1): 54-9. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=10864604&dopt=Abstract
•
Fas and Fas-L expression in Huntington's disease and Parkinson's disease. Author(s): Ferrer I, Blanco R, Cutillas B, Ambrosio S. Source: Neuropathology and Applied Neurobiology. 2000 October; 26(5): 424-33. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11054182&dopt=Abstract
Studies
79
•
Features of the blink reflex in individuals at risk for Huntington's disease. Author(s): de Tommaso M, Sciruicchio V, Spinelli A, Specchio N, Difruscolo O, Puca F, Specchio LM. Source: Muscle & Nerve. 2001 November; 24(11): 1520-5. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11745955&dopt=Abstract
•
Fetal neural grafts for Huntington's disease: a prospective view. Author(s): Bachoud-Levi AC, Hantraye P, Peschanski M. Source: Movement Disorders : Official Journal of the Movement Disorder Society. 2002 May; 17(3): 439-44. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12112189&dopt=Abstract
•
Fetal striatal transplantation in Huntington's disease: time for a pause. Author(s): Albin RL. Source: Journal of Neurology, Neurosurgery, and Psychiatry. 2002 December; 73(6): 612. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12438457&dopt=Abstract
•
Fetal striatal transplants restore electrophysiological sensitivity to dopamine in the lesioned striatum of rats with experimental Huntington's disease. Author(s): Chen GJ, Jeng CH, Lin SZ, Tsai SH, Wang Y, Chiang YH. Source: Journal of Biomedical Science. 2002 July-August; 9(4): 303-10. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12145527&dopt=Abstract
•
Fetal tissue transplants in animal models of Huntington's disease: the effects on damaged neuronal circuitry and behavioral deficits. Author(s): Nakao N, Itakura T. Source: Progress in Neurobiology. 2000 June; 61(3): 313-38. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=10727778&dopt=Abstract
•
First diagnostic applications of transcallosal inhibition in diseases affecting callosal neurones (multiple sclerosis, hydrocephalus, Huntington's disease). Author(s): Meyer BU, Roricht S, Schmierer K, Irlbacher K, Meierkord H, Niehaus L, Grosse P. Source: Electroencephalogr Clin Neurophysiol Suppl. 1999; 51: 233-42. No Abstract Available. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=10590955&dopt=Abstract
•
First step towards cell therapy for Huntington's disease. Author(s): Lindvall O, Bjorklund A. Source: Lancet. 2000 December 9; 356(9246): 1945-6. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11130518&dopt=Abstract
80
Huntington’s Disease
•
Fluorescence PCR and GeneScan analysis for the detection of CAG repeat expansions associated with Huntington's disease. Author(s): Vnencak-Jones CL. Source: Methods in Molecular Biology (Clifton, N.J.). 2003; 217: 101-8. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12491925&dopt=Abstract
•
Fluoxetine in the treatment of Huntington's disease. Author(s): De Marchi N, Daniele F, Ragone MA. Source: Psychopharmacology. 2001 January 1; 153(2): 264-6. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11205429&dopt=Abstract
•
Fluoxetine-induced exacerbation of chorea in Huntington's disease? A case report. Author(s): Chari S, Quraishi SH, Jainer AK. Source: Pharmacopsychiatry. 2003 January; 36(1): 41-3. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12649776&dopt=Abstract
•
From neuronal inclusions to neurodegeneration: neuropathological investigation of a transgenic mouse model of Huntington's disease. Author(s): Davies SW, Turmaine M, Cozens BA, Raza AS, Mahal A, Mangiarini L, Bates GP. Source: Philosophical Transactions of the Royal Society of London. Series B, Biological Sciences. 1999 June 29; 354(1386): 981-9. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=10434295&dopt=Abstract
•
Full length huntingtin is not detected in intranuclear inclusions in Huntington's disease brain. Author(s): Thomas P, Wilkinson F, Nguyen TM, Harper PS, Neal JW, Morris GE, Jones AL. Source: Biochemical Society Transactions. 1998 August; 26(3): S243. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=9765962&dopt=Abstract
•
Functional analysis of the Huntington's disease (HD) gene promoter. Author(s): Coles R, Caswell R, Rubinsztein DC. Source: Human Molecular Genetics. 1998 May; 7(5): 791-800. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=9536082&dopt=Abstract
•
Functional characterization of the human Huntington's disease gene promoter. Author(s): Holzmann C, Schmidt T, Thiel G, Epplen JT, Riess O. Source: Brain Research. Molecular Brain Research. 2001 August 15; 92(1-2): 85-97. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11483245&dopt=Abstract
Studies
81
•
Functional decline in Huntington's disease. Author(s): Feigin A, Kieburtz K, Bordwell K, Como P, Steinberg K, Sotack J, Zimmerman C, Hickey C, Orme C, Shoulson I. Source: Movement Disorders : Official Journal of the Movement Disorder Society. 1995 March; 10(2): 211-4. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=7753064&dopt=Abstract
•
Future directions in research with presymptomatic individuals carrying the gene for Huntington's disease. Author(s): Georgiou-Karistianis N, Smith E, Bradshaw JL, Chua P, Lloyd J, Churchyard A, Chiu E. Source: Brain Research Bulletin. 2003 January 30; 59(5): 331-8. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12507683&dopt=Abstract
•
Gait dysfunction in Huntington's disease: parkinsonism and a disorder of timing. Implications for movement rehabilitation. Author(s): Churchyard AJ, Morris ME, Georgiou N, Chiu E, Cooper R, Iansek R. Source: Adv Neurol. 2001; 87: 375-85. No Abstract Available. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11347241&dopt=Abstract
•
Gait variability and basal ganglia disorders: stride-to-stride variations of gait cycle timing in Parkinson's disease and Huntington's disease. Author(s): Hausdorff JM, Cudkowicz ME, Firtion R, Wei JY, Goldberger AL. Source: Movement Disorders : Official Journal of the Movement Disorder Society. 1998 May; 13(3): 428-37. Erratum In: Mov Disord 1998 July; 13(4): 757. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=9613733&dopt=Abstract
•
Gametic but not somatic instability of CAG repeat length in Huntington's disease. Author(s): MacDonald ME, Barnes G, Srinidhi J, Duyao MP, Ambrose CM, Myers RH, Gray J, Conneally PM, Young A, Penney J, et al. Source: Journal of Medical Genetics. 1993 December; 30(12): 982-6. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=8133508&dopt=Abstract
•
Gender of the embryo contributes to CAG instability in transgenic mice containing a Huntington's disease gene. Author(s): Kovtun IV, Therneau TM, McMurray CT. Source: Human Molecular Genetics. 2000 November 1; 9(18): 2767-75. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11063736&dopt=Abstract
82
Huntington’s Disease
•
Genetic association of Huntington's disease and restless legs syndrome? A family report. Author(s): Evers S, Stogbauer F. Source: Movement Disorders : Official Journal of the Movement Disorder Society. 2003 February; 18(2): 225-7. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12539222&dopt=Abstract
•
Genetic discrimination: Huntington's disease and the Americans with Disabilities Act. Author(s): Gin BR. Source: Columbia Law Rev. 1997 June; 97(5): 1406-34. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=10175166&dopt=Abstract
•
Genetic fitness in Huntington's Disease and Spinocerebellar Ataxia 1: a population genetics model for CAG repeat expansions. Author(s): Frontali M, Sabbadini G, Novelletto A, Jodice C, Naso F, Spadaro M, Giunti P, Jacopini AG, Veneziano L, Mantuano E, Malaspina P, Ulizzi L, Brice A, Durr A, Terrenato L. Source: Annals of Human Genetics. 1996 September; 60 ( Pt 5): 423-35. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=8912795&dopt=Abstract
•
Genetic polymorphisms adjacent to the CAG repeat influence clinical features at onset in Huntington's disease. Author(s): Vuillaume I, Vermersch P, Destee A, Petit H, Sablonniere B. Source: Journal of Neurology, Neurosurgery, and Psychiatry. 1998 June; 64(6): 758-62. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=9647305&dopt=Abstract
•
Genetic screening for Huntington's disease in Chinese patients with involuntary movements. Author(s): Shan DE, Soong BW, Yeh SI, Cheng CH, Wu ZA. Source: Clinical Neurology and Neurosurgery. 1997 December; 99(4): 244-7. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=9491297&dopt=Abstract
•
Genetic testing for Huntington's disease--a family issue. Author(s): Hayes CV. Source: The New England Journal of Medicine. 1992 November 12; 327(20): 1449-51. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=1406861&dopt=Abstract
•
Genetic testing of children at risk for Huntington's disease. US Huntington Disease Genetic Testing Group. Author(s): Nance MA. Source: Neurology. 1997 October; 49(4): 1048-53. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=9339688&dopt=Abstract
Studies
83
•
Genetically confirmed clinical Huntington's disease with no observable cell loss. Author(s): Caramins M, Halliday G, McCusker E, Trent RJ. Source: Journal of Neurology, Neurosurgery, and Psychiatry. 2003 July; 74(7): 968-70. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12810795&dopt=Abstract
•
Genetics and molecular biology of Huntington's disease. Author(s): Albin RL, Tagle DA. Source: Trends in Neurosciences. 1995 January; 18(1): 11-4. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=7535483&dopt=Abstract
•
Genomic organization and expression analysis of mouse kynurenine aminotransferase II, a possible factor in the pathophysiology of Huntington's disease. Author(s): Yu P, Mosbrook DM, Tagle DA. Source: Mammalian Genome : Official Journal of the International Mammalian Genome Society. 1999 September; 10(9): 845-52. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=10441733&dopt=Abstract
•
Geographical distribution of haplotypes in Swedish families with Huntington's disease. Author(s): Almqvist E, Andrew S, Theilmann J, Goldberg P, Zeisler J, Drugge U, Grandell U, Tapper-Persson M, Winblad B, Hayden M, et al. Source: Human Genetics. 1994 August; 94(2): 124-8. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=8045558&dopt=Abstract
•
Glucose transporter isoform expression in Huntington's disease brain. Author(s): Gamberino WC, Brennan WA Jr. Source: Journal of Neurochemistry. 1994 October; 63(4): 1392-7. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=7931291&dopt=Abstract
•
Glutamate in Huntington's disease. Author(s): Reynolds GP, Pearson SJ. Source: Lancet. 1994 July 16; 344(8916): 189-90. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=7912778&dopt=Abstract
•
Glycogen synthase kinase-3beta inhibitors prevent cellular polyglutamine toxicity caused by the Huntington's disease mutation. Author(s): Carmichael J, Sugars KL, Bao YP, Rubinsztein DC. Source: The Journal of Biological Chemistry. 2002 September 13; 277(37): 33791-8. Epub 2002 July 03. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12097329&dopt=Abstract
84
Huntington’s Disease
•
Grafts of EGF-responsive neural stem cells derived from GFAP-hNGF transgenic mice: trophic and tropic effects in a rodent model of Huntington's disease. Author(s): Kordower JH, Chen EY, Winkler C, Fricker R, Charles V, Messing A, Mufson EJ, Wong SC, Rosenstein JM, Bjorklund A, Emerich DF, Hammang J, Carpenter MK. Source: The Journal of Comparative Neurology. 1997 October 13; 387(1): 96-113. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=9331174&dopt=Abstract
•
Grip force scaling and sequencing of events during a manipulative task in Huntington's disease. Author(s): Serrien DJ, Burgunder JM, Wiesendanger M. Source: Neuropsychologia. 2001; 39(7): 734-41. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11311303&dopt=Abstract
•
High-dose olanzapine in Huntington's disease. Author(s): Bonelli RM, Niederwieser G, Tribl GG, Koltringer P. Source: International Clinical Psychopharmacology. 2002 March; 17(2): 91-3. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11890191&dopt=Abstract
•
Homozygosity in Huntington's disease: new ethical dilemma caused by molecular diagnosis. Author(s): Alonso ME, Yescas P, Rasmussen A, Ochoa A, Macias R, Ruiz I, Suastegui R. Source: Clinical Genetics. 2002 June; 61(6): 437-42. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12121351&dopt=Abstract
•
How does the Huntington's disease mutation damage cells? Author(s): Rubinsztein DC. Source: Science of Aging Knowledge Environment [electronic Resource] : Sage Ke. 2003 September 17; 2003(37): Pe26. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=13679594&dopt=Abstract
•
Hunting for excitement: NMDA receptors in Huntington's disease. Author(s): Ellerby LM. Source: Neuron. 2002 March 14; 33(6): 841-2. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11906690&dopt=Abstract
•
Huntingtin aggregation and toxicity in Huntington's disease. Author(s): Bates G. Source: Lancet. 2003 May 10; 361(9369): 1642-4. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12747895&dopt=Abstract
Studies
85
•
Huntington's disease age-of-onset linked to polyglutamine aggregation nucleation. Author(s): Chen S, Ferrone FA, Wetzel R. Source: Proceedings of the National Academy of Sciences of the United States of America. 2002 September 3; 99(18): 11884-9. Epub 2002 August 19. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12186976&dopt=Abstract
•
Huntington's disease provides cancer clues. Author(s): Kerr C. Source: The Lancet Oncology. 2002 September; 3(9): 518. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12217772&dopt=Abstract
•
Huntington's disease transgenic mice are resistant to global cerebral ischemia. Author(s): Schiefer J, Alberty A, Dose T, Oliva S, Noth J, Kosinski CM. Source: Neuroscience Letters. 2002 December 13; 334(2): 99-102. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12435481&dopt=Abstract
•
Huntington's disease. Author(s): Davies S, Ramsden DB. Source: Molecular Pathology : Mp. 2001 December; 54(6): 409-13. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11724916&dopt=Abstract
•
Huntington's disease. A sports star and a cook. Author(s): McMurray SE, McMurray CT. Source: Lancet. 2001 December; 358 Suppl: S38. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11784587&dopt=Abstract
•
Huntington's disease. Expanding horizons for treatment. Author(s): McMurray CT. Source: Lancet. 2001 December; 358 Suppl: S37. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11784586&dopt=Abstract
•
Huntington's disease: a decade beyond gene discovery. Author(s): Hogarth P. Source: Curr Neurol Neurosci Rep. 2003 July; 3(4): 279-84. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12930696&dopt=Abstract
•
Huntington's disease: a randomized, controlled trial using the NMDA-antagonist amantadine. Author(s): Verhagen Metman L, Morris MJ, Farmer C, Gillespie M, Mosby K, Wuu J, Chase TN. Source: Neurology. 2002 September 10; 59(5): 694-9. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12221159&dopt=Abstract
86
Huntington’s Disease
•
Huntington's disease: a review of the literature on prevalence and treatment of neuropsychiatric phenomena. Author(s): Naarding P, Kremer HP, Zitman FG. Source: European Psychiatry : the Journal of the Association of European Psychiatrists. 2001 December; 16(8): 439-45. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11777733&dopt=Abstract
•
Huntington's disease: new hope for therapeutics. Author(s): McMurray CT. Source: Trends in Neurosciences. 2001 November; 24(11 Suppl): S32-8. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11881743&dopt=Abstract
•
Huntington's disease: seldom seen--seldom heard? Author(s): McGarva K. Source: Health Bull (Edinb). 2001 September; 59(5): 306-8. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12664744&dopt=Abstract
•
Huntington's disease: the mystery unfolds? Author(s): Petersen A, Brundin P. Source: Int Rev Neurobiol. 2002; 53: 315-39. Review. No Abstract Available. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12512345&dopt=Abstract
•
Huntington's disease: what we learned from the original essay. Author(s): Okun MS. Source: The Neurologist. 2003 July; 9(4): 175-9. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12864927&dopt=Abstract
•
Huntington's disease-like phenotype due to trinucleotide repeat expansions in the TBP and JPH3 genes. Author(s): Stevanin G, Fujigasaki H, Lebre AS, Camuzat A, Jeannequin C, Dode C, Takahashi J, San C, Bellance R, Brice A, Durr A. Source: Brain; a Journal of Neurology. 2003 July; 126(Pt 7): 1599-603. Epub 2003 May 06. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12805114&dopt=Abstract
•
Hypometric primary saccades and increased variability in visually-guided saccades in Huntington's disease. Author(s): Winograd-Gurvich CT, Georgiou-Karistianis N, Evans A, Millist L, Bradshaw JL, Churchyard A, Chiu E, White OB. Source: Neuropsychologia. 2003; 41(12): 1683-92. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12887992&dopt=Abstract
Studies
87
•
Identification of benzothiazoles as potential polyglutamine aggregation inhibitors of Huntington's disease by using an automated filter retardation assay. Author(s): Heiser V, Engemann S, Brocker W, Dunkel I, Boeddrich A, Waelter S, Nordhoff E, Lurz R, Schugardt N, Rautenberg S, Herhaus C, Barnickel G, Bottcher H, Lehrach H, Wanker EE. Source: Proceedings of the National Academy of Sciences of the United States of America. 2002 December 10; 99 Suppl 4: 16400-6. Epub 2002 August 28. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12200548&dopt=Abstract
•
Ideomotor limb apraxia in Huntington's disease: implications for corticostriate involvement. Author(s): Hamilton JM, Haaland KY, Adair JC, Brandt J. Source: Neuropsychologia. 2003; 41(5): 614-21. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12559154&dopt=Abstract
•
Impaired antagonist inhibition may contribute to akinesia and bradykinesia in Huntington's disease. Author(s): van Vugt JP, Stijl M, Roos RA, van Dijk JG. Source: Clinical Neurophysiology : Official Journal of the International Federation of Clinical Neurophysiology. 2003 February; 114(2): 295-305. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12559237&dopt=Abstract
•
In vitro effects of polyglutamine tracts on Ca2+-dependent depolarization of rat and human mitochondria: relevance to Huntington's disease. Author(s): Panov AV, Burke JR, Strittmatter WJ, Greenamyre JT. Source: Archives of Biochemistry and Biophysics. 2003 February 1; 410(1): 1-6. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12559971&dopt=Abstract
•
Increased cell proliferation and neurogenesis in the adult human Huntington's disease brain. Author(s): Curtis MA, Penney EB, Pearson AG, van Roon-Mom WM, Butterworth NJ, Dragunow M, Connor B, Faull RL. Source: Proceedings of the National Academy of Sciences of the United States of America. 2003 July 22; 100(15): 9023-7. Epub 2003 Jul 09. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12853570&dopt=Abstract
•
Increased huntingtin protein length reduces the number of polyglutamine-induced gene expression changes in mouse models of Huntington's disease. Author(s): Chan EY, Luthi-Carter R, Strand A, Solano SM, Hanson SA, DeJohn MM, Kooperberg C, Chase KO, DiFiglia M, Young AB, Leavitt BR, Cha JH, Aronin N, Hayden MR, Olson JM. Source: Human Molecular Genetics. 2002 August 15; 11(17): 1939-51. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12165556&dopt=Abstract
88
Huntington’s Disease
•
Inducible PC12 cell model of Huntington's disease shows toxicity and decreased histone acetylation. Author(s): Igarashi S, Morita H, Bennett KM, Tanaka Y, Engelender S, Peters MF, Cooper JK, Wood JD, Sawa A, Ross CA. Source: Neuroreport. 2003 March 24; 14(4): 565-8. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12657886&dopt=Abstract
•
Inhibition of subliminally primed responses is mediated by the caudate and thalamus: evidence from functional MRI and Huntington's disease. Author(s): Aron AR, Schlaghecken F, Fletcher PC, Bullmore ET, Eimer M, Barker R, Sahakian BJ, Robbins TW. Source: Brain; a Journal of Neurology. 2003 March; 126(Pt 3): 713-23. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12566291&dopt=Abstract
•
Inhibition of tryptophan hydroxylase activity and decreased 5-HT1A receptor binding in a mouse model of Huntington's disease. Author(s): Yohrling IV GJ, Jiang GC, DeJohn MM, Robertson DJ, Vrana KE, Cha JH. Source: Journal of Neurochemistry. 2002 September; 82(6): 1416-23. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12354289&dopt=Abstract
•
Insight into the psychosocial aspects of Huntington's disease in Chinese society. Author(s): Leung TY, Leung CM. Source: International Journal of Psychiatry in Medicine. 2002; 32(3): 305-10. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12489705&dopt=Abstract
•
Insoluble TATA-binding protein accumulation in Huntington's disease cortex. Author(s): van Roon-Mom WM, Reid SJ, Jones AL, MacDonald ME, Faull RL, Snell RG. Source: Brain Research. Molecular Brain Research. 2002 December 30; 109(1-2): 1-10. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12531510&dopt=Abstract
•
Juvenile form of Huntington's disease: MR imaging appearance. Author(s): Comunale JP Jr, Heier LA, Chutorian AM. Source: Ajr. American Journal of Roentgenology. 1995 August; 165(2): 414-5. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=7618569&dopt=Abstract
•
Juvenile Huntington's disease confirmed by genetic examination in twins. Author(s): Levy G, Nobre ME, Cimini VT, Raskin S, Engelhardt E. Source: Arquivos De Neuro-Psiquiatria. 1999 September; 57(3B): 867-9. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=10751926&dopt=Abstract
Studies
89
•
Juvenile Huntington's disease presenting as progressive myoclonic epilepsy. Author(s): Gambardella A, Muglia M, Labate A, Magariello A, Gabriele AL, Mazzei R, Pirritano D, Conforti FL, Patitucci A, Valentino P, Zappia M, Quattrone A. Source: Neurology. 2001 August 28; 57(4): 708-11. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11524486&dopt=Abstract
•
Juvenile Huntington's disease. Author(s): Srivastava T, Lal V, Prabhakar S. Source: Neurology India. 1999 December; 47(4): 340-1. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=10625918&dopt=Abstract
•
Juvenile Huntington's disease: report of one case. Author(s): Sue WC, Hwu WL, Chen CY. Source: Zhonghua Min Guo Xiao Er Ke Yi Xue Hui Za Zhi. 1998 September-October; 39(5): 342-5. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=9823684&dopt=Abstract
•
Juvenile onset Huntington's disease in an Omani child with asymptomatic, at risk parents. Author(s): Scrimgeour EM, Koul RL, Chand PR, Tharakan JK, Frew CA. Source: Journal of Medical Genetics. 1997 August; 34(8): 701. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=9279769&dopt=Abstract
•
Juvenile onset Huntington's disease--clinical and research perspectives. Author(s): Ann Neurol. 2001 Dec;50(6):373-80 Source: Mental Retardation and Developmental Disabilities Research Reviews. 2001; 7(3): 153-7. Review. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=11761463
•
Kinematic analysis of the reach to grasp movement in Parkinson's and Huntington's disease subjects. Author(s): Bonfiglioli C, De Berti G, Nichelli P, Nicoletti R, Castiello U. Source: Neuropsychologia. 1998 November; 36(11): 1203-8. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=9842765&dopt=Abstract
•
Knowledge, attitude, and the decision to be tested for Huntington's disease. Author(s): Quaid KA, Brandt J, Faden RR, Folstein SE. Source: Clinical Genetics. 1989 December; 36(6): 431-8. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=2531636&dopt=Abstract
90
Huntington’s Disease
•
Kynurenic acid concentrations are reduced in Huntington's disease cerebral cortex. Author(s): Beal MF, Matson WR, Storey E, Milbury P, Ryan EA, Ogawa T, Bird ED. Source: Journal of the Neurological Sciences. 1992 March; 108(1): 80-7. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=1385624&dopt=Abstract
•
Kynurenine pathway measurements in Huntington's disease striatum: evidence for reduced formation of kynurenic acid. Author(s): Beal MF, Matson WR, Swartz KJ, Gamache PH, Bird ED. Source: Journal of Neurochemistry. 1990 October; 55(4): 1327-39. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=2144582&dopt=Abstract
•
Late onset levodopa responsive Huntington's disease with minimal chorea masquerading as Parkinson plus syndrome. Author(s): Reuter I, Hu MT, Andrews TC, Brooks DJ, Clough C, Chaudhuri KR. Source: Journal of Neurology, Neurosurgery, and Psychiatry. 2000 February; 68(2): 23841. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=10644798&dopt=Abstract
•
Late-life obsessive-compulsive disorder and Huntington's disease. Author(s): Scicutella A. Source: The Journal of Neuropsychiatry and Clinical Neurosciences. 2000 Spring; 12(2): 288-9. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11001616&dopt=Abstract
•
Lessons from animal models of Huntington's disease. Author(s): Rubinsztein DC. Source: Trends in Genetics : Tig. 2002 April; 18(4): 202-9. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11932021&dopt=Abstract
•
Levodopa responsive parkinsonism in an adult with Huntington's disease. Author(s): Racette BA, Perlmutter JS. Source: Journal of Neurology, Neurosurgery, and Psychiatry. 1998 October; 65(4): 577-9. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=9771791&dopt=Abstract
•
Living with Huntington's disease: illness perceptions, coping mechanisms, and spouses' quality of life. Author(s): Helder DI, Kaptein AA, Van Kempen GM, Weinman J, Van Houwelingen JC, Roos RA. Source: International Journal of Behavioral Medicine. 2002; 9(1): 37-52. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12112995&dopt=Abstract
Studies
91
•
Longitudinal evaluation of cognitive disorder in Huntington's disease. Author(s): Snowden J, Craufurd D, Griffiths H, Thompson J, Neary D. Source: Journal of the International Neuropsychological Society : Jins. 2001 January; 7(1): 33-44. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11253840&dopt=Abstract
•
Longitudinal study evaluating neuropsychological changes in so-called asymptomatic carriers of the Huntington's disease mutation after 1 year. Author(s): Lemiere J, Decruyenaere M, Evers-Kiebooms G, Vandenbussche E, Dom R. Source: Acta Neurologica Scandinavica. 2002 September; 106(3): 131-41. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12174172&dopt=Abstract
•
Long-lasting improvement following (-)-OSU6162 in a patient with Huntington's disease. Author(s): Tedroff J, Ekesbo A, Sonesson C, Waters N, Carlsson A. Source: Neurology. 1999 October 22; 53(7): 1605-6. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=10534281&dopt=Abstract
•
Loss of huntingtin-mediated BDNF gene transcription in Huntington's disease. Author(s): Zuccato C, Ciammola A, Rigamonti D, Leavitt BR, Goffredo D, Conti L, MacDonald ME, Friedlander RM, Silani V, Hayden MR, Timmusk T, Sipione S, Cattaneo E. Source: Science. 2001 July 20; 293(5529): 493-8. Epub 2001 June 14. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11408619&dopt=Abstract
•
Loss of normal huntingtin function: new developments in Huntington's disease research. Author(s): Cattaneo E, Rigamonti D, Goffredo D, Zuccato C, Squitieri F, Sipione S. Source: Trends in Neurosciences. 2001 March; 24(3): 182-8. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11182459&dopt=Abstract
•
Maintained improvement with minocycline of a patient with advanced Huntington's disease. Author(s): Denovan-Wright EM, Devarajan S, Dursun SM, Robertson HA. Source: Journal of Psychopharmacology (Oxford, England). 2002 December; 16(4): 393-4. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12503842&dopt=Abstract
•
Maintenance of susceptibility to neurodegeneration following intrastriatal injections of quinolinic acid in a new transgenic mouse model of Huntington's disease. Author(s): Petersen A, Chase K, Puschban Z, DiFiglia M, Brundin P, Aronin N. Source: Experimental Neurology. 2002 May; 175(1): 297-300. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12009780&dopt=Abstract
92
Huntington’s Disease
•
Metabolic changes in the basal ganglia of patients with Huntington's disease: an in situ hybridization study of cytochrome oxidase subunit I mRNA. Author(s): Gourfinkel-An I, Vila M, Faucheux B, Duyckaerts C, Viallet F, Hauw JJ, Brice A, Agid Y, Hirsch EC. Source: Journal of Neurochemistry. 2002 February; 80(3): 466-76. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11905993&dopt=Abstract
•
Mice transgenic for exon 1 of Huntington's disease: properties of cholinergic and dopaminergic pre-synaptic function in the striatum. Author(s): Vetter JM, Jehle T, Heinemeyer J, Franz P, Behrens PF, Jackisch R, Landwehrmeyer GB, Feuerstein TJ. Source: Journal of Neurochemistry. 2003 May; 85(4): 1054-63. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12716437&dopt=Abstract
•
Minocycline and other tetracycline derivatives: a neuroprotective strategy in Parkinson's disease and Huntington's disease. Author(s): Thomas M, Le WD, Jankovic J. Source: Clinical Neuropharmacology. 2003 January-February; 26(1): 18-23. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12567160&dopt=Abstract
•
Minocycline inhibits caspase-independent and -dependent mitochondrial cell death pathways in models of Huntington's disease. Author(s): Wang X, Zhu S, Drozda M, Zhang W, Stavrovskaya IG, Cattaneo E, Ferrante RJ, Kristal BS, Friedlander RM. Source: Proceedings of the National Academy of Sciences of the United States of America. 2003 September 2; 100(18): 10483-7. Epub 2003 August 20. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12930891&dopt=Abstract
•
Mirtazapine in suicidal Huntington's disease. Author(s): Bonelli RM. Source: The Annals of Pharmacotherapy. 2003 March; 37(3): 452. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12639181&dopt=Abstract
•
Modeling protein homopolymeric repeats: possible polyglutamine structural motifs for Huntington's disease. Author(s): Lathrop RH, Casale M, Tobias DJ, Marsh JL, Thompson LM. Source: Proc Int Conf Intell Syst Mol Biol. 1998; 6: 105-14. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=9783215&dopt=Abstract
Studies
93
•
Modulation of age at onset in Huntington's disease and spinocerebellar ataxia type 2 patients originated from eastern India. Author(s): Chattopadhyay B, Ghosh S, Gangopadhyay PK, Das SK, Roy T, Sinha KK, Jha DK, Mukherjee SC, Chakraborty A, Singhal BS, Bhattacharya AK, Bhattacharyya NP. Source: Neuroscience Letters. 2003 July 17; 345(2): 93-6. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12821179&dopt=Abstract
•
Mutation analysis and association studies of the ubiquitin carboxy-terminal hydrolase L1 gene in Huntington's disease. Author(s): Naze P, Vuillaume I, Destee A, Pasquier F, Sablonniere B. Source: Neuroscience Letters. 2002 August 2; 328(1): 1-4. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12123845&dopt=Abstract
•
N(epsilon)-(gamma-L-glutamyl)-L-lysine (GGEL) is increased in cerebrospinal fluid of patients with Huntington's disease. Author(s): Jeitner TM, Bogdanov MB, Matson WR, Daikhin Y, Yudkoff M, Folk JE, Steinman L, Browne SE, Beal MF, Blass JP, Cooper AJ. Source: Journal of Neurochemistry. 2001 December; 79(5): 1109-12. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11739625&dopt=Abstract
•
Neural transplantation for the treatment of Huntington's disease. Author(s): Freeman TB, Hauser RA, Sanberg PR, Saporta S. Source: Prog Brain Res. 2000; 127: 405-11. Review. No Abstract Available. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11142038&dopt=Abstract
•
Neural transplantation in patients with Huntington's disease. Author(s): Rosser AE, Dunnett SB. Source: Cns Drugs. 2003; 17(12): 853-67. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12962526&dopt=Abstract
•
Neurophysiological study of facial chorea in patients with Huntington's disease. Author(s): Munoz E, Cervera A, Valls-Sole J. Source: Clinical Neurophysiology : Official Journal of the International Federation of Clinical Neurophysiology. 2003 July; 114(7): 1246-52. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12842721&dopt=Abstract
•
Neuroprotection by neurotrophins and GDNF family members in the excitotoxic model of Huntington's disease. Author(s): Alberch J, Perez-Navarro E, Canals JM. Source: Brain Research Bulletin. 2002 April; 57(6): 817-22. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12031278&dopt=Abstract
94
Huntington’s Disease
•
Neuroprotective possibilities for Huntington's disease. Author(s): Emerich DF. Source: Expert Opinion on Biological Therapy. 2001 May; 1(3): 467-79. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11727519&dopt=Abstract
•
Neuropsychological manifestations of the genetic mutation for Huntington's disease in presymptomatic individuals. Author(s): Brandt J, Shpritz B, Codori AM, Margolis R, Rosenblatt A. Source: Journal of the International Neuropsychological Society : Jins. 2002 November; 8(7): 918-24. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12405543&dopt=Abstract
•
New therapeutic approaches for the treatment of Huntington's disease. Author(s): Mazurova Y. Source: Acta Medica (Hradec Kralove). 2001; 44(4): 119-23. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11836846&dopt=Abstract
•
No difference in plasma or urinary F2-isoprostanes among patients with Huntington's disease or Alzheimer's disease and controls. Author(s): Montine TJ, Shinobu L, Montine KS, Roberts LJ 2nd, Kowall NW, Beal MF, Morrow JD. Source: Annals of Neurology. 2000 December; 48(6): 950. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11117557&dopt=Abstract
•
Novel therapies in the search for a cure for Huntington's disease. Author(s): Beal MF, Hantraye P. Source: Proceedings of the National Academy of Sciences of the United States of America. 2001 January 2; 98(1): 3-4. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11136240&dopt=Abstract
•
Objective assessment of progression in Huntington's disease: a 3-year follow-up study. Author(s): Reilmann R, Kirsten F, Quinn L, Henningsen H, Marder K, Gordon AM. Source: Neurology. 2001 September 11; 57(5): 920-4. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11552034&dopt=Abstract
•
Odor detection, learning, and memory in Huntington's disease. Author(s): Hamilton JM, Murphy C, Paulsen JS. Source: Journal of the International Neuropsychological Society : Jins. 1999 November; 5(7): 609-15. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=10645703&dopt=Abstract
Studies
95
•
Of mice and men: solving the molecular mysteries of Huntington's disease. Author(s): Shelbourne PF. Source: Journal of Anatomy. 2000 May; 196 ( Pt 4): 617-28. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=10923992&dopt=Abstract
•
Olanzapine and Huntington's disease. Author(s): Bogelman G, Hirschmann S, Modai I. Source: Journal of Clinical Psychopharmacology. 2001 April; 21(2): 245-6. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11270928&dopt=Abstract
•
Olanzapine for Huntington's disease: an open label study. Author(s): Bonelli RM, Mahnert FA, Niederwieser G. Source: Clinical Neuropharmacology. 2002 September-October; 25(5): 263-5. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12410058&dopt=Abstract
•
Olanzapine in Huntington's disease. Author(s): Paleacu D, Anca M, Giladi N. Source: Acta Neurologica Scandinavica. 2002 June; 105(6): 441-4. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12027832&dopt=Abstract
•
On the pathological progression of Huntington's disease. Author(s): Sieradzan KA, Mann DM. Source: Annals of Neurology. 1998 July; 44(1): 148-9. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=9667607&dopt=Abstract
•
Onset and pre-onset studies to define the Huntington's disease natural history. Author(s): Squitieri F, Cannella M, Giallonardo P, Maglione V, Mariotti C, Hayden MR. Source: Brain Research Bulletin. 2001 October-November 1; 56(3-4): 233-8. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11719256&dopt=Abstract
•
Open interconnected model of basal ganglia-thalamocortical circuitry and its relevance to the clinical syndrome of Huntington's disease. Author(s): Joel D. Source: Movement Disorders : Official Journal of the Movement Disorder Society. 2001 May; 16(3): 407-23. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11391734&dopt=Abstract
•
Overexpression of heat shock protein 70 in R6/2 Huntington's disease mice has only modest effects on disease progression. Author(s): Hansson O, Nylandsted J, Castilho RF, Leist M, Jaattela M, Brundin P. Source: Brain Research. 2003 April 25; 970(1-2): 47-57. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12706247&dopt=Abstract
96
Huntington’s Disease
•
Perceptual categorization is impaired in Huntington's disease: an electrophysiological study. Author(s): Antal A, Beniczky S, Kincses TZ, Jakab K, Benedek G, Vecsei L. Source: Dementia and Geriatric Cognitive Disorders. 2003; 16(4): 187-92. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=14512712&dopt=Abstract
•
Polyglutamine expansion and Huntington's disease. Author(s): Bates GP, Mangiarini L, Wanker EE, Davies SW. Source: Biochemical Society Transactions. 1998 August; 26(3): 471-5. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=9765898&dopt=Abstract
•
Predictive testing for Huntington's disease: a universal model? Author(s): Hayden MR. Source: Lancet. Neurology. 2003 March; 2(3): 141-2. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12849232&dopt=Abstract
•
Predictors of neuropathological severity in 100 patients with Huntington's disease. Author(s): Rosenblatt A, Abbott MH, Gourley LM, Troncoso JC, Margolis RL, Brandt J, Ross CA. Source: Annals of Neurology. 2003 October; 54(4): 488-93. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=14520661&dopt=Abstract
•
Prenatal diagnosis requests for Huntington's disease when the father is at risk and does not want to know his genetic status: clinical, legal, and ethical viewpoints. Author(s): Tassicker R, Savulescu J, Skene L, Marshall P, Fitzgerald L, Delatycki MB. Source: Bmj (Clinical Research Ed.). 2003 February 8; 326(7384): 331-3. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12574051&dopt=Abstract
•
Progressive striatal and cortical dopamine receptor dysfunction in Huntington's disease: a PET study. Author(s): Pavese N, Andrews TC, Brooks DJ, Ho AK, Rosser AE, Barker RA, Robbins TW, Sahakian BJ, Dunnett SB, Piccini P. Source: Brain; a Journal of Neurology. 2003 May; 126(Pt 5): 1127-35. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12690052&dopt=Abstract
•
Proprioceptive sensory function in Parkinson's disease and Huntington's disease: evidence from proprioception-related EEG potentials. Author(s): Seiss E, Praamstra P, Hesse CW, Rickards H. Source: Experimental Brain Research. Experimentelle Hirnforschung. Experimentation Cerebrale. 2003 February; 148(3): 308-19. Epub 2002 November 30. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12541142&dopt=Abstract
Studies
97
•
Psychiatric and neuropsychological abnormalities in Huntington's disease: a case study. Author(s): Madhusoodanan S, Brenner R, Moise D, Sindagi J, Brafman I. Source: Annals of Clinical Psychiatry : Official Journal of the American Academy of Clinical Psychiatrists. 1998 September; 10(3): 117-20. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=9781475&dopt=Abstract
•
Psychological distress in the 5-year period after predictive testing for Huntington's disease. Author(s): Decruyenaere M, Evers-Kiebooms G, Cloostermans T, Boogaerts A, Demyttenaere K, Dom R, Fryns JP. Source: European Journal of Human Genetics : Ejhg. 2003 January; 11(1): 30-8. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12529703&dopt=Abstract
•
Psychopathological changes preceding motor symptoms in Huntington's disease: a report on four cases. Author(s): Amann B, Sterr A, Thoma H, Messer T, Kapfhammer HP, Grunze H. Source: World J Biol Psychiatry. 2000 January; 1(1): 55-8. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12607233&dopt=Abstract
•
Quantitative analysis of morphological features in Huntington's disease. Author(s): Roos RA, Bots GT, Hermans J. Source: Acta Neurologica Scandinavica. 1986 February; 73(2): 131-5. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=2939683&dopt=Abstract
•
Quantitative and qualitative analyses of clock drawings in Alzheimer's and Huntington's disease. Author(s): Rouleau I, Salmon DP, Butters N, Kennedy C, McGuire K. Source: Brain and Cognition. 1992 January; 18(1): 70-87. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=1543577&dopt=Abstract
•
Quantitative assessment of daytime motor activity provides a responsive measure of functional decline in patients with Huntington's disease. Author(s): van Vugt JP, Siesling S, Piet KK, Zwinderman AH, Middelkoop HA, van Hilten JJ, Roos RA. Source: Movement Disorders : Official Journal of the Movement Disorder Society. 2001 May; 16(3): 481-8. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11391742&dopt=Abstract
•
Quantitative longitudinal assessment of saccades in Huntington's disease. Author(s): Rubin AJ, King WM, Reinbold KA, Shoulson I. Source: J Clin Neuroophthalmol. 1993 March; 13(1): 59-66. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=8501265&dopt=Abstract
98
Huntington’s Disease
•
Quantitative neuropathological changes in presymptomatic Huntington's disease. Author(s): Gomez-Tortosa E, MacDonald ME, Friend JC, Taylor SA, Weiler LJ, Cupples LA, Srinidhi J, Gusella JF, Bird ED, Vonsattel JP, Myers RH. Source: Annals of Neurology. 2001 January; 49(1): 29-34. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11198293&dopt=Abstract
•
Questions and problems in direct predictive testing for Huntington's disease. Author(s): Toth T, Papp C, Nemeti M, Papp Z. Source: American Journal of Medical Genetics. 1997 August 8; 71(2): 238-9. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=9217232&dopt=Abstract
•
Quetiapine in Huntington's disease: a first case report. Author(s): Bonelli RM, Niederwieser G. Source: Journal of Neurology. 2002 August; 249(8): 1114-5. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12420714&dopt=Abstract
•
Quinolinic acid phosphoribosyltransferase in human and rat brain: activity in Huntington's disease and in quinolinate-lesioned rat striatum. Author(s): Foster AC, Whetsell WO Jr, Bird ED, Schwarcz R. Source: Brain Research. 1985 June 17; 336(2): 207-14. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=3159462&dopt=Abstract
•
Quinolinic acid-induced increases in calbindin D28k immunoreactivity in rat striatal neurons in vivo and in vitro mimic the pattern seen in Huntington's disease. Author(s): Huang Q, Zhou D, Sapp E, Aizawa H, Ge P, Bird ED, Vonsattel JP, DiFiglia M. Source: Neuroscience. 1995 March; 65(2): 397-407. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=7777157&dopt=Abstract
•
Recent advances in Huntington's disease: implications for experimental therapeutics. Author(s): Feigin A, Zgaljardic D. Source: Current Opinion in Neurology. 2002 August; 15(4): 483-9. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12151847&dopt=Abstract
•
Recognition memory for hand positions and spatial locations in patients with Huntington's disease: differential visuospatial memory impairment? Author(s): Davis JD, Filoteo JV, Kesner RP, Roberts JW. Source: Cortex. 2003 April; 39(2): 239-53. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12784887&dopt=Abstract
Studies
99
•
Regional and progressive thinning of the cortical ribbon in Huntington's disease. Author(s): Rosas HD, Liu AK, Hersch S, Glessner M, Ferrante RJ, Salat DH, van der Kouwe A, Jenkins BG, Dale AM, Fischl B. Source: Neurology. 2002 March 12; 58(5): 695-701. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11889230&dopt=Abstract
•
Relationship between CAG repeat length and late-stage outcomes in Huntington's disease. Author(s): Marder K, Sandler S, Lechich A, Klager J, Albert SM. Source: Neurology. 2002 November 26; 59(10): 1622-4. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12451208&dopt=Abstract
•
Riluzole and olanzapine in Huntington's disease. Author(s): Bonelli RM, Niederwieser G, Diez J, Koltringer P. Source: European Journal of Neurology : the Official Journal of the European Federation of Neurological Societies. 2002 March; 9(2): 183-4. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11882065&dopt=Abstract
•
Riluzole in Huntington's disease (HD): an open label study with one year follow up. Author(s): Seppi K, Mueller J, Bodner T, Brandauer E, Benke T, Weirich-Schwaiger H, Poewe W, Wenning GK. Source: Journal of Neurology. 2001 October; 248(10): 866-9. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11697523&dopt=Abstract
•
Riluzole prolongs survival time and alters nuclear inclusion formation in a transgenic mouse model of Huntington's disease. Author(s): Schiefer J, Landwehrmeyer GB, Luesse HG, Sprunken A, Puls C, Milkereit A, Milkereit E, Kosinski CM. Source: Movement Disorders : Official Journal of the Movement Disorder Society. 2002 July; 17(4): 748-57. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12210870&dopt=Abstract
•
Risky decision making in Huntington's disease. Author(s): Stout JC, Rodawalt WC, Siemers ER. Source: Journal of the International Neuropsychological Society : Jins. 2001 January; 7(1): 92-101. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11253845&dopt=Abstract
•
Risperidone in chorea and psychosis of Huntington's disease. Author(s): Erdemoglu AK, Boratav C. Source: European Journal of Neurology : the Official Journal of the European Federation of Neurological Societies. 2002 March; 9(2): 182-3. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11882064&dopt=Abstract
100 Huntington’s Disease
•
Rivastigmine in the treatment of Huntington's disease. Author(s): Rot U, Kobal J, Sever A, Pirtosek Z, Mesec A. Source: European Journal of Neurology : the Official Journal of the European Federation of Neurological Societies. 2002 November; 9(6): 689-90. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12453090&dopt=Abstract
•
Selective loss of striatal preprotachykinin neurons in a phenocopy of Huntington's disease. Author(s): Richfield EK, Vonsattel JP, MacDonald ME, Sun Z, Deng YP, Reiner A. Source: Movement Disorders : Official Journal of the Movement Disorder Society. 2002 March; 17(2): 327-32. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11921119&dopt=Abstract
•
Sensation of effort is altered in Huntington's disease. Author(s): Lafargue G, Sirigu A. Source: Neuropsychologia. 2002; 40(10): 1654-61. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11992653&dopt=Abstract
•
Severe deficiencies in dopamine signaling in presymptomatic Huntington's disease mice. Author(s): Bibb JA, Yan Z, Svenningsson P, Snyder GL, Pieribone VA, Horiuchi A, Nairn AC, Messer A, Greengard P. Source: Proceedings of the National Academy of Sciences of the United States of America. 2000 June 6; 97(12): 6809-14. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=10829080&dopt=Abstract
•
Single photon emission computerized tomography (SPECT) in detecting neurodegeneration in Huntington's disease. Author(s): Reynolds NC Jr, Hellman RS, Tikofsky RS, Prost RW, Mark LP, Elejalde BR, Lebel R, Hamsher KS, Swanson S, Benezra EE. Source: Nuclear Medicine Communications. 2002 January; 23(1): 13-8. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11748433&dopt=Abstract
•
Social cognition in frontotemporal dementia and Huntington's disease. Author(s): Snowden JS, Gibbons ZC, Blackshaw A, Doubleday E, Thompson J, Craufurd D, Foster J, Happe F, Neary D. Source: Neuropsychologia. 2003; 41(6): 688-701. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12591026&dopt=Abstract
•
Somatosensory evoked potentials correlate with genetics in Huntington's disease. Author(s): Beniczky S, Keri S, Antal A, Jakab K, Nagy H, Benedek G, Janka Z, Vecsei L. Source: Neuroreport. 2002 December 3; 13(17): 2295-8. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12488814&dopt=Abstract
Studies
101
•
Sp1 and TAFII130 transcriptional activity disrupted in early Huntington's disease. Author(s): Dunah AW, Jeong H, Griffin A, Kim YM, Standaert DG, Hersch SM, Mouradian MM, Young AB, Tanese N, Krainc D. Source: Science. 2002 June 21; 296(5576): 2238-43. Epub 2002 May 02. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11988536&dopt=Abstract
•
Sub-movement cueing and motor sequence execution in patients with Huntington's disease. Author(s): Curra A, Agostino R, Galizia P, Fittipaldi F, Manfredi M, Berardelli A. Source: Clinical Neurophysiology : Official Journal of the International Federation of Clinical Neurophysiology. 2000 July; 111(7): 1184-90. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=10880791&dopt=Abstract
•
Subtle changes among presymptomatic carriers of the Huntington's disease gene. Author(s): Kirkwood SC, Siemers E, Hodes ME, Conneally PM, Christian JC, Foroud T. Source: Journal of Neurology, Neurosurgery, and Psychiatry. 2000 December; 69(6): 7739. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11080230&dopt=Abstract
•
Successful multimodality treatment of severe behavioral disturbance in a patient with advanced Huntington's disease. Author(s): Blass DM, Steinberg M, Leroi I, Lyketsos CG. Source: The American Journal of Psychiatry. 2001 December; 158(12): 1966-72. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11729010&dopt=Abstract
•
Task-set switching deficits in early-stage Huntington's disease: implications for basal ganglia function. Author(s): Aron AR, Watkins L, Sahakian BJ, Monsell S, Barker RA, Robbins TW. Source: Journal of Cognitive Neuroscience. 2003 July 1; 15(5): 629-42. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12965037&dopt=Abstract
•
Teacher was refused job because relatives have Huntington's disease. Author(s): Burgermeister J. Source: Bmj (Clinical Research Ed.). 2003 October 11; 327(7419): 827. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=14551070&dopt=Abstract
•
The distribution of structural neuropathology in pre-clinical Huntington's disease. Author(s): Thieben MJ, Duggins AJ, Good CD, Gomes L, Mahant N, Richards F, McCusker E, Frackowiak RS. Source: Brain; a Journal of Neurology. 2002 August; 125(Pt 8): 1815-28. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12135972&dopt=Abstract
102 Huntington’s Disease
•
The enigma of Huntington's disease. Author(s): Cattaneo E, Rigamonti D, Zuccato C. Source: Scientific American. 2002 December; 287(6): 92-7. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12469651&dopt=Abstract
•
The hung-up knee jerk in Huntington's Disease. Author(s): Brannan T. Source: Parkinsonism & Related Disorders. 2003 June; 9(5): 257-9. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12781590&dopt=Abstract
•
The midlatency auditory evoked potential P50 is abnormal in Huntington's disease. Author(s): Uc EY, Skinner RD, Rodnitzky RL, Garcia-Rill E. Source: Journal of the Neurological Sciences. 2003 August 15; 212(1-2): 1-5. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12809992&dopt=Abstract
•
The primary structure and genomic organization of five novel transcripts located close to the Huntington's disease gene on human chromosome 4p16.3. Author(s): Hadano S, Ishida Y, Ikeda JE. Source: Dna Res. 1998 June 30; 5(3): 177-86. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=9734812&dopt=Abstract
•
Therapeutic effects of cystamine in a murine model of Huntington's disease. Author(s): Dedeoglu A, Kubilus JK, Jeitner TM, Matson SA, Bogdanov M, Kowall NW, Matson WR, Cooper AJ, Ratan RR, Beal MF, Hersch SM, Ferrante RJ. Source: The Journal of Neuroscience : the Official Journal of the Society for Neuroscience. 2002 October 15; 22(20): 8942-50. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12388601&dopt=Abstract
•
Therapeutic options for Huntington's disease. Author(s): Grimbergen YA, Roos RA. Source: Curr Opin Investig Drugs. 2003 January; 4(1): 51-4. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12625029&dopt=Abstract
•
Trinucleotide (CAG) repeat length is positively correlated with the degree of DNA fragmentation in Huntington's disease striatum. Author(s): Butterworth NJ, Williams L, Bullock JY, Love DR, Faull RL, Dragunow M. Source: Neuroscience. 1998 November; 87(1): 49-53. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=9722140&dopt=Abstract
Studies
103
•
UK allows insurers to use gene test for Huntington's disease. Author(s): Mayor S. Source: Bmj (Clinical Research Ed.). 2000 October 21; 321(7267): 977. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11039944&dopt=Abstract
•
Ultrastructural localization and progressive formation of neuropil aggregates in Huntington's disease transgenic mice. Author(s): Li H, Li SH, Cheng AL, Mangiarini L, Bates GP, Li XJ. Source: Human Molecular Genetics. 1999 July; 8(7): 1227-36. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=10369868&dopt=Abstract
•
Understanding the neuropsychiatric symptoms of Huntington's disease. Author(s): Hofmann N. Source: The Journal of Neuroscience Nursing : Journal of the American Association of Neuroscience Nurses. 1999 October; 31(5): 309-13. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=10633308&dopt=Abstract
•
Unilateral transplantation of human primary fetal tissue in four patients with Huntington's disease: NEST-UK safety report ISRCTN no 36485475. Author(s): Rosser AE, Barker RA, Harrower T, Watts C, Farrington M, Ho AK, Burnstein RM, Menon DK, Gillard JH, Pickard J, Dunnett SB; NEST-UK. Source: Journal of Neurology, Neurosurgery, and Psychiatry. 2002 December; 73(6): 67885. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12438470&dopt=Abstract
•
Unimanual and bimanual voluntary movement in Huntington's disease. Author(s): Verbessem P, Op't Eijnde B, Swinnen SP, Vangheluwe S, Hespel P, Dom R. Source: Experimental Brain Research. Experimentelle Hirnforschung. Experimentation Cerebrale. 2002 December; 147(4): 529-37. Epub 2002 October 15. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12444485&dopt=Abstract
•
United Kingdom experience with presymptomatic testing of individuals at 25% risk for Huntington's disease. Author(s): Benjamin CM, Lashwood A. Source: Clinical Genetics. 2000 July; 58(1): 41-9. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=10945660&dopt=Abstract
•
Use of risperidone in psychosis associated with Huntington's disease. Author(s): Madhusoodanan S, Brenner R. Source: The American Journal of Geriatric Psychiatry : Official Journal of the American Association for Geriatric Psychiatry. 1998 Fall; 6(4): 347-9. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=9793585&dopt=Abstract
104 Huntington’s Disease
•
Usefulness of molecular testing in Huntington's disease. Author(s): Wang V, Yeh TP, Chen CM, Yan SH, Soong BW. Source: Zhonghua Yi Xue Za Zhi (Taipei). 1999 September; 62(9): 586-90. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=10502848&dopt=Abstract
•
Utilisation of predictive, prenatal and diagnostic testing for Huntington's disease in Johannesburg. Author(s): Kromberg JG, Krause A, Spurdle AB, Temlett JA, Lucas M, Rodseth D, Stevens G, Jenkins T. Source: South African Medical Journal. Suid-Afrikaanse Tydskrif Vir Geneeskunde. 1999 July; 89(7): 774-8. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=10470316&dopt=Abstract
•
UVB irradiation-induced apoptosis increased in lymphocytes of Huntington's disease patients. Author(s): Jakab K, Novak Z, Engelhardt JI, Kemeny L, Kalman J, Vecsei L, Rasko I. Source: Neuroreport. 2001 June 13; 12(8): 1653-6. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11409734&dopt=Abstract
•
Variability in cognitive function among persons at high genetic risk of Huntington's disease. Author(s): Lundervold AJ, Reinvang I. Source: Acta Neurologica Scandinavica. 1995 June; 91(6): 462-9. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=7572041&dopt=Abstract
•
Vasomotor hyporeactivity in the anterior cerebral artery during motor activation in Huntington's disease patients. Author(s): Deckel AW, Duffy JD. Source: Brain Research. 2000 July 28; 872(1-2): 258-61. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=10924705&dopt=Abstract
•
Velocity modulation and rhythmic synchronization of gait in Huntington's disease. Author(s): Thaut MH, Miltner R, Lange HW, Hurt CP, Hoemberg V. Source: Movement Disorders : Official Journal of the Movement Disorder Society. 1999 September; 14(5): 808-19. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=10495043&dopt=Abstract
•
Verbal fluency in Huntington's disease: a longitudinal analysis of phonemic and semantic clustering and switching. Author(s): Ho AK, Sahakian BJ, Robbins TW, Barker RA, Rosser AE, Hodges JR. Source: Neuropsychologia. 2002; 40(8): 1277-84. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11931930&dopt=Abstract
Studies
105
•
Vesicular neurotransmitter transporters in Huntington's disease: initial observations and comparison with traditional synaptic markers. Author(s): Suzuki M, Desmond TJ, Albin RL, Frey KA. Source: Synapse (New York, N.Y.). 2001 September 15; 41(4): 329-36. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11494403&dopt=Abstract
•
Visual attention and perception in patients with Huntington's disease: comparisons with other subcortical and cortical dementias. Author(s): Filoteo JV, Delis DC, Roman MJ, Demadura T, Ford E, Butters N, Salmon DP, Paulsen J, Shults CW, Swenson M, et al. Source: J Clin Exp Neuropsychol. 1995 October; 17(5): 654-67. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=8557807&dopt=Abstract
•
Visual attention in Huntington's disease: the effect of cueing on saccade latencies and manual reaction times. Author(s): Tsai TT, Lasker A, Zee DS. Source: Neuropsychologia. 1995 December; 33(12): 1617-26. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=8745119&dopt=Abstract
•
Visual object and visuospatial cognition in Huntington's disease: implications for information processing in corticostriatal circuits. Author(s): Lawrence AD, Watkins LH, Sahakian BJ, Hodges JR, Robbins TW. Source: Brain; a Journal of Neurology. 2000 July; 123 ( Pt 7): 1349-64. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=10869048&dopt=Abstract
•
Visual processing disorders in patients with Huntington's disease and asymptomatic carriers. Author(s): Gomez-Tortosa E, del Barrio A, Barroso T, Garcia Ruiz PJ. Source: Journal of Neurology. 1996 March; 243(3): 286-92. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=8936361&dopt=Abstract
•
Visuospatial cognition in Huntington's disease. Author(s): Mohr E, Brouwers P, Claus JJ, Mann UM, Fedio P, Chase TN. Source: Movement Disorders : Official Journal of the Movement Disorder Society. 1991; 6(2): 127-32. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=1829137&dopt=Abstract
•
We need something better, and we need it now: fetal striatal transplantation in Huntington's disease? Author(s): Greenamyre JT, Shoulson I. Source: Neurology. 2002 March 12; 58(5): 675-6. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11889226&dopt=Abstract
106 Huntington’s Disease
•
Weight loss in early stage of Huntington's disease. Author(s): Djousse L, Knowlton B, Cupples LA, Marder K, Shoulson I, Myers RH. Source: Neurology. 2002 November 12; 59(9): 1325-30. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12427878&dopt=Abstract
•
Weight loss in Huntington's disease. Author(s): Stoy N, McKay E. Source: Annals of Neurology. 2000 July; 48(1): 130-1. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=10894233&dopt=Abstract
•
What is needed versus what would be interesting to know before undertaking neural transplantation in patients with Huntington's disease. Author(s): Peschanski M, Cesaro P, Hantraye P. Source: Neuroscience. 1996 April; 71(3): 899-900. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=8867058&dopt=Abstract
•
When does Huntington's disease begin? Author(s): Campodonico JR, Aylward E, Codori AM, Young C, Krafft L, Magdalinski M, Ranen N, Slavney PR, Brandt J. Source: Journal of the International Neuropsychological Society : Jins. 1998 September; 4(5): 467-73. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=9745236&dopt=Abstract
•
When is it not Huntington's disease? Author(s): Heckmann JM, Bryer A, Greenberg LJ. Source: South African Medical Journal. Suid-Afrikaanse Tydskrif Vir Geneeskunde. 2001 February; 91(2): 132-3. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11288392&dopt=Abstract
•
Which diagnostic procedures in the elderly? The case of late-onset Huntington's disease. Author(s): Appollonio I, Frisoni GB, Curto N, Trabucchi M, Frattola L. Source: Journal of Geriatric Psychiatry and Neurology. 1997 January; 10(1): 39-46. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=9100158&dopt=Abstract
•
Wild type Huntingtin reduces the cellular toxicity of mutant Huntingtin in mammalian cell models of Huntington's disease. Author(s): Ho LW, Brown R, Maxwell M, Wyttenbach A, Rubinsztein DC. Source: Journal of Medical Genetics. 2001 July; 38(7): 450-2. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11432963&dopt=Abstract
Studies
•
107
Wild-type huntingtin up-regulates BDNF transcription in Huntington's disease. Author(s): Reilly CE. Source: Journal of Neurology. 2001 October; 248(10): 920-2. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11697536&dopt=Abstract
109
CHAPTER 2. NUTRITION AND HUNTINGTON’S DISEASE Overview In this chapter, we will show you how to find studies dedicated specifically to nutrition and Huntington’s disease.
Finding Nutrition Studies on Huntington’s Disease The National Institutes of Health’s Office of Dietary Supplements (ODS) offers a searchable bibliographic database called the IBIDS (International Bibliographic Information on Dietary Supplements; National Institutes of Health, Building 31, Room 1B29, 31 Center Drive, MSC 2086, Bethesda, Maryland 20892-2086, Tel: 301-435-2920, Fax: 301-480-1845, E-mail:
[email protected]). The IBIDS contains over 460,000 scientific citations and summaries about dietary supplements and nutrition as well as references to published international, scientific literature on dietary supplements such as vitamins, minerals, and botanicals.7 The IBIDS includes references and citations to both human and animal research studies. As a service of the ODS, access to the IBIDS database is available free of charge at the following Web address: http://ods.od.nih.gov/databases/ibids.html. After entering the search area, you have three choices: (1) IBIDS Consumer Database, (2) Full IBIDS Database, or (3) Peer Reviewed Citations Only. Now that you have selected a database, click on the “Advanced” tab. An advanced search allows you to retrieve up to 100 fully explained references in a comprehensive format. Type “Huntington’s disease” (or synonyms) into the search box, and click “Go.” To narrow the search, you can also select the “Title” field.
7 Adapted from http://ods.od.nih.gov. IBIDS is produced by the Office of Dietary Supplements (ODS) at the National Institutes of Health to assist the public, healthcare providers, educators, and researchers in locating credible, scientific information on dietary supplements. IBIDS was developed and will be maintained through an interagency partnership with the Food and Nutrition Information Center of the National Agricultural Library, U.S. Department of Agriculture.
110 Huntington’s Disease
The following information is typical of that found when using the “Full IBIDS Database” to search for “Huntington’s disease” (or a synonym): •
3-Nitropropionic acid induces a spectrum of Huntington's disease-like neuropathology in rat striatum. Author(s): Department of Neurology; Department of Pathology, University Hospital Nijmegen, The Netherlands.
[email protected] Source: Vis, J C Verbeek, M M De Waal, R M Ten Donkelaar, H J Kremer, H P Neuropathol-Appl-Neurobiol. 1999 December; 25(6): 513-21 0305-1846
•
A controlled trial of idebenone in Huntington's disease. Author(s): Department of Psychiatry, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA. Source: Ranen, N G Peyser, C E Coyle, J T Bylsma, F W Sherr, M Day, L Folstein, M F Brandt, J Ross, C A Folstein, S E Mov-Disord. 1996 September; 11(5): 549-54 0885-3185
•
A randomised, placebo-controlled, double blind study of treatment of Huntington's disease with unsaturated fatty acids. Author(s): Department of Psychological Medicine, Monash University, Maroondah Hospital, Victoria, Australia. Source: Vaddadi, K S Soosai, E Chiu, E DingJanuary, P Neuroreport. 2002 Jan 21; 13(1): 29-33 0959-4965
•
A randomized, placebo-controlled trial of coenzyme Q10 and remacemide in Huntington's disease. Source: Neurology. 2001 August 14; 57(3): 397-404 0028-3878
•
Abnormalities in the functioning of adipocytes from R6/2 mice that are transgenic for the Huntington's disease mutation. Author(s): Departments of Molecular Sciences and Anatomy and Neurobiology, College of Medicine, University of Tennessee Health Science Center, Memphis, TN 38163, USA.
[email protected] Source: Fain, J N Del March , N A Meade, C A Reiner, A Goldowitz, D Hum-Mol-Genet. 2001 January 15; 10(2): 145-52 0964-6906
•
Administration of recombinant human Activin-A has powerful neurotrophic effects on select striatal phenotypes in the quinolinic acid lesion model of Huntington's disease. Author(s): Research Centre for Developmental Medicine and Biology, School of Medicine, University of Auckland, New Zealand. Source: Hughes, P E Alexi, T Williams, C E Clark, R G Gluckman, P D Neuroscience. 1999; 92(1): 197-209 0306-4522
•
Age-dependent changes in nitric oxide synthase activity and protein expression in striata of mice transgenic for the Huntington's disease mutation. Author(s): Departamento de Fisiologi;a, Biofi;sica y Neurociencias, Centro de Investigacion y de Estudios Avanzados del IPN, Avenida Instituto Politecnico Nacional # 2508, 07300, DF, Mexico, Mexico. Source: Perez Severiano, F Escalante, B Vergara, P Rios, C Segovia, J Brain-Res. 2002 September 27; 951(1): 36-42 0006-8993
•
Alleviation of motor hyperactivity and neurochemical deficits by endocannabinoid uptake inhibition in a rat model of Huntington's disease. Author(s): Departamento de Bioquimica y Biologia Molecular, Facultad de Medicina, Universidad Complutense, 28040-Madrid, Spain.
Nutrition
111
Source: Lastres Becker, Isabel Hansen, Henrik H Berrendero, Fernando De Miguel, Rosario Perez Rosado, Alberto Manzanares, Jorge Ramos, Jose A Fernandez Ruiz, Javier Synapse. 2002 April; 44(1): 23-35 0887-4476 •
Amantadine in Huntington's disease: open-label video-blinded study. Author(s): Department of Neuroscience, University of Pisa, Pisa, Italy. Source: Lucetti, C Gambaccini, G Bernardini, S Dell'Agnello, G Petrozzi, L Rossi, G Bonuccelli, U Neurol-Sci. 2002 September; 23 Suppl 2: S83-4 1590-1874
•
An abnormal striatal synaptic plasticity may account for the selective neuronal vulnerability in Huntington's disease. Author(s): Neurosciences Department, University of Rome Tor Vergata, Rome, Italy. Source: Centonze, D Gubellini, P Picconi, B Saulle, E Tolu, M Bonsi, P Giacomini, P Calabresi, P Neurol-Sci. 2001 February; 22(1): 61-2 1590-1874
•
Assessment of coenzyme Q10 tolerability in Huntington's disease. Author(s): Department of Neurology, University of Rochester School of Medicine and Dentistry, New York, USA. Source: Feigin, A Kieburtz, K Como, P Hickey, C Claude, K Abwender, D Zimmerman, C Steinberg, K Shoulson, I Mov-Disord. 1996 May; 11(3): 321-3 0885-3185
•
Behavioral and morphological comparison of two nonhuman primate models of Huntington's disease. Author(s): Department of Neurosurgery, University of Illinois, 912 S. Wood Street, M/C 799, Chicago, IL 60612, USA.
[email protected] Source: Roitberg, Ben Zion Emborg, Marina E Sramek, Joseph G Palfi, Stephane Kordower, Jeffrey H Neurosurgery. 2002 January; 50(1): 137-45; discussion 145-6 0148396X
•
Calpain activation in Huntington's disease. Author(s): Buck Institute for Age Research, Novato, California 94945, USA. Source: Gafni, Juliette Ellerby, Lisa M J-Neurosci. 2002 June 15; 22(12): 4842-9 1529-2401
•
Cerebrospinal fluid acetylcholinesterase and choline measurements in Huntington's disease. Author(s): Department of Medicine, Southern Illinois University School of Medicine, Springfield 62794-9230. Source: Manyam, B V Giacobini, E Colliver, J A J-Neurol. 1990 August; 237(5): 281-4 0340-5354
•
Changes in endocannabinoid transmission in the basal ganglia in a rat model of Huntington's disease. Author(s): Departamento de Bioquimica y Biologia Molecular, Facultad de Medicina, Universidad Complutense, 28040-Madrid, Spain. Source: Lastres Becker, I Fezza, F Cebeira, M Bisogno, T Ramos, J A Milone, A Fernandez Ruiz, J Marzo, V D Neuroreport. 2001 July 20; 12(10): 2125-9 0959-4965
•
Characterization of a yeast artificial chromosome contig spanning the Huntington's disease gene candidate region. Source: Bates, G.P. Valdes, J. Hummerich, H. Baxendale, S. Le Paslier, D.L. Monaco, A.P. Tagle, D. MacDonald, M.E. Altherr, M. Ross, M. Nat-Gen. New York, NY : Nature Publishing Co. June 1992. volume 1 (3) page 180-187. 1061-4036
•
Coenzyme Q10 and remacemide hydrochloride ameliorate motor deficits in a Huntington's disease transgenic mouse model. Author(s): Department of Pathology, The Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA.
[email protected]
112 Huntington’s Disease
Source: Schilling, G Coonfield, M L Ross, C A Borchelt, D R Neurosci-Lett. 2001 November 27; 315(3): 149-53 0304-3940 •
Cognitive deficits in Huntington's disease are predicted by dopaminergic PET markers and brain volumes. Author(s): Department of Psychology, Goteborg University, Sweden. Source: Backman, L Robins Wahlin, T B Lundin, A Ginovart, N Farde, L Brain. 1997 December; 120 ( Pt 12)2207-17 0006-8950
•
Compounds acting at the endocannabinoid and/or endovanilloid systems reduce hyperkinesia in a rat model of Huntington's disease. Author(s): Departamento de Bioquimica y Biologia Molecular, Facultad de Medicina, Universidad Complutense, 28040-Madrid, Spain. Source: Lastres Becker, I de Miguel, R De Petrocellis, L Makriyannis, A Di Marzo, V Fernandez Ruiz, J J-Neurochem. 2003 Mar; 84(5): 1097-109 0022-3042
•
Creatine increase survival and delays motor symptoms in a transgenic animal model of Huntington's disease. Author(s): Neurochemistry Laboratory, Neurology Service, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusets, USA. Source: Andreassen, O A Dedeoglu, A Ferrante, R J Jenkins, B G Ferrante, K L Thomas, M Friedlich, A Browne, S E Schilling, G Borchelt, D R Hersch, S M Ross, C A Beal, M F Neurobiol-Dis. 2001 June; 8(3): 479-91 0969-9961
•
Dietary arginine alters time of symptom onset in Huntington's disease transgenic mice. Author(s): Department of Psychiatry, MC 2103, University of Connecticut Health Center, 263 Farmington Avenue, Farmington, CT 06030-2103, USA.
[email protected] Source: Deckel, A W Volmer, P Weiner, R Gary, K A Covault, J Sasso, D Schmerler, N Watts, D Yan, Z Abeles, I Brain-Res. 2000 September 1; 875(1-2): 187-95 0006-8993
•
Differential regulation of the expression of nerve growth factor, brain-derived neurotrophic factor, and neurotrophin-3 after excitotoxicity in a rat model of Huntington's disease. Author(s): Departament de Biologia Cellular i Anatomia Patologica, Facultat de Medicina, Universitat de Barcelona, IDIBAPS, Spain. Source: Canals, J M Marco, S Checa, N Michels, A Perez Navarro, E Arenas, E Alberch, J Neurobiol-Dis. 1998 November; 5(5): 357-64 0969-9961
•
Dysregulation of ascorbate release in the striatum of behaving mice expressing the Huntington's disease gene. Author(s): Program in Neural Science, Department of Psychology, Indiana University, Bloomington, Indiana 47405-7007, USA.
[email protected] Source: Rebec, George V Barton, Scott J Ennis, Michelle D J-Neurosci. 2002 January 15; 22(2): RC202 1529-2401
•
Early mitochondrial calcium defects in Huntington's disease are a direct effect of polyglutamines. Author(s): Department of Neurology, Emory University School of Medicine, Whitehead Biomedical Research Building, 615 Michael Street, Atlanta, Georgia 30322, USA. Source: PaNovember, Alexander V Gutekunst, Claire Anne Leavitt, Blair R Hayden, Michael R Burke, James R Strittmatter, Warren J Greenamyre, J Timothy Nat-Neurosci. 2002 August; 5(8): 731-6 1097-6256
Nutrition
113
•
Effects of nerve and fibroblast growth factors on the production of nitric oxide in experimental model of Huntington's disease. Author(s): Military Medical Academy, Institute for Medical Research, Belgrade. Source: Maksimovic, Ivana D Jovanovic, Marina D Malicevic, Zivorad Colic, Miodrag Ninkovic, Milica Vojnosanit-Pregl. 2002 Mar-April; 59(2): 119-23 0042-8450
•
Embryonic striatal grafts restore neuronal activity of the globus pallidus in a rodent model of Huntington's disease. Author(s): Department of Neurological Surgery, Wakayama Medical College, Japan. Source: Nakao, N Ogura, M Nakai, K Itakura, T Neuroscience. 1999 January; 88(2): 46977 0306-4522
•
Environmental stimulation increases survival in mice transgenic for exon 1 of the Huntington's disease gene. Author(s): Department of Pharmacology, University of Cambridge, UK. Source: Carter, R J Hunt, M J Morton, A J Mov-Disord. 2000 September; 15(5): 925-37 0885-3185
•
Essential fatty acids given from conception prevent topographies of motor deficit in a transgenic model of Huntington's disease. Author(s): Department of Clinical Pharmacology, Royal College of Surgeons in Ireland, St. Stephen's Green, Dublin 2, Ireland.
[email protected] Source: Clifford, J J Drago, J Natoli, A L Wong, J Y F Kinsella, A Waddington, J L Vaddadi, K S Neuroscience. 2002; 109(1): 81-8 0306-4522
•
Evaluation of R6/2 HD transgenic mice for therapeutic studies in Huntington's disease: behavioral testing and impact of diabetes mellitus. Author(s): Department of Neurology, University Hospital RWTH Aachen, Pauwelsstrasse 30, D-52074, Aachen, Germany Source: Luesse, H G Schiefer, J Spruenken, A Puls, C Block, F Kosinski, C M BehavBrain-Res. 2001 November 29; 126(1-2): 185-95 0166-4328
•
Evidence for dysfunction of the nigrostriatal pathway in the R6/1 line of transgenic Huntington's disease mice. Author(s): Section for Neuronal Survival, Wallenberg Neuroscience Center, Lund University, Sweden. Source: Petersen, A Puschban, Z Lotharius, J NicNiocaill, B Wiekop, P O'Connor, W T Brundin, P Neurobiol-Dis. 2002 October; 11(1): 134-46 0969-9961
•
Fetal striatal transplants restore electrophysiological sensitivity to dopamine in the lesioned striatum of rats with experimental Huntington's disease. Author(s): Department of Neurological Surgery, Tri-Service General Hospital, National Defense Medical Center, Taipei, Taiwan, ROC. Source: Chen, G J Jeng, C H Lin, S Z Tsai, S H Wang, Y Chiang, Y H J-Biomed-Sci. 2002 Jul-August; 9(4): 303-10 1021-7770
•
Huntington's disease and low tryptophan diet. Author(s): Royal Children's Hospital, Melbourne, Australia. Source: Pascoe, M Med-Hypotheses. 1993 October; 41(4): 325-6 0306-9877
•
Hyperactivity and hypoactivity in a rat model of Huntington's disease: the systemic 3nitropropionic acid model. Author(s): Department of Surgery, University of South Florida College of Medicine, Tampa 33612, USA.
[email protected] Source: Borlongan, C V Koutouzis, T K Freeman, T B Hauser, R A Cahill, D W Sanberg, P R Brain-Res-Brain-Res-Protoc. 1997 August; 1(3): 253-7 1385-299X
114 Huntington’s Disease
•
Impaired glutamate uptake in the R6 Huntington's disease transgenic mice. Author(s): Medical and Molecular Genetics, GKT School of Medicine, London, UK. Source: Lievens, J C Woodman, B Mahal, A Spasic Boscovic, O Samuel, D Kerkerian Le Goff, L Bates, G P Neurobiol-Dis. 2001 October; 8(5): 807-21 0969-9961
•
Impaired phospholipid-related signal transduction in advanced Huntington's disease. Author(s): MRI Unit, MRC Clinical Sciences Centre, Imperial College School of Medicine, Hammersmith Hospital, London W12 0HS, UK.
[email protected] Source: Puri, B K Exp-Physiol. 2001 September; 86(5): 683-5 0958-0670
•
In vitro effects of polyglutamine tracts on Ca2+-dependent depolarization of rat and human mitochondria: relevance to Huntington's disease. Author(s): Emory Center for Neurodegenerative Diseases, Emory University School of Medicine, Whitehead Biomedical Research Building, 615 Michael Street, Room 575, Atlanta, GA 30322, USA.
[email protected] Source: PaNovember, A V Burke, J R Strittmatter, W J Greenamyre, J T Arch-BiochemBiophys. 2003 February 1; 410(1): 1-6 0003-9861
•
Increased sensitivity to N-methyl-D-aspartate receptor-mediated excitotoxicity in a mouse model of Huntington's disease. Author(s): Kinsmen Laboratory of Neurological Research, Department of Psychiatry, 221 84, Lund, Sweden. Source: Zeron, M M Hansson, O Chen, N Wellington, C L Leavitt, B R Brundin, P Hayden, M R Raymond, L A Neuron. 2002 March 14; 33(6): 849-60 0896-6273
•
Intranuclear inclusions in subtypes of striatal neurons in Huntington's disease transgenic mice. Author(s): Department of Neurology, University Hospital RWTH Aachen, Germany. Source: Kosinski, C M Cha, J H Young, A B Mangiarini, L Bates, G Schiefer, J Schwarz, M Neuroreport. 1999 December 16; 10(18): 3891-6 0959-4965
•
Leuprolide acetate for exhibitionism in Huntington's disease. Author(s): Department of Psychiatry, University of Chicago, Illinois. Source: Rich, S S Ovsiew, F Mov-Disord. 1994 May; 9(3): 353-7 0885-3185
•
Lipoic acid improves survival in transgenic mouse models of Huntington's disease. Author(s): Neurochemistry Laboratory, Neurology Service, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA. Source: Andreassen, O A Ferrante, R J Dedeoglu, A Beal, M F Neuroreport. 2001 October 29; 12(15): 3371-3 0959-4965
•
Lithium suppresses excitotoxicity-induced striatal lesions in a rat model of Huntington's disease. Author(s): Section on Molecular Neurobiology, Biological Psychiatry Branch, National Institute of Mental Health, National Institutes of Health, Bethesda, MD 20892-1363, USA. Source: Wei, H Qin, Z H Senatorov, V V Wei, W Wang, Y Qian, Y Chuang, D M Neuroscience. 2001; 106(3): 603-12 0306-4522
•
Mice transgenic for exon 1 of the Huntington's disease gene display reduced striatal sensitivity to neurotoxicity induced by dopamine and 6-hydroxydopamine. Author(s): Section for Neuronal Survival, Wallenberg Neuroscience Center, Lund University, Sweden.
[email protected] Source: Petersen, A Hansson, O Puschban, Z Sapp, E Romero, N Castilho, R F Sulzer, D Rice, M DiFiglia, M Przedborski, S Brundin, P Eur-J-Neurosci. 2001 November; 14(9): 1425-35 0953-816X
Nutrition
115
•
Modeling Huntington's disease in cells, flies, and mice. Author(s): Department of Pharmacological Sciences, University of Milano, Center of Excellence on Neurodegenerative Diseases, Italy. Source: Sipione, S Cattaneo, E Mol-Neurobiol. 2001 February; 23(1): 21-51 0893-7648
•
Mouse models of Huntington's disease. Author(s): Dept of Neurology, Reed Neurological Research Center, UCLA School of Medicine, 710 Westwood Plaza, Los Angeles, CA 90095, USA.
[email protected] Source: Menalled, Liliana B Chesselet, Marie Francoise Trends-Pharmacol-Sci. 2002 January; 23(1): 32-9 0165-6147
•
Nabilone increases choreatic movements in Huntington's disease. Author(s): Department of Clinical Psychiatry and Psychotherapy Medical School, Hannover, Germany. Source: Muller Vahl, K R Schneider, U Emrich, H M Mov-Disord. 1999 November; 14(6): 1038-40 0885-3185
•
N-Acetylaspartate and DARPP-32 levels decrease in the corpus striatum of Huntington's disease mice. Author(s): University Laboratory of Physiology, University of Oxford. Source: van Dellen, A Welch, J Dixon, R M Cordery, P York, D Styles, P Blakemore, C Hannan, A J Neuroreport. 2000 November 27; 11(17): 3751-7 0959-4965
•
Neurochemistry and toxin models in Huntington's disease. Author(s): Massachusetts General Hospital, Boston 02114. Source: Beal, M F Curr-Opin-Neurol. 1994 December; 7(6): 542-7 1350-7540
•
Neuroprotective role for the p50 subunit of NF-kappaB in an experimental model of Huntington's disease. Author(s): Sanders-Brown Research Center on Aging, National Institute on Aging Gerontology Research Center, Baltimore, MD 21224, USA. Source: Yu, Z Zhou, D Cheng, G Mattson, M P J-Mol-Neurosci. 2000 August; 15(1): 31-44 0895-8696
•
Neurturin protects striatal projection neurons but not interneurons in a rat model of Huntington's disease. Author(s): Departament de Biologia Cellular i Anatomia Patologica, Facultat de Medicina, IDIBAPS, Universitat de Barcelona, Casanova 143, E-08036, Barcelona, Spain. Source: Perez Navarro, E Akerud, P Marco, S Canals, J M Tolosa, E Arenas, E Alberch, J Neuroscience. 2000; 98(1): 89-96 0306-4522
•
NGF attenuates 3-nitrotyrosine formation in a 3-NP model of Huntington's disease. Author(s): Neuroregeneration Laboratory, McLean Hospital, Harvard Medical School, Belmont, MA 02178, USA. Source: Galpern, W R Matthews, R T Beal, M F Isacson, O Neuroreport. 1996 November 4; 7(15-17): 2639-42 0959-4965
•
PET study of the pre- and post-synaptic dopaminergic markers for the neurodegenerative process in Huntington's disease. Author(s): Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden. Source: Ginovart, N Lundin, A Farde, L Halldin, C Backman, L Swahn, C G Pauli, S Sedvall, G Brain. 1997 March; 120 ( Pt 3)503-14 0006-8950
116 Huntington’s Disease
•
Possible cellular mechanism accounting for the cell type-specific vulnerability in Huntington's disease. Author(s): Neurological Clinic, Department of Neurosciences, University Tor Vergata and IRCCS S. Lucia Hospital, Rome, Italy. Source: Centonze, D Giacomini, P Tolu, M Bernardi, G Calabresi, P Funct-Neurol. 2000 Oct-December; 15(4): 253-8 0393-5264
•
Progressive formation of inclusions in the striatum and hippocampus of mice transgenic for the human Huntington's disease mutation. Author(s): Departments of Pharmacology, University of Cambridge, Tennis Court Road, Cambridge CB2 1QJ, UK. Source: Morton, A J Lagan, M A Skepper, J N Dunnett, S B J-Neurocytol. 2000 September; 29(9): 679-702 0300-4864
•
Proteasomal-dependent aggregate reversal and absence of cell death in a conditional mouse model of Huntington's disease. Author(s): Centro de Biologia Molecular “Severo Ochoa,” Consejo Superior de Investigaciones Cientificas-Universidad Autonoma de Madrid, 28049 Madrid, Spain. Source: Martin Aparicio, E Yamamoto, A Hernandez, F Hen, R Avila, J Lucas, J J JNeurosci. 2001 November 15; 21(22): 8772-81 1529-2401
•
Quantifiable bradykinesia, gait abnormalities and Huntington's disease-like striatal lesions in rats chronically treated with 3-nitropropionic acid. Author(s): Service Hospitalier Frederic Joliot, Unite de Recherche Associee 2210,Commissariat a l'Energie Atomique-Centre National de Recherche Scientifique, Departement de Recherche Medicale, Orsay, France. Source: Guyot, M C Hantraye, P Dolan, R Palfi, S Maziere, M Brouillet, E Neuroscience. 1997 July; 79(1): 45-56 0306-4522
•
Quinolinic acid-induced increases in calbindin D28k immunoreactivity in rat striatal neurons in vivo and in vitro mimic the pattern seen in Huntington's disease. Author(s): Laboratory of Cellular Neurobiology, Massachusetts General Hospital, Boston 02114, USA. Source: Huang, Q Zhou, D Sapp, E Aizawa, H Ge, P Bird, E D Vonsattel, J P DiFiglia, M Neuroscience. 1995 March; 65(2): 397-407 0306-4522
•
Restoration of cognitive and motor functions by ciliary neurotrophic factor in a primate model of Huntington's disease. Author(s): URA CEA CNRS 2210, SHFJ, DRM, DSV, CEA, Orsay, France. Source: Mittoux, V Joseph, J M Conde, F Palfi, S Dautry, C Poyot, T Bloch, J Deglon, N Ouary, S Nimchinsky, E A Brouillet, E Hof, P R Peschanski, M Aebischer, P Hantraye, P Hum-Gene-Ther. 2000 May 20; 11(8): 1177-87 1043-0342
•
Steroid therapy in Huntington's disease. Author(s): Institute of Clinical Neurology, University of Pisa, Italy. Source: Bonuccelli, U Nuti, A Maremmani, C Ceravolo, R Muratorio, A Adv-BiochemPsychopharmacol. 1992; 47149-54 0065-2229
•
Striatal and cortical neurochemical changes induced by chronic metabolic compromise in the 3-nitropropionic model of Huntington's disease. Author(s): Laboratoire de Neurophysiologie, ULB-Erasme, CP601, 808 Route de Lennik, 1070 Brussels, Belgium.
[email protected] Source: Blum, D Galas, M C Gall, D Cuvelier, L Schiffmann, S N Neurobiol-Dis. 2002 August; 10(3): 410-26 0969-9961
Nutrition
117
•
Tauroursodeoxycholic acid, a bile acid, is neuroprotective in a transgenic animal model of Huntington's disease. Author(s): Graduate Program in Neuroscience and Department of Neurosurgery, University of Minnesota Medical School, Minneapolis, MN 55455, USA. Source: Keene, C D Rodrigues, C M Eich, T Chhabra, M S Steer, C J Low, W C Proc-NatlAcad-Sci-U-S-A. 2002 August 6; 99(16): 10671-6 0027-8424
•
The differential vulnerability of striatal projection neurons in 3-nitropropionic acidtreated rats does not match that typical of adult-onset Huntington's disease. Author(s): Department of Anatomy and Neurobiology, The University of Tennessee Health Science Center, Memphis, Tennessee 38163, USA. Source: Sun, Z Xie, J Reiner, A Exp-Neurol. 2002 July; 176(1): 55-65 0014-4886
•
The Gln-Ala repeat transcriptional activator CA150 interacts with huntingtin: neuropathologic and genetic evidence for a role in Huntington's disease pathogenesis. Author(s): Laboratory of Genomic Biology, Fondation Jean Dausset, Centre d'Etude du Polymorphisme Humain, 75010 Paris, France. Source: Holbert, S Denghien, I Kiechle, T Rosenblatt, A Wellington, C Hayden, M R Margolis, R L Ross, C A Dausset, J Ferrante, R J Neri, C Proc-Natl-Acad-Sci-U-S-A. 2001 February 13; 98(4): 1811-6 0027-8424
•
The role of dopamine in motor symptoms in the R6/2 transgenic mouse model of Huntington's disease. Author(s): Department of Pharmacology, University of Cambridge, UK. Source: Hickey, Miriam A Reynolds, Gavin P Morton, A Jennifer J-Neurochem. 2002 April; 81(1): 46-59 0022-3042
•
Therapeutic effects of coenzyme Q10 and remacemide in transgenic mouse models of Huntington's disease. Author(s): Geriatric Research Education and Clinical Center, Bedford Veterans Administration Medical Center, Bedford, Massachusetts 01730, USA.
[email protected] Source: Ferrante, Robert J Andreassen, Ole A Dedeoglu, Alpaslan Ferrante, Kimberly L Jenkins, Bruce G Hersch, Steven M Beal, M Flint J-Neurosci. 2002 March 1; 22(5): 1592-9 1529-2401
Federal Resources on Nutrition In addition to the IBIDS, the United States Department of Health and Human Services (HHS) and the United States Department of Agriculture (USDA) provide many sources of information on general nutrition and health. Recommended resources include: •
healthfinder®, HHS’s gateway to health information, including diet and nutrition: http://www.healthfinder.gov/scripts/SearchContext.asp?topic=238&page=0
•
The United States Department of Agriculture’s Web site dedicated to nutrition information: www.nutrition.gov
•
The Food and Drug Administration’s Web site for federal food safety information: www.foodsafety.gov
•
The National Action Plan on Overweight and Obesity sponsored by the United States Surgeon General: http://www.surgeongeneral.gov/topics/obesity/
118 Huntington’s Disease
•
The Center for Food Safety and Applied Nutrition has an Internet site sponsored by the Food and Drug Administration and the Department of Health and Human Services: http://vm.cfsan.fda.gov/
•
Center for Nutrition Policy and Promotion sponsored by the United States Department of Agriculture: http://www.usda.gov/cnpp/
•
Food and Nutrition Information Center, National Agricultural Library sponsored by the United States Department of Agriculture: http://www.nal.usda.gov/fnic/
•
Food and Nutrition Service sponsored by the United States Department of Agriculture: http://www.fns.usda.gov/fns/
Additional Web Resources A number of additional Web sites offer encyclopedic information covering food and nutrition. The following is a representative sample: •
AOL: http://search.aol.com/cat.adp?id=174&layer=&from=subcats
•
Family Village: http://www.familyvillage.wisc.edu/med_nutrition.html
•
Google: http://directory.google.com/Top/Health/Nutrition/
•
Healthnotes: http://www.healthnotes.com/
•
Open Directory Project: http://dmoz.org/Health/Nutrition/
•
Yahoo.com: http://dir.yahoo.com/Health/Nutrition/
•
WebMD®Health: http://my.webmd.com/nutrition
•
WholeHealthMD.com: http://www.wholehealthmd.com/reflib/0,1529,00.html
The following is a specific Web list relating to Huntington’s disease; please note that any particular subject below may indicate either a therapeutic use, or a contraindication (potential danger), and does not reflect an official recommendation: •
Minerals Creatine Source: Prima Communications, Inc.www.personalhealthzone.com Iron Source: Healthnotes, Inc.; www.healthnotes.com
119
CHAPTER 3. ALTERNATIVE HUNTINGTON’S DISEASE
MEDICINE
AND
Overview In this chapter, we will begin by introducing you to official information sources on complementary and alternative medicine (CAM) relating to Huntington’s disease. At the conclusion of this chapter, we will provide additional sources.
National Center for Complementary and Alternative Medicine The National Center for Complementary and Alternative Medicine (NCCAM) of the National Institutes of Health (http://nccam.nih.gov/) has created a link to the National Library of Medicine’s databases to facilitate research for articles that specifically relate to Huntington’s disease and complementary medicine. To search the database, go to the following Web site: http://www.nlm.nih.gov/nccam/camonpubmed.html. Select “CAM on PubMed.” Enter “Huntington’s disease” (or synonyms) into the search box. Click “Go.” The following references provide information on particular aspects of complementary and alternative medicine that are related to Huntington’s disease: •
A primate model of Huntington's disease: functional neural transplantation and CTguided stereotactic procedures. Author(s): Schumacher JM, Hantraye P, Brownell AL, Riche D, Madras BK, Davenport PD, Maziere M, Elmaleh DR, Brownell GL, Isacson O. Source: Cell Transplantation. 1992; 1(4): 313-22. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=1344304&dopt=Abstract
•
Aspects of PET imaging relevant to the assessment of striatal transplantation in Huntington's disease. Author(s): Besret L, Kendall AL, Dunnett SB. Source: Journal of Anatomy. 2000 May; 196 ( Pt 4): 597-607. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=10923990&dopt=Abstract
120 Huntington’s Disease
•
Assessing Huntington's disease. Author(s): Fillingham K. Source: Community Nurse. 1998 October; 4(9): 51. No Abstract Available. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=10326374&dopt=Abstract
•
Behavioural relaxation training with Huntington's disease patients: a pilot study. Author(s): Fecteau GW, Boyne J. Source: Psychological Reports. 1987 August; 61(1): 151-7. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=2959978&dopt=Abstract
•
Bilateral human fetal striatal transplantation in Huntington's disease. Author(s): Hauser RA, Furtado S, Cimino CR, Delgado H, Eichler S, Schwartz S, Scott D, Nauert GM, Soety E, Sossi V, Holt DA, Sanberg PR, Stoessl AJ, Freeman TB. Source: Neurology. 2002 March 12; 58(5): 687-95. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11889229&dopt=Abstract
•
Brain SPECT imaging in Huntington's disease before and after therapy with olanzapine. Case report. Author(s): Etchebehere EC, Lima MC, Passos W, Maciel Junior JA, Santos AO, Ramos CD, Camargo EE. Source: Arquivos De Neuro-Psiquiatria. 1999 September; 57(3B): 863-6. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=10751925&dopt=Abstract
•
Caspase cleavage of mutant huntingtin precedes neurodegeneration in Huntington's disease. Author(s): Wellington CL, Ellerby LM, Gutekunst CA, Rogers D, Warby S, Graham RK, Loubser O, van Raamsdonk J, Singaraja R, Yang YZ, Gafni J, Bredesen D, Hersch SM, Leavitt BR, Roy S, Nicholson DW, Hayden MR. Source: The Journal of Neuroscience : the Official Journal of the Society for Neuroscience. 2002 September 15; 22(18): 7862-72. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12223539&dopt=Abstract
•
Cdc42-interacting protein 4 binds to huntingtin: neuropathologic and biological evidence for a role in Huntington's disease. Author(s): Holbert S, Dedeoglu A, Humbert S, Saudou F, Ferrante RJ, Neri C. Source: Proceedings of the National Academy of Sciences of the United States of America. 2003 March 4; 100(5): 2712-7. Epub 2003 February 25. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12604778&dopt=Abstract
•
Cell therapy for Huntington's disease, the next step forward. Author(s): Peschanski M, Dunnett SB.
Alternative Medicine 121
Source: Lancet. Neurology. 2002 June; 1(2): 81. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12849508&dopt=Abstract •
Cellular delivery of trophic factors for the treatment of Huntington's disease: is neuroprotection possible? Author(s): Kordower JH, Isacson O, Leventhal L, Emerich DF. Source: Prog Brain Res. 2000; 127: 414-30. Review. No Abstract Available. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11142039&dopt=Abstract
•
Characterization of progressive motor deficits in mice transgenic for the human Huntington's disease mutation. Author(s): Carter RJ, Lione LA, Humby T, Mangiarini L, Mahal A, Bates GP, Dunnett SB, Morton AJ. Source: The Journal of Neuroscience : the Official Journal of the Society for Neuroscience. 1999 April 15; 19(8): 3248-57. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=10191337&dopt=Abstract
•
Comparison of ribosomal subunit proteins from normal human and Huntington's disease skin fibroblasts. Author(s): Prashad N, Rosenberg RN. Source: Annals of Neurology. 1977 May; 1(5): 475-7. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=152599&dopt=Abstract
•
Creatine increase survival and delays motor symptoms in a transgenic animal model of Huntington's disease. Author(s): Andreassen OA, Dedeoglu A, Ferrante RJ, Jenkins BG, Ferrante KL, Thomas M, Friedlich A, Browne SE, Schilling G, Borchelt DR, Hersch SM, Ross CA, Beal MF. Source: Neurobiology of Disease. 2001 June; 8(3): 479-91. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11447996&dopt=Abstract
•
Creatine therapy provides neuroprotection after onset of clinical symptoms in Huntington's disease transgenic mice. Author(s): Dedeoglu A, Kubilus JK, Yang L, Ferrante KL, Hersch SM, Beal MF, Ferrante RJ. Source: Journal of Neurochemistry. 2003 June; 85(6): 1359-67. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12787055&dopt=Abstract
•
Cytochrome C and caspase-9 expression in Huntington's disease. Author(s): Kiechle T, Dedeoglu A, Kubilus J, Kowall NW, Beal MF, Friedlander RM, Hersch SM, Ferrante RJ. Source: Neuromolecular Medicine. 2002; 1(3): 183-95. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12095160&dopt=Abstract
122 Huntington’s Disease
•
Effects of multisensory stimulation in people with Huntington's disease: a randomized controlled pilot study. Author(s): Leng TR, Woodward MJ, Stokes MJ, Swan AV, Wareing LA, Baker R. Source: Clinical Rehabilitation. 2003 February; 17(1): 30-41. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12617377&dopt=Abstract
•
Electrodermal activity in patients with Huntington's disease and their progeny. Author(s): Iacono WG, Roshi D, Lacoste D. Source: Psychophysiology. 1987 September; 24(5): 522-7. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=2960997&dopt=Abstract
•
First step towards cell therapy for Huntington's disease. Author(s): Lindvall O, Bjorklund A. Source: Lancet. 2000 December 9; 356(9246): 1945-6. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11130518&dopt=Abstract
•
Functional caudate imaging in symptomatic Huntington's disease: positron emission tomography versus single-photon emission computed tomography. Author(s): Martin WR, Hoskinson M, Kremer B, Maguire C, McEwan A. Source: Journal of Neuroimaging : Official Journal of the American Society of Neuroimaging. 1995 October; 5(4): 227-32. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=7579751&dopt=Abstract
•
Histone deacetylase inhibition by sodium butyrate chemotherapy ameliorates the neurodegenerative phenotype in Huntington's disease mice. Author(s): Ferrante RJ, Kubilus JK, Lee J, Ryu H, Beesen A, Zucker B, Smith K, Kowall NW, Ratan RR, Luthi-Carter R, Hersch SM. Source: The Journal of Neuroscience : the Official Journal of the Society for Neuroscience. 2003 October 15; 23(28): 9418-27. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=14561870&dopt=Abstract
•
Huntington's chorea: striking the right chord. Author(s): Hoskyns S. Source: Nurs Mirror. 1982 June 2; 154(22): 14-7. No Abstract Available. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=6211657&dopt=Abstract
•
Huntington's disease: prospects for neuroprotective therapy 10 years after the discovery of the causative genetic mutation. Author(s): Hersch SM. Source: Current Opinion in Neurology. 2003 August; 16(4): 501-6. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12869810&dopt=Abstract
Alternative Medicine 123
•
Hydrotherapy in Huntington's disease. Author(s): Sheaff F. Source: Nurs Times. 1990 January 24-30; 86(4): 46-9. No Abstract Available. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=2137214&dopt=Abstract
•
Hypnosis and the treatment of Huntington's disease. Author(s): Witz M, Kahn S. Source: Am J Clin Hypn. 1991 October; 34(2): 79-90. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=1835562&dopt=Abstract
•
Hypnosis as an adjunctive treatment in Huntington's disease. Author(s): Moldawsky RJ. Source: Am J Clin Hypn. 1984 April; 26(4): 229-31. No Abstract Available. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=6237574&dopt=Abstract
•
Imagery, encoding, and retrieval of information from memory: some specific encoding--retrieval changes in Huntington's disease. Author(s): Weingartner H, Caine ED, Ebert MH. Source: Journal of Abnormal Psychology. 1979 February; 88(1): 52-8. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=154532&dopt=Abstract
•
Impaired prepulse inhibition of acoustic and tactile startle response in patients with Huntington's disease. Author(s): Swerdlow NR, Paulsen J, Braff DL, Butters N, Geyer MA, Swenson MR. Source: Journal of Neurology, Neurosurgery, and Psychiatry. 1995 February; 58(2): 192200. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=7876851&dopt=Abstract
•
Late onset levodopa responsive Huntington's disease with minimal chorea masquerading as Parkinson plus syndrome. Author(s): Reuter I, Hu MT, Andrews TC, Brooks DJ, Clough C, Chaudhuri KR. Source: Journal of Neurology, Neurosurgery, and Psychiatry. 2000 February; 68(2): 23841. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=10644798&dopt=Abstract
•
Learning to live at risk for Huntington's disease. Author(s): Hunt V, Walker FO. Source: The Journal of Neuroscience Nursing : Journal of the American Association of Neuroscience Nurses. 1991 June; 23(3): 179-82. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=1831483&dopt=Abstract
•
Motor and cognitive improvements in patients with Huntington's disease after neural transplantation.
124 Huntington’s Disease
Author(s): Bachoud-Levi AC, Remy P, Nguyen JP, Brugieres P, Lefaucheur JP, Bourdet C, Baudic S, Gaura V, Maison P, Haddad B, Boisse MF, Grandmougin T, Jeny R, Bartolomeo P, Dalla Barba G, Degos JD, Lisovoski F, Ergis AM, Pailhous E, Cesaro P, Hantraye P, Peschanski M. Source: Lancet. 2000 December 9; 356(9246): 1975-9. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11130527&dopt=Abstract •
Motor imagery in Huntington's disease. Author(s): McLennan NL, Georgiou NL, Mattingley JL, Bradshaw JL, Chiu E. Source: J Clin Exp Neuropsychol. 2000 June; 22(3): 379-90. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=10855045&dopt=Abstract
•
Motor learning by imagery is differentially affected in Parkinson's and Huntington's diseases. Author(s): Yaguez L, Canavan AG, Lange HW, Homberg V. Source: Behavioural Brain Research. 1999 July; 102(1-2): 115-27. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=10403020&dopt=Abstract
•
Neurophysiological study of facial chorea in patients with Huntington's disease. Author(s): Munoz E, Cervera A, Valls-Sole J. Source: Clinical Neurophysiology : Official Journal of the International Federation of Clinical Neurophysiology. 2003 July; 114(7): 1246-52. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12842721&dopt=Abstract
•
Neuroprotective effects of creatine in a transgenic mouse model of Huntington's disease. Author(s): Ferrante RJ, Andreassen OA, Jenkins BG, Dedeoglu A, Kuemmerle S, Kubilus JK, Kaddurah-Daouk R, Hersch SM, Beal MF. Source: The Journal of Neuroscience : the Official Journal of the Society for Neuroscience. 2000 June 15; 20(12): 4389-97. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=10844007&dopt=Abstract
•
Neuroprotective gene therapy for Huntington's disease using a polymer encapsulated BHK cell line engineered to secrete human CNTF. Author(s): Bachoud-Levi AC, Deglon N, Nguyen JP, Bloch J, Bourdet C, Winkel L, Remy P, Goddard M, Lefaucheur JP, Brugieres P, Baudic S, Cesaro P, Peschanski M, Aebischer P. Source: Human Gene Therapy. 2000 August 10; 11(12): 1723-9. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=10954906&dopt=Abstract
•
PET scan investigations of Huntington's disease: cerebral metabolic correlates of neurological features and functional decline. Author(s): Young AB, Penney JB, Starosta-Rubinstein S, Markel DS, Berent S, Giordani B, Ehrenkaufer R, Jewett D, Hichwa R.
Alternative Medicine 125
Source: Annals of Neurology. 1986 September; 20(3): 296-303. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=2945510&dopt=Abstract •
Predictive genetic test decisions for Huntington's disease: context, appraisal and new moral imperatives. Author(s): Taylor SD. Source: Social Science & Medicine (1982). 2004 January; 58(1): 137-49. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=14572927&dopt=Abstract
•
Regional and progressive thinning of the cortical ribbon in Huntington's disease. Author(s): Rosas HD, Liu AK, Hersch S, Glessner M, Ferrante RJ, Salat DH, van der Kouwe A, Jenkins BG, Dale AM, Fischl B. Source: Neurology. 2002 March 12; 58(5): 695-701. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11889230&dopt=Abstract
•
Relationship between evoked potential and neuropsychological findings in persons “at risk” for Huntington's disease. Author(s): Josiassen RC, Curry LM, Mancall EL, Shagass C, Roemer RA. Source: J Clin Exp Neuropsychol. 1986 January; 8(1): 21-36. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=2935556&dopt=Abstract
•
Replicating Huntington's disease phenotype in experimental animals. Author(s): Brouillet E, Conde F, Beal MF, Hantraye P. Source: Progress in Neurobiology. 1999 December; 59(5): 427-68. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=10515664&dopt=Abstract
•
Self-help groups: association to combat Huntington's chorea. Author(s): Jones IH. Source: Nurs Times. 1979 November 8; 75(45): 1949. No Abstract Available. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=160034&dopt=Abstract
•
Sp1 and TAFII130 transcriptional activity disrupted in early Huntington's disease. Author(s): Dunah AW, Jeong H, Griffin A, Kim YM, Standaert DG, Hersch SM, Mouradian MM, Young AB, Tanese N, Krainc D. Source: Science. 2002 June 21; 296(5576): 2238-43. Epub 2002 May 02. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11988536&dopt=Abstract
•
Striatal grafts in a rat model of Huntington's disease: time course comparison of MRI and histology. Author(s): Guzman R, Meyer M, Lovblad KO, Ozdoba C, Schroth G, Seiler RW, Widmer HR.
126 Huntington’s Disease
Source: Experimental Neurology. 1999 March; 156(1): 180-90. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=10192789&dopt=Abstract •
The midlatency auditory evoked potential P50 is abnormal in Huntington's disease. Author(s): Uc EY, Skinner RD, Rodnitzky RL, Garcia-Rill E. Source: Journal of the Neurological Sciences. 2003 August 15; 212(1-2): 1-5. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12809992&dopt=Abstract
•
The problem of antipsychotic treatment for functional imaging in Huntington's disease: receptor binding, gene expression and locomotor activity after sub-chronic administration and wash-out of haloperidol in the rat. Author(s): Besret L, Page KJ, Dunnett SB. Source: Brain Research. 2000 January 17; 853(1): 125-35. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=10627316&dopt=Abstract
•
The scintigraphic evaluation of Huntington's disease and other movement disorders using single photon emission computed tomography perfusion brain scans. Author(s): Nagel JS, Ichise M, Holman BL. Source: Semin Nucl Med. 1991 January; 21(1): 11-23. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=1825359&dopt=Abstract
•
Therapeutic effects of coenzyme Q10 and remacemide in transgenic mouse models of Huntington's disease. Author(s): Ferrante RJ, Andreassen OA, Dedeoglu A, Ferrante KL, Jenkins BG, Hersch SM, Beal MF. Source: The Journal of Neuroscience : the Official Journal of the Society for Neuroscience. 2002 March 1; 22(5): 1592-9. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11880489&dopt=Abstract
•
Therapeutic effects of cystamine in a murine model of Huntington's disease. Author(s): Dedeoglu A, Kubilus JK, Jeitner TM, Matson SA, Bogdanov M, Kowall NW, Matson WR, Cooper AJ, Ratan RR, Beal MF, Hersch SM, Ferrante RJ. Source: The Journal of Neuroscience : the Official Journal of the Society for Neuroscience. 2002 October 15; 22(20): 8942-50. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12388601&dopt=Abstract
•
Tracing Woody Guthrie and Huntington's disease. Author(s): Arevalo J, Wojcieszek J, Conneally PM. Source: Seminars in Neurology. 2001 June; 21(2): 209-23. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11442329&dopt=Abstract
•
Velocity modulation and rhythmic synchronization of gait in Huntington's disease. Author(s): Thaut MH, Miltner R, Lange HW, Hurt CP, Hoemberg V.
Alternative Medicine 127
Source: Movement Disorders : Official Journal of the Movement Disorder Society. 1999 September; 14(5): 808-19. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=10495043&dopt=Abstract
Additional Web Resources A number of additional Web sites offer encyclopedic information covering CAM and related topics. The following is a representative sample: •
Alternative Medicine Foundation, Inc.: http://www.herbmed.org/
•
AOL: http://search.aol.com/cat.adp?id=169&layer=&from=subcats
•
Chinese Medicine: http://www.newcenturynutrition.com/
•
drkoop.com®: http://www.drkoop.com/InteractiveMedicine/IndexC.html
•
Family Village: http://www.familyvillage.wisc.edu/med_altn.htm
•
Google: http://directory.google.com/Top/Health/Alternative/
•
Healthnotes: http://www.healthnotes.com/
•
MedWebPlus: http://medwebplus.com/subject/Alternative_and_Complementary_Medicine
•
Open Directory Project: http://dmoz.org/Health/Alternative/
•
HealthGate: http://www.tnp.com/
•
WebMD®Health: http://my.webmd.com/drugs_and_herbs
•
WholeHealthMD.com: http://www.wholehealthmd.com/reflib/0,1529,00.html
•
Yahoo.com: http://dir.yahoo.com/Health/Alternative_Medicine/
The following is a specific Web list relating to Huntington’s disease; please note that any particular subject below may indicate either a therapeutic use, or a contraindication (potential danger), and does not reflect an official recommendation: •
General Overview Parkinson's Disease Source: Integrative Medicine Communications; www.drkoop.com Tardive Dyskinesia Source: Healthnotes, Inc.; www.healthnotes.com
General References A good place to find general background information on CAM is the National Library of Medicine. It has prepared within the MEDLINEplus system an information topic page dedicated to complementary and alternative medicine. To access this page, go to the
128 Huntington’s Disease
MEDLINEplus site at http://www.nlm.nih.gov/medlineplus/alternativemedicine.html. This Web site provides a general overview of various topics and can lead to a number of general sources.
129
CHAPTER 4. DISSERTATIONS ON HUNTINGTON’S DISEASE Overview In this chapter, we will give you a bibliography on recent dissertations relating to Huntington’s disease. We will also provide you with information on how to use the Internet to stay current on dissertations. IMPORTANT NOTE: When following the search strategy described below, you may discover non-medical dissertations that use the generic term “Huntington’s disease” (or a synonym) in their titles. To accurately reflect the results that you might find while conducting research on Huntington’s disease, we have not necessarily excluded non-medical dissertations in this bibliography.
Dissertations on Huntington’s Disease ProQuest Digital Dissertations, the largest archive of academic dissertations available, is located at the following Web address: http://wwwlib.umi.com/dissertations. From this archive, we have compiled the following list covering dissertations devoted to Huntington’s disease. You will see that the information provided includes the dissertation’s title, its author, and the institution with which the author is associated. The following covers recent dissertations found when using this search procedure: •
3-nitropropionic Acid: a Mode for Huntington's Disease by Nasr, Payman; PhD from University of Kentucky, 2003, 225 pages http://wwwlib.umi.com/dissertations/fullcit/3082702
•
A Genealogy of Genealogical Practices: the Development and Use of Medical Pedigrees in the Case of Huntington's Disease by Nukaga, Yoshio; PhD from McGill University (Canada), 2001, 392 pages http://wwwlib.umi.com/dissertations/fullcit/NQ70116
•
A Model for the Early Identification of Individuals with Juvenile Onset Huntington's Disease (huntington Disease) by Artigliere-cavalier, Julia Marie, PhD from University of Colorado at Boulder, 1989, 155 pages http://wwwlib.umi.com/dissertations/fullcit/8923478
•
Coping with the Risk of Huntington's Disease by Dorn, Margaret Beatty, PhD from University of Denver, 1990, 282 pages http://wwwlib.umi.com/dissertations/fullcit/9102132
130 Huntington’s Disease
•
Energy Needs in People with Huntington's Disease by Gaba, Ann; EDD from Columbia University Teachers College, 2002, 157 pages http://wwwlib.umi.com/dissertations/fullcit/3052880
•
Olfactory Psychophysics and Electrophysiology in Huntington's Disease by Wetter, Spencer Ryan; PhD from University of California, San Diego and San Diego State University, 2003, 140 pages http://wwwlib.umi.com/dissertations/fullcit/3083456
•
Performance on the Repeated Patterns Test by Individuals with Brain Injury, Huntington's Disease, and Stroke by Nijhawan, Sunita R.; PsyD from Argosy University/twin Cities, 2002, 88 pages http://wwwlib.umi.com/dissertations/fullcit/3041665
•
Testing an Action Selection Model of Basal Ganglia Function in Parkinson's Disease and Huntington's Disease by Wylie, Scott Alan; PhD from Indiana University, 2002, 156 pages http://wwwlib.umi.com/dissertations/fullcit/3076073
•
Transplantation of Sertoli Cells into a 3-nitropropionic Acid Rat Model of Huntington's Disease by Rodriguez, Alba I.; PhD from University of South Florida, 2002, 137 pages http://wwwlib.umi.com/dissertations/fullcit/3052667
Keeping Current Ask the medical librarian at your library if it has full and unlimited access to the ProQuest Digital Dissertations database. From the library, you should be able to do more complete searches via http://wwwlib.umi.com/dissertations.
131
CHAPTER 5. CLINICAL TRIALS AND HUNTINGTON’S DISEASE Overview In this chapter, we will show you how to keep informed of the latest clinical trials concerning Huntington’s disease.
Recent Trials on Huntington’s Disease The following is a list of recent trials dedicated to Huntington’s disease.8 Further information on a trial is available at the Web site indicated. •
Minocycline in Patients with Huntington's Disease Condition(s): Huntington's Disease Study Status: This study is currently recruiting patients. Sponsor(s): FDA Office of Orphan Products Development Purpose - Excerpt: This is a study to determine whether treatment with minocycline is safe and tolerable in patients with Huntington's disease (HD) and whether minocycline reduces symptoms of HD in these patients. Phase(s): Phase I; Phase II Study Type: Interventional Contact(s): see Web site below Web Site: http://clinicaltrials.gov/ct/show/NCT00029874
•
Neurobiological Predictors of Huntington's Disease (PREDICT-HD) Condition(s): Huntington Disease Study Status: This study is currently recruiting patients. Sponsor(s): National Institute of Neurological Disorders and Stroke (NINDS)
8
These are listed at www.ClinicalTrials.gov.
132 Huntington’s Disease
Purpose - Excerpt: The purpose of this trial is to study early brain and behavioral changes in people who have the gene expansion for Huntington's disease, but are currently healthy and have no symptoms. Study Type: Observational Contact(s): see Web site below Web Site: http://clinicaltrials.gov/ct/show/NCT00051324 •
Creatine Therapy for Huntington's Disease Condition(s): Huntington's Disease Study Status: This study is no longer recruiting patients. Sponsor(s): National Center for Complementary and Alternative Medicine (NCCAM) Purpose - Excerpt: This study, CREST-HD, will examine the safety and tolerability of 8 grams of creatine in subjects affected by Huntington's disease (HD). Biochemistry and neuroimaging will be used to examine the potential effects of creatine on HD. Phase(s): Phase I; Phase II Study Type: Interventional Contact(s): see Web site below Web Site: http://clinicaltrials.gov/ct/show/NCT00026988
•
Long-Term Study of Cerebral Glucose Metabolism in Huntington's Disease Condition(s): Huntington's Disease Study Status: This study is completed. Sponsor(s): National Center for Research Resources (NCRR); National Institute of Neurological Disorders and Stroke (NINDS); University of California, Los Angeles Purpose - Excerpt: Objectives: I. Correlate clinical outcome with cerebral glucose metabolism in patients with Huntington's disease (HD) and their at-risk relatives. II. Evaluate the efficacy of cerebral glucose metabolism in observing the pathophysiologic development of HD, monitoring responses to experimental therapy, and predicting HD genotype. III. Identify, define, and describe the natural history of pathophysiologic lesions in HD. IV. Characterize the genotypic and phenotypic expression of the HD gene. Study Type: Observational Contact(s): see Web site below Web Site: http://clinicaltrials.gov/ct/show/NCT00004753
•
Treatment of Huntington's Chorea with Amantadine Condition(s): Chorea; Huntington's Disease Study Status: This study is completed. Sponsor(s): National Institute of Neurological Disorders and Stroke (NINDS) Purpose - Excerpt: Huntington's disease is a chronic disorder passed on through genetic autosomal dominant inheritance. The condition usually begins between the ages of 30 and 50 years and it is characterized by involuntary movements in the face and extremities, (chorea), accompanied by changes in behavior and gradual loss of the
Clinical Trials 133
mental function. The disease typically ends in a state of disorientation, impaired memory, judgement, and intellect (dementia). The objective of this study is to test the effectiveness of the drug amantadine for the treatment of chorea associated with Huntington's disease. Amantadine is an antiviral drug that has been used to treat a variety of illnesses including Parkinson's disease. Amantadine works by attaching to special sites called NMDA (N-methyl-D-aspartate) receptors and blocking the normal activity of glutamate there. Glutamate is an amino acid released by brain cells and has been associated with the symptoms of Parkinson's disease. Phase(s): Phase II Study Type: Interventional Contact(s): see Web site below Web Site: http://clinicaltrials.gov/ct/show/NCT00001930
Keeping Current on Clinical Trials The U.S. National Institutes of Health, through the National Library of Medicine, has developed ClinicalTrials.gov to provide current information about clinical research across the broadest number of diseases and conditions. The site was launched in February 2000 and currently contains approximately 5,700 clinical studies in over 59,000 locations worldwide, with most studies being conducted in the United States. ClinicalTrials.gov receives about 2 million hits per month and hosts approximately 5,400 visitors daily. To access this database, simply go to the Web site at http://www.clinicaltrials.gov/ and search by “Huntington’s disease” (or synonyms). While ClinicalTrials.gov is the most comprehensive listing of NIH-supported clinical trials available, not all trials are in the database. The database is updated regularly, so clinical trials are continually being added. The following is a list of specialty databases affiliated with the National Institutes of Health that offer additional information on trials: •
For clinical studies at the Warren Grant Magnuson Clinical Center located in Bethesda, Maryland, visit their Web site: http://clinicalstudies.info.nih.gov/
•
For clinical studies conducted at the Bayview Campus in Baltimore, Maryland, visit their Web site: http://www.jhbmc.jhu.edu/studies/index.html
•
For cancer trials, visit the National Cancer Institute: http://cancertrials.nci.nih.gov/
•
For eye-related trials, visit and search the Web page of the National Eye Institute: http://www.nei.nih.gov/neitrials/index.htm
•
For heart, lung and blood trials, visit the Web page of the National Heart, Lung and Blood Institute: http://www.nhlbi.nih.gov/studies/index.htm
•
For trials on aging, visit and search the Web site of the National Institute on Aging: http://www.grc.nia.nih.gov/studies/index.htm
•
For rare diseases, visit and search the Web site sponsored by the Office of Rare Diseases: http://ord.aspensys.com/asp/resources/rsch_trials.asp
•
For alcoholism, visit the National Institute on Alcohol Abuse and Alcoholism: http://www.niaaa.nih.gov/intramural/Web_dicbr_hp/particip.htm
134 Huntington’s Disease
•
For trials on infectious, immune, and allergic diseases, visit the site of the National Institute of Allergy and Infectious Diseases: http://www.niaid.nih.gov/clintrials/
•
For trials on arthritis, musculoskeletal and skin diseases, visit newly revised site of the National Institute of Arthritis and Musculoskeletal and Skin Diseases of the National Institutes of Health: http://www.niams.nih.gov/hi/studies/index.htm
•
For hearing-related trials, visit the National Institute on Deafness and Other Communication Disorders: http://www.nidcd.nih.gov/health/clinical/index.htm
•
For trials on diseases of the digestive system and kidneys, and diabetes, visit the National Institute of Diabetes and Digestive and Kidney Diseases: http://www.niddk.nih.gov/patient/patient.htm
•
For drug abuse trials, visit and search the Web site sponsored by the National Institute on Drug Abuse: http://www.nida.nih.gov/CTN/Index.htm
•
For trials on mental disorders, visit and search the Web site of the National Institute of Mental Health: http://www.nimh.nih.gov/studies/index.cfm
•
For trials on neurological disorders and stroke, visit and search the Web site sponsored by the National Institute of Neurological Disorders and Stroke of the NIH: http://www.ninds.nih.gov/funding/funding_opportunities.htm#Clinical_Trials
135
CHAPTER 6. BOOKS ON HUNTINGTON’S DISEASE Overview This chapter provides bibliographic book references relating to Huntington’s disease. In addition to online booksellers such as www.amazon.com and www.bn.com, excellent sources for book titles on Huntington’s disease include the Combined Health Information Database and the National Library of Medicine. Your local medical library also may have these titles available for loan.
Book Summaries: Online Booksellers Commercial Internet-based booksellers, such as Amazon.com and Barnes&Noble.com, offer summaries which have been supplied by each title’s publisher. Some summaries also include customer reviews. Your local bookseller may have access to in-house and commercial databases that index all published books (e.g. Books in Print®). IMPORTANT NOTE: Online booksellers typically produce search results for medical and non-medical books. When searching for “Huntington’s disease” at online booksellers’ Web sites, you may discover non-medical books that use the generic term “Huntington’s disease” (or a synonym) in their titles. The following is indicative of the results you might find when searching for “Huntington’s disease” (sorted alphabetically by title; follow the hyperlink to view more details at Amazon.com): •
A physician's guide to the management of Huntington's disease; ISBN: 096377302X; http://www.amazon.com/exec/obidos/ASIN/096377302X/icongroupinterna
•
Cell Transplantation for Huntington's Disease (Medical Intelligence Unit) by Paul R. Sanberg (Editor), et al; ISBN: 1570590796; http://www.amazon.com/exec/obidos/ASIN/1570590796/icongroupinterna
•
Genetic Disorders Sourcebook: Basic Consumer Health Information About Hereditary Diseases and Disorders, Including Cystic Fibrosis, Down Syndrome, Hemophilia, Huntington's Disease by Kathy Massimini (Editor) (2000); ISBN: 0780802411; http://www.amazon.com/exec/obidos/ASIN/0780802411/icongroupinterna
•
Heading for Better Care: Commissioning and Providing Mental Health Services for People with Huntington's Disease, Acquired Brain Injury and Early Onset Dementia
136 Huntington’s Disease
(An NHS Health Advisory Service Thematic Review) by Richard Williams, et al (1997); ISBN: 0113219377; http://www.amazon.com/exec/obidos/ASIN/0113219377/icongroupinterna •
Huntington's Chorea by Michael R. Hayden; ISBN: 0387105883; http://www.amazon.com/exec/obidos/ASIN/0387105883/icongroupinterna
•
Huntington's chorea : a booklet for the families and friends of patients with the disease by David Lawrence Stevens; ISBN: 0950536407; http://www.amazon.com/exec/obidos/ASIN/0950536407/icongroupinterna
•
Huntington's disease; ISBN: 0890043744; http://www.amazon.com/exec/obidos/ASIN/0890043744/icongroupinterna
•
Huntington's Disease (Oxford Monographs on Medical Genetics, 45) by Gillian Bates (Editor), et al (2002); ISBN: 0198510608; http://www.amazon.com/exec/obidos/ASIN/0198510608/icongroupinterna
•
Huntington's disease : hope through research (SuDoc HE 20.3502:H 92/998) by Stephanie E. Clipper; ISBN: B00010WRK0; http://www.amazon.com/exec/obidos/ASIN/B00010WRK0/icongroupinterna
•
Huntington's Disease: A Disorder of Families (Johns Hopkins Series in Contemporary Medicine and Public Health) by Susan E. Folstein; ISBN: 0801838606; http://www.amazon.com/exec/obidos/ASIN/0801838606/icongroupinterna
•
Huntington's Disease: The Facts by Oliver Quarrell; ISBN: 0192629301; http://www.amazon.com/exec/obidos/ASIN/0192629301/icongroupinterna
•
Living With Huntington's Disease: A Book for Patients and Families by Dennis Phillips; ISBN: 0299086704; http://www.amazon.com/exec/obidos/ASIN/0299086704/icongroupinterna
•
The Official Patient's Sourcebook on Huntington's Disease: A Revised and Updated Directory for the Internet Age by Icon Health Publications (2002); ISBN: 0597830487; http://www.amazon.com/exec/obidos/ASIN/0597830487/icongroupinterna
The National Library of Medicine Book Index The National Library of Medicine at the National Institutes of Health has a massive database of books published on healthcare and biomedicine. Go to the following Internet site, http://locatorplus.gov/, and then select “Search LOCATORplus.” Once you are in the search area, simply type “Huntington’s disease” (or synonyms) into the search box, and select “books only.” From there, results can be sorted by publication date, author, or relevance. The following was recently catalogued by the National Library of Medicine:9
9
In addition to LOCATORPlus, in collaboration with authors and publishers, the National Center for Biotechnology Information (NCBI) is currently adapting biomedical books for the Web. The books may be accessed in two ways: (1) by searching directly using any search term or phrase (in the same way as the bibliographic database PubMed), or (2) by following the links to PubMed abstracts. Each PubMed abstract has a "Books" button that displays a facsimile of the abstract in which some phrases are hypertext links. These phrases are also found in the books available at NCBI. Click on hyperlinked results in the list of books in which the phrase is found. Currently, the majority of the links are between the books and PubMed. In the future, more links will be created between the books and other types of information, such as gene and protein sequences and macromolecular structures. See http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=Books.
Books
137
•
A centennial bibliography of Huntington's chorea, 1872-1972 by G. W. Bruyn, F. Baro, and N. C. Myrianthopoulos. Author: Bruyn, G. W.; Year: 1982; Louvain, Leuven Univ. Press, 1974; ISBN: 9061860113 http://www.amazon.com/exec/obidos/ASIN/9061860113/icongroupinterna
•
A physician's guide to the management of Huntington's disease: pharmacologic and non-pharmacologic interventions Author: Ranen, Neal G.; Year: 1999; New York:; ISBN: 0963773003
•
Cell transplantation for Huntington's disease Author: Sanberg, Paul R.; Year: 1994; Austin: R.G. Landes; Boca Raton, FL: CRC Press [distributor], 1994; ISBN: 1570590790
•
Huntington's chorea Author: Hayden, Michael R.; Year: 1983; Berlin; New York: Springer-Verlag, 1981; ISBN: 3540105883
•
Huntington's chorea: a booklet for family doctors and other professionals. Author: Association to Combat Huntington's Chorea (Great Britain); Year: 1998; Hinckley, Leicestershire: Association to Combat Hungtington's Chorea, 1983
•
Huntington's chorea, 1872-1972. Editors: André Barbeau, Thomas N. Chase [and] George W. Paulson. Author: Barbeau, André.; Year: 1981; New York, Raven Press [c1973]; ISBN: 091216405
•
Huntington's disease Author: Harper, Peter S.; Year: 2002; London; Philadelphia: W.B. Saunders, c1996; ISBN: 0702021539 http://www.amazon.com/exec/obidos/ASIN/0702021539/icongroupinterna
•
Huntington's disease (Huntington's chorea). Author: National Institute of Neurological Diseases and Stroke.; Year: 1971; [Bethesda, Md., For sale by the Supt. of Docs., U. S. Govt. Print. Off., Washington, 1971]
•
Huntington's disease: hearing before a subcommittee of the Committee on Appropriations, United States Senate, Ninety-fifth Congress, first session. Author: United States. Congress. Senate. Committee on Appropriations. Subcommittee on Departments of Labor, and Health, Education, and Welfare, and Related Agencies.; Year: 1977; Washington: U. S. Govt. Print. Off., 1977
•
Huntington's disease: research highlights, 1992 Author: National Institute of Neurological Disorders and Stroke (U.S.); Year: 1992; [Bethesda, Md.?: The Institute, 1992?]
•
Neostriatal and thalamic interneurons: their role in the pathophysiology of Huntington's chorea, Parkinson's disease, and catatonic schizophrenia Author: Dom, René.; Year: 1976; Leuven: ACCO, 1976
•
On nursing Huntington's chorea Author: Gardham, Frank.; Year: 1992; Hinckley, Leicestershire: Association to Combat
Chapters on Huntington’s Disease In order to find chapters that specifically relate to Huntington’s disease, an excellent source of abstracts is the Combined Health Information Database. You will need to limit your search to book chapters and Huntington’s disease using the “Detailed Search” option. Go to the following hyperlink: http://chid.nih.gov/detail/detail.html. To find book chapters, use the drop boxes at the bottom of the search page where “You may refine your search by.” Select the dates and language you prefer, and the format option “Book Chapter.” Type “Huntington’s disease” (or synonyms) into the “For these words:” box.
139
CHAPTER 7. MULTIMEDIA ON HUNTINGTON’S DISEASE Overview In this chapter, we show you how to keep current on multimedia sources of information on Huntington’s disease. We start with sources that have been summarized by federal agencies, and then show you how to find bibliographic information catalogued by the National Library of Medicine.
Bibliography: Multimedia on Huntington’s Disease The National Library of Medicine is a rich source of information on healthcare-related multimedia productions including slides, computer software, and databases. To access the multimedia database, go to the following Web site: http://locatorplus.gov/. Select “Search LOCATORplus.” Once in the search area, simply type in Huntington’s disease (or synonyms). Then, in the option box provided below the search box, select “Audiovisuals and Computer Files.” From there, you can choose to sort results by publication date, author, or relevance. The following multimedia has been indexed on Huntington’s disease: •
[Huntington's chorea] [motion picture] Source: [production company unknown]; produced by Max Rossman; Year: 1939; Format: Huntington's chorea; United States: [s.n.], 1939
•
Clinical features of myotonic dystrophy and Huntington's disease [videorecording] Source: a presentation of Films for the Humanities & Sciences; produced for the Centre for Human Genetics by Sheffield University Television; Year: 1998; Format: Videorecording; Princeton, N.J.: Films for the Humanities & Sciences, c1998
•
Huntington's chorea [slide] Source: K.W.G. Heathfield; Year: 1981; Format: Slide; Chelmsford, Essex, UK: Graves Medical Audiovisual Library, [1981]
•
Huntington's chorea [videorecording] Source: W. O. McCormick; Year: 1976; Format: Videorecording; Toronto: IMS, Faculty of Medicine, University of Toronto, c1976
•
Huntington's disease [videorecording]: the Woody Guthrie story Source: as told by Marjorie Guthrie; Year: 1983; Format: Videorecording; Washington, DC: National Audiovisual Center, [1983]
•
The Pharmacology and biochemical pathology of choreatic disorders [sound recording]; Biochemical pathology of Huntington's chorea Source: Dept. of Neurology,
140 Huntington’s Disease
University of Miami, School of Medicine; Year: 1977; Format: Sound recording; Dallas: Medisette, 1977
141
CHAPTER 8. PERIODICALS AND NEWS ON HUNTINGTON’S DISEASE Overview In this chapter, we suggest a number of news sources and present various periodicals that cover Huntington’s disease.
News Services and Press Releases One of the simplest ways of tracking press releases on Huntington’s disease is to search the news wires. In the following sample of sources, we will briefly describe how to access each service. These services only post recent news intended for public viewing. PR Newswire To access the PR Newswire archive, simply go to http://www.prnewswire.com/. Select your country. Type “Huntington’s disease” (or synonyms) into the search box. You will automatically receive information on relevant news releases posted within the last 30 days. The search results are shown by order of relevance. Reuters Health The Reuters’ Medical News and Health eLine databases can be very useful in exploring news archives relating to Huntington’s disease. While some of the listed articles are free to view, others are available for purchase for a nominal fee. To access this archive, go to http://www.reutershealth.com/en/index.html and search by “Huntington’s disease” (or synonyms). The following was recently listed in this archive for Huntington’s disease: •
NaPro shares jump on Huntington's disease news Source: Reuters Industry Breifing Date: June 09, 2003
142 Huntington’s Disease
•
Amarin to conduct another phase III trial of Huntington's disease treatment Source: Reuters Industry Breifing Date: February 03, 2003
•
Findings support protein aggregation as key factor in Huntington's disease Source: Reuters Medical News Date: January 22, 2003
•
Study zeroes in on causes of Huntington's disease Source: Reuters Health eLine Date: August 01, 2002
•
Mitochondrial calcium defect seen early in Huntington's disease Source: Reuters Medical News Date: July 16, 2002
•
DNA transcription reduced before symptom onset in Huntington's disease Source: Reuters Industry Breifing Date: May 03, 2002
•
Fetal striatal cell transplant feasible for Huntington's disease, but benefit unclear Source: Reuters Medical News Date: March 22, 2002
•
Environmental stimulation slows course of experimental Huntington's disease Source: Reuters Medical News Date: March 08, 2002
•
Amarin reports clinical advance with Huntington's disease drug Source: Reuters Industry Breifing Date: January 23, 2002
•
Cognitive testing detects early Huntington's disease Source: Reuters Medical News Date: September 05, 2001
•
Tetrabenazine can be helpful in chorea associated with Huntington's disease Source: Reuters Industry Breifing Date: May 08, 2001
•
Research offers new hope for Huntington's disease Source: Reuters Health eLine Date: March 22, 2001
•
Mechanism of Huntington's disease cellular toxicity revealed Source: Reuters Industry Breifing Date: March 22, 2001
•
Carbamazepine may prevent precipitate micturition in Huntington's disease Source: Reuters Medical News Date: January 12, 2001
•
Fetal cells 'take' in Huntington's disease patient Source: Reuters Health eLine Date: January 02, 2001
•
Neurologic deficits precede clinical diagnosis of Huntington's disease Source: Reuters Medical News Date: December 21, 2000
Periodicals and News
•
Amarin to launch study of first Huntington's disease therapy Source: Reuters Industry Breifing Date: December 11, 2000
•
Fetal nerve cell grafts may improve outcome in Huntington's disease Source: Reuters Medical News Date: November 29, 2000
•
Fetal cell therapy promising for Huntington's disease Source: Reuters Health eLine Date: November 29, 2000
•
Better test for Huntington's disease raises questions and concerns Source: Reuters Medical News Date: October 27, 2000
•
Aurora in Huntington's disease research pact Source: Reuters Industry Breifing Date: September 13, 2000
•
Jellyfish chemical may help Huntington's disease research Source: Reuters Health eLine Date: September 12, 2000
•
Minocycline slows Huntington's disease in mice Source: Reuters Industry Breifing Date: June 28, 2000
•
Antibiotic may treat Huntington's disease Source: Reuters Health eLine Date: June 27, 2000
•
Early reduction in striatal signaling seen in model of Huntington's disease Source: Reuters Industry Breifing Date: June 12, 2000
•
Heat shock protein reverses Huntington's disease-like pathology in C. elegans Source: Reuters Medical News Date: May 30, 2000
•
Mouse model suggests Huntington's disease may be reversible Source: Reuters Medical News Date: April 19, 2000
•
Growth factor delivery beneficial in monkey model of Huntington's disease Source: Reuters Medical News Date: April 18, 2000
•
Enriched environment may delay Huntington's disease Source: Reuters Health eLine Date: April 12, 2000
•
Symptoms of Huntington's disease present up to 7 years before onset in mutation carriers Source: Reuters Medical News Date: February 03, 2000
•
New clues identified in Huntington's disease Source: Reuters Health eLine Date: February 03, 2000
143
144 Huntington’s Disease
•
Huntington's disease testing should be a family affair Source: Reuters Medical News Date: January 03, 2000
•
Caspase-1 inhibition slows Huntington's disease in mice Source: Reuters Medical News Date: May 20, 1999
•
Blocking enzyme may help Huntington's disease Source: Reuters Health eLine Date: May 19, 1999
•
Striatal allografts successful in primate model of Huntington's disease Source: Reuters Medical News Date: June 02, 1998
•
Transplants help Huntington's disease Source: Reuters Health eLine Date: June 01, 1998
•
Two Orphan Drugs May Help Advanced Parkinson's, Huntington's Disease Source: Reuters Medical News Date: January 13, 1997
•
Regeneron And Medtronic To Collaborate On Huntington's Disease Therapies Source: Reuters Medical News Date: July 01, 1996 The NIH
Within MEDLINEplus, the NIH has made an agreement with the New York Times Syndicate, the AP News Service, and Reuters to deliver news that can be browsed by the public. Search news releases at http://www.nlm.nih.gov/medlineplus/alphanews_a.html. MEDLINEplus allows you to browse across an alphabetical index. Or you can search by date at the following Web page: http://www.nlm.nih.gov/medlineplus/newsbydate.html. Often, news items are indexed by MEDLINEplus within its search engine. Business Wire Business Wire is similar to PR Newswire. To access this archive, simply go to http://www.businesswire.com/. You can scan the news by industry category or company name. Market Wire Market Wire is more focused on technology than the other wires. To browse the latest press releases by topic, such as alternative medicine, biotechnology, fitness, healthcare, legal, nutrition, and pharmaceuticals, access Market Wire’s Medical/Health channel at http://www.marketwire.com/mw/release_index?channel=MedicalHealth. Or simply go to Market Wire’s home page at http://www.marketwire.com/mw/home, type “Huntington’s disease” (or synonyms) into the search box, and click on “Search News.” As this service is
Periodicals and News
145
technology oriented, you may wish to use it when searching for press releases covering diagnostic procedures or tests. Search Engines Medical news is also available in the news sections of commercial Internet search engines. See the health news page at Yahoo (http://dir.yahoo.com/Health/News_and_Media/), or you can use this Web site’s general news search page at http://news.yahoo.com/. Type in “Huntington’s disease” (or synonyms). If you know the name of a company that is relevant to Huntington’s disease, you can go to any stock trading Web site (such as http://www.etrade.com/) and search for the company name there. News items across various news sources are reported on indicated hyperlinks. Google offers a similar service at http://news.google.com/. BBC Covering news from a more European perspective, the British Broadcasting Corporation (BBC) allows the public free access to their news archive located at http://www.bbc.co.uk/. Search by “Huntington’s disease” (or synonyms).
Academic Periodicals covering Huntington’s Disease Numerous periodicals are currently indexed within the National Library of Medicine’s PubMed database that are known to publish articles relating to Huntington’s disease. In addition to these sources, you can search for articles covering Huntington’s disease that have been published by any of the periodicals listed in previous chapters. To find the latest studies published, go to http://www.ncbi.nlm.nih.gov/pubmed, type the name of the periodical into the search box, and click “Go.” If you want complete details about the historical contents of a journal, you can also visit the following Web site: http://www.ncbi.nlm.nih.gov/entrez/jrbrowser.cgi. Here, type in the name of the journal or its abbreviation, and you will receive an index of published articles. At http://locatorplus.gov/, you can retrieve more indexing information on medical periodicals (e.g. the name of the publisher). Select the button “Search LOCATORplus.” Then type in the name of the journal and select the advanced search option “Journal Title Search.”
147
CHAPTER 9. RESEARCHING MEDICATIONS Overview While a number of hard copy or CD-ROM resources are available for researching medications, a more flexible method is to use Internet-based databases. Broadly speaking, there are two sources of information on approved medications: public sources and private sources. We will emphasize free-to-use public sources.
U.S. Pharmacopeia Because of historical investments by various organizations and the emergence of the Internet, it has become rather simple to learn about the medications recommended for Huntington’s disease. One such source is the United States Pharmacopeia. In 1820, eleven physicians met in Washington, D.C. to establish the first compendium of standard drugs for the United States. They called this compendium the U.S. Pharmacopeia (USP). Today, the USP is a non-profit organization consisting of 800 volunteer scientists, eleven elected officials, and 400 representatives of state associations and colleges of medicine and pharmacy. The USP is located in Rockville, Maryland, and its home page is located at http://www.usp.org/. The USP currently provides standards for over 3,700 medications. The resulting USP DI® Advice for the Patient® can be accessed through the National Library of Medicine of the National Institutes of Health. The database is partially derived from lists of federally approved medications in the Food and Drug Administration’s (FDA) Drug Approvals database, located at http://www.fda.gov/cder/da/da.htm. While the FDA database is rather large and difficult to navigate, the Phamacopeia is both user-friendly and free to use. It covers more than 9,000 prescription and over-the-counter medications. To access this database, simply type the following hyperlink into your Web browser: http://www.nlm.nih.gov/medlineplus/druginformation.html. To view examples of a given medication (brand names, category, description, preparation, proper use, precautions, side effects, etc.), simply follow the hyperlinks indicated within the United States Pharmacopeia (USP). Below, we have compiled a list of medications associated with Huntington’s disease. If you would like more information on a particular medication, the provided hyperlinks will direct you to ample documentation (e.g. typical dosage, side effects, drug-interaction risks, etc.).
148 Huntington’s Disease
The following drugs have been mentioned in the Pharmacopeia and other sources as being potentially applicable to Huntington’s disease: Anticholinergics/Antispasmodics •
Systemic - U.S. Brands: Anaspaz; A-Spas S/L; Banthine; Bentyl; Cantil; Cystospaz; Cystospaz-M; Donnamar; ED-SPAZ; Gastrosed; Homapin; Levbid; Levsin; Levsin/SL; Levsinex Timecaps; Pro-Banthine; Quarzan; Robinul; Robinul Forte; Symax SL; Transderm-Scop http://www.nlm.nih.gov/medlineplus/druginfo/uspdi/202049.html
Anticonvulsants, Dione •
Systemic - U.S. Brands: http://www.nlm.nih.gov/medlineplus/druginfo/uspdi/202049.html
Anticonvulsants, Hydantoin •
Systemic - U.S. Brands: Cerebyx; Dilantin; Dilantin Infatabs; Dilantin Kapseals; Dilantin-125; Mesantoin; Peganone; Phenytex http://www.nlm.nih.gov/medlineplus/druginfo/uspdi/202052.html
Anticonvulsants, Succinimide •
Systemic - U.S. Brands: Celontin; Zarontin http://www.nlm.nih.gov/medlineplus/druginfo/uspdi/202053.html
Baclofen •
Systemic - U.S. Brands: http://www.nlm.nih.gov/medlineplus/druginfo/uspdi/202053.html
•
Systemic - U.S. Brands: Lioresal http://www.nlm.nih.gov/medlineplus/druginfo/uspdi/202080.html
Fluoxetine •
Systemic - U.S. Brands: Prozac; Sarafem http://www.nlm.nih.gov/medlineplus/druginfo/uspdi/202247.html
Haloperidol •
Systemic - U.S. Brands: Haldol http://www.nlm.nih.gov/medlineplus/druginfo/uspdi/202278.html
Isoniazid •
Systemic - U.S. Brands: Laniazid; Nydrazid http://www.nlm.nih.gov/medlineplus/druginfo/uspdi/202307.html
Isoniazid and Thiacetazone •
Systemic - U.S. Brands: http://www.nlm.nih.gov/medlineplus/druginfo/uspdi/202307.html
Levodopa •
Systemic - U.S. Brands: Atamet; Larodopa; Sinemet; Sinemet CR http://www.nlm.nih.gov/medlineplus/druginfo/uspdi/202326.html
Researching Medications
149
Levodopa and Benserazide •
Systemic - U.S. Brands: http://www.nlm.nih.gov/medlineplus/druginfo/uspdi/202326.html
Phenothiazines •
Systemic - U.S. Brands: Chlorpromazine Hydrochloride Intensol; Compazine; Compazine Spansule; Mellaril; Mellaril Concentrate; Mellaril-S; Permitil; Permitil Concentrate; Prolixin; Prolixin Concentrate; Prolixin Decanoate; Prolixin Enanthate; Serentil; Serentil Concentrate; Ste http://www.nlm.nih.gov/medlineplus/druginfo/uspdi/202457.html
Commercial Databases In addition to the medications listed in the USP above, a number of commercial sites are available by subscription to physicians and their institutions. Or, you may be able to access these sources from your local medical library.
Mosby’s Drug Consult™ Mosby’s Drug Consult™ database (also available on CD-ROM and book format) covers 45,000 drug products including generics and international brands. It provides prescribing information, drug interactions, and patient information. Subscription information is available at the following hyperlink: http://www.mosbysdrugconsult.com/. PDRhealth The PDRhealth database is a free-to-use, drug information search engine that has been written for the public in layman’s terms. It contains FDA-approved drug information adapted from the Physicians’ Desk Reference (PDR) database. PDRhealth can be searched by brand name, generic name, or indication. It features multiple drug interactions reports. Search PDRhealth at http://www.pdrhealth.com/drug_info/index.html. Other Web Sites Drugs.com (www.drugs.com) reproduces the information in the Pharmacopeia as well as commercial information. You may also want to consider the Web site of the Medical Letter, Inc. (http://www.medletter.com/) which allows users to download articles on various drugs and therapeutics for a nominal fee.
Researching Orphan Drugs Although the list of orphan drugs is revised on a daily basis, you can quickly research orphan drugs that might be applicable to Huntington’s disease by using the database managed by the National Organization for Rare Disorders, Inc. (NORD), at http://www.rarediseases.org/. Scroll down the page, and on the left toolbar, click on
150 Huntington’s Disease
“Orphan Drug Designation Database.” On this page (http://www.rarediseases.org/search/noddsearch.html), type “Huntington’s disease” (or synonyms) into the search box, and click “Submit Query.” When you receive your results, note that not all of the drugs may be relevant, as some may have been withdrawn from orphan status. Write down or print out the name of each drug and the relevant contact information. From there, visit the Pharmacopeia Web site and type the name of each orphan drug into the search box at http://www.nlm.nih.gov/medlineplus/druginformation.html. You may need to contact the sponsor or NORD for further information. NORD conducts “early access programs for investigational new drugs (IND) under the Food and Drug Administration’s (FDA’s) approval ‘Treatment INDs’ programs which allow for a limited number of individuals to receive investigational drugs before FDA marketing approval.” If the orphan product about which you are seeking information is approved for marketing, information on side effects can be found on the product’s label. If the product is not approved, you may need to contact the sponsor. The following is a list of orphan drugs currently listed in the NORD Orphan Drug Designation Database for Huntington’s disease: •
Remacemide (trade name: Ecovia) http://www.rarediseases.org/nord/search/nodd_full?code=1029
•
Ethyl eicosapentaenoate (trade name: Venticute) http://www.rarediseases.org/nord/search/nodd_full?code=1037
•
Coenzyme Q10 http://www.rarediseases.org/nord/search/nodd_full?code=1097
•
Coenzyme Q10 http://www.rarediseases.org/nord/search/nodd_full?code=1102
•
Coenzyme Q10 (trade name: NONE Assigned) http://www.rarediseases.org/nord/search/nodd_full?code=1155
•
Porcine fetal neural gabaergic cells and/or precur (trade name: anti-MHC-1 Ab for intracerebral implantation. TN=) http://www.rarediseases.org/nord/search/nodd_full?code=827
•
Porcine fetal neural gabaergic cells and/or precur (trade name: implantation for Huntington's disease. TN=Ne) http://www.rarediseases.org/nord/search/nodd_full?code=828
•
Riluzole (trade name: Rilutek) http://www.rarediseases.org/nord/search/nodd_full?code=799
•
Tetrabenzine http://www.rarediseases.org/nord/search/nodd_full?code=866
If you have any questions about a medical treatment, the FDA may have an office near you. Look for their number in the blue pages of the phone book. You can also contact the FDA through its toll-free number, 1-888-INFO-FDA (1-888-463-6332), or on the World Wide Web at www.fda.gov.
151
APPENDICES
153
APPENDIX A. PHYSICIAN RESOURCES Overview In this chapter, we focus on databases and Internet-based guidelines and information resources created or written for a professional audience.
NIH Guidelines Commonly referred to as “clinical” or “professional” guidelines, the National Institutes of Health publish physician guidelines for the most common diseases. Publications are available at the following by relevant Institute10: •
Office of the Director (OD); guidelines consolidated across agencies available at http://www.nih.gov/health/consumer/conkey.htm
•
National Institute of General Medical Sciences (NIGMS); fact sheets available at http://www.nigms.nih.gov/news/facts/
•
National Library of Medicine (NLM); extensive encyclopedia (A.D.A.M., Inc.) with guidelines: http://www.nlm.nih.gov/medlineplus/healthtopics.html
•
National Cancer Institute (NCI); guidelines available at http://www.cancer.gov/cancerinfo/list.aspx?viewid=5f35036e-5497-4d86-8c2c714a9f7c8d25
•
National Eye Institute (NEI); guidelines available at http://www.nei.nih.gov/order/index.htm
•
National Heart, Lung, and Blood Institute (NHLBI); guidelines available at http://www.nhlbi.nih.gov/guidelines/index.htm
•
National Human Genome Research Institute (NHGRI); research available at http://www.genome.gov/page.cfm?pageID=10000375
•
National Institute on Aging (NIA); guidelines available at http://www.nia.nih.gov/health/
10
These publications are typically written by one or more of the various NIH Institutes.
154 Huntington’s Disease
•
National Institute on Alcohol Abuse and Alcoholism (NIAAA); guidelines available at http://www.niaaa.nih.gov/publications/publications.htm
•
National Institute of Allergy and Infectious Diseases (NIAID); guidelines available at http://www.niaid.nih.gov/publications/
•
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS); fact sheets and guidelines available at http://www.niams.nih.gov/hi/index.htm
•
National Institute of Child Health and Human Development (NICHD); guidelines available at http://www.nichd.nih.gov/publications/pubskey.cfm
•
National Institute on Deafness and Other Communication Disorders (NIDCD); fact sheets and guidelines at http://www.nidcd.nih.gov/health/
•
National Institute of Dental and Craniofacial Research (NIDCR); guidelines available at http://www.nidr.nih.gov/health/
•
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); guidelines available at http://www.niddk.nih.gov/health/health.htm
•
National Institute on Drug Abuse (NIDA); guidelines available at http://www.nida.nih.gov/DrugAbuse.html
•
National Institute of Environmental Health Sciences (NIEHS); environmental health information available at http://www.niehs.nih.gov/external/facts.htm
•
National Institute of Mental Health (NIMH); guidelines available at http://www.nimh.nih.gov/practitioners/index.cfm
•
National Institute of Neurological Disorders and Stroke (NINDS); neurological disorder information pages available at http://www.ninds.nih.gov/health_and_medical/disorder_index.htm
•
National Institute of Nursing Research (NINR); publications on selected illnesses at http://www.nih.gov/ninr/news-info/publications.html
•
National Institute of Biomedical Imaging and Bioengineering; general information at http://grants.nih.gov/grants/becon/becon_info.htm
•
Center for Information Technology (CIT); referrals to other agencies based on keyword searches available at http://kb.nih.gov/www_query_main.asp
•
National Center for Complementary and Alternative Medicine (NCCAM); health information available at http://nccam.nih.gov/health/
•
National Center for Research Resources (NCRR); various information directories available at http://www.ncrr.nih.gov/publications.asp
•
Office of Rare Diseases; various fact sheets available at http://rarediseases.info.nih.gov/html/resources/rep_pubs.html
•
Centers for Disease Control and Prevention; various fact sheets on infectious diseases available at http://www.cdc.gov/publications.htm
Physician Resources
155
NIH Databases In addition to the various Institutes of Health that publish professional guidelines, the NIH has designed a number of databases for professionals.11 Physician-oriented resources provide a wide variety of information related to the biomedical and health sciences, both past and present. The format of these resources varies. Searchable databases, bibliographic citations, full-text articles (when available), archival collections, and images are all available. The following are referenced by the National Library of Medicine:12 •
Bioethics: Access to published literature on the ethical, legal, and public policy issues surrounding healthcare and biomedical research. This information is provided in conjunction with the Kennedy Institute of Ethics located at Georgetown University, Washington, D.C.: http://www.nlm.nih.gov/databases/databases_bioethics.html
•
HIV/AIDS Resources: Describes various links and databases dedicated to HIV/AIDS research: http://www.nlm.nih.gov/pubs/factsheets/aidsinfs.html
•
NLM Online Exhibitions: Describes “Exhibitions in the History of Medicine”: http://www.nlm.nih.gov/exhibition/exhibition.html. Additional resources for historical scholarship in medicine: http://www.nlm.nih.gov/hmd/hmd.html
•
Biotechnology Information: Access to public databases. The National Center for Biotechnology Information conducts research in computational biology, develops software tools for analyzing genome data, and disseminates biomedical information for the better understanding of molecular processes affecting human health and disease: http://www.ncbi.nlm.nih.gov/
•
Population Information: The National Library of Medicine provides access to worldwide coverage of population, family planning, and related health issues, including family planning technology and programs, fertility, and population law and policy: http://www.nlm.nih.gov/databases/databases_population.html
•
Cancer Information: Access to cancer-oriented databases: http://www.nlm.nih.gov/databases/databases_cancer.html
•
Profiles in Science: Offering the archival collections of prominent twentieth-century biomedical scientists to the public through modern digital technology: http://www.profiles.nlm.nih.gov/
•
Chemical Information: Provides links to various chemical databases and references: http://sis.nlm.nih.gov/Chem/ChemMain.html
•
Clinical Alerts: Reports the release of findings from the NIH-funded clinical trials where such release could significantly affect morbidity and mortality: http://www.nlm.nih.gov/databases/alerts/clinical_alerts.html
•
Space Life Sciences: Provides links and information to space-based research (including NASA): http://www.nlm.nih.gov/databases/databases_space.html
•
MEDLINE: Bibliographic database covering the fields of medicine, nursing, dentistry, veterinary medicine, the healthcare system, and the pre-clinical sciences: http://www.nlm.nih.gov/databases/databases_medline.html
11
Remember, for the general public, the National Library of Medicine recommends the databases referenced in MEDLINEplus (http://medlineplus.gov/ or http://www.nlm.nih.gov/medlineplus/databases.html). 12 See http://www.nlm.nih.gov/databases/databases.html.
156 Huntington’s Disease
•
Toxicology and Environmental Health Information (TOXNET): Databases covering toxicology and environmental health: http://sis.nlm.nih.gov/Tox/ToxMain.html
•
Visible Human Interface: Anatomically detailed, three-dimensional representations of normal male and female human bodies: http://www.nlm.nih.gov/research/visible/visible_human.html
The NLM Gateway13 The NLM (National Library of Medicine) Gateway is a Web-based system that lets users search simultaneously in multiple retrieval systems at the U.S. National Library of Medicine (NLM). It allows users of NLM services to initiate searches from one Web interface, providing one-stop searching for many of NLM’s information resources or databases.14 To use the NLM Gateway, simply go to the search site at http://gateway.nlm.nih.gov/gw/Cmd. Type “Huntington’s disease” (or synonyms) into the search box and click “Search.” The results will be presented in a tabular form, indicating the number of references in each database category. Results Summary Category Journal Articles Books / Periodicals / Audio Visual Consumer Health Meeting Abstracts Other Collections Total
Items Found 6111 164 1038 5 0 7318
HSTAT15 HSTAT is a free, Web-based resource that provides access to full-text documents used in healthcare decision-making.16 These documents include clinical practice guidelines, quickreference guides for clinicians, consumer health brochures, evidence reports and technology assessments from the Agency for Healthcare Research and Quality (AHRQ), as well as AHRQ’s Put Prevention Into Practice.17 Simply search by “Huntington’s disease” (or synonyms) at the following Web site: http://text.nlm.nih.gov.
13
Adapted from NLM: http://gateway.nlm.nih.gov/gw/Cmd?Overview.x.
14
The NLM Gateway is currently being developed by the Lister Hill National Center for Biomedical Communications (LHNCBC) at the National Library of Medicine (NLM) of the National Institutes of Health (NIH). 15 Adapted from HSTAT: http://www.nlm.nih.gov/pubs/factsheets/hstat.html. 16 17
The HSTAT URL is http://hstat.nlm.nih.gov/.
Other important documents in HSTAT include: the National Institutes of Health (NIH) Consensus Conference Reports and Technology Assessment Reports; the HIV/AIDS Treatment Information Service (ATIS) resource documents; the Substance Abuse and Mental Health Services Administration's Center for Substance Abuse Treatment (SAMHSA/CSAT) Treatment Improvement Protocols (TIP) and Center for Substance Abuse Prevention (SAMHSA/CSAP) Prevention Enhancement Protocols System (PEPS); the Public Health Service (PHS) Preventive Services Task Force's Guide to Clinical Preventive Services; the independent, nonfederal Task Force on Community Services’ Guide to Community Preventive Services; and the Health Technology Advisory Committee (HTAC) of the Minnesota Health Care Commission (MHCC) health technology evaluations.
Physician Resources
157
Coffee Break: Tutorials for Biologists18 Coffee Break is a general healthcare site that takes a scientific view of the news and covers recent breakthroughs in biology that may one day assist physicians in developing treatments. Here you will find a collection of short reports on recent biological discoveries. Each report incorporates interactive tutorials that demonstrate how bioinformatics tools are used as a part of the research process. Currently, all Coffee Breaks are written by NCBI staff.19 Each report is about 400 words and is usually based on a discovery reported in one or more articles from recently published, peer-reviewed literature.20 This site has new articles every few weeks, so it can be considered an online magazine of sorts. It is intended for general background information. You can access the Coffee Break Web site at the following hyperlink: http://www.ncbi.nlm.nih.gov/Coffeebreak/.
Other Commercial Databases In addition to resources maintained by official agencies, other databases exist that are commercial ventures addressing medical professionals. Here are some examples that may interest you: •
CliniWeb International: Index and table of contents to selected clinical information on the Internet; see http://www.ohsu.edu/cliniweb/.
•
Medical World Search: Searches full text from thousands of selected medical sites on the Internet; see http://www.mwsearch.com/.
18 Adapted 19
from http://www.ncbi.nlm.nih.gov/Coffeebreak/Archive/FAQ.html.
The figure that accompanies each article is frequently supplied by an expert external to NCBI, in which case the source of the figure is cited. The result is an interactive tutorial that tells a biological story. 20 After a brief introduction that sets the work described into a broader context, the report focuses on how a molecular understanding can provide explanations of observed biology and lead to therapies for diseases. Each vignette is accompanied by a figure and hypertext links that lead to a series of pages that interactively show how NCBI tools and resources are used in the research process.
159
APPENDIX B. PATIENT RESOURCES Overview Official agencies, as well as federally funded institutions supported by national grants, frequently publish a variety of guidelines written with the patient in mind. These are typically called “Fact Sheets” or “Guidelines.” They can take the form of a brochure, information kit, pamphlet, or flyer. Often they are only a few pages in length. Since new guidelines on Huntington’s disease can appear at any moment and be published by a number of sources, the best approach to finding guidelines is to systematically scan the Internet-based services that post them.
Patient Guideline Sources The remainder of this chapter directs you to sources which either publish or can help you find additional guidelines on topics related to Huntington’s disease. Due to space limitations, these sources are listed in a concise manner. Do not hesitate to consult the following sources by either using the Internet hyperlink provided, or, in cases where the contact information is provided, contacting the publisher or author directly. The National Institutes of Health The NIH gateway to patients is located at http://health.nih.gov/. From this site, you can search across various sources and institutes, a number of which are summarized below. Topic Pages: MEDLINEplus The National Library of Medicine has created a vast and patient-oriented healthcare information portal called MEDLINEplus. Within this Internet-based system are “health topic pages” which list links to available materials relevant to Huntington’s disease. To access this system, log on to http://www.nlm.nih.gov/medlineplus/healthtopics.html. From there you can either search using the alphabetical index or browse by broad topic areas. Recently, MEDLINEplus listed the following when searched for “Huntington’s disease”:
160 Huntington’s Disease
•
Other guides AIDS http://www.nlm.nih.gov/medlineplus/aids.html Alcohol Consumption http://www.nlm.nih.gov/medlineplus/alcoholconsumption.html Alcoholism http://www.nlm.nih.gov/medlineplus/alcoholism.html Alzheimer's Disease http://www.nlm.nih.gov/medlineplus/alzheimersdisease.html Brain Diseases http://www.nlm.nih.gov/medlineplus/braindiseases.html Cancer Alternative Therapy http://www.nlm.nih.gov/medlineplus/canceralternativetherapy.html Degenerative Nerve Diseases http://www.nlm.nih.gov/medlineplus/degenerativenervediseases.html Dementia http://www.nlm.nih.gov/medlineplus/dementia.html Gaucher's Disease http://www.nlm.nih.gov/medlineplus/gauchersdisease.html Hearing Disorders & Deafness http://www.nlm.nih.gov/medlineplus/hearingdisordersdeafness.html Huntington's Disease http://www.nlm.nih.gov/medlineplus/huntingtonsdisease.html Movement Disorders http://www.nlm.nih.gov/medlineplus/movementdisorders.html Neuromuscular Disorders http://www.nlm.nih.gov/medlineplus/neuromusculardisorders.html Parkinson's Disease http://www.nlm.nih.gov/medlineplus/parkinsonsdisease.html Peripheral Nerve Disorders http://www.nlm.nih.gov/medlineplus/peripheralnervedisorders.html
Within the health topic page dedicated to Huntington’s disease, the following was listed: •
General/Overviews Huntington's Disease Source: Mayo Foundation for Medical Education and Research http://www.mayoclinic.com/invoke.cfm?id=DS00401
•
Diagnosis/Symptoms How Is Huntington Disease Diagnosed? Source: Dolan DNA Learning Center http://www.yourgenesyourhealth.org/hd/diagnosis.htm
Patient Resources
•
161
Treatment Scientists Identify Potential New Treatment for Huntington's Disease Source: National Institute of Neurological Disorders and Stroke http://www.ninds.nih.gov/news_and_events/news_article_huntington_cystamine .htm
•
Specific Conditions/Aspects Huntington's Disease: Why Communication and Swallowing Symptoms Arise Source: American Speech-Language-Hearing Association http://www.asha.org/public/speech/disorders/Huntington-Disease.htm Symptoms, Findings, and Clinical Course of Huntington's Disease Source: We Move http://www.wemove.org/hd_sym.html
•
Children What Is the Best Way to Discuss Huntington's Disease with Young Children if a Parent Has HD or Is at Risk? Source: Huntington's Disease Society of America http://www.hdsa.org/edu/AskADoctor.pl?show=9
•
From the National Institutes of Health Huntington's Disease Source: National Institute of Neurological Disorders and Stroke http://www.ninds.nih.gov/health_and_medical/disorders/huntington.htm Huntington's Disease: Hope through Research Source: National Institute of Neurological Disorders and Stroke http://www.ninds.nih.gov/health_and_medical/pubs/huntington_diseasehtr.htm
•
Latest News Investigators Explore Selective Silencing of Disease Genes Source: 10/15/2003, National Institute of Neurological Disorders and Stroke http://www.ninds.nih.gov/news_and_events/news_article_gene_silencing.htm
•
Organizations Huntington's Disease Society of America http://www.hdsa.org/ National Center for Biotechnology Information http://www.ncbi.nlm.nih.gov/ National Institute of Neurological Disorders and Stroke http://www.ninds.nih.gov/ We Move http://www.wemove.org/
162 Huntington’s Disease
Your Genes, Your Health Source: Dolan DNA Learning Center http://www.yourgenesyourhealth.org/ •
Research Fasting Forestalls Huntington's Disease in Mice Source: National Institute on Aging http://www.nia.nih.gov/news/pr/2003/0210.htm Investigators Explore Selective Silencing of Disease Genes Source: National Institute of Neurological Disorders and Stroke http://www.ninds.nih.gov/news_and_events/news_article_gene_silencing.htm Trial Drugs for Huntington's Disease Inconclusive in Slowing Disease Source: National Institute of Neurological Disorders and Stroke http://www.ninds.nih.gov/news_and_events/pressrelease_huntingtons_drugs_08 1301.htm
•
Teenagers How Can an HDSA Social Worker Help My Family Deal with Juvenile Huntington's Disease (HD)? Source: Huntington's Disease Society of America http://www.hdsa.org/edu/AskADoctor.pl?show=1 Juvenile HD Source: We Move http://www.wemove.org/hd_sym_jhd.html
You may also choose to use the search utility provided by MEDLINEplus at the following Web address: http://www.nlm.nih.gov/medlineplus/. Simply type a keyword into the search box and click “Search.” This utility is similar to the NIH search utility, with the exception that it only includes materials that are linked within the MEDLINEplus system (mostly patient-oriented information). It also has the disadvantage of generating unstructured results. We recommend, therefore, that you use this method only if you have a very targeted search. Healthfinder™ Healthfinder™ is sponsored by the U.S. Department of Health and Human Services and offers links to hundreds of other sites that contain healthcare information. This Web site is located at http://www.healthfinder.gov. Again, keyword searches can be used to find guidelines. The following was recently found in this database: •
Huntington's Disease Information Summary: A general overview of Huntington's disease that includes a description of the disorder, and treatment, prognosis and research information. Source: National Institute of Neurological Disorders and Stroke, National Institutes of Health http://www.healthfinder.gov/scripts/recordpass.asp?RecordType=0&RecordID=781
Patient Resources
163
The NIH Search Utility The NIH search utility allows you to search for documents on over 100 selected Web sites that comprise the NIH-WEB-SPACE. Each of these servers is “crawled” and indexed on an ongoing basis. Your search will produce a list of various documents, all of which will relate in some way to Huntington’s disease. The drawbacks of this approach are that the information is not organized by theme and that the references are often a mix of information for professionals and patients. Nevertheless, a large number of the listed Web sites provide useful background information. We can only recommend this route, therefore, for relatively rare or specific disorders, or when using highly targeted searches. To use the NIH search utility, visit the following Web page: http://search.nih.gov/index.html. Additional Web Sources A number of Web sites are available to the public that often link to government sites. These can also point you in the direction of essential information. The following is a representative sample: •
AOL: http://search.aol.com/cat.adp?id=168&layer=&from=subcats
•
Family Village: http://www.familyvillage.wisc.edu/specific.htm
•
Google: http://directory.google.com/Top/Health/Conditions_and_Diseases/
•
Med Help International: http://www.medhelp.org/HealthTopics/A.html
•
Open Directory Project: http://dmoz.org/Health/Conditions_and_Diseases/
•
Yahoo.com: http://dir.yahoo.com/Health/Diseases_and_Conditions/
•
WebMD®Health: http://my.webmd.com/health_topics
Associations and Huntington’s Disease The following is a list of associations that provide information on and resources relating to Huntington’s disease: •
Huntington's Disease Society of America Telephone: (212) 242-1968 Toll-free: (800) 345-4372 Fax: (212) 239-3430 Email:
[email protected] Web Site: http://www.hdsa.org Background: The Huntington's Disease Society of America (HDSA) is a national voluntary health organization dedicated to improving the lives of people with Huntington's disease and to finding a cure for this disease. Huntington's disease is an inherited degenerative brain disorder characterized by irregular, involuntary movements; abnormal gait; slurred speech; and progressive disorientation and loss of intellectual function (dementia). Currently consisting of 40,000 members and 32 chapters across the United States, the society supports medical research into the causes and treatment of Huntington's disease, maintains a national network of services and referrals to assist affected individuals and families and offers a variety of materials through its brochures, newsletters, reports, audiovisual aids, and directory.
164 Huntington’s Disease
Finding Associations There are several Internet directories that provide lists of medical associations with information on or resources relating to Huntington’s disease. By consulting all of associations listed in this chapter, you will have nearly exhausted all sources for patient associations concerned with Huntington’s disease. The National Health Information Center (NHIC) The National Health Information Center (NHIC) offers a free referral service to help people find organizations that provide information about Huntington’s disease. For more information, see the NHIC’s Web site at http://www.health.gov/NHIC/ or contact an information specialist by calling 1-800-336-4797. Directory of Health Organizations The Directory of Health Organizations, provided by the National Library of Medicine Specialized Information Services, is a comprehensive source of information on associations. The Directory of Health Organizations database can be accessed via the Internet at http://www.sis.nlm.nih.gov/Dir/DirMain.html. It is composed of two parts: DIRLINE and Health Hotlines. The DIRLINE database comprises some 10,000 records of organizations, research centers, and government institutes and associations that primarily focus on health and biomedicine. To access DIRLINE directly, go to the following Web site: http://dirline.nlm.nih.gov/. Simply type in “Huntington’s disease” (or a synonym), and you will receive information on all relevant organizations listed in the database. Health Hotlines directs you to toll-free numbers to over 300 organizations. You can access this database directly at http://www.sis.nlm.nih.gov/hotlines/. On this page, you are given the option to search by keyword or by browsing the subject list. When you have received your search results, click on the name of the organization for its description and contact information. The Combined Health Information Database Another comprehensive source of information on healthcare associations is the Combined Health Information Database. Using the “Detailed Search” option, you will need to limit your search to “Organizations” and “Huntington’s disease”. Type the following hyperlink into your Web browser: http://chid.nih.gov/detail/detail.html. To find associations, use the drop boxes at the bottom of the search page where “You may refine your search by.” For publication date, select “All Years.” Then, select your preferred language and the format option “Organization Resource Sheet.” Type “Huntington’s disease” (or synonyms) into the “For these words:” box. You should check back periodically with this database since it is updated every three months.
Patient Resources
165
The National Organization for Rare Disorders, Inc. The National Organization for Rare Disorders, Inc. has prepared a Web site that provides, at no charge, lists of associations organized by health topic. You can access this database at the following Web site: http://www.rarediseases.org/search/orgsearch.html. Type “Huntington’s disease” (or a synonym) into the search box, and click “Submit Query.”
167
APPENDIX C. FINDING MEDICAL LIBRARIES Overview In this Appendix, we show you how to quickly find a medical library in your area.
Preparation Your local public library and medical libraries have interlibrary loan programs with the National Library of Medicine (NLM), one of the largest medical collections in the world. According to the NLM, most of the literature in the general and historical collections of the National Library of Medicine is available on interlibrary loan to any library. If you would like to access NLM medical literature, then visit a library in your area that can request the publications for you.21
Finding a Local Medical Library The quickest method to locate medical libraries is to use the Internet-based directory published by the National Network of Libraries of Medicine (NN/LM). This network includes 4626 members and affiliates that provide many services to librarians, health professionals, and the public. To find a library in your area, simply visit http://nnlm.gov/members/adv.html or call 1-800-338-7657.
Medical Libraries in the U.S. and Canada In addition to the NN/LM, the National Library of Medicine (NLM) lists a number of libraries with reference facilities that are open to the public. The following is the NLM’s list and includes hyperlinks to each library’s Web site. These Web pages can provide information on hours of operation and other restrictions. The list below is a small sample of
21
Adapted from the NLM: http://www.nlm.nih.gov/psd/cas/interlibrary.html.
168 Huntington’s Disease
libraries recommended by the National Library of Medicine (sorted alphabetically by name of the U.S. state or Canadian province where the library is located)22: •
Alabama: Health InfoNet of Jefferson County (Jefferson County Library Cooperative, Lister Hill Library of the Health Sciences), http://www.uab.edu/infonet/
•
Alabama: Richard M. Scrushy Library (American Sports Medicine Institute)
•
Arizona: Samaritan Regional Medical Center: The Learning Center (Samaritan Health System, Phoenix, Arizona), http://www.samaritan.edu/library/bannerlibs.htm
•
California: Kris Kelly Health Information Center (St. Joseph Health System, Humboldt), http://www.humboldt1.com/~kkhic/index.html
•
California: Community Health Library of Los Gatos, http://www.healthlib.org/orgresources.html
•
California: Consumer Health Program and Services (CHIPS) (County of Los Angeles Public Library, Los Angeles County Harbor-UCLA Medical Center Library) - Carson, CA, http://www.colapublib.org/services/chips.html
•
California: Gateway Health Library (Sutter Gould Medical Foundation)
•
California: Health Library (Stanford University Medical Center), http://wwwmed.stanford.edu/healthlibrary/
•
California: Patient Education Resource Center - Health Information and Resources (University of California, San Francisco), http://sfghdean.ucsf.edu/barnett/PERC/default.asp
•
California: Redwood Health Library (Petaluma Health Care District), http://www.phcd.org/rdwdlib.html
•
California: Los Gatos PlaneTree Health Library, http://planetreesanjose.org/
•
California: Sutter Resource Library (Sutter Hospitals Foundation, Sacramento), http://suttermedicalcenter.org/library/
•
California: Health Sciences Libraries (University of California, Davis), http://www.lib.ucdavis.edu/healthsci/
•
California: ValleyCare Health Library & Ryan Comer Cancer Resource Center (ValleyCare Health System, Pleasanton), http://gaelnet.stmarysca.edu/other.libs/gbal/east/vchl.html
•
California: Washington Community Health Resource Library (Fremont), http://www.healthlibrary.org/
•
Colorado: William V. Gervasini Memorial Library (Exempla Healthcare), http://www.saintjosephdenver.org/yourhealth/libraries/
•
Connecticut: Hartford Hospital Health Science Libraries (Hartford Hospital), http://www.harthosp.org/library/
•
Connecticut: Healthnet: Connecticut Consumer Health Information Center (University of Connecticut Health Center, Lyman Maynard Stowe Library), http://library.uchc.edu/departm/hnet/
22
Abstracted from http://www.nlm.nih.gov/medlineplus/libraries.html.
Finding Medical Libraries
169
•
Connecticut: Waterbury Hospital Health Center Library (Waterbury Hospital, Waterbury), http://www.waterburyhospital.com/library/consumer.shtml
•
Delaware: Consumer Health Library (Christiana Care Health System, Eugene du Pont Preventive Medicine & Rehabilitation Institute, Wilmington), http://www.christianacare.org/health_guide/health_guide_pmri_health_info.cfm
•
Delaware: Lewis B. Flinn Library (Delaware Academy of Medicine, Wilmington), http://www.delamed.org/chls.html
•
Georgia: Family Resource Library (Medical College of Georgia, Augusta), http://cmc.mcg.edu/kids_families/fam_resources/fam_res_lib/frl.htm
•
Georgia: Health Resource Center (Medical Center of Central Georgia, Macon), http://www.mccg.org/hrc/hrchome.asp
•
Hawaii: Hawaii Medical Library: Consumer Health Information Service (Hawaii Medical Library, Honolulu), http://hml.org/CHIS/
•
Idaho: DeArmond Consumer Health Library (Kootenai Medical Center, Coeur d’Alene), http://www.nicon.org/DeArmond/index.htm
•
Illinois: Health Learning Center of Northwestern Memorial Hospital (Chicago), http://www.nmh.org/health_info/hlc.html
•
Illinois: Medical Library (OSF Saint Francis Medical Center, Peoria), http://www.osfsaintfrancis.org/general/library/
•
Kentucky: Medical Library - Services for Patients, Families, Students & the Public (Central Baptist Hospital, Lexington), http://www.centralbap.com/education/community/library.cfm
•
Kentucky: University of Kentucky - Health Information Library (Chandler Medical Center, Lexington), http://www.mc.uky.edu/PatientEd/
•
Louisiana: Alton Ochsner Medical Foundation Library (Alton Ochsner Medical Foundation, New Orleans), http://www.ochsner.org/library/
•
Louisiana: Louisiana State University Health Sciences Center Medical LibraryShreveport, http://lib-sh.lsuhsc.edu/
•
Maine: Franklin Memorial Hospital Medical Library (Franklin Memorial Hospital, Farmington), http://www.fchn.org/fmh/lib.htm
•
Maine: Gerrish-True Health Sciences Library (Central Maine Medical Center, Lewiston), http://www.cmmc.org/library/library.html
•
Maine: Hadley Parrot Health Science Library (Eastern Maine Healthcare, Bangor), http://www.emh.org/hll/hpl/guide.htm
•
Maine: Maine Medical Center Library (Maine Medical Center, Portland), http://www.mmc.org/library/
•
Maine: Parkview Hospital (Brunswick), http://www.parkviewhospital.org/
•
Maine: Southern Maine Medical Center Health Sciences Library (Southern Maine Medical Center, Biddeford), http://www.smmc.org/services/service.php3?choice=10
•
Maine: Stephens Memorial Hospital’s Health Information Library (Western Maine Health, Norway), http://www.wmhcc.org/Library/
170 Huntington’s Disease
•
Manitoba, Canada: Consumer & Patient Health Information Service (University of Manitoba Libraries), http://www.umanitoba.ca/libraries/units/health/reference/chis.html
•
Manitoba, Canada: J.W. Crane Memorial Library (Deer Lodge Centre, Winnipeg), http://www.deerlodge.mb.ca/crane_library/about.asp
•
Maryland: Health Information Center at the Wheaton Regional Library (Montgomery County, Dept. of Public Libraries, Wheaton Regional Library), http://www.mont.lib.md.us/healthinfo/hic.asp
•
Massachusetts: Baystate Medical Center Library (Baystate Health System), http://www.baystatehealth.com/1024/
•
Massachusetts: Boston University Medical Center Alumni Medical Library (Boston University Medical Center), http://med-libwww.bu.edu/library/lib.html
•
Massachusetts: Lowell General Hospital Health Sciences Library (Lowell General Hospital, Lowell), http://www.lowellgeneral.org/library/HomePageLinks/WWW.htm
•
Massachusetts: Paul E. Woodard Health Sciences Library (New England Baptist Hospital, Boston), http://www.nebh.org/health_lib.asp
•
Massachusetts: St. Luke’s Hospital Health Sciences Library (St. Luke’s Hospital, Southcoast Health System, New Bedford), http://www.southcoast.org/library/
•
Massachusetts: Treadwell Library Consumer Health Reference Center (Massachusetts General Hospital), http://www.mgh.harvard.edu/library/chrcindex.html
•
Massachusetts: UMass HealthNet (University of Massachusetts Medical School, Worchester), http://healthnet.umassmed.edu/
•
Michigan: Botsford General Hospital Library - Consumer Health (Botsford General Hospital, Library & Internet Services), http://www.botsfordlibrary.org/consumer.htm
•
Michigan: Helen DeRoy Medical Library (Providence Hospital and Medical Centers), http://www.providence-hospital.org/library/
•
Michigan: Marquette General Hospital - Consumer Health Library (Marquette General Hospital, Health Information Center), http://www.mgh.org/center.html
•
Michigan: Patient Education Resouce Center - University of Michigan Cancer Center (University of Michigan Comprehensive Cancer Center, Ann Arbor), http://www.cancer.med.umich.edu/learn/leares.htm
•
Michigan: Sladen Library & Center for Health Information Resources - Consumer Health Information (Detroit), http://www.henryford.com/body.cfm?id=39330
•
Montana: Center for Health Information (St. Patrick Hospital and Health Sciences Center, Missoula)
•
National: Consumer Health Library Directory (Medical Library Association, Consumer and Patient Health Information Section), http://caphis.mlanet.org/directory/index.html
•
National: National Network of Libraries of Medicine (National Library of Medicine) provides library services for health professionals in the United States who do not have access to a medical library, http://nnlm.gov/
•
National: NN/LM List of Libraries Serving the Public (National Network of Libraries of Medicine), http://nnlm.gov/members/
Finding Medical Libraries
171
•
Nevada: Health Science Library, West Charleston Library (Las Vegas-Clark County Library District, Las Vegas), http://www.lvccld.org/special_collections/medical/index.htm
•
New Hampshire: Dartmouth Biomedical Libraries (Dartmouth College Library, Hanover), http://www.dartmouth.edu/~biomed/resources.htmld/conshealth.htmld/
•
New Jersey: Consumer Health Library (Rahway Hospital, Rahway), http://www.rahwayhospital.com/library.htm
•
New Jersey: Dr. Walter Phillips Health Sciences Library (Englewood Hospital and Medical Center, Englewood), http://www.englewoodhospital.com/links/index.htm
•
New Jersey: Meland Foundation (Englewood Hospital and Medical Center, Englewood), http://www.geocities.com/ResearchTriangle/9360/
•
New York: Choices in Health Information (New York Public Library) - NLM Consumer Pilot Project participant, http://www.nypl.org/branch/health/links.html
•
New York: Health Information Center (Upstate Medical University, State University of New York, Syracuse), http://www.upstate.edu/library/hic/
•
New York: Health Sciences Library (Long Island Jewish Medical Center, New Hyde Park), http://www.lij.edu/library/library.html
•
New York: ViaHealth Medical Library (Rochester General Hospital), http://www.nyam.org/library/
•
Ohio: Consumer Health Library (Akron General Medical Center, Medical & Consumer Health Library), http://www.akrongeneral.org/hwlibrary.htm
•
Oklahoma: The Health Information Center at Saint Francis Hospital (Saint Francis Health System, Tulsa), http://www.sfh-tulsa.com/services/healthinfo.asp
•
Oregon: Planetree Health Resource Center (Mid-Columbia Medical Center, The Dalles), http://www.mcmc.net/phrc/
•
Pennsylvania: Community Health Information Library (Milton S. Hershey Medical Center, Hershey), http://www.hmc.psu.edu/commhealth/
•
Pennsylvania: Community Health Resource Library (Geisinger Medical Center, Danville), http://www.geisinger.edu/education/commlib.shtml
•
Pennsylvania: HealthInfo Library (Moses Taylor Hospital, Scranton), http://www.mth.org/healthwellness.html
•
Pennsylvania: Hopwood Library (University of Pittsburgh, Health Sciences Library System, Pittsburgh), http://www.hsls.pitt.edu/guides/chi/hopwood/index_html
•
Pennsylvania: Koop Community Health Information Center (College of Physicians of Philadelphia), http://www.collphyphil.org/kooppg1.shtml
•
Pennsylvania: Learning Resources Center - Medical Library (Susquehanna Health System, Williamsport), http://www.shscares.org/services/lrc/index.asp
•
Pennsylvania: Medical Library (UPMC Health System, Pittsburgh), http://www.upmc.edu/passavant/library.htm
•
Quebec, Canada: Medical Library (Montreal General Hospital), http://www.mghlib.mcgill.ca/
172 Huntington’s Disease
•
South Dakota: Rapid City Regional Hospital Medical Library (Rapid City Regional Hospital), http://www.rcrh.org/Services/Library/Default.asp
•
Texas: Houston HealthWays (Houston Academy of Medicine-Texas Medical Center Library), http://hhw.library.tmc.edu/
•
Washington: Community Health Library (Kittitas Valley Community Hospital), http://www.kvch.com/
•
Washington: Southwest Washington Medical Center Library (Southwest Washington Medical Center, Vancouver), http://www.swmedicalcenter.com/body.cfm?id=72
173
ONLINE GLOSSARIES The Internet provides access to a number of free-to-use medical dictionaries. The National Library of Medicine has compiled the following list of online dictionaries: •
ADAM Medical Encyclopedia (A.D.A.M., Inc.), comprehensive medical reference: http://www.nlm.nih.gov/medlineplus/encyclopedia.html
•
MedicineNet.com Medical Dictionary (MedicineNet, Inc.): http://www.medterms.com/Script/Main/hp.asp
•
Merriam-Webster Medical Dictionary (Inteli-Health, Inc.): http://www.intelihealth.com/IH/
•
Multilingual Glossary of Technical and Popular Medical Terms in Eight European Languages (European Commission) - Danish, Dutch, English, French, German, Italian, Portuguese, and Spanish: http://allserv.rug.ac.be/~rvdstich/eugloss/welcome.html
•
On-line Medical Dictionary (CancerWEB): http://cancerweb.ncl.ac.uk/omd/
•
Rare Diseases Terms (Office of Rare Diseases): http://ord.aspensys.com/asp/diseases/diseases.asp
•
Technology Glossary (National Library of Medicine) - Health Care Technology: http://www.nlm.nih.gov/nichsr/ta101/ta10108.htm
Beyond these, MEDLINEplus contains a very patient-friendly encyclopedia covering every aspect of medicine (licensed from A.D.A.M., Inc.). The ADAM Medical Encyclopedia can be accessed at http://www.nlm.nih.gov/medlineplus/encyclopedia.html. ADAM is also available on commercial Web sites such as drkoop.com (http://www.drkoop.com/) and Web MD (http://my.webmd.com/adam/asset/adam_disease_articles/a_to_z/a). The NIH suggests the following Web sites in the ADAM Medical Encyclopedia when searching for information on Huntington’s disease: •
Basic Guidelines for Huntington’s Disease Huntington's disease Web site: http://www.nlm.nih.gov/medlineplus/ency/article/000770.htm
•
Signs & Symptoms for Huntington’s Disease Agitation Web site: http://www.nlm.nih.gov/medlineplus/ency/article/003212.htm Anxiety Web site: http://www.nlm.nih.gov/medlineplus/ency/article/003211.htm Anxiety, stress, and tension Web site: http://www.nlm.nih.gov/medlineplus/ency/article/003211.htm Behavior changes Web site: http://www.nlm.nih.gov/medlineplus/ency/article/003255.htm
174 Huntington’s Disease
Bowel incontinence Web site: http://www.nlm.nih.gov/medlineplus/ency/article/003135.htm Change in mental status Web site: http://www.nlm.nih.gov/medlineplus/ency/article/003205.htm Chorea Web site: http://www.nlm.nih.gov/medlineplus/ency/article/003196.htm Confusion Web site: http://www.nlm.nih.gov/medlineplus/ency/article/003205.htm Depression Web site: http://www.nlm.nih.gov/medlineplus/ency/article/003213.htm Difficulty swallowing Web site: http://www.nlm.nih.gov/medlineplus/ency/article/003115.htm Dysarthria Web site: http://www.nlm.nih.gov/medlineplus/ency/article/003204.htm Dysphagia Web site: http://www.nlm.nih.gov/medlineplus/ency/article/003115.htm Hallucinations Web site: http://www.nlm.nih.gov/medlineplus/ency/article/003258.htm Hypotonia Web site: http://www.nlm.nih.gov/medlineplus/ency/article/003298.htm Incontinence Web site: http://www.nlm.nih.gov/medlineplus/ency/article/003142.htm Loss of memory Web site: http://www.nlm.nih.gov/medlineplus/ency/article/003257.htm Movement, uncontrolled - slow Web site: http://www.nlm.nih.gov/medlineplus/ency/article/003197.htm Movement, unpredictable - jerky Web site: http://www.nlm.nih.gov/medlineplus/ency/article/003196.htm Primitive reflexes Web site: http://www.nlm.nih.gov/medlineplus/ency/article/003292.htm Restless Web site: http://www.nlm.nih.gov/medlineplus/ency/article/003212.htm Speech impairment Web site: http://www.nlm.nih.gov/medlineplus/ency/article/003204.htm
Online Glossaries 175
Unsteady gait Web site: http://www.nlm.nih.gov/medlineplus/ency/article/003199.htm Wasting Web site: http://www.nlm.nih.gov/medlineplus/ency/article/003188.htm •
Diagnostics and Tests for Huntington’s Disease ANA Web site: http://www.nlm.nih.gov/medlineplus/ency/article/003535.htm CT Web site: http://www.nlm.nih.gov/medlineplus/ency/article/003330.htm Dopamine Web site: http://www.nlm.nih.gov/medlineplus/ency/article/003561.htm Head CT scan Web site: http://www.nlm.nih.gov/medlineplus/ency/article/003786.htm Head MRI scan Web site: http://www.nlm.nih.gov/medlineplus/ency/article/003791.htm MRI Web site: http://www.nlm.nih.gov/medlineplus/ency/article/003335.htm PET (isotope) scan of the brain Web site: http://www.nlm.nih.gov/medlineplus/ency/article/003827.htm
•
Background Topics for Huntington’s Disease Genetics Web site: http://www.nlm.nih.gov/medlineplus/ency/article/002048.htm Symptomatic Web site: http://www.nlm.nih.gov/medlineplus/ency/article/002293.htm
Online Dictionary Directories The following are additional online directories compiled by the National Library of Medicine, including a number of specialized medical dictionaries: •
Medical Dictionaries: Medical & Biological (World Health Organization): http://www.who.int/hlt/virtuallibrary/English/diction.htm#Medical
•
MEL-Michigan Electronic Library List of Online Health and Medical Dictionaries (Michigan Electronic Library): http://mel.lib.mi.us/health/health-dictionaries.html
•
Patient Education: Glossaries (DMOZ Open Directory Project): http://dmoz.org/Health/Education/Patient_Education/Glossaries/
176 Huntington’s Disease
•
Web of Online Dictionaries (Bucknell University): http://www.yourdictionary.com/diction5.html#medicine
177
HUNTINGTON’S DISEASE DICTIONARY The definitions below are derived from official public sources, including the National Institutes of Health [NIH] and the European Union [EU]. 3-dimensional: 3-D. A graphic display of depth, width, and height. Three-dimensional radiation therapy uses computers to create a 3-dimensional picture of the tumor. This allows doctors to give the highest possible dose of radiation to the tumor, while sparing the normal tissue as much as possible. [NIH] Abdomen: That portion of the body that lies between the thorax and the pelvis. [NIH] Abdominal: Having to do with the abdomen, which is the part of the body between the chest and the hips that contains the pancreas, stomach, intestines, liver, gallbladder, and other organs. [NIH] Aberrant: Wandering or deviating from the usual or normal course. [EU] Acetylcholine: A neurotransmitter. Acetylcholine in vertebrates is the major transmitter at neuromuscular junctions, autonomic ganglia, parasympathetic effector junctions, a subset of sympathetic effector junctions, and at many sites in the central nervous system. It is generally not used as an administered drug because it is broken down very rapidly by cholinesterases, but it is useful in some ophthalmological applications. [NIH] Acetylcholinesterase: An enzyme that catalyzes the hydrolysis of acetylcholine to choline and acetate. In the CNS, this enzyme plays a role in the function of peripheral neuromuscular junctions. EC 3.1.1.7. [NIH] Acoustic: Having to do with sound or hearing. [NIH] Actin: Essential component of the cell skeleton. [NIH] Adaptability: Ability to develop some form of tolerance to conditions extremely different from those under which a living organism evolved. [NIH] Adaptation: 1. The adjustment of an organism to its environment, or the process by which it enhances such fitness. 2. The normal ability of the eye to adjust itself to variations in the intensity of light; the adjustment to such variations. 3. The decline in the frequency of firing of a neuron, particularly of a receptor, under conditions of constant stimulation. 4. In dentistry, (a) the proper fitting of a denture, (b) the degree of proximity and interlocking of restorative material to a tooth preparation, (c) the exact adjustment of bands to teeth. 5. In microbiology, the adjustment of bacterial physiology to a new environment. [EU] Adenosine: A nucleoside that is composed of adenine and d-ribose. Adenosine or adenosine derivatives play many important biological roles in addition to being components of DNA and RNA. Adenosine itself is a neurotransmitter. [NIH] Adenylate Cyclase: An enzyme of the lyase class that catalyzes the formation of cyclic AMP and pyrophosphate from ATP. EC 4.6.1.1. [NIH] Adipocytes: Fat-storing cells found mostly in the abdominal cavity and subcutaneous tissue. Fat is usually stored in the form of tryglycerides. [NIH] Adrenergic: Activated by, characteristic of, or secreting epinephrine or substances with similar activity; the term is applied to those nerve fibres that liberate norepinephrine at a synapse when a nerve impulse passes, i.e., the sympathetic fibres. [EU] Adverse Effect: An unwanted side effect of treatment. [NIH] Aerobic: In biochemistry, reactions that need oxygen to happen or happen when oxygen is
178 Huntington’s Disease
present. [NIH] Afferent: Concerned with the transmission of neural impulse toward the central part of the nervous system. [NIH] Affinity: 1. Inherent likeness or relationship. 2. A special attraction for a specific element, organ, or structure. 3. Chemical affinity; the force that binds atoms in molecules; the tendency of substances to combine by chemical reaction. 4. The strength of noncovalent chemical binding between two substances as measured by the dissociation constant of the complex. 5. In immunology, a thermodynamic expression of the strength of interaction between a single antigen-binding site and a single antigenic determinant (and thus of the stereochemical compatibility between them), most accurately applied to interactions among simple, uniform antigenic determinants such as haptens. Expressed as the association constant (K litres mole -1), which, owing to the heterogeneity of affinities in a population of antibody molecules of a given specificity, actually represents an average value (mean intrinsic association constant). 6. The reciprocal of the dissociation constant. [EU] Age of Onset: The age or period of life at which a disease or the initial symptoms or manifestations of a disease appear in an individual. [NIH] Agonist: In anatomy, a prime mover. In pharmacology, a drug that has affinity for and stimulates physiologic activity at cell receptors normally stimulated by naturally occurring substances. [EU] Akathisia: 1. A condition of motor restlessness in which there is a feeling of muscular quivering, an urge to move about constantly, and an inability to sit still, a common extrapyramidal side effect of neuroleptic drugs. 2. An inability to sit down because of intense anxiety at the thought of doing so. [EU] Akinesia: 1. Absence or poverty of movements. 2. The temporary paralysis of a muscle by the injection of procaine. [EU] Alanine: A non-essential amino acid that occurs in high levels in its free state in plasma. It is produced from pyruvate by transamination. It is involved in sugar and acid metabolism, increases immunity, and provides energy for muscle tissue, brain, and the central nervous system. [NIH] Alertness: A state of readiness to detect and respond to certain specified small changes occurring at random intervals in the environment. [NIH] Algorithms: A procedure consisting of a sequence of algebraic formulas and/or logical steps to calculate or determine a given task. [NIH] Alkaline: Having the reactions of an alkali. [EU] Alkaloid: A member of a large group of chemicals that are made by plants and have nitrogen in them. Some alkaloids have been shown to work against cancer. [NIH] Alleles: Mutually exclusive forms of the same gene, occupying the same locus on homologous chromosomes, and governing the same biochemical and developmental process. [NIH] Allergen: An antigenic substance capable of producing immediate-type hypersensitivity (allergy). [EU] Allografts: A graft of tissue obtained from the body of another animal of the same species but with genotype differing from that of the recipient; tissue graft from a donor of one genotype to a host of another genotype with host and donor being members of the same species. [NIH] Allylamine: Possesses an unusual and selective cytotoxicity for vascular smooth muscle cells in dogs and rats. Useful for experiments dealing with arterial injury, myocardial
Dictionary 179
fibrosis or cardiac decompensation. [NIH] Alternative medicine: Practices not generally recognized by the medical community as standard or conventional medical approaches and used instead of standard treatments. Alternative medicine includes the taking of dietary supplements, megadose vitamins, and herbal preparations; the drinking of special teas; and practices such as massage therapy, magnet therapy, spiritual healing, and meditation. [NIH] Amantadine: An antiviral that is used in the prophylactic or symptomatic treatment of Influenza A. It is also used as an antiparkinsonian agent, to treat extrapyramidal reactions, and for postherpetic neuralgia. The mechanisms of its effects in movement disorders are not well understood but probably reflect an increase in synthesis and release of dopamine, with perhaps some inhibition of dopamine uptake. [NIH] Amine: An organic compound containing nitrogen; any member of a group of chemical compounds formed from ammonia by replacement of one or more of the hydrogen atoms by organic (hydrocarbon) radicals. The amines are distinguished as primary, secondary, and tertiary, according to whether one, two, or three hydrogen atoms are replaced. The amines include allylamine, amylamine, ethylamine, methylamine, phenylamine, propylamine, and many other compounds. [EU] Amino Acid Sequence: The order of amino acids as they occur in a polypeptide chain. This is referred to as the primary structure of proteins. It is of fundamental importance in determining protein conformation. [NIH] Amino Acids: Organic compounds that generally contain an amino (-NH2) and a carboxyl (COOH) group. Twenty alpha-amino acids are the subunits which are polymerized to form proteins. [NIH] Amino Acids: Organic compounds that generally contain an amino (-NH2) and a carboxyl (COOH) group. Twenty alpha-amino acids are the subunits which are polymerized to form proteins. [NIH] Ammonia: A colorless alkaline gas. It is formed in the body during decomposition of organic materials during a large number of metabolically important reactions. [NIH] Amplification: The production of additional copies of a chromosomal DNA sequence, found as either intrachromosomal or extrachromosomal DNA. [NIH] Amygdala: Almond-shaped group of basal nuclei anterior to the inferior horn of the lateral ventricle of the brain, within the temporal lobe. The amygdala is part of the limbic system. [NIH]
Amyloid: A general term for a variety of different proteins that accumulate as extracellular fibrils of 7-10 nm and have common structural features, including a beta-pleated sheet conformation and the ability to bind such dyes as Congo red and thioflavine (Kandel, Schwartz, and Jessel, Principles of Neural Science, 3rd ed). [NIH] Anaesthesia: Loss of feeling or sensation. Although the term is used for loss of tactile sensibility, or of any of the other senses, it is applied especially to loss of the sensation of pain, as it is induced to permit performance of surgery or other painful procedures. [EU] Anal: Having to do with the anus, which is the posterior opening of the large bowel. [NIH] Anaphylatoxins: The family of peptides C3a, C4a, C5a, and C5a des-arginine produced in the serum during complement activation. They produce smooth muscle contraction, mast cell histamine release, affect platelet aggregation, and act as mediators of the local inflammatory process. The order of anaphylatoxin activity from strongest to weakest is C5a, C3a, C4a, and C5a des-arginine. The latter is the so-called "classical" anaphylatoxin but shows no spasmogenic activity though it contains some chemotactic ability. [NIH]
180 Huntington’s Disease
Anatomical: Pertaining to anatomy, or to the structure of the organism. [EU] Anemia: A reduction in the number of circulating erythrocytes or in the quantity of hemoglobin. [NIH] Animal model: An animal with a disease either the same as or like a disease in humans. Animal models are used to study the development and progression of diseases and to test new treatments before they are given to humans. Animals with transplanted human cancers or other tissues are called xenograft models. [NIH] Anions: Negatively charged atoms, radicals or groups of atoms which travel to the anode or positive pole during electrolysis. [NIH] Annealing: The spontaneous alignment of two single DNA strands to form a double helix. [NIH]
Anomalies: Birth defects; abnormalities. [NIH] Anterior Cerebral Artery: Artery formed by the bifurcation of the internal carotid artery. Branches of the anterior cerebral artery supply the caudate nucleus, internal capsule, putamen, septal nuclei, gyrus cinguli, and surfaces of the frontal lobe and parietal lobe. [NIH] Anterograde: Moving or extending forward; called also antegrade. [EU] Antibacterial: A substance that destroys bacteria or suppresses their growth or reproduction. [EU] Antibiotic: A drug used to treat infections caused by bacteria and other microorganisms. [NIH]
Antibodies: Immunoglobulin molecules having a specific amino acid sequence by virtue of which they interact only with the antigen that induced their synthesis in cells of the lymphoid series (especially plasma cells), or with an antigen closely related to it. [NIH] Antibody: A type of protein made by certain white blood cells in response to a foreign substance (antigen). Each antibody can bind to only a specific antigen. The purpose of this binding is to help destroy the antigen. Antibodies can work in several ways, depending on the nature of the antigen. Some antibodies destroy antigens directly. Others make it easier for white blood cells to destroy the antigen. [NIH] Anticoagulant: A drug that helps prevent blood clots from forming. Also called a blood thinner. [NIH] Anticonvulsant: An agent that prevents or relieves convulsions. [EU] Antiemetic: An agent that prevents or alleviates nausea and vomiting. Also antinauseant. [EU]
Antigen: Any substance which is capable, under appropriate conditions, of inducing a specific immune response and of reacting with the products of that response, that is, with specific antibody or specifically sensitized T-lymphocytes, or both. Antigens may be soluble substances, such as toxins and foreign proteins, or particulate, such as bacteria and tissue cells; however, only the portion of the protein or polysaccharide molecule known as the antigenic determinant (q.v.) combines with antibody or a specific receptor on a lymphocyte. Abbreviated Ag. [EU] Antigen-Antibody Complex: The complex formed by the binding of antigen and antibody molecules. The deposition of large antigen-antibody complexes leading to tissue damage causes immune complex diseases. [NIH] Antimetabolite: A chemical that is very similar to one required in a normal biochemical reaction in cells. Antimetabolites can stop or slow down the reaction. [NIH] Antineoplastic: Inhibiting or preventing the development of neoplasms, checking the
Dictionary 181
maturation and proliferation of malignant cells. [EU] Antioxidant: A substance that prevents damage caused by free radicals. Free radicals are highly reactive chemicals that often contain oxygen. They are produced when molecules are split to give products that have unpaired electrons. This process is called oxidation. [NIH] Antipsychotic: Effective in the treatment of psychosis. Antipsychotic drugs (called also neuroleptic drugs and major tranquilizers) are a chemically diverse (including phenothiazines, thioxanthenes, butyrophenones, dibenzoxazepines, dibenzodiazepines, and diphenylbutylpiperidines) but pharmacologically similar class of drugs used to treat schizophrenic, paranoid, schizoaffective, and other psychotic disorders; acute delirium and dementia, and manic episodes (during induction of lithium therapy); to control the movement disorders associated with Huntington's chorea, Gilles de la Tourette's syndrome, and ballismus; and to treat intractable hiccups and severe nausea and vomiting. Antipsychotic agents bind to dopamine, histamine, muscarinic cholinergic, a-adrenergic, and serotonin receptors. Blockade of dopaminergic transmission in various areas is thought to be responsible for their major effects : antipsychotic action by blockade in the mesolimbic and mesocortical areas; extrapyramidal side effects (dystonia, akathisia, parkinsonism, and tardive dyskinesia) by blockade in the basal ganglia; and antiemetic effects by blockade in the chemoreceptor trigger zone of the medulla. Sedation and autonomic side effects (orthostatic hypotension, blurred vision, dry mouth, nasal congestion and constipation) are caused by blockade of histamine, cholinergic, and adrenergic receptors. [EU] Antiviral: Destroying viruses or suppressing their replication. [EU] Aorta: The main trunk of the systemic arteries. [NIH] Apoptosis: One of the two mechanisms by which cell death occurs (the other being the pathological process of necrosis). Apoptosis is the mechanism responsible for the physiological deletion of cells and appears to be intrinsically programmed. It is characterized by distinctive morphologic changes in the nucleus and cytoplasm, chromatin cleavage at regularly spaced sites, and the endonucleolytic cleavage of genomic DNA (DNA fragmentation) at internucleosomal sites. This mode of cell death serves as a balance to mitosis in regulating the size of animal tissues and in mediating pathologic processes associated with tumor growth. [NIH] Approximate: Approximal [EU] Apraxia: Loss of ability to perform purposeful movements, in the absence of paralysis or sensory disturbance, caused by lesions in the cortex. [NIH] Aqueous: Having to do with water. [NIH] Arginine: An essential amino acid that is physiologically active in the L-form. [NIH] Arterial: Pertaining to an artery or to the arteries. [EU] Arteries: The vessels carrying blood away from the heart. [NIH] Aspartate: A synthetic amino acid. [NIH] Assay: Determination of the amount of a particular constituent of a mixture, or of the biological or pharmacological potency of a drug. [EU] Astrocytes: The largest and most numerous neuroglial cells in the brain and spinal cord. Astrocytes (from "star" cells) are irregularly shaped with many long processes, including those with "end feet" which form the glial (limiting) membrane and directly and indirectly contribute to the blood brain barrier. They regulate the extracellular ionic and chemical environment, and "reactive astrocytes" (along with microglia) respond to injury. Astrocytes have high- affinity transmitter uptake systems, voltage-dependent and transmitter-gated ion channels, and can release transmitter, but their role in signaling (as in many other functions)
182 Huntington’s Disease
is not well understood. [NIH] Asymptomatic: Having no signs or symptoms of disease. [NIH] Ataxia: Impairment of the ability to perform smoothly coordinated voluntary movements. This condition may affect the limbs, trunk, eyes, pharnyx, larnyx, and other structures. Ataxia may result from impaired sensory or motor function. Sensory ataxia may result from posterior column injury or peripheral nerve diseases. Motor ataxia may be associated with cerebellar diseases; cerebral cortex diseases; thalamic diseases; basal ganglia diseases; injury to the red nucleus; and other conditions. [NIH] Atrium: A chamber; used in anatomical nomenclature to designate a chamber affording entrance to another structure or organ. Usually used alone to designate an atrium of the heart. [EU] Atrophy: Decrease in the size of a cell, tissue, organ, or multiple organs, associated with a variety of pathological conditions such as abnormal cellular changes, ischemia, malnutrition, or hormonal changes. [NIH] Attenuated: Strain with weakened or reduced virulence. [NIH] Atypical: Irregular; not conformable to the type; in microbiology, applied specifically to strains of unusual type. [EU] Audiovisual Aids: Auditory and visual instructional materials. [NIH] Auditory: Pertaining to the sense of hearing. [EU] Autoimmune disease: A condition in which the body recognizes its own tissues as foreign and directs an immune response against them. [NIH] Autonomic: Self-controlling; functionally independent. [EU] Autoradiography: A process in which radioactive material within an object produces an image when it is in close proximity to a radiation sensitive emulsion. [NIH] Axonal: Condition associated with metabolic derangement of the entire neuron and is manifest by degeneration of the distal portion of the nerve fiber. [NIH] Axons: Nerve fibers that are capable of rapidly conducting impulses away from the neuron cell body. [NIH] Bacteria: Unicellular prokaryotic microorganisms which generally possess rigid cell walls, multiply by cell division, and exhibit three principal forms: round or coccal, rodlike or bacillary, and spiral or spirochetal. [NIH] Bacteriophage: A virus whose host is a bacterial cell; A virus that exclusively infects bacteria. It generally has a protein coat surrounding the genome (DNA or RNA). One of the coliphages most extensively studied is the lambda phage, which is also one of the most important. [NIH] Basal Ganglia: Large subcortical nuclear masses derived from the telencephalon and located in the basal regions of the cerebral hemispheres. [NIH] Basal Ganglia Diseases: Diseases of the basal ganglia including the putamen; globus pallidus; claustrum; amygdala; and caudate nucleus. Dyskinesias (most notably involuntary movements and alterations of the rate of movement) represent the primary clinical manifestations of these disorders. Common etiologies include cerebrovascular disease; neurodegenerative diseases; and craniocerebral trauma. [NIH] Base: In chemistry, the nonacid part of a salt; a substance that combines with acids to form salts; a substance that dissociates to give hydroxide ions in aqueous solutions; a substance whose molecule or ion can combine with a proton (hydrogen ion); a substance capable of donating a pair of electrons (to an acid) for the formation of a coordinate covalent bond. [EU]
Dictionary 183
Behavioral Symptoms: Observable manifestions of impaired psychological functioning. [NIH]
Benign: Not cancerous; does not invade nearby tissue or spread to other parts of the body. [NIH]
Beta-pleated: Particular three-dimensional pattern of amyloidoses. [NIH] Beta-sheet: Two or more parallel or anti-parallel strands are arranged in rows. [NIH] Bewilderment: Impairment or loss of will power. [NIH] Bile: An emulsifying agent produced in the liver and secreted into the duodenum. Its composition includes bile acids and salts, cholesterol, and electrolytes. It aids digestion of fats in the duodenum. [NIH] Bile Acids: Acids made by the liver that work with bile to break down fats. [NIH] Bile Acids and Salts: Steroid acids and salts. The primary bile acids are derived from cholesterol in the liver and usually conjugated with glycine or taurine. The secondary bile acids are further modified by bacteria in the intestine. They play an important role in the digestion and absorption of fat. They have also been used pharmacologically, especially in the treatment of gallstones. [NIH] Binding Sites: The reactive parts of a macromolecule that directly participate in its specific combination with another molecule. [NIH] Biochemical: Relating to biochemistry; characterized by, produced by, or involving chemical reactions in living organisms. [EU] Biological therapy: Treatment to stimulate or restore the ability of the immune system to fight infection and disease. Also used to lessen side effects that may be caused by some cancer treatments. Also known as immunotherapy, biotherapy, or biological response modifier (BRM) therapy. [NIH] Biomarkers: Substances sometimes found in an increased amount in the blood, other body fluids, or tissues and that may suggest the presence of some types of cancer. Biomarkers include CA 125 (ovarian cancer), CA 15-3 (breast cancer), CEA (ovarian, lung, breast, pancreas, and GI tract cancers), and PSA (prostate cancer). Also called tumor markers. [NIH] Biomedical Engineering: Application of principles and practices of engineering science to biomedical research and health care. [NIH] Biophysics: The science of physical phenomena and processes in living organisms. [NIH] Biosynthesis: The building up of a chemical compound in the physiologic processes of a living organism. [EU] Biotechnology: Body of knowledge related to the use of organisms, cells or cell-derived constituents for the purpose of developing products which are technically, scientifically and clinically useful. Alteration of biologic function at the molecular level (i.e., genetic engineering) is a central focus; laboratory methods used include transfection and cloning technologies, sequence and structure analysis algorithms, computer databases, and gene and protein structure function analysis and prediction. [NIH] Bipolar Disorder: A major affective disorder marked by severe mood swings (manic or major depressive episodes) and a tendency to remission and recurrence. [NIH] Birth Order: The sequence in which children are born into the family. [NIH] Bladder: The organ that stores urine. [NIH] Blastocyst: The mammalian embryo in the post-morula stage in which a fluid-filled cavity, enclosed primarily by trophoblast, contains an inner cell mass which becomes the embryonic disc. [NIH]
184 Huntington’s Disease
Blepharospasm: Excessive winking; tonic or clonic spasm of the orbicularis oculi muscle. [NIH]
Blood Coagulation: The process of the interaction of blood coagulation factors that results in an insoluble fibrin clot. [NIH] Blood pressure: The pressure of blood against the walls of a blood vessel or heart chamber. Unless there is reference to another location, such as the pulmonary artery or one of the heart chambers, it refers to the pressure in the systemic arteries, as measured, for example, in the forearm. [NIH] Blood vessel: A tube in the body through which blood circulates. Blood vessels include a network of arteries, arterioles, capillaries, venules, and veins. [NIH] Blood-Brain Barrier: Specialized non-fenestrated tightly-joined endothelial cells (tight junctions) that form a transport barrier for certain substances between the cerebral capillaries and the brain tissue. [NIH] Blot: To transfer DNA, RNA, or proteins to an immobilizing matrix such as nitrocellulose. [NIH]
Blotting, Western: Identification of proteins or peptides that have been electrophoretically separated by blotting and transferred to strips of nitrocellulose paper. The blots are then detected by radiolabeled antibody probes. [NIH] Body Fluids: Liquid components of living organisms. [NIH] Bone Marrow: The soft tissue filling the cavities of bones. Bone marrow exists in two types, yellow and red. Yellow marrow is found in the large cavities of large bones and consists mostly of fat cells and a few primitive blood cells. Red marrow is a hematopoietic tissue and is the site of production of erythrocytes and granular leukocytes. Bone marrow is made up of a framework of connective tissue containing branching fibers with the frame being filled with marrow cells. [NIH] Bone scan: A technique to create images of bones on a computer screen or on film. A small amount of radioactive material is injected into a blood vessel and travels through the bloodstream; it collects in the bones and is detected by a scanner. [NIH] Bowel: The long tube-shaped organ in the abdomen that completes the process of digestion. There is both a small and a large bowel. Also called the intestine. [NIH] Bowel Movement: Body wastes passed through the rectum and anus. [NIH] Brachytherapy: A collective term for interstitial, intracavity, and surface radiotherapy. It uses small sealed or partly-sealed sources that may be placed on or near the body surface or within a natural body cavity or implanted directly into the tissues. [NIH] Bradykinesia: Abnormal slowness of movement; sluggishness of physical and mental responses. [EU] Bradykinin: A nonapeptide messenger that is enzymatically produced from kallidin in the blood where it is a potent but short-lived agent of arteriolar dilation and increased capillary permeability. Bradykinin is also released from mast cells during asthma attacks, from gut walls as a gastrointestinal vasodilator, from damaged tissues as a pain signal, and may be a neurotransmitter. [NIH] Brain Neoplasms: Neoplasms of the intracranial components of the central nervous system, including the cerebral hemispheres, basal ganglia, hypothalamus, thalamus, brain stem, and cerebellum. Brain neoplasms are subdivided into primary (originating from brain tissue) and secondary (i.e., metastatic) forms. Primary neoplasms are subdivided into benign and malignant forms. In general, brain tumors may also be classified by age of onset, histologic type, or presenting location in the brain. [NIH]
Dictionary 185
Brain Stem: The part of the brain that connects the cerebral hemispheres with the spinal cord. It consists of the mesencephalon, pons, and medulla oblongata. [NIH] Branch: Most commonly used for branches of nerves, but applied also to other structures. [NIH]
Broad-spectrum: Effective against a wide range of microorganisms; said of an antibiotic. [EU] Bromodeoxyuridine: A nucleoside that substitutes for thymidine in DNA and thus acts as an antimetabolite. It causes breaks in chromosomes and has been proposed as an antiviral and antineoplastic agent. It has been given orphan drug status for use in the treatment of primary brain tumors. [NIH] Calcium: A basic element found in nearly all organized tissues. It is a member of the alkaline earth family of metals with the atomic symbol Ca, atomic number 20, and atomic weight 40. Calcium is the most abundant mineral in the body and combines with phosphorus to form calcium phosphate in the bones and teeth. It is essential for the normal functioning of nerves and muscles and plays a role in blood coagulation (as factor IV) and in many enzymatic processes. [NIH] Calcium Signaling: Signal transduction mechanisms whereby calcium mobilization (from outside the cell or from intracellular storage pools) to the cytoplasm is triggered by external stimuli. Calcium signals are often seen to propagate as waves, oscillations, spikes or puffs. The calcium acts as an intracellular messenger by activating calcium-responsive proteins. [NIH]
Calmodulin: A heat-stable, low-molecular-weight activator protein found mainly in the brain and heart. The binding of calcium ions to this protein allows this protein to bind to cyclic nucleotide phosphodiesterases and to adenyl cyclase with subsequent activation. Thereby this protein modulates cyclic AMP and cyclic GMP levels. [NIH] Calpain: Cysteine proteinase found in many tissues. Hydrolyzes a variety of endogenous proteins including neuropeptides, cytoskeletal proteins, proteins from smooth muscle, cardiac muscle, liver, platelets and erythrocytes. Two subclasses having high and low calcium sensitivity are known. Removes Z-discs and M-lines from myofibrils. Activates phosphorylase kinase and cyclic nucleotide-independent protein kinase. [NIH] Cannabidiol: Compound isolated from Cannabis sativa extract. [NIH] Cannabinoids: Compounds extracted from Cannabis sativa L. and metabolites having the cannabinoid structure. The most active constituents are tetrahydrocannabinol, cannabinol, and cannabidiol. [NIH] Cannabinol: A physiologically inactive constituent of Cannabis sativa L. [NIH] Carboxy: Cannabinoid. [NIH] Carboxy-terminal: The end of any polypeptide or protein that bears a free carboxyl group. [NIH]
Carcinogenic: Producing carcinoma. [EU] Carcinogens: Substances that increase the risk of neoplasms in humans or animals. Both genotoxic chemicals, which affect DNA directly, and nongenotoxic chemicals, which induce neoplasms by other mechanism, are included. [NIH] Cardiac: Having to do with the heart. [NIH] Cardiopulmonary: Having to do with the heart and lungs. [NIH] Cardiopulmonary Bypass: Diversion of the flow of blood from the entrance of the right atrium directly to the aorta (or femoral artery) via an oxygenator thus bypassing both the heart and lungs. [NIH]
186 Huntington’s Disease
Case report: A detailed report of the diagnosis, treatment, and follow-up of an individual patient. Case reports also contain some demographic information about the patient (for example, age, gender, ethnic origin). [NIH] Case series: A group or series of case reports involving patients who were given similar treatment. Reports of case series usually contain detailed information about the individual patients. This includes demographic information (for example, age, gender, ethnic origin) and information on diagnosis, treatment, response to treatment, and follow-up after treatment. [NIH] Caspase: Enzyme released by the cell at a crucial stage in apoptosis in order to shred all cellular proteins. [NIH] Catecholamine: A group of chemical substances manufactured by the adrenal medulla and secreted during physiological stress. [NIH] Caudal: Denoting a position more toward the cauda, or tail, than some specified point of reference; same as inferior, in human anatomy. [EU] Caudate Nucleus: Elongated gray mass of the neostriatum located adjacent to the lateral ventricle of the brain. [NIH] Cell: The individual unit that makes up all of the tissues of the body. All living things are made up of one or more cells. [NIH] Cell Cycle: The complex series of phenomena, occurring between the end of one cell division and the end of the next, by which cellular material is divided between daughter cells. [NIH] Cell Death: The termination of the cell's ability to carry out vital functions such as metabolism, growth, reproduc